[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fcgiE-rC8QWMEbflEarstKsBcXFsGfGSI3DSxvLzKU_4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":38,"phaseBuckets":87,"rows":94},"Amgen",[4,6],"Amgen Research (Munich) GmbH",1042,false,107,306,969694,100,60,[15,18,21,24,27,30,33,36],{"name":16,"count":17},"Anemia",46,{"name":19,"count":20},"Rheumatoid Arthritis",45,{"name":22,"count":23},"Psoriasis",40,{"name":25,"count":26},"Cancer",32,{"name":28,"count":29},"Chronic Kidney Disease",29,{"name":31,"count":32},"Multiple Myeloma",25,{"name":34,"count":35},"Colorectal Cancer",21,{"name":37,"count":35},"Metastatic Colorectal Cancer",[39,44,49,54,59,63,68,73,78,83],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT04303780","Study to Compare AMG 510 \"Proposed INN Sotorasib\" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).","2022-08-02","AMG 510",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT04540497","A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease","2024-04-09","Inebilizumab",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT04524273","Myasthenia Gravis Inebilizumab Trial","2024-05-28","inebilizumab",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT05740566","Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer","2025-01-29","Tarlatamab",{"nctId":60,"briefTitle":61,"date":62,"intervention":58},"NCT06502977","Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment","2025-03-28",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT06660173","A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)","2025-10-06","Maridebart Cafraglutide",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT05111626","Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.","2025-10-14","Bemarituzumab",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT03836040","Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine","2025-11-19","Erenumab Dose 1",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT05565560","A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis","2025-11-20","Apremilast",{"nctId":84,"briefTitle":85,"date":86,"intervention":72},"NCT05322577","A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.","2025-11-21",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,207,324,395,420,445,473,497,882,1069,1250,1452,1544,1835,1973,2007,2411,2741,2893,3023,3113,3156,3199,3242,3336,3450,3495,3521,3547,3569,3591,3764,3914,3962,3992,4023,4056,4078,4100,4118,4136,4154,4182,4200,4218,4244,4262,4280,4298,4316,4334,4352,4370,4550,4658,4770,4799,4853,4886,4947,4965,4983,5001,5019,5051,5084,5106,5223,5282,5312,5334,5372,5394,5412,5430,5448,5473,5496,5520,5538,5556,5574,5592,5610,5628,5646,5664,5682,5700,5718,5736,5754,5772,5790,5814,5832,5850,5868,5886,5916,5939,6119,6211,6290,6382,6446,6501,6547,6581,6603,6634,6667,6696,6730,6763,6793,6816,6840,6858,6876,6897,6915,6933,6959,6977,7001,7028,7046,7067,7092,7116,7134,7152,7176,7198,7225,7243,7266,7291,7309,7534,7640,7740,7817,7901,7973,8025,8071,8113,8172,8240,8278,8316,8375,8440,8474,8521,8578,8612,8652,8703,8733,8763,8801,8841,8872,8904,8943,8983,9020,9060,9090,9112,9134,9156,9178,9200,9222,9249,9271,9293,9315,9346,9379,9412,9434,9459,9481,9503,9537,9567,9589,9611,9645,9667,9692,9710,9736,9754,9776,9794,9812,9830,9848,9866,9888,9912,9930,9948,9966,9984,10002,10020,10038,10063,10081,10103,10121,10147,10165,10183,10209,10227,10249,10267,10288,10312,10337,10355,10373,10396,10414,10432,10450,10468,10493,10518,10536,10554,10572,10590,10608,10626,10650,10668,10691,10709,10736,10754,10772,10794,10812,10837,10855,10879,10904,10922,10943,10961,10984,11002,11020,11038,11056,11074,11095,11113,11134,11155,11213,11289,11350,11400,11455,11504,11565,11609,11654,11684,11714,11763,11802,11832,11868,11894,11928,11969,12005,12043,12073,12095,12117,12149,12171,12201,12223,12252,12283,12311,12337,12375,12406,12434,12462,12494,12523,12556,12578,12600,12622,12644,12666,12688,12718,12736,12759,12777,12795,12813,12831,12849,12867,12893,12911,12929,12951,12973,12991,13009,13031,13049,13070,13091,13109,13127,13145,13168,13186,13210,13228,13246,13264,13285,13307,13325,13343,13361,13379,13397,13415,13437,13455,13479,13497,13515,13537,13555,13577,13595,13616,13634,13652,13670,13695,13713,13737,13755,13778,13796,13814,13832,13850,13874,13895,13918,13936,13954,13972,13995,14013,14031,14049,14072,14090,14108,14130,14148,14173,14195,14213,14231,14253,14271,14294,14352,14382,14425,14451,14480,14514,14542,14566,14594,14621,14649,14671,14699,14727,14749,14776,14809,14836,14865,14883,14906,14924,14948,14972,14990,15008,15026,15044,15065,15089,15112,15133,15157,15179,15197,15219,15244,15262,15285,15306,15329,15351,15372,15394,15412,15436,15460,15478,15496,15514,15539,15557,15581,15599,15620,15644,15662,15680,15705,15723,15741,15763,15781,15799,15824,15842,15860,15883,15901,15919,15937,15955,15973,15991,16013,16037,16058,16082,16100,16126,16144,16165,16189,16212,16230,16252,16277,16301,16319,16337,16355,16390,16408,16426,16444,16462,16480,16498,16516,16534,16552,16570,16588,16606,16631,16649,16667,16685,16703,16724,16742,16767,16785,16809,16827,16848,16872,16890,16916,16934,16952,16970,16993,17017,17042,17064,17082,17106,17124,17142,17166,17189,17212,17230,17248,17553,17875,18127,18260,18430,18509,18606,18657,18700,18737,18770,18802,18826,18850,18880,18902,18924,18948,18969,18993,19014,19039,19060,19082,19104],{"intervention":48,"totalTrials":96,"cells":97},9,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":161,"PHASE4":194,"NA":205},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":160,"soonestReadout":122},[105,118,128,141,151],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":116},"NCT06570798","A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases","RECRUITING",[90],"2028-07-21","2025-07-16",220,[114,115],"Systemic Lupus Erythematosus","Active Refractory Rheumatoid Arthritis",[48,117],"Blinatumomab",{"nctId":119,"briefTitle":120,"status":108,"phases":121,"primaryCompletion":122,"completion":122,"start":123,"enrollment":124,"conditions":125,"interventions":127},"NCT05549258","Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder",[90],"2027-04-13","2023-07-03",15,[126],"Neuromyelitis Optica Spectrum Disorder",[48],{"nctId":129,"briefTitle":130,"status":131,"phases":132,"primaryCompletion":133,"completion":134,"start":135,"enrollment":100,"conditions":136,"interventions":138},"NCT04174677","Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor","WITHDRAWN",[90],"2021-12","2022-04","2019-12-27",[137],"Highly Sensitized Patients on Waiting List for Kidney Transplantation",[48,139,140],"VIB4920","Inebilzumab+VIB4920",{"nctId":142,"briefTitle":143,"status":144,"phases":145,"primaryCompletion":146,"completion":146,"start":147,"enrollment":124,"conditions":148,"interventions":150},"NCT07222553","Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD","NOT_YET_RECRUITING",[90],"2031-06-10","2026-07-31",[149],"Immunoglobulin G4-related Disease",[48],{"nctId":152,"briefTitle":153,"status":108,"phases":154,"primaryCompletion":155,"completion":155,"start":156,"enrollment":124,"conditions":157,"interventions":159},"NCT06987539","A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)",[90],"2030-03-13","2026-08-31",[158],"Generalized Myasthenia Gravis",[48],4,{"trials":162,"activeCount":193,"soonestReadout":47},[163,172,181],{"nctId":45,"briefTitle":46,"status":164,"phases":165,"primaryCompletion":47,"completion":166,"start":167,"enrollment":168,"conditions":169,"interventions":171},"ACTIVE_NOT_RECRUITING",[91],"2028-10-31","2020-12-04",135,[170],"IgG4 Related Disease",[48],{"nctId":50,"briefTitle":51,"status":164,"phases":173,"primaryCompletion":52,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":179},[91],"2029-06-07","2020-10-15",238,[178],"Myasthenia Gravis",[53,180],"IV Placebo",{"nctId":182,"briefTitle":183,"status":144,"phases":184,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":189,"interventions":192},"NCT07598825","A Trial of Inebilizumab in Participants With Autoimmune Hepatitis",[91],"2031-07-30","2034-02-11","2026-09-07",180,[190,191],"Autoimmune Hepatitis","AIH",[48],3,{"trials":195,"activeCount":204,"soonestReadout":200},[196],{"nctId":197,"briefTitle":198,"status":164,"phases":199,"primaryCompletion":200,"completion":200,"start":201,"enrollment":26,"conditions":202,"interventions":203},"NCT06180278","Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)",[92],"2028-06-26","2024-04-02",[126],[48],1,{"trials":206,"activeCount":100},[],{"intervention":208,"totalTrials":96,"cells":209},"Avacopan",{"EARLY_PHASE1":210,"PHASE1":212,"PHASE2":257,"PHASE3":282,"PHASE4":309,"NA":322},{"trials":211,"activeCount":100},[],{"trials":213,"activeCount":100},[214,225,235,247],{"nctId":215,"briefTitle":216,"status":217,"phases":218,"primaryCompletion":219,"completion":219,"start":220,"enrollment":26,"conditions":221,"interventions":223},"NCT06207682","Effect of Repeated Oral Doses of Avacopan on the Pharmacokinetics (PK) of a Single Dose of Simvastatin","COMPLETED",[89],"2022-08-11","2022-06-28",[222],"Healthy Volunteers",[208,224],"Simvastatin",{"nctId":226,"briefTitle":227,"status":217,"phases":228,"primaryCompletion":229,"completion":229,"start":230,"enrollment":231,"conditions":232,"interventions":234},"NCT06468826","A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)",[89],"2024-10-05","2024-06-18",13,[233],"End-Stage Renal Disease (ESRD)",[208],{"nctId":236,"briefTitle":237,"status":217,"phases":238,"primaryCompletion":239,"completion":240,"start":241,"enrollment":242,"conditions":243,"interventions":245},"NCT05988034","A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT\u002FQTc Interval in Healthy Participants",[89],"2020-01-22","2020-03-31","2019-11-08",58,[244],"Electrocardiography",[208,246],"Moxifloxacin",{"nctId":248,"briefTitle":249,"status":217,"phases":250,"primaryCompletion":251,"completion":251,"start":252,"enrollment":253,"conditions":254,"interventions":256},"NCT06004934","A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment",[89],"2018-09-18","2018-04-17",24,[255],"Hepatic Impairment",[208],{"trials":258,"activeCount":100},[259,271],{"nctId":260,"briefTitle":261,"status":217,"phases":262,"primaryCompletion":263,"completion":264,"start":265,"enrollment":266,"conditions":267,"interventions":270},"NCT03852472","Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)",[90],"2021-01-14","2021-03-09","2018-12-21",435,[268,269],"Hidradenitis Suppurativa","Acne Inversa",[208],{"nctId":272,"briefTitle":273,"status":217,"phases":274,"primaryCompletion":275,"completion":276,"start":277,"enrollment":278,"conditions":279,"interventions":281},"NCT03301467","Controlled Trial Evaluating Avacopan in C3 Glomerulopathy",[90],"2021-03-03","2021-10-27","2017-09-29",57,[280],"C3 Glomerulopathy (C3G)",[208],{"trials":283,"activeCount":204,"soonestReadout":303},[284,299],{"nctId":285,"briefTitle":286,"status":217,"phases":287,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":292,"interventions":294},"NCT02994927","A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis",[91],"2019-09-07","2019-11-01","2017-03-15",331,[293],"ANCA-Associated Vasculitis",[208,295,296,297,298],"Prednisone","Cyclophosphamide","Rituximab","Azathioprine",{"nctId":300,"briefTitle":301,"status":108,"phases":302,"primaryCompletion":303,"completion":303,"start":304,"enrollment":305,"conditions":306,"interventions":308},"NCT06321601","Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to \u003C 18 Years of Age With AAV.",[91],"2028-09-26","2024-10-22",20,[307],"Vasculitis",[208],{"trials":310,"activeCount":204,"soonestReadout":315},[311],{"nctId":312,"briefTitle":313,"status":108,"phases":314,"primaryCompletion":315,"completion":315,"start":316,"enrollment":317,"conditions":318,"interventions":320},"NCT06072482","A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis",[92],"2036-12-31","2024-02-07",300,[319],"Antineutrophil Cytoplasmic Antibody-associated Vasculitis",[208,321],"Standard of Care",{"trials":323,"activeCount":100},[],{"intervention":321,"totalTrials":325,"cells":326},5,{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":331,"PHASE3":345,"PHASE4":387,"NA":393},{"trials":328,"activeCount":100},[],{"trials":330,"activeCount":100},[],{"trials":332,"activeCount":100},[333],{"nctId":334,"briefTitle":335,"status":336,"phases":337,"primaryCompletion":338,"completion":338,"start":339,"enrollment":340,"conditions":341,"interventions":343},"NCT01439867","Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism","TERMINATED",[90],"2016-06-03","2012-06-22",18,[28,342],"Hyperparathyroidism, Secondary",[344,321],"Cinacalcet hydrochloride",{"trials":346,"activeCount":100},[347,363,374],{"nctId":348,"briefTitle":349,"status":217,"phases":350,"primaryCompletion":351,"completion":351,"start":352,"enrollment":353,"conditions":354,"interventions":356},"NCT04590586","Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients",[91],"2021-08-03","2020-11-24",515,[355],"COVID-19",[357,82,358,359,360,361,362],"Standard of care","Apremilast placebo","Lanadelumab","Lanadelumab placebo","Zilucoplan","Zilucoplan placebo",{"nctId":364,"briefTitle":365,"status":217,"phases":366,"primaryCompletion":367,"completion":367,"start":368,"enrollment":369,"conditions":370,"interventions":372},"NCT01854918","Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia",[91],"2018-05-31","2013-04-23",3681,[371],"Hyperlipidemia and Mixed Dyslipidemia",[373,321],"Evolocumab",{"nctId":375,"briefTitle":376,"status":336,"phases":377,"primaryCompletion":378,"start":379,"enrollment":380,"conditions":381,"interventions":385},"NCT01277510","Pediatric Chronic Kidney Disease Safety and Efficacy",[91],"2014-04-30","2011-06-28",43,[28,382,342,383,384],"Hyperparathyroidism","Kidney Disease","Secondary Hyperparathyroidism",[386,321],"cinacalcet",{"trials":388,"activeCount":204,"soonestReadout":315},[389],{"nctId":312,"briefTitle":313,"status":108,"phases":390,"primaryCompletion":315,"completion":315,"start":316,"enrollment":317,"conditions":391,"interventions":392},[92],[319],[208,321],{"trials":394,"activeCount":100},[],{"intervention":396,"totalTrials":204,"cells":397},"Prolia®",{"EARLY_PHASE1":398,"PHASE1":400,"PHASE2":402,"PHASE3":404,"PHASE4":406,"NA":418},{"trials":399,"activeCount":100},[],{"trials":401,"activeCount":100},[],{"trials":403,"activeCount":100},[],{"trials":405,"activeCount":100},[],{"trials":407,"activeCount":204,"soonestReadout":412},[408],{"nctId":409,"briefTitle":410,"status":164,"phases":411,"primaryCompletion":412,"completion":412,"start":413,"enrollment":414,"conditions":415,"interventions":417},"NCT06588153","A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China",[92],"2027-04-27","2025-05-24",102,[416],"Glucocorticoid-induced Osteoporosis",[396],{"trials":419,"activeCount":100},[],{"intervention":421,"totalTrials":204,"cells":422},"XGEVA®",{"EARLY_PHASE1":423,"PHASE1":425,"PHASE2":427,"PHASE3":429,"PHASE4":431,"NA":443},{"trials":424,"activeCount":100},[],{"trials":426,"activeCount":100},[],{"trials":428,"activeCount":100},[],{"trials":430,"activeCount":100},[],{"trials":432,"activeCount":204,"soonestReadout":437},[433],{"nctId":434,"briefTitle":435,"status":164,"phases":436,"primaryCompletion":437,"completion":437,"start":438,"enrollment":439,"conditions":440,"interventions":442},"NCT04586660","Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone",[92],"2028-03-07","2023-08-17",36,[441],"Giant Cell Tumor of Bone",[421],{"trials":444,"activeCount":100},[],{"intervention":446,"totalTrials":204,"cells":447},"Routine Lipid Management",{"EARLY_PHASE1":448,"PHASE1":450,"PHASE2":452,"PHASE3":454,"PHASE4":456,"NA":471},{"trials":449,"activeCount":100},[],{"trials":451,"activeCount":100},[],{"trials":453,"activeCount":100},[],{"trials":455,"activeCount":100},[],{"trials":457,"activeCount":204,"soonestReadout":462},[458],{"nctId":459,"briefTitle":460,"status":164,"phases":461,"primaryCompletion":462,"completion":462,"start":463,"enrollment":464,"conditions":465,"interventions":470},"NCT05284747","EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction",[92],"2027-05-29","2022-10-26",6019,[466,467,468,469],"Cardiovascular Disease","Myocardial Infarction","Stroke","Coronary Revascularization",[373,446],{"trials":472,"activeCount":100},[],{"intervention":474,"totalTrials":204,"cells":475},"Prolia",{"EARLY_PHASE1":476,"PHASE1":478,"PHASE2":480,"PHASE3":482,"PHASE4":484,"NA":495},{"trials":477,"activeCount":100},[],{"trials":479,"activeCount":100},[],{"trials":481,"activeCount":100},[],{"trials":483,"activeCount":100},[],{"trials":485,"activeCount":204,"soonestReadout":490},[486],{"nctId":487,"briefTitle":488,"status":164,"phases":489,"primaryCompletion":490,"completion":490,"start":491,"enrollment":414,"conditions":492,"interventions":494},"NCT06332014","Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China",[92],"2027-01-23","2024-08-06",[493],"Osteoporosis",[474],{"trials":496,"activeCount":100},[],{"intervention":373,"totalTrials":498,"cells":499},39,{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":522,"PHASE3":582,"PHASE4":854,"NA":870},{"trials":501,"activeCount":100},[],{"trials":503,"activeCount":100},[504,513],{"nctId":505,"briefTitle":506,"status":217,"phases":507,"primaryCompletion":508,"completion":508,"start":509,"enrollment":13,"conditions":510,"interventions":512},"NCT01133522","Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin",[89],"2011-09-14","2010-06-01",[511],"Hyperlipidemia",[373],{"nctId":514,"briefTitle":515,"status":217,"phases":516,"primaryCompletion":517,"completion":517,"start":518,"enrollment":340,"conditions":519,"interventions":521},"NCT02275156","Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab",[89],"2014-12-19","2014-08-19",[511,520],"Mixed Dyslipidemia",[373],{"trials":523,"activeCount":100},[524,534,544,554,564,573],{"nctId":525,"briefTitle":526,"status":217,"phases":527,"primaryCompletion":528,"completion":528,"start":529,"enrollment":530,"conditions":531,"interventions":533},"NCT01375751","Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study",[90],"2012-05-16","2011-08-02",168,[532],"Hypercholesterolemia, Familial",[373],{"nctId":535,"briefTitle":536,"status":217,"phases":537,"primaryCompletion":538,"start":539,"enrollment":540,"conditions":541,"interventions":543},"NCT01652703","A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects",[90],"2013-05-14","2012-07-10",310,[542],"Hypercholesterolemia and High Risk for Cardiovascular Events",[373],{"nctId":545,"briefTitle":546,"status":217,"phases":547,"primaryCompletion":548,"completion":548,"start":549,"enrollment":550,"conditions":551,"interventions":552},"NCT01375777","Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels",[90],"2012-03-02","2011-07-06",411,[511],[373,553],"Ezetimibe",{"nctId":555,"briefTitle":556,"status":217,"phases":557,"primaryCompletion":558,"completion":558,"start":559,"enrollment":560,"conditions":561,"interventions":563},"NCT01439880","Open Label Study of Long Term Evaluation Against LDL-C Trial",[90],"2018-06-20","2011-10-07",1324,[562],"Hypercholesterolemia",[373],{"nctId":565,"briefTitle":566,"status":217,"phases":567,"primaryCompletion":568,"completion":568,"start":569,"enrollment":570,"conditions":571,"interventions":572},"NCT01380730","LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy",[90],"2012-04-05","2011-07-01",631,[511],[373],{"nctId":574,"briefTitle":575,"status":217,"phases":576,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":580,"interventions":581},"NCT01375764","Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects",[90],"2012-05-08","2011-07-28",160,[511],[373,553],{"trials":583,"activeCount":100},[584,594,603,613,623,635,645,654,662,672,682,691,702,714,724,734,738,746,756,766,777,787,796,805,817,826,835,844],{"nctId":585,"briefTitle":586,"status":217,"phases":587,"primaryCompletion":588,"completion":588,"start":589,"enrollment":590,"conditions":591,"interventions":593},"NCT02739984","Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia\u002FMixed Dyslipidemia",[91],"2017-08-03","2016-05-17",424,[562,520,592],"Type 2 Diabetes",[373],{"nctId":595,"briefTitle":596,"status":217,"phases":597,"primaryCompletion":598,"completion":599,"start":600,"enrollment":291,"conditions":601,"interventions":602},"NCT01763918","Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2",[91],"2013-11-27","2013-12-19","2013-02-07",[511],[373],{"nctId":604,"briefTitle":605,"status":336,"phases":606,"primaryCompletion":607,"completion":607,"start":608,"enrollment":609,"conditions":610,"interventions":612},"NCT03080935","Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries",[91],"2022-03-04","2017-03-13",1600,[611],"Dyslipidemia",[373],{"nctId":614,"briefTitle":615,"status":217,"phases":616,"primaryCompletion":617,"completion":617,"start":618,"enrollment":619,"conditions":620,"interventions":622},"NCT03872401","Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke",[91],"2025-07-25","2019-06-11",12301,[621],"Coronary Heart Disease (CHD)",[373],{"nctId":624,"briefTitle":625,"status":217,"phases":626,"primaryCompletion":627,"completion":628,"start":629,"enrollment":630,"conditions":631,"interventions":632},"NCT01763866","LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2",[91],"2013-11-12","2013-12-04","2013-01-15",2067,[511],[373,553,633,634,224],"Atorvastatin","Rosuvastatin",{"nctId":636,"briefTitle":637,"status":217,"phases":638,"primaryCompletion":639,"completion":640,"start":641,"enrollment":642,"conditions":643,"interventions":644},"NCT01813422","GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound",[91],"2016-07-12","2016-07-29","2013-04-18",970,[562],[373],{"nctId":646,"briefTitle":647,"status":217,"phases":648,"primaryCompletion":649,"completion":649,"start":650,"enrollment":317,"conditions":651,"interventions":653},"NCT01624142","Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders",[90,91],"2018-05-11","2012-06-01",[652],"Severe Familial Hypercholesterolemia",[373],{"nctId":655,"briefTitle":656,"status":217,"phases":657,"primaryCompletion":658,"completion":658,"start":568,"enrollment":242,"conditions":659,"interventions":661},"NCT01588496","Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities",[90,91],"2014-01-31",[660],"Homozygous Familial Hypercholesterolemia",[373],{"nctId":663,"briefTitle":664,"status":217,"phases":665,"primaryCompletion":666,"completion":666,"start":667,"enrollment":668,"conditions":669,"interventions":670},"NCT02207634","Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects",[91],"2016-11-11","2014-09-10",1974,[611],[373,671],"Background Statin Therapy",{"nctId":673,"briefTitle":674,"status":217,"phases":675,"primaryCompletion":676,"completion":676,"start":677,"enrollment":678,"conditions":679,"interventions":681},"NCT02624869","Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)",[91],"2021-06-01","2016-09-10",163,[680],"Familial Hypercholesterolemia",[373],{"nctId":683,"briefTitle":684,"status":217,"phases":685,"primaryCompletion":686,"completion":686,"start":687,"enrollment":688,"conditions":689,"interventions":690},"NCT02867813","Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension",[91],"2022-03-21","2016-09-02",5035,[611],[373],{"nctId":692,"briefTitle":693,"status":217,"phases":694,"primaryCompletion":695,"completion":696,"start":697,"enrollment":698,"conditions":699,"interventions":701},"NCT02189837","Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody",[91],"2015-02-13","2015-03-05","2014-07-08",89,[700],"Primary Hyperlipidemia and Mixed Dyslipidemia",[373,633],{"nctId":703,"briefTitle":704,"status":217,"phases":705,"primaryCompletion":706,"completion":707,"start":708,"enrollment":709,"conditions":710,"interventions":712},"NCT03570697","Imaging of Coronary Plaques in Participants Treated With Evolocumab",[91],"2020-12-18","2021-01-21","2018-11-19",164,[711],"Coronary Artery Disease (CAD)",[373,713],"Statin therapy",{"nctId":715,"briefTitle":716,"status":217,"phases":717,"primaryCompletion":718,"completion":718,"start":719,"enrollment":720,"conditions":721,"interventions":723},"NCT02729025","Effects of Proprotein Convertase Subtilisin\u002FKexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))",[91],"2018-04-05","2016-04-14",129,[722],"Subjects With Hyperlipidemia, Dyslipidemia",[373],{"nctId":725,"briefTitle":726,"status":217,"phases":727,"primaryCompletion":728,"completion":729,"start":730,"enrollment":731,"conditions":732,"interventions":733},"NCT02634580","Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4",[91],"2017-08-10","2018-05-26","2016-02-27",61,[562],[373,553],{"nctId":364,"briefTitle":365,"status":217,"phases":735,"primaryCompletion":367,"completion":367,"start":368,"enrollment":369,"conditions":736,"interventions":737},[91],[371],[373,321],{"nctId":739,"briefTitle":740,"status":217,"phases":741,"primaryCompletion":666,"completion":666,"start":742,"enrollment":743,"conditions":744,"interventions":745},"NCT01764633","Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk",[91],"2013-02-08",27564,[611],[373],{"nctId":747,"briefTitle":748,"status":217,"phases":749,"primaryCompletion":750,"completion":750,"start":751,"enrollment":752,"conditions":753,"interventions":755},"NCT02392559","Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin\u002FKexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders",[91],"2019-11-25","2016-03-24",158,[754],"Heterozygous Familial Hypercholesterolemia",[373],{"nctId":757,"briefTitle":758,"status":217,"phases":759,"primaryCompletion":760,"completion":761,"start":762,"enrollment":763,"conditions":764,"interventions":765},"NCT01984424","Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3",[91],"2015-11-10","2017-11-21","2013-12-10",511,[511],[633,553,373],{"nctId":767,"briefTitle":768,"status":217,"phases":769,"primaryCompletion":770,"completion":771,"start":772,"enrollment":773,"conditions":774,"interventions":776},"NCT02833844","Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia\u002FMixed Dyslipidemia",[91],"2019-07-09","2020-01-27","2017-05-22",467,[775],"Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection",[373],{"nctId":778,"briefTitle":779,"status":217,"phases":780,"primaryCompletion":781,"completion":781,"start":782,"enrollment":783,"conditions":784,"interventions":786},"NCT01953328","Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk",[91],"2014-06","2013-10",409,[785],"Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events",[633,373],{"nctId":788,"briefTitle":789,"status":217,"phases":790,"primaryCompletion":791,"completion":791,"start":719,"enrollment":792,"conditions":793,"interventions":795},"NCT02662569","Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia",[91],"2017-12-06",986,[794],"Diabetes, Hyperlipidemia, Mixed Dyslipidemia",[373,633],{"nctId":797,"briefTitle":798,"status":217,"phases":799,"primaryCompletion":800,"completion":800,"start":801,"enrollment":802,"conditions":803,"interventions":804},"NCT01516879","Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study",[91],"2013-10-14","2012-01-05",905,[562],[373,633,553],{"nctId":806,"briefTitle":807,"status":336,"phases":808,"primaryCompletion":809,"completion":810,"start":811,"enrollment":812,"conditions":813,"interventions":815},"NCT03433755","Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia",[91],"2020-04-24","2020-05-09","2019-05-09",259,[814,520],"Primary Hypercholesterolemia",[816],"evolocumab",{"nctId":818,"briefTitle":819,"status":217,"phases":820,"primaryCompletion":821,"completion":821,"start":822,"enrollment":823,"conditions":824,"interventions":825},"NCT02304484","Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab",[91],"2018-03-09","2014-11-24",770,[562],[373],{"nctId":827,"briefTitle":828,"status":217,"phases":829,"primaryCompletion":830,"completion":830,"start":831,"enrollment":832,"conditions":833,"interventions":834},"NCT01763905","Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2",[91],"2013-11-19","2013-01-24",307,[511],[373,553],{"nctId":836,"briefTitle":837,"status":217,"phases":838,"primaryCompletion":839,"completion":840,"start":841,"enrollment":498,"conditions":842,"interventions":843},"NCT02585895","Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment",[91],"2016-09-01","2017-01-20","2015-12-21",[562],[373],{"nctId":845,"briefTitle":846,"status":217,"phases":847,"primaryCompletion":848,"completion":849,"start":850,"enrollment":851,"conditions":852,"interventions":853},"NCT01763827","Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2",[91],"2013-10-10","2013-10-29","2013-01-21",615,[511],[373,553],{"trials":855,"activeCount":204,"soonestReadout":462},[856,860],{"nctId":459,"briefTitle":460,"status":164,"phases":857,"primaryCompletion":462,"completion":462,"start":463,"enrollment":464,"conditions":858,"interventions":859},[92],[466,467,468,469],[373,446],{"nctId":861,"briefTitle":862,"status":217,"phases":863,"primaryCompletion":864,"completion":864,"start":865,"enrollment":866,"conditions":867,"interventions":869},"NCT03403374","Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia",[92],"2019-11-27","2018-08-04",30,[868],"Homozygous Familial Hypercholesterolemia HoFH",[816],{"trials":871,"activeCount":100},[872],{"nctId":873,"briefTitle":874,"status":336,"phases":875,"primaryCompletion":876,"completion":876,"start":877,"enrollment":878,"conditions":879,"interventions":881},"NCT02957604","Evolocumab Pregnancy Exposure Registry",[],"2020-09-02","2016-12-22",140,[880],"Hypercholesterolemia; ASCVD; Pregnancy",[816],{"intervention":67,"totalTrials":340,"cells":883},{"EARLY_PHASE1":884,"PHASE1":886,"PHASE2":956,"PHASE3":986,"PHASE4":1065,"NA":1067},{"trials":885,"activeCount":100},[],{"trials":887,"activeCount":325,"soonestReadout":942},[888,899,910,920,928,938,947],{"nctId":889,"briefTitle":890,"status":164,"phases":891,"primaryCompletion":892,"completion":892,"start":893,"enrollment":894,"conditions":895,"interventions":898},"NCT07229157","Effect of Maridebart Cafraglutide on the Heart's Electrical Activity",[89],"2026-08-26","2025-10-22",81,[896,897],"Overweight","Obesity",[67,246],{"nctId":900,"briefTitle":901,"status":108,"phases":902,"primaryCompletion":903,"completion":904,"start":905,"enrollment":278,"conditions":906,"interventions":908},"NCT07160257","A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus",[89],"2026-11-02","2027-02-19","2025-08-05",[907],"Type 2 Diabetes Mellitus",[909],"Maridebart cafraglutide",{"nctId":911,"briefTitle":912,"status":217,"phases":913,"primaryCompletion":914,"completion":914,"start":915,"enrollment":916,"conditions":917,"interventions":918},"NCT04478708","Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity",[89],"2022-11-18","2020-08-07",110,[897],[919],"maridebart cafraglutide",{"nctId":921,"briefTitle":922,"status":217,"phases":923,"primaryCompletion":924,"completion":924,"start":925,"enrollment":305,"conditions":926,"interventions":927},"NCT06352892","A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight",[89],"2024-08-27","2024-04-25",[897],[67],{"nctId":929,"briefTitle":930,"status":164,"phases":931,"primaryCompletion":932,"completion":932,"start":933,"enrollment":934,"conditions":935,"interventions":937},"NCT07313761","A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations",[89],"2026-06-26","2025-12-15",349,[936],"Overweight and Obesity",[67],{"nctId":939,"briefTitle":940,"status":164,"phases":941,"primaryCompletion":942,"completion":942,"start":943,"enrollment":944,"conditions":945,"interventions":946},"NCT07226778","Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations",[89],"2026-05-28","2025-10-10",348,[896,897],[67],{"nctId":948,"briefTitle":949,"status":108,"phases":950,"primaryCompletion":951,"completion":951,"start":952,"enrollment":20,"conditions":953,"interventions":954},"NCT07523711","Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity",[89],"2026-10-07","2026-04-09",[896,897],[955,67],"COC",{"trials":957,"activeCount":985,"soonestReadout":66},[958,965,975],{"nctId":64,"briefTitle":65,"status":164,"phases":959,"primaryCompletion":66,"completion":960,"start":961,"enrollment":783,"conditions":962,"interventions":964},[90],"2026-11-10","2024-11-07",[963],"Type 2 Diabetes Mellitus (T2DM)",[67],{"nctId":966,"briefTitle":967,"status":217,"phases":968,"primaryCompletion":969,"completion":970,"start":971,"enrollment":972,"conditions":973,"interventions":974},"NCT05669599","Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus",[90],"2024-10-08","2025-12-16","2023-01-18",592,[897,896,907],[67],{"nctId":976,"briefTitle":977,"status":108,"phases":978,"primaryCompletion":979,"completion":980,"start":981,"enrollment":188,"conditions":982,"interventions":984},"NCT07441252","A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight",[90],"2027-09-29","2027-12-22","2026-03-05",[983],"Overweight or Obesity and Elevated Liver Fat",[909],2,{"trials":987,"activeCount":1064,"soonestReadout":1031},[988,998,1010,1017,1027,1037,1046,1056],{"nctId":989,"briefTitle":990,"status":108,"phases":991,"primaryCompletion":979,"completion":992,"start":993,"enrollment":994,"conditions":995,"interventions":997},"NCT07226765","Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy",[91],"2028-09-13","2025-11-25",250,[996],"Obstructive Sleep Apnea",[909],{"nctId":999,"briefTitle":1000,"status":108,"phases":1001,"primaryCompletion":1002,"completion":1003,"start":1004,"enrollment":1005,"conditions":1006,"interventions":1009},"NCT07037459","Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity",[91],"2028-06-30","2030-09-29","2025-06-25",5056,[1007,1008,897],"Heart Failure With Preserved Ejection Fraction","Heart Failure With Mildly Reduced Ejection Fraction",[909],{"nctId":1011,"briefTitle":1012,"status":108,"phases":1013,"primaryCompletion":979,"completion":992,"start":1014,"enrollment":994,"conditions":1015,"interventions":1016},"NCT07225686","Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy",[91],"2025-12-19",[897,996],[909],{"nctId":1018,"briefTitle":1019,"status":164,"phases":1020,"primaryCompletion":412,"completion":1021,"start":1022,"enrollment":1023,"conditions":1024,"interventions":1026},"NCT06987695","Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease",[91],"2027-07-21","2025-06-13",279,[1025],"Obesity Disease",[909],{"nctId":1028,"briefTitle":1029,"status":164,"phases":1030,"primaryCompletion":1031,"completion":1032,"start":1033,"enrollment":1034,"conditions":1035,"interventions":1036},"NCT06858839","Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight",[91],"2027-01-21","2027-04-16","2025-03-12",3853,[897],[67],{"nctId":1038,"briefTitle":1039,"status":164,"phases":1040,"primaryCompletion":1031,"completion":1032,"start":1041,"enrollment":1042,"conditions":1043,"interventions":1045},"NCT06858878","Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight",[91],"2025-03-17",1105,[1044],"Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight",[909],{"nctId":1047,"briefTitle":1048,"status":144,"phases":1049,"primaryCompletion":1050,"completion":1051,"start":1052,"enrollment":317,"conditions":1053,"interventions":1055},"NCT07575399","Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)",[91],"2028-01-03","2028-02-28","2026-05-25",[1054],"Obesity or Overweight",[67],{"nctId":1057,"briefTitle":1058,"status":108,"phases":1059,"primaryCompletion":1002,"completion":1003,"start":617,"enrollment":1060,"conditions":1061,"interventions":1063},"NCT07037433","Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity",[91],12800,[1062,896,897],"Atherosclerotic Cardiovascular Disease",[67],8,{"trials":1066,"activeCount":100},[],{"trials":1068,"activeCount":100},[],{"intervention":58,"totalTrials":1070,"cells":1071},16,{"EARLY_PHASE1":1072,"PHASE1":1074,"PHASE2":1165,"PHASE3":1193,"PHASE4":1239,"NA":1241},{"trials":1073,"activeCount":100},[],{"trials":1075,"activeCount":1164,"soonestReadout":1145},[1076,1088,1100,1113,1122,1131,1141,1154],{"nctId":1077,"briefTitle":1078,"status":108,"phases":1079,"primaryCompletion":1080,"completion":1081,"start":1082,"enrollment":1083,"conditions":1084,"interventions":1086},"NCT07037758","A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)",[89],"2028-03-18","2031-01-18","2025-09-16",380,[1085],"Extensive Stage Small Cell Lung Cancer",[58,1087],"AB248",{"nctId":1089,"briefTitle":1090,"status":217,"phases":1091,"primaryCompletion":1092,"completion":1093,"start":1094,"enrollment":1095,"conditions":1096,"interventions":1098},"NCT04885998","AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)",[89],"2023-07-12","2024-09-11","2021-09-27",23,[1097],"Small Cell Lung Cancer",[58,1099],"AMG 404",{"nctId":1101,"briefTitle":1102,"status":164,"phases":1103,"primaryCompletion":1104,"completion":1104,"start":1105,"enrollment":1106,"conditions":1107,"interventions":1108},"NCT05361395","First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)",[89],"2028-08-28","2022-08-24",184,[1085],[58,1109,1110,1111,1112],"Carboplatin","Etoposide","Atezolizumab","Durvalumab",{"nctId":1114,"briefTitle":1115,"status":164,"phases":1116,"primaryCompletion":1117,"completion":1117,"start":1118,"enrollment":29,"conditions":1119,"interventions":1120},"NCT06898957","Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)",[89],"2031-06-23","2025-05-16",[1097],[1121,58,1112],"YL201",{"nctId":1123,"briefTitle":1124,"status":108,"phases":1125,"primaryCompletion":1126,"completion":1127,"start":1128,"enrollment":112,"conditions":1129,"interventions":1130},"NCT06598306","Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)",[89],"2027-03-03","2030-04-24","2024-10-07",[1085],[58],{"nctId":1132,"briefTitle":1133,"status":108,"phases":1134,"primaryCompletion":1135,"completion":1136,"start":1137,"enrollment":579,"conditions":1138,"interventions":1139},"NCT07531095","Study of Tarlatamab + ZL-1310 +\u002F- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)",[89],"2028-05-21","2031-05-21","2026-04-21",[1097],[1140,58,1112],"ZL-1310",{"nctId":1142,"briefTitle":1143,"status":164,"phases":1144,"primaryCompletion":1145,"completion":1146,"start":1147,"enrollment":1148,"conditions":1149,"interventions":1151},"NCT03319940","Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)",[89],"2026-12-31","2027-12-31","2017-12-26",269,[1150],"Small Cell Lung Carcinoma",[58,1152,1153],"Pembrolizumab","CRS Mitigation Strategies",{"nctId":1155,"briefTitle":1156,"status":217,"phases":1157,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":1160,"conditions":1161,"interventions":1163},"NCT04702737","A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer",[89],"2024-07-22","2021-06-10",41,[1162],"Neuroendocrine Prostate Cancer",[58],6,{"trials":1166,"activeCount":193,"soonestReadout":62},[1167,1177,1182],{"nctId":1168,"briefTitle":1169,"status":164,"phases":1170,"primaryCompletion":1171,"completion":1171,"start":1172,"enrollment":1173,"conditions":1174,"interventions":1176},"NCT06745323","A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC",[90],"2029-02-09","2025-02-26",252,[1175],"Small Cell Lung Cancer (SCLC)",[58],{"nctId":60,"briefTitle":61,"status":164,"phases":1178,"primaryCompletion":62,"completion":1179,"start":924,"enrollment":26,"conditions":1180,"interventions":1181},[90],"2027-01-08",[1085],[58],{"nctId":1183,"briefTitle":1184,"status":164,"phases":1185,"primaryCompletion":1186,"completion":1187,"start":1188,"enrollment":1189,"conditions":1190,"interventions":1192},"NCT05060016","A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)",[90],"2026-12-30","2027-12-30","2021-12-01",222,[1191],"Relapsed\u002FRefractory Small Cell Lung Cancer",[58],{"trials":1194,"activeCount":160,"soonestReadout":57},[1195,1205,1217,1229],{"nctId":1196,"briefTitle":1197,"status":164,"phases":1198,"primaryCompletion":1199,"completion":1199,"start":1200,"enrollment":1201,"conditions":1202,"interventions":1204},"NCT06117774","Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)",[91],"2030-04-20","2024-02-20",404,[1203,1097],"Limited Stage Small Cell Lung Cancer",[58],{"nctId":1206,"briefTitle":1207,"status":108,"phases":1208,"primaryCompletion":1209,"completion":1210,"start":1211,"enrollment":1212,"conditions":1213,"interventions":1216},"NCT07005128","A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)",[91],"2029-01-04","2029-07-15","2025-08-18",330,[1214,1215],"Small-cell Lung Cancer","Extensive Stage Small-cell Lung Cancer",[58,1112,1109,1110],{"nctId":1218,"briefTitle":1219,"status":164,"phases":1220,"primaryCompletion":1221,"completion":1222,"start":1223,"enrollment":1224,"conditions":1225,"interventions":1228},"NCT06211036","Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab",[91],"2027-07-05","2028-09-30","2024-06-05",563,[1226,1227],"Extensive-Stage Small-Cell Lung Cancer","Small-Cell Lung Cancer",[58,1112],{"nctId":55,"briefTitle":56,"status":164,"phases":1230,"primaryCompletion":57,"completion":1231,"start":1232,"enrollment":1233,"conditions":1234,"interventions":1235},[91],"2028-03-26","2023-05-31",509,[1175],[58,1236,1237,1238],"Lurbinectedin","Topotecan","Amrubicin",{"trials":1240,"activeCount":100},[],{"trials":1242,"activeCount":100},[1243],{"nctId":1244,"briefTitle":1245,"status":1246,"phases":1247,"conditions":1248,"interventions":1249},"NCT06064500","Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer","APPROVED_FOR_MARKETING",[],[1097],[58],{"intervention":1152,"totalTrials":1070,"cells":1251},{"EARLY_PHASE1":1252,"PHASE1":1254,"PHASE2":1378,"PHASE3":1405,"PHASE4":1448,"NA":1450},{"trials":1253,"activeCount":100},[],{"trials":1255,"activeCount":325,"soonestReadout":1286},[1256,1270,1282,1293,1308,1330,1341,1352,1362,1374],{"nctId":1257,"briefTitle":1258,"status":336,"phases":1259,"primaryCompletion":1260,"completion":1260,"start":1261,"enrollment":1262,"conditions":1263,"interventions":1266},"NCT03792841","Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC",[89],"2023-06-29","2019-02-05",212,[1264,1265],"Metastatic Castration-resistant Prostate Cancer","Prostate Cancer",[1267,1152,1268,1269],"acapatamab","Etanercept","Cytochrome P450 (CYP) Cocktail",{"nctId":1271,"briefTitle":1272,"status":336,"phases":1273,"primaryCompletion":52,"completion":52,"start":1274,"enrollment":1275,"conditions":1276,"interventions":1278},"NCT05267470","A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)",[89],"2022-03-29",74,[1277],"Squamous-Cell Non-Small-Cell Lung Cancer",[72,1279,1152,1109,1280,1281],"Docetaxel","Paclitaxel","Nab-paclitaxel",{"nctId":1283,"briefTitle":1284,"status":164,"phases":1285,"primaryCompletion":1286,"completion":1286,"start":1287,"enrollment":1288,"conditions":1289,"interventions":1291},"NCT06131398","A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors",[89],"2026-07-21","2024-03-07",77,[1290],"Advanced Solid Tumors",[1292,1152],"AMG 355",{"nctId":1294,"briefTitle":1295,"status":164,"phases":1296,"primaryCompletion":1297,"completion":1298,"start":1299,"enrollment":1300,"conditions":1301,"interventions":1304},"NCT06333951","Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).",[89],"2026-10-31","2026-11-30","2024-09-17",49,[1302,1303],"Thoracic Tumors","Non-small Cell Lung Cancer",[1305,1109,1280,1152,1306,1307],"Anvumetostat","Pemetrexed","Sotorasib",{"nctId":1309,"briefTitle":1310,"status":164,"phases":1311,"primaryCompletion":1312,"completion":1313,"start":1314,"enrollment":1315,"conditions":1316,"interventions":1318},"NCT04185883","Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)",[89],"2026-12-17","2027-12-05","2019-12-17",610,[1290,1317],"Kirsten Rat Sarcoma (KRAS) pG12C Mutation",[1307,1319,1320,1321,1152,1322,1323,1111,1324,1325,1326,1327,1327,1328,1099,1329],"Trametinib","RMC-4630","Afatinib","Panitumumab","Carboplatin, pemetrexed, docetaxel, paclitaxel","Palbociclib","MVASI®","TNO155","IV Chemotherapy","BI 1701963","Everolimus",{"nctId":1331,"briefTitle":1332,"status":217,"phases":1333,"primaryCompletion":1334,"completion":1335,"start":1336,"enrollment":1337,"conditions":1338,"interventions":1340},"NCT03340766","Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)",[89],"2020-11-06","2023-08-14","2018-03-16",31,[1339],"Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)",[117,1152],{"nctId":1342,"briefTitle":1343,"status":217,"phases":1344,"primaryCompletion":1345,"completion":1346,"start":1347,"enrollment":439,"conditions":1348,"interventions":1350},"NCT02626000","Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 \u002F KEYNOTE-137)",[89],"2017-11-02","2020-08-28","2016-04-06",[1349],"Carcinoma of the Head and Neck",[1351,1152],"Talimogene Laherparepvec",{"nctId":1353,"briefTitle":1354,"status":336,"phases":1355,"primaryCompletion":1356,"completion":1356,"start":1357,"enrollment":204,"conditions":1358,"interventions":1360},"NCT04478695","Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia",[89],"2020-10-23","2020-09-29",[1359],"Relapsed or Refractory Acute Myeloid Leukemia",[1361,1152],"AMG 330",{"nctId":1363,"briefTitle":1364,"status":108,"phases":1365,"primaryCompletion":1366,"completion":1367,"start":1368,"enrollment":1369,"conditions":1370,"interventions":1372},"NCT07094113","AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors",[89],"2028-04-18","2031-04-20","2025-07-31",434,[1371],"KRAS Altered Advanced or Metastatic Solid Tumors",[1373,1152,1322],"AMG 410",{"nctId":1142,"briefTitle":1143,"status":164,"phases":1375,"primaryCompletion":1145,"completion":1146,"start":1147,"enrollment":1148,"conditions":1376,"interventions":1377},[89],[1150],[58,1152,1153],{"trials":1379,"activeCount":100},[1380,1394],{"nctId":1381,"briefTitle":1382,"status":217,"phases":1383,"primaryCompletion":1384,"completion":1385,"start":1386,"enrollment":1387,"conditions":1388,"interventions":1393},"NCT02509507","Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611\u002FKeynote-611",[89,90],"2022-02-14","2023-07-11","2016-02-05",127,[1389,1390,1391,1392],"Hepatocellular Carcinoma","Liver Metastases","Cutaneous or Subcutaneous Lymph Node","Liver Tumors",[1351,1152],{"nctId":1395,"briefTitle":1396,"status":217,"phases":1397,"primaryCompletion":1398,"completion":1399,"start":239,"enrollment":1400,"conditions":1401,"interventions":1403},"NCT04068181","Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07\u002FKEYNOTE-A07).",[90],"2021-08-19","2024-02-26",72,[1402],"Melanoma",[1404,1152],"Talimogene laherparepvec",{"trials":1406,"activeCount":193,"soonestReadout":1420},[1407,1416,1426,1437],{"nctId":1408,"briefTitle":1409,"status":336,"phases":1410,"primaryCompletion":1411,"completion":1411,"start":1412,"enrollment":1413,"conditions":1414,"interventions":1415},"NCT02263508","Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma",[91],"2021-03-11","2014-12-08",713,[1402],[1351,1152],{"nctId":1417,"briefTitle":1418,"status":164,"phases":1419,"primaryCompletion":1420,"completion":1420,"start":1421,"enrollment":678,"conditions":1422,"interventions":1424},"NCT06430866","Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)",[91],"2026-12-14","2024-09-12",[1423],"Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)",[1425,1152],"ABP 234",{"nctId":1427,"briefTitle":1428,"status":108,"phases":1429,"primaryCompletion":1430,"completion":1431,"start":1432,"enrollment":1433,"conditions":1434,"interventions":1436},"NCT05920356","A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB\u002FC Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)",[91],"2027-06-30","2032-06-29","2023-11-16",750,[1435],"Non-Small Cell Lung Cancer (NSCLC)",[1307,1152],{"nctId":1438,"briefTitle":1439,"status":164,"phases":1440,"primaryCompletion":1441,"completion":1442,"start":1443,"enrollment":1444,"conditions":1445,"interventions":1447},"NCT06311721","A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer",[91],"2028-01-10","2028-04-24","2024-09-09",315,[1446],"Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer",[1425,1152,1152],{"trials":1449,"activeCount":100},[],{"trials":1451,"activeCount":100},[],{"intervention":1453,"totalTrials":1454,"cells":1455},"Xaluritamig",7,{"EARLY_PHASE1":1456,"PHASE1":1458,"PHASE2":1514,"PHASE3":1516,"PHASE4":1540,"NA":1542},{"trials":1457,"activeCount":100},[],{"trials":1459,"activeCount":325,"soonestReadout":1484},[1460,1470,1480,1492,1504],{"nctId":1461,"briefTitle":1462,"status":108,"phases":1463,"primaryCompletion":1464,"completion":1465,"start":1466,"enrollment":23,"conditions":1467,"interventions":1469},"NCT07493512","Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer",[89],"2028-01-30","2030-07-30","2026-04-28",[1468],"Metastatic Castration-resistant Prostate Cancer (mCRPC)",[1453],{"nctId":1471,"briefTitle":1472,"status":108,"phases":1473,"primaryCompletion":1474,"completion":1474,"start":1475,"enrollment":1476,"conditions":1477,"interventions":1479},"NCT07297979","Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)",[89],"2030-05-26","2026-04-08",50,[1478],"Ewing Sarcoma",[1453],{"nctId":1481,"briefTitle":1482,"status":164,"phases":1483,"primaryCompletion":1484,"completion":1485,"start":1486,"enrollment":1476,"conditions":1487,"interventions":1491},"NCT06555796","Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer",[89],"2026-10-08","2028-12-02","2024-09-23",[1265,1488,1489,1490],"High-risk Biochemical Recurrence","High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer","Non-metastatic Castration-sensitive Prostate Cancer",[1453],{"nctId":1493,"briefTitle":1494,"status":108,"phases":1495,"primaryCompletion":1496,"completion":1497,"start":1498,"enrollment":13,"conditions":1499,"interventions":1501},"NCT07140900","Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer",[89],"2028-03-27","2030-03-30","2025-10-07",[1500],"Metastatic Hormone-sensitive Prostate Cancer (mHSPC)",[1453,1502,1503],"Darolutamide","Abiraterone",{"nctId":1505,"briefTitle":1506,"status":108,"phases":1507,"primaryCompletion":1508,"completion":1509,"start":1510,"enrollment":23,"conditions":1511,"interventions":1512},"NCT06613100","Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer",[89],"2027-01-22","2030-01-23","2024-11-25",[1265],[1453,1513],"GnRH Antagonist",{"trials":1515,"activeCount":100},[],{"trials":1517,"activeCount":985,"soonestReadout":1533},[1518,1529],{"nctId":1519,"briefTitle":1520,"status":108,"phases":1521,"primaryCompletion":1522,"completion":1523,"start":1524,"enrollment":1433,"conditions":1525,"interventions":1526},"NCT07213674","A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer",[91],"2030-01-07","2032-08-30","2025-11-28",[1264],[1453,1527,1279,1528],"Abiraterone acetate","Cabazitaxel",{"nctId":1530,"briefTitle":1531,"status":164,"phases":1532,"primaryCompletion":1533,"completion":1534,"start":1535,"enrollment":1536,"conditions":1537,"interventions":1538},"NCT06691984","Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)",[91],"2029-01-02","2029-07-30","2024-12-09",707,[1264],[1453,1503,1539,1528],"Enzalutamide",{"trials":1541,"activeCount":100},[],{"trials":1543,"activeCount":100},[],{"intervention":117,"totalTrials":1545,"cells":1546},27,{"EARLY_PHASE1":1547,"PHASE1":1549,"PHASE2":1598,"PHASE3":1740,"PHASE4":1814,"NA":1825},{"trials":1548,"activeCount":100},[],{"trials":1550,"activeCount":100},[1551,1561,1572,1576,1587],{"nctId":1552,"briefTitle":1553,"status":217,"phases":1554,"primaryCompletion":1555,"completion":1556,"start":1557,"enrollment":1164,"conditions":1558,"interventions":1560},"NCT06649006","Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)",[89],"2025-07-30","2025-12-04","2025-01-08",[1559],"B-precursor Acute Lymphoblastic Leukemia",[117],{"nctId":1562,"briefTitle":1563,"status":217,"phases":1564,"primaryCompletion":1565,"completion":1566,"start":1567,"enrollment":1568,"conditions":1569,"interventions":1571},"NCT00274742","Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL",[89],"2011-08","2012-04","2004-06",76,[1570],"Non-Hodgkin's Lymphoma, Relapsed",[117],{"nctId":1331,"briefTitle":1332,"status":217,"phases":1573,"primaryCompletion":1334,"completion":1335,"start":1336,"enrollment":1337,"conditions":1574,"interventions":1575},[89],[1339],[117,1152],{"nctId":1577,"briefTitle":1578,"status":217,"phases":1579,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":1582,"conditions":1583,"interventions":1585},"NCT02961881","A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed\u002FRefractory Indolent Non-Hodgkin's Lymphoma",[89],"2021-09-02","2017-09-18",35,[1584],"Non-Hodgkin's Lymphoma",[1586],"blinatumomab",{"nctId":1588,"briefTitle":1589,"status":217,"phases":1590,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":1593,"conditions":1594,"interventions":1596},"NCT04524455","Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL",[89],"2023-01-24","2020-10-02",17,[1595],"Acute Lymphoblastic Leukemia",[117,1099,1597],"Dexamethasone Premedication",{"trials":1599,"activeCount":160,"soonestReadout":1673},[1600,1610,1621,1632,1641,1645,1657,1669,1680,1689,1699,1709,1720,1730],{"nctId":1601,"briefTitle":1602,"status":217,"phases":1603,"primaryCompletion":1604,"completion":1605,"start":1606,"enrollment":439,"conditions":1607,"interventions":1609},"NCT01209286","Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed\u002FRefractory B-Precursor Acute Lymphoblastic Leukemia (ALL)",[90],"2012-03","2016-10","2010-10",[1608],"B-ALL",[117],{"nctId":1611,"briefTitle":1612,"status":217,"phases":1613,"primaryCompletion":1614,"completion":1615,"start":1616,"enrollment":1617,"conditions":1618,"interventions":1620},"NCT02412306","Study of Blinatumomab in Japanese Patients With Relapsed\u002FRefractory B-precursor Acute Lymphoblastic Leukemia",[89,90],"2019-02-06","2019-07-04","2015-06-04",66,[1619],"Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia",[117],{"nctId":1622,"briefTitle":1623,"status":217,"phases":1624,"primaryCompletion":1625,"completion":1626,"start":1627,"enrollment":1628,"conditions":1629,"interventions":1631},"NCT01207388","Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)",[90],"2014-02","2019-01-07","2010-11",116,[1630],"B-cell Acute Lymphoblastic Leukemia",[117],{"nctId":1633,"briefTitle":1634,"status":217,"phases":1635,"primaryCompletion":1636,"completion":1637,"start":1638,"enrollment":35,"conditions":1639,"interventions":1640},"NCT00560794","Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)",[90],"2009-09","2014-11","2008-01",[1595],[117],{"nctId":106,"briefTitle":107,"status":108,"phases":1642,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":1643,"interventions":1644},[90],[114,115],[48,117],{"nctId":1646,"briefTitle":1647,"status":217,"phases":1648,"primaryCompletion":1649,"completion":1650,"start":608,"enrollment":1651,"conditions":1652,"interventions":1654},"NCT03023878","Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma",[90],"2019-04-04","2019-10-28",47,[1653],"High-risk Diffuse Large B-Cell Lymphoma",[117,1655,1656],"Investigator's Choice Chemotherapy","Dexamethasone",{"nctId":1658,"briefTitle":1659,"status":164,"phases":1660,"primaryCompletion":1661,"completion":1662,"start":1663,"enrollment":1664,"conditions":1665,"interventions":1668},"NCT07134088","A Study of Subcutaneous Blinatumomab in Children With R\u002FR and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia",[89,90],"2028-12-05","2030-06-18","2025-12-08",104,[1666,1667],"Relapsed\u002FRefractory B-Cell Precursor Acute Lymphoblastic Leukemia","Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia",[117],{"nctId":1670,"briefTitle":1671,"status":164,"phases":1672,"primaryCompletion":1673,"completion":1674,"start":1675,"enrollment":340,"conditions":1676,"interventions":1679},"NCT06054113","Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed\u002FRefractory B Precursor Acute Lymphoblastic Leukemia (R\u002FR B-ALL)",[90],"2026-01-05","2027-10-14","2024-07-23",[1677,1678],"B Precursor Acute Lymphoblastic Leukemia","Relapsed\u002FRefractory B Precursor Acute Lymphoblastic Leukemia",[117],{"nctId":1681,"briefTitle":1682,"status":217,"phases":1683,"primaryCompletion":782,"completion":1684,"start":1685,"enrollment":1686,"conditions":1687,"interventions":1688},"NCT01466179","Clinical Study With Blinatumomab in Patients With Relapsed\u002FRefractory B-precursor Acute Lymphoblastic Leukemia (ALL)",[90],"2017-01","2011-12",225,[1595],[117],{"nctId":1690,"briefTitle":1691,"status":217,"phases":1692,"primaryCompletion":1693,"completion":1694,"start":1695,"enrollment":32,"conditions":1696,"interventions":1698},"NCT01741792","Clinical Study With Blinatumomab in Patients With Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma (DLBCL)",[90],"2014-07","2015-09","2012-07",[1697],"Diffuse Large B-cell Lymphoma",[117],{"nctId":1700,"briefTitle":1701,"status":217,"phases":1702,"primaryCompletion":1703,"completion":1704,"start":1705,"enrollment":1706,"conditions":1707,"interventions":1708},"NCT01471782","Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed\u002FRefractory B-precursor Acute Lymphoblastic Leukemia",[89,90],"2014-08","2016-05","2012-01",93,[1595],[117],{"nctId":1710,"briefTitle":1711,"status":164,"phases":1712,"primaryCompletion":1713,"completion":1714,"start":1715,"enrollment":1716,"conditions":1717,"interventions":1719},"NCT04521231","A Study of Subcutaneous Blinatumomab Administration in Participants With R\u002FR and MRD+ B-ALL",[89,90],"2027-11-24","2029-05-25","2021-01-04",181,[1718],"B Cell Precursor Acute Lymphoblastic Leukemia",[117],{"nctId":1721,"briefTitle":1722,"status":336,"phases":1723,"primaryCompletion":1724,"completion":1724,"start":1725,"enrollment":1726,"conditions":1727,"interventions":1729},"NCT03298412","Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)",[90],"2019-09-30","2018-05-23",10,[1728],"High-risk Diffuse Large B-cell Lymphoma",[117],{"nctId":1731,"briefTitle":1732,"status":217,"phases":1733,"primaryCompletion":1734,"completion":1735,"start":1736,"enrollment":20,"conditions":1737,"interventions":1739},"NCT02000427","Blinatumomab in Adults With Relapsed\u002FRefractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia",[90],"2015-05-20","2017-01-06","2014-01-03",[1738],"Relapsed\u002FRefractory Philadelphia Positive B-precursor ALL",[117],{"trials":1741,"activeCount":985,"soonestReadout":1773},[1742,1753,1769,1782,1793,1805],{"nctId":1743,"briefTitle":1744,"status":336,"phases":1745,"primaryCompletion":1746,"completion":1747,"start":1736,"enrollment":1748,"conditions":1749,"interventions":1751},"NCT02013167","Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)",[91],"2015-12-29","2017-03-14",405,[1750],"Relapsed\u002FRefractory B-precursor Acute Lymphoblastic Leukemia",[117,1752],"Standard of Care Chemotherapy",{"nctId":1754,"briefTitle":1755,"status":217,"phases":1756,"primaryCompletion":1757,"completion":1758,"start":760,"enrollment":1759,"conditions":1760,"interventions":1762},"NCT02393859","Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)",[91],"2019-07-17","2022-11-21",111,[1761],"Leukemia, Acute Lymphoblastic",[117,1656,1763,1764,1765,1766,1767,1768],"Vincrisitne","Daunorubicin","Methotrexate","Ifosfamide","PEG-asparaginase","Erwinia-asparaginase",{"nctId":1770,"briefTitle":1771,"status":164,"phases":1772,"primaryCompletion":1773,"completion":1774,"start":1775,"enrollment":1776,"conditions":1777,"interventions":1779},"NCT04994717","Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia",[91],"2029-09-07","2031-05-12","2021-11-02",303,[1778],"Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)",[117,1780,1781],"Low-intensity chemotherapy regimen","SOC chemotherapy regimen",{"nctId":1783,"briefTitle":1784,"status":217,"phases":1785,"primaryCompletion":1786,"completion":1787,"start":1788,"enrollment":1789,"conditions":1790,"interventions":1791},"NCT03476239","Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed\u002FRefractory B-precursor Acute Lymphoblastic Leukemia (ALL)",[91],"2019-08-21","2021-04-08","2017-10-18",121,[1595],[117,1792],"Dexamthasone",{"nctId":1794,"briefTitle":1795,"status":144,"phases":1796,"primaryCompletion":1797,"completion":1798,"start":1799,"enrollment":1800,"conditions":1801,"interventions":1803},"NCT07223190","A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia",[91],"2030-05-10","2033-08-09","2026-06-11",560,[1802],"Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia",[117,117,1804],"HyperCVAD",{"nctId":1806,"briefTitle":1807,"status":217,"phases":1808,"primaryCompletion":1809,"completion":1809,"start":1810,"enrollment":1160,"conditions":1811,"interventions":1813},"NCT02910063","Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed\u002FRefractory (R\u002FR) Aggressive B-Cell NHL",[90,91],"2020-03-12","2017-01-23",[1812],"B-Cell Non Hodgkin Lymphoma",[117],{"trials":1815,"activeCount":100},[1816],{"nctId":1817,"briefTitle":1818,"status":336,"phases":1819,"primaryCompletion":1820,"completion":1821,"start":1822,"enrollment":1726,"conditions":1823,"interventions":1824},"NCT04506086","Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)",[92],"2024-07-04","2024-09-16","2021-08-26",[1559],[117],{"trials":1826,"activeCount":100},[1827],{"nctId":1828,"briefTitle":1829,"status":1830,"phases":1831,"conditions":1832,"interventions":1834},"NCT02187354","Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed\u002FRefractory B-precursor ALL","NO_LONGER_AVAILABLE",[],[1833],"Relapsed\u002FRefractory B-Precursor Acute Lymphoblastic Leukemia",[117],{"intervention":1307,"totalTrials":124,"cells":1836},{"EARLY_PHASE1":1837,"PHASE1":1839,"PHASE2":1899,"PHASE3":1931,"PHASE4":1960,"NA":1962},{"trials":1838,"activeCount":100},[],{"trials":1840,"activeCount":985,"soonestReadout":1297},[1841,1850,1859,1867,1871,1880,1884,1892],{"nctId":1842,"briefTitle":1843,"status":217,"phases":1844,"primaryCompletion":1845,"completion":1845,"start":1846,"enrollment":1070,"conditions":1847,"interventions":1848},"NCT05497557","A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy Volunteers",[89],"2022-09-08","2022-07-14",[222],[1849,1307],"Omeprazole",{"nctId":1851,"briefTitle":1852,"status":217,"phases":1853,"primaryCompletion":1854,"completion":1854,"start":1855,"enrollment":231,"conditions":1856,"interventions":1858},"NCT05045638","Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants",[89],"2021-10-10","2021-08-20",[1857],"Healthy Participants",[634,1307],{"nctId":1860,"briefTitle":1861,"status":217,"phases":1862,"primaryCompletion":1863,"completion":1863,"start":686,"enrollment":1864,"conditions":1865,"interventions":1866},"NCT05327491","A Study in Healthy Volunteers to Compare the Pharmacokinetics of Sotorasib Administered as 1 or 2 Tablets",[89],"2022-07-17",146,[1857],[1307],{"nctId":1294,"briefTitle":1295,"status":164,"phases":1868,"primaryCompletion":1297,"completion":1298,"start":1299,"enrollment":1300,"conditions":1869,"interventions":1870},[89],[1302,1303],[1305,1109,1280,1152,1306,1307],{"nctId":1872,"briefTitle":1873,"status":217,"phases":1874,"primaryCompletion":1875,"completion":1875,"start":1876,"enrollment":1877,"conditions":1878,"interventions":1879},"NCT05048784","A Study to Compare the Pharmacokinetics of Two Different Tablets of Sotorasib in Healthy Participants",[89],"2022-02-18","2021-08-16",145,[1857],[1307],{"nctId":1309,"briefTitle":1310,"status":164,"phases":1881,"primaryCompletion":1312,"completion":1313,"start":1314,"enrollment":1315,"conditions":1882,"interventions":1883},[89],[1290,1317],[1307,1319,1320,1321,1152,1322,1323,1111,1324,1325,1326,1327,1327,1328,1099,1329],{"nctId":1885,"briefTitle":1886,"status":217,"phases":1887,"primaryCompletion":1888,"completion":1888,"start":1889,"enrollment":305,"conditions":1890,"interventions":1891},"NCT04887064","Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment",[89],"2022-03-09","2021-04-22",[255],[1307],{"nctId":1893,"briefTitle":1894,"status":131,"phases":1895,"primaryCompletion":1443,"completion":1443,"start":1896,"enrollment":100,"conditions":1897,"interventions":1898},"NCT06061523","A Clinical Trial to Evaluate Bioavailability and Effect of Food for Sotorasib in Healthy Participants",[89],"2024-07-15",[1857],[1307],{"trials":1900,"activeCount":985,"soonestReadout":1923},[1901,1910,1919],{"nctId":1902,"briefTitle":1903,"status":108,"phases":1904,"primaryCompletion":1905,"completion":1905,"start":1906,"enrollment":1907,"conditions":1908,"interventions":1909},"NCT07172919","A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation",[90],"2028-01-02","2026-01-02",14,[1290],[1307,1322],{"nctId":1911,"briefTitle":1912,"status":217,"phases":1913,"primaryCompletion":1914,"completion":1914,"start":1915,"enrollment":1916,"conditions":1917,"interventions":1918},"NCT04933695","A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment",[90],"2025-05-27","2022-01-28",42,[1303],[1307],{"nctId":1920,"briefTitle":1921,"status":164,"phases":1922,"primaryCompletion":1923,"completion":1923,"start":1924,"enrollment":1413,"conditions":1925,"interventions":1927},"NCT03600883","A Phase 1\u002F2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)",[89,90],"2026-05-30","2018-08-27",[1926],"KRAS p.G12C Mutant Advanced Solid Tumors",[1928,1929,1930],"sotorasib","Anti PD-1\u002FL1","Midazolam",{"trials":1932,"activeCount":985,"soonestReadout":1430},[1933,1945,1956],{"nctId":1934,"briefTitle":1935,"status":108,"phases":1936,"primaryCompletion":1937,"completion":1938,"start":1939,"enrollment":1940,"conditions":1941,"interventions":1942},"NCT06252649","Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation",[91],"2028-01-31","2031-08-31","2024-07-17",450,[37],[1943,1307,1322,1944],"FOLFIRI Regimen","Bevacizumab-awwb",{"nctId":1946,"briefTitle":1947,"status":217,"phases":1948,"primaryCompletion":111,"completion":1949,"start":1950,"enrollment":579,"conditions":1951,"interventions":1953},"NCT05198934","Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation",[91],"2026-04-14","2022-04-19",[1952],"Colorectal Cancer (CRC)",[1307,1322,1954,1955],"Trifluridine and Tipiracil","Regorafenib",{"nctId":1427,"briefTitle":1428,"status":108,"phases":1957,"primaryCompletion":1430,"completion":1431,"start":1432,"enrollment":1433,"conditions":1958,"interventions":1959},[91],[1435],[1307,1152],{"trials":1961,"activeCount":100},[],{"trials":1963,"activeCount":100},[1964],{"nctId":1965,"briefTitle":1966,"status":217,"phases":1967,"primaryCompletion":1968,"completion":1968,"start":1969,"enrollment":414,"conditions":1970,"interventions":1972},"NCT07143513","Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients",[],"2025-12-07","2025-08-11",[1971],"Non-Small Cell Lung Cancer",[1307],{"intervention":1112,"totalTrials":325,"cells":1974},{"EARLY_PHASE1":1975,"PHASE1":1977,"PHASE2":1991,"PHASE3":1993,"PHASE4":2003,"NA":2005},{"trials":1976,"activeCount":100},[],{"trials":1978,"activeCount":193,"soonestReadout":1135},[1979,1983,1987],{"nctId":1101,"briefTitle":1102,"status":164,"phases":1980,"primaryCompletion":1104,"completion":1104,"start":1105,"enrollment":1106,"conditions":1981,"interventions":1982},[89],[1085],[58,1109,1110,1111,1112],{"nctId":1114,"briefTitle":1115,"status":164,"phases":1984,"primaryCompletion":1117,"completion":1117,"start":1118,"enrollment":29,"conditions":1985,"interventions":1986},[89],[1097],[1121,58,1112],{"nctId":1132,"briefTitle":1133,"status":108,"phases":1988,"primaryCompletion":1135,"completion":1136,"start":1137,"enrollment":579,"conditions":1989,"interventions":1990},[89],[1097],[1140,58,1112],{"trials":1992,"activeCount":100},[],{"trials":1994,"activeCount":985,"soonestReadout":1221},[1995,1999],{"nctId":1206,"briefTitle":1207,"status":108,"phases":1996,"primaryCompletion":1209,"completion":1210,"start":1211,"enrollment":1212,"conditions":1997,"interventions":1998},[91],[1214,1215],[58,1112,1109,1110],{"nctId":1218,"briefTitle":1219,"status":164,"phases":2000,"primaryCompletion":1221,"completion":1222,"start":1223,"enrollment":1224,"conditions":2001,"interventions":2002},[91],[1226,1227],[58,1112],{"trials":2004,"activeCount":100},[],{"trials":2006,"activeCount":100},[],{"intervention":82,"totalTrials":1160,"cells":2008},{"EARLY_PHASE1":2009,"PHASE1":2011,"PHASE2":2057,"PHASE3":2141,"PHASE4":2315,"NA":2356},{"trials":2010,"activeCount":100},[],{"trials":2012,"activeCount":100},[2013,2023,2032,2038,2048],{"nctId":2014,"briefTitle":2015,"status":217,"phases":2016,"primaryCompletion":2017,"completion":2018,"start":2019,"enrollment":439,"conditions":2020,"interventions":2022},"NCT01634191","Effects of Age and Sex on the Pharmacokinetics of Apremilast in Healthy Adults",[89],"2012-03-01","2012-04-01","2012-02-01",[2021],"Healthy Volunteer",[82],{"nctId":2024,"briefTitle":2025,"status":217,"phases":2026,"primaryCompletion":730,"completion":730,"start":2027,"enrollment":2028,"conditions":2029,"interventions":2030},"NCT02641353","Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral Suspension",[89],"2016-01-05",34,[222],[82,2031],"Apremilast Oral Suspension",{"nctId":2033,"briefTitle":2034,"status":217,"phases":2035,"primaryCompletion":2017,"completion":2017,"start":2019,"enrollment":17,"conditions":2036,"interventions":2037},"NCT01634178","Effect of Food on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Adults",[89],[2021],[82],{"nctId":2039,"briefTitle":2040,"status":217,"phases":2041,"primaryCompletion":2042,"completion":2042,"start":2043,"enrollment":2044,"conditions":2045,"interventions":2047},"NCT02802735","Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Apremilast in Healthy Adult Male Korean Subjects",[89],"2016-08-05","2016-06-22",28,[2046],"Pharmacokinetics",[82],{"nctId":2049,"briefTitle":2050,"status":217,"phases":2051,"primaryCompletion":2018,"completion":2018,"start":2019,"enrollment":35,"conditions":2052,"interventions":2054},"NCT01561963","A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast",[89],[2053],"Healthy Subjects",[82,2055,2056],"Rifampin Oral","Rifampin IV Solution",{"trials":2058,"activeCount":100},[2059,2070,2080,2091,2100,2109,2119,2130],{"nctId":2060,"briefTitle":2061,"status":217,"phases":2062,"primaryCompletion":2063,"completion":2064,"start":2065,"enrollment":2066,"conditions":2067,"interventions":2069},"NCT02289417","Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis",[90],"2017-09-25","2019-06-03","2015-01-08",170,[2068],"Ulcerative Colitis",[82],{"nctId":2071,"briefTitle":2072,"status":217,"phases":2073,"primaryCompletion":2074,"completion":2074,"start":2075,"enrollment":2076,"conditions":2077,"interventions":2079},"NCT00456092","Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis",[90],"2009-05-09","2007-03-05",204,[2078],"Psoriatic Arthritis",[82],{"nctId":2081,"briefTitle":2082,"status":217,"phases":2083,"primaryCompletion":2084,"completion":2085,"start":2086,"enrollment":1337,"conditions":2087,"interventions":2090},"NCT00521339","Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis",[90],"2009-04-01","2009-05-01","2007-08-01",[2088,2089],"Psoriasis-Type Psoriasis","Plaque-Type Psoriasis",[82],{"nctId":2092,"briefTitle":2093,"status":217,"phases":2094,"primaryCompletion":2095,"completion":2095,"start":2096,"enrollment":1759,"conditions":2097,"interventions":2099},"NCT00866359","A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease",[90],"2012-05-01","2009-08-01",[2098],"Behcet Syndrome",[82],{"nctId":2101,"briefTitle":2102,"status":217,"phases":2103,"primaryCompletion":2104,"completion":2105,"start":2106,"enrollment":1916,"conditions":2107,"interventions":2108},"NCT02576678","A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis",[90],"2017-09-04","2019-07-29","2015-10-13",[22],[82],{"nctId":2110,"briefTitle":2111,"status":217,"phases":2112,"primaryCompletion":2113,"completion":2114,"start":781,"enrollment":2115,"conditions":2116,"interventions":2118},"NCT02087943","Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis",[90],"2015-10","2016-02",191,[2117],"Dermatitis, Atopic Dermatitis",[82,82],{"nctId":2120,"briefTitle":2121,"status":217,"phases":2122,"primaryCompletion":2123,"completion":2124,"start":2125,"enrollment":2126,"conditions":2127,"interventions":2129},"NCT04057937","A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis",[90],"2021-01-18","2021-06-07","2019-10-16",90,[2128],"Palmoplantaris Pustulosis",[82],{"nctId":2131,"briefTitle":2132,"status":217,"phases":2133,"primaryCompletion":2134,"completion":2135,"start":2136,"enrollment":2137,"conditions":2138,"interventions":2140},"NCT01988103","Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis",[90],"2014-11-20","2015-12-15","2013-07-09",254,[22,2078,2139],"Psoriasis Arthropatica",[82,82],{"trials":2142,"activeCount":325,"soonestReadout":81},[2143,2155,2161,2171,2181,2191,2202,2212,2223,2232,2241,2251,2260,2271,2275,2285,2295,2306],{"nctId":2144,"briefTitle":2145,"status":217,"phases":2146,"primaryCompletion":2147,"completion":2148,"start":2149,"enrollment":2150,"conditions":2151,"interventions":2153},"NCT01194219","Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis",[91],"2012-02-23","2016-11-22","2010-09-09",844,[2152],"Plaque Psoriasis",[82,2154],"Topical treatments or phototherapy",{"nctId":79,"briefTitle":80,"status":164,"phases":2156,"primaryCompletion":81,"completion":2157,"start":2158,"enrollment":1593,"conditions":2159,"interventions":2160},[91],"2026-09-06","2023-01-25",[2152],[82],{"nctId":2162,"briefTitle":2163,"status":217,"phases":2164,"primaryCompletion":2165,"completion":2166,"start":2167,"enrollment":2168,"conditions":2169,"interventions":2170},"NCT03777436","An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis",[91],"2021-09-23","2022-02-09","2019-02-11",289,[22],[82],{"nctId":2172,"briefTitle":2173,"status":217,"phases":2174,"primaryCompletion":2175,"completion":2176,"start":2177,"enrollment":2178,"conditions":2179,"interventions":2180},"NCT01232283","Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.",[91],"2012-03-15","2016-11-30","2010-11-22",413,[2152],[82],{"nctId":2182,"briefTitle":2183,"status":217,"phases":2184,"primaryCompletion":2185,"completion":2186,"start":2187,"enrollment":2188,"conditions":2189,"interventions":2190},"NCT03701763","Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis",[91],"2022-04-25","2023-03-27","2018-12-19",245,[22],[82],{"nctId":2192,"briefTitle":2193,"status":108,"phases":2194,"primaryCompletion":2195,"completion":2195,"start":2196,"enrollment":2197,"conditions":2198,"interventions":2201},"NCT05767047","A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis",[91],"2036-03-17","2023-03-23",48,[2199,2200],"Behçet's Disease","Juvenile Psoriatic Arthritis",[82],{"nctId":2203,"briefTitle":2204,"status":217,"phases":2205,"primaryCompletion":2063,"completion":2206,"start":2207,"enrollment":2208,"conditions":2209,"interventions":2211},"NCT02307513","A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease",[91],"2020-07-17","2014-12-30",207,[2210],"Behçet's Syndrome",[82],{"nctId":2213,"briefTitle":2214,"status":217,"phases":2215,"primaryCompletion":2216,"completion":2217,"start":2218,"enrollment":2219,"conditions":2220,"interventions":2221},"NCT06122649","A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)",[91],"2025-02-28","2025-12-05","2023-11-27",203,[2152],[2222],"apremilast",{"nctId":2224,"briefTitle":2225,"status":217,"phases":2226,"primaryCompletion":2227,"completion":2228,"start":2229,"enrollment":579,"conditions":2230,"interventions":2231},"NCT04175613","A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis",[91],"2025-10-30","2025-12-12","2019-12-20",[22],[82],{"nctId":2233,"briefTitle":2234,"status":217,"phases":2235,"primaryCompletion":2236,"completion":2237,"start":2238,"enrollment":994,"conditions":2239,"interventions":2240},"NCT01690299","Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis",[91],"2014-07-03","2016-04-04","2012-10-01",[22,2078],[82,1268],{"nctId":2242,"briefTitle":2243,"status":108,"phases":2244,"primaryCompletion":2245,"completion":2246,"start":2247,"enrollment":13,"conditions":2248,"interventions":2250},"NCT04804553","Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis",[91],"2028-03-21","2028-12-29","2022-03-17",[2249],"Active Juvenile Psoriatic Arthritis",[82],{"nctId":2252,"briefTitle":2253,"status":164,"phases":2254,"primaryCompletion":2255,"completion":2255,"start":2256,"enrollment":2257,"conditions":2258,"interventions":2259},"NCT06088199","A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis",[91],"2026-08-06","2023-10-24",51,[2152],[82],{"nctId":2261,"briefTitle":2262,"status":217,"phases":2263,"primaryCompletion":2264,"completion":2265,"start":2266,"enrollment":2267,"conditions":2268,"interventions":2270},"NCT05174065","Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)",[91],"2023-08-19","2024-06-01","2022-03-08",176,[2269],"Palmoplantar Pustulosis",[82],{"nctId":348,"briefTitle":349,"status":217,"phases":2272,"primaryCompletion":351,"completion":351,"start":352,"enrollment":353,"conditions":2273,"interventions":2274},[91],[355],[357,82,358,359,360,361,362],{"nctId":2276,"briefTitle":2277,"status":217,"phases":2278,"primaryCompletion":2279,"completion":2280,"start":2281,"enrollment":2282,"conditions":2283,"interventions":2284},"NCT03721172","Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy",[91],"2020-03-06","2020-07-24","2019-03-11",595,[22],[82],{"nctId":2286,"briefTitle":2287,"status":108,"phases":2288,"primaryCompletion":2289,"completion":2290,"start":2291,"enrollment":13,"conditions":2292,"interventions":2294},"NCT04528082","Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease",[91],"2030-02-07","2030-12-17","2021-09-09",[2293],"Behçet Disease",[82],{"nctId":2296,"briefTitle":2297,"status":217,"phases":2298,"primaryCompletion":2299,"completion":2300,"start":2301,"enrollment":2302,"conditions":2303,"interventions":2304},"NCT03930186","A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy",[91],"2020-05-08","2020-09-25","2019-06-17",152,[2152],[82,2305],"Topical Therapy",{"nctId":2307,"briefTitle":2308,"status":217,"phases":2309,"primaryCompletion":2310,"completion":2311,"start":2312,"enrollment":1776,"conditions":2313,"interventions":2314},"NCT03123471","A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp",[91],"2018-08-13","2019-01-09","2017-05-16",[22],[82],{"trials":2316,"activeCount":100},[2317,2326,2336,2346],{"nctId":2318,"briefTitle":2319,"status":217,"phases":2320,"primaryCompletion":2321,"completion":2322,"start":1614,"enrollment":2323,"conditions":2324,"interventions":2325},"NCT03783026","A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis",[92],"2021-10-26","2022-05-11",123,[2078],[82],{"nctId":2327,"briefTitle":2328,"status":217,"phases":2329,"primaryCompletion":2330,"completion":2148,"start":2331,"enrollment":2332,"conditions":2333,"interventions":2335},"NCT02425826","A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.",[92],"2016-02-12","2015-04-20",221,[2334],"Parapsoriasis",[82],{"nctId":2337,"briefTitle":2338,"status":217,"phases":2339,"primaryCompletion":2340,"completion":2341,"start":2342,"enrollment":2343,"conditions":2344,"interventions":2345},"NCT03774875","A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life",[92],"2021-02-01","2021-11-03","2019-03-28",277,[22],[82],{"nctId":2347,"briefTitle":2348,"status":217,"phases":2349,"primaryCompletion":2350,"completion":2351,"start":2352,"enrollment":540,"conditions":2353,"interventions":2355},"NCT03747939","Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.",[92],"2022-12-19","2023-07-05","2018-12-31",[2354],"Arthritis, Psoriatic",[82],{"trials":2357,"activeCount":100},[2358,2366,2375,2385,2393,2402],{"nctId":2359,"briefTitle":2360,"status":217,"phases":2361,"primaryCompletion":2362,"completion":2362,"start":1614,"enrollment":2363,"conditions":2364,"interventions":2365},"NCT03828045","A Study to Evaluate the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological Treatment",[],"2021-10-20",119,[2354],[82],{"nctId":2367,"briefTitle":2368,"status":217,"phases":2369,"primaryCompletion":2370,"completion":2370,"start":2371,"enrollment":2372,"conditions":2373,"interventions":2374},"NCT03097003","A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium",[],"2018-12-20","2017-04-06",124,[22],[82],{"nctId":2376,"briefTitle":2377,"status":217,"phases":2378,"primaryCompletion":2379,"completion":2380,"start":2381,"enrollment":2382,"conditions":2383,"interventions":2384},"NCT03757013","A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France",[],"2021-07-21","2021-09-10","2018-09-25",453,[22],[82],{"nctId":2386,"briefTitle":2387,"status":217,"phases":2388,"primaryCompletion":2389,"completion":2389,"start":2390,"enrollment":1106,"conditions":2391,"interventions":2392},"NCT04031027","A Study to Describe the Characteristics of Patients Treated With Apremilast for Plaque Psoriasis in Italian Routine Clinical Practice",[],"2021-01-27","2019-07-22",[2152],[82],{"nctId":2394,"briefTitle":2395,"status":217,"phases":2396,"primaryCompletion":2397,"completion":2398,"start":2399,"enrollment":414,"conditions":2400,"interventions":2401},"NCT03608657","Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE)",[],"2021-04-12","2022-03-30","2018-07-31",[2354],[82],{"nctId":2403,"briefTitle":2404,"status":217,"phases":2405,"primaryCompletion":2406,"completion":2406,"start":2407,"enrollment":2408,"conditions":2409,"interventions":2410},"NCT03096990","A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium",[],"2018-12-27","2017-04-21",106,[2354],[2222],{"intervention":1322,"totalTrials":2028,"cells":2412},{"EARLY_PHASE1":2413,"PHASE1":2415,"PHASE2":2482,"PHASE3":2668,"PHASE4":2737,"NA":2739},{"trials":2414,"activeCount":100},[],{"trials":2416,"activeCount":985,"soonestReadout":1312},[2417,2430,2434,2443,2447,2456,2469],{"nctId":2418,"briefTitle":2419,"status":217,"phases":2420,"primaryCompletion":2421,"completion":1685,"start":2422,"enrollment":2363,"conditions":2423,"interventions":2426},"NCT00101894","Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer",[89],"2010-04","2004-12",[2424,2425],"Rectal Cancer","Colon Cancer",[2427,2428,1322,2429],"FOLFOX-4","AMG 706","FOLFIRI",{"nctId":1309,"briefTitle":1310,"status":164,"phases":2431,"primaryCompletion":1312,"completion":1313,"start":1314,"enrollment":1315,"conditions":2432,"interventions":2433},[89],[1290,1317],[1307,1319,1320,1321,1152,1322,1323,1111,1324,1325,1326,1327,1327,1328,1099,1329],{"nctId":2435,"briefTitle":2436,"status":217,"phases":2437,"primaryCompletion":2438,"completion":2438,"start":2439,"enrollment":1337,"conditions":2440,"interventions":2442},"NCT00658658","Panitumumab in Children With Solid Tumors",[89],"2015-03","2008-03",[2441],"Solid Tumors",[1322],{"nctId":1363,"briefTitle":1364,"status":108,"phases":2444,"primaryCompletion":1366,"completion":1367,"start":1368,"enrollment":1369,"conditions":2445,"interventions":2446},[89],[1371],[1373,1152,1322],{"nctId":2448,"briefTitle":2449,"status":217,"phases":2450,"primaryCompletion":2451,"completion":2452,"start":2439,"enrollment":2044,"conditions":2453,"interventions":2454},"NCT00563316","Effect of Panitumumab on the Pharmacokinetics of Irinotecan",[89],"2009-03","2010-06",[37],[1322,2455],"Irinotecan",{"nctId":2457,"briefTitle":2458,"status":336,"phases":2459,"primaryCompletion":2460,"completion":2461,"start":2422,"enrollment":1160,"conditions":2462,"interventions":2466},"NCT00101907","Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer",[89],"2007-06","2008-04",[2463,2464,2465],"Lung Cancer","Pancreatic Cancer","Esophageal Cancer",[2428,1322,2467,2468],"Gemcitabine","Cisplatin",{"nctId":2470,"briefTitle":2471,"status":217,"phases":2472,"primaryCompletion":2473,"completion":2474,"start":2475,"enrollment":2476,"conditions":2477,"interventions":2480},"NCT00091806","Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors",[89],"2006-04","2006-10","2004-08",86,[2478,2479,2441],"Tumors","Oncology",[2481,1322],"panitumumab",{"trials":2483,"activeCount":204,"soonestReadout":1905},[2484,2495,2504,2508,2520,2536,2546,2556,2566,2574,2582,2590,2597,2606,2618,2626,2638,2647,2657],{"nctId":2485,"briefTitle":2486,"status":217,"phases":2487,"primaryCompletion":2488,"completion":2488,"start":2489,"enrollment":2490,"conditions":2491,"interventions":2493},"NCT00756444","A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and\u002For Recurrent Squamous Cell Carcinoma of the Head and Neck",[90],"2012-03-30","2008-10-21",67,[2492],"Squamous Cell Carcinoma of Head and Neck",[1322,2468,2494],"5FU",{"nctId":2496,"briefTitle":2497,"status":217,"phases":2498,"primaryCompletion":2499,"completion":1627,"start":1638,"enrollment":2500,"conditions":2501,"interventions":2502},"NCT00630786","Conatumumab\u002FPanitumumab Combination Metastatic Colorectal Cancer Study",[89,90],"2009-05",53,[2425,34,2424,37,2479],[1322,2503],"Conatumumab",{"nctId":1902,"briefTitle":1903,"status":108,"phases":2505,"primaryCompletion":1905,"completion":1905,"start":1906,"enrollment":1907,"conditions":2506,"interventions":2507},[90],[1290],[1307,1322],{"nctId":2509,"briefTitle":2510,"status":217,"phases":2511,"primaryCompletion":1638,"completion":2512,"start":2473,"enrollment":2513,"conditions":2514,"interventions":2517},"NCT00332163","Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy",[90],"2008-09",95,[37,2515,2516,2425,34],"Skin Rash","Skin Toxicities",[1322,2455,2429,2518,2519],"Pre-emptive Skin Treatment","Reactive Skin Treatment",{"nctId":2521,"briefTitle":2522,"status":217,"phases":2523,"primaryCompletion":2524,"completion":2525,"start":2526,"enrollment":2527,"conditions":2528,"interventions":2535},"NCT00446446","PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)",[90],"2010-12-15","2017-11-29","2007-10-30",52,[25,2529,2530,2531,2532,2533,2479,2534,2478],"Carcinoma","Head and Neck Cancer","Metastases","Metastatic Cancer","Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck","Squamous Cell Carcinoma",[1322],{"nctId":2537,"briefTitle":2538,"status":217,"phases":2539,"primaryCompletion":2540,"completion":2541,"start":2542,"enrollment":2543,"conditions":2544,"interventions":2545},"NCT00083616","Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy",[90],"2007-05","2008-12","2004-03",185,[34,2532],[1322],{"nctId":2547,"briefTitle":2548,"status":217,"phases":2549,"primaryCompletion":2550,"completion":2551,"start":2552,"enrollment":2553,"conditions":2554,"interventions":2555},"NCT00508404","Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer",[90],"2009-06-01","2012-06-12","2007-05-09",154,[37],[1322,2429],{"nctId":2557,"briefTitle":2558,"status":217,"phases":2559,"primaryCompletion":2560,"completion":2561,"start":2562,"enrollment":2563,"conditions":2564,"interventions":2565},"NCT00454779","PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response",[90],"2012-06-11","2014-01-01","2007-01-01",113,[2533],[2468,1322,1279,2468,1279],{"nctId":2567,"briefTitle":2568,"status":217,"phases":2569,"primaryCompletion":2570,"completion":2439,"start":2542,"enrollment":1337,"conditions":2571,"interventions":2573},"NCT00425204","Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment",[90],"2007-09",[34,1971,1265,2441,2572],"Advanced Renal Cell Carcinoma",[1322],{"nctId":2575,"briefTitle":2576,"status":217,"phases":2577,"start":2578,"enrollment":2579,"conditions":2580,"interventions":2581},"NCT00425035","Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2",[90],"2003-02",115,[2572],[1322],{"nctId":2583,"briefTitle":2584,"status":217,"phases":2585,"primaryCompletion":2586,"completion":1606,"start":2587,"enrollment":1628,"conditions":2588,"interventions":2589},"NCT00411450","Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment",[90],"2009-01","2006-11",[2425,34,2424,25,2532,37,2479],[1322,2429],{"nctId":2591,"briefTitle":2592,"status":217,"phases":2593,"primaryCompletion":1685,"completion":1604,"start":2594,"enrollment":2302,"conditions":2595,"interventions":2596},"NCT00547157","Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck",[90],"2007-11",[25,2530,2479,2534],[1322,2468],{"nctId":2598,"briefTitle":2599,"status":217,"phases":2600,"primaryCompletion":2601,"completion":2601,"start":2602,"enrollment":2257,"conditions":2603,"interventions":2604},"NCT00094835","Study to Evaluate Motesanib With or Without Carboplatin\u002FPaclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)",[89,90],"2007-03","2005-01",[2463,1971],[1322,2605,1280,1109],"Motesanib diphosphate",{"nctId":2607,"briefTitle":2608,"status":217,"phases":2609,"primaryCompletion":2610,"completion":2611,"start":2612,"enrollment":2613,"conditions":2614,"interventions":2615},"NCT00819780","PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors",[90],"2012-05-30","2016-07-07","2009-04-24",285,[2425,34,2424,37],[1322,2616,2617],"Bevacizumab","mFOLFOX6",{"nctId":2619,"briefTitle":2620,"status":217,"phases":2621,"primaryCompletion":2562,"completion":2622,"start":2623,"enrollment":2219,"conditions":2624,"interventions":2625},"NCT00089635","Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer",[90],"2008-08-01","2004-08-01",[34,2531],[1322],{"nctId":2627,"briefTitle":2628,"status":217,"phases":2629,"primaryCompletion":2630,"completion":2631,"start":2632,"enrollment":2633,"conditions":2634,"interventions":2635},"NCT00418938","SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial",[90],"2012-05-10","2013-04-01","2006-11-01",266,[25,2425,34,2532,2424,37],[1322,2616,2636,2455,2637],"Leucovorin","5-Fluorouracil",{"nctId":2639,"briefTitle":2640,"status":217,"phases":2641,"primaryCompletion":2642,"completion":2643,"start":2644,"enrollment":380,"conditions":2645,"interventions":2646},"NCT00111761","Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer",[90],"2008-02","2008-10","2002-07",[34],[2455,1322,2637,2636],{"nctId":2648,"briefTitle":2649,"status":217,"phases":2650,"primaryCompletion":2651,"completion":2652,"start":2653,"enrollment":2654,"conditions":2655,"interventions":2656},"NCT00500760","Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer",[90],"2011-03-29","2011-04-26","2007-10-01",153,[2530,2534],[2468,1322],{"nctId":2658,"briefTitle":2659,"status":336,"phases":2660,"primaryCompletion":2661,"completion":2661,"start":2662,"enrollment":193,"conditions":2663,"interventions":2667},"NCT00613730","Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint",[90],"2009-04","2007-01",[2664,2665,2666,2464],"Cancer of Pancreas","Cancer of the Pancreas","Pancreas Cancer",[2467,2481],{"trials":2669,"activeCount":204,"soonestReadout":1937},[2670,2674,2685,2689,2700,2710,2719,2728],{"nctId":1934,"briefTitle":1935,"status":108,"phases":2671,"primaryCompletion":1937,"completion":1938,"start":1939,"enrollment":1940,"conditions":2672,"interventions":2673},[91],[37],[1943,1307,1322,1944],{"nctId":2675,"briefTitle":2676,"status":217,"phases":2677,"primaryCompletion":2678,"completion":2679,"start":2680,"enrollment":2681,"conditions":2682,"interventions":2683},"NCT01001377","ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer",[91],"2013-02-05","2017-03-07","2010-02-02",1010,[37],[2684,1322],"Cetuximab",{"nctId":1946,"briefTitle":1947,"status":217,"phases":2686,"primaryCompletion":111,"completion":1949,"start":1950,"enrollment":579,"conditions":2687,"interventions":2688},[91],[1952],[1307,1322,1954,1955],{"nctId":2690,"briefTitle":2691,"status":217,"phases":2692,"primaryCompletion":2693,"completion":2085,"start":2694,"enrollment":2695,"conditions":2696,"interventions":2697},"NCT00115765","PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study",[91],"2007-05-31","2005-06-01",1053,[34],[2698,1322,2699,2616],"Oxaliplatin Based Chemotherapy","Irinotecan Based Chemotherapy",{"nctId":2701,"briefTitle":2702,"status":217,"phases":2703,"primaryCompletion":2096,"completion":2704,"start":2705,"enrollment":2706,"conditions":2707,"interventions":2708},"NCT00364013","PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy",[91],"2013-03-22","2006-08-01",1183,[37],[1322,2709],"FOLFOX regimen",{"nctId":2711,"briefTitle":2712,"status":217,"phases":2713,"primaryCompletion":2714,"completion":2550,"start":2715,"enrollment":2716,"conditions":2717,"interventions":2718},"NCT00113763","Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer",[91],"2008-10-01","2004-01-01",463,[34,2531],[1322],{"nctId":2720,"briefTitle":2721,"status":217,"phases":2722,"primaryCompletion":2084,"completion":2723,"start":2724,"enrollment":2725,"conditions":2726,"interventions":2727},"NCT00339183","Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone",[91],"2010-11-01","2006-06-30",1186,[37],[1322,2429],{"nctId":2729,"briefTitle":2730,"status":217,"phases":2731,"primaryCompletion":781,"completion":2732,"start":2733,"enrollment":2734,"conditions":2735,"interventions":2736},"NCT01412957","Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer",[91],"2016-11","2011-11",377,[37],[1322],{"trials":2738,"activeCount":100},[],{"trials":2740,"activeCount":100},[],{"intervention":1109,"totalTrials":1070,"cells":2742},{"EARLY_PHASE1":2743,"PHASE1":2745,"PHASE2":2759,"PHASE3":2841,"PHASE4":2889,"NA":2891},{"trials":2744,"activeCount":100},[],{"trials":2746,"activeCount":985,"soonestReadout":1297},[2747,2751,2755],{"nctId":1271,"briefTitle":1272,"status":336,"phases":2748,"primaryCompletion":52,"completion":52,"start":1274,"enrollment":1275,"conditions":2749,"interventions":2750},[89],[1277],[72,1279,1152,1109,1280,1281],{"nctId":1294,"briefTitle":1295,"status":164,"phases":2752,"primaryCompletion":1297,"completion":1298,"start":1299,"enrollment":1300,"conditions":2753,"interventions":2754},[89],[1302,1303],[1305,1109,1280,1152,1306,1307],{"nctId":1101,"briefTitle":1102,"status":164,"phases":2756,"primaryCompletion":1104,"completion":1104,"start":1105,"enrollment":1106,"conditions":2757,"interventions":2758},[89],[1085],[58,1109,1110,1111,1112],{"trials":2760,"activeCount":100},[2761,2772,2784,2788,2798,2809,2818,2828],{"nctId":2762,"briefTitle":2763,"status":336,"phases":2764,"primaryCompletion":2765,"completion":2766,"start":2767,"enrollment":2768,"conditions":2769,"interventions":2771},"NCT00369070","A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC",[90],"2008-04-23","2011-08-03","2007-01-31",186,[2770],"Advanced Non-squamous NSCLC",[2616,2428,1280,1109],{"nctId":2773,"briefTitle":2774,"status":217,"phases":2775,"start":2776,"enrollment":2777,"conditions":2778,"interventions":2780},"NCT00034346","ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)",[90],"2002-01",194,[1971,2779,2463],"Neoplasm Metastasis",[2781,2782,2783],"ABX-EGF","paclitaxel","carboplatin",{"nctId":2598,"briefTitle":2599,"status":217,"phases":2785,"primaryCompletion":2601,"completion":2601,"start":2602,"enrollment":2257,"conditions":2786,"interventions":2787},[89,90],[2463,1971],[1322,2605,1280,1109],{"nctId":2789,"briefTitle":2790,"status":217,"phases":2791,"primaryCompletion":2475,"completion":2422,"start":2792,"enrollment":731,"conditions":2793,"interventions":2796},"NCT00117442","A Study of Carboplatin\u002FPaclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood",[90],"2002-08",[2794,2463,2795],"Breast Cancer","Ovarian Cancer",[2783,2782,2797],"pegfilgrastim",{"nctId":2799,"briefTitle":2800,"status":217,"phases":2801,"primaryCompletion":2802,"completion":2802,"start":2803,"enrollment":439,"conditions":2804,"interventions":2806},"NCT01666977","Phase 1b\u002F2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer",[89,90],"2015-11","2012-08",[2805],"Non Small Cell Lung Cancer",[2807,2807,2808,1306,1109],"AMG 386","AMG 386 Placebo",{"nctId":2810,"briefTitle":2811,"status":217,"phases":2812,"primaryCompletion":2451,"completion":2733,"start":2813,"enrollment":2814,"conditions":2815,"interventions":2816},"NCT00508625","A Study of AMG 951 [rhApo2L\u002FTRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +\u002F- Bevacizumab",[90],"2006-06",213,[1971],[2817,2616,1109,1280],"AMG 951",{"nctId":2819,"briefTitle":2820,"status":217,"phases":2821,"primaryCompletion":2822,"completion":2823,"start":2824,"enrollment":26,"conditions":2825,"interventions":2826},"NCT01987232","Phase 1b\u002F2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer",[89,90],"2016-08","2017-05-04","2013-11-05",[1226],[2827,1109,1110],"Carfilzomib",{"nctId":2829,"briefTitle":2830,"status":217,"phases":2831,"primaryCompletion":2541,"completion":2832,"start":2833,"enrollment":2834,"conditions":2835,"interventions":2839},"NCT00413283","Dose\u002F Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)",[90],"2009-02","2006-12",63,[2463,2836,1971,25,2837,2479,2441,2838],"Chemotherapy-Induced Thrombocytopenia","Lung Neoplasms","Thrombocytopenia",[2840,2467,1109,2468],"Romiplostim",{"trials":2842,"activeCount":204,"soonestReadout":1209},[2843,2854,2864,2868,2878],{"nctId":2844,"briefTitle":2845,"status":131,"phases":2846,"primaryCompletion":2847,"completion":2847,"start":2848,"enrollment":100,"conditions":2849,"interventions":2852},"NCT04466917","A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer",[91],"2022-11-13","2021-05-15",[2850,2851],"Metastatic Non-small Cell Lung Cancer (NSCLC)","Non-squamous NSCLC",[2853,2616,1280,1109],"ABP 215",{"nctId":2855,"briefTitle":2856,"status":217,"phases":2857,"primaryCompletion":2858,"completion":2858,"start":2859,"enrollment":2860,"conditions":2861,"interventions":2863},"NCT01966003","Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer",[91],"2015-07-23","2013-11-11",642,[2862],"Non-small Cell Lung Cancer Metastatic",[1109,1280,2853,2616],{"nctId":1206,"briefTitle":1207,"status":108,"phases":2865,"primaryCompletion":1209,"completion":1210,"start":1211,"enrollment":1212,"conditions":2866,"interventions":2867},[91],[1214,1215],[58,1112,1109,1110],{"nctId":2869,"briefTitle":2870,"status":336,"phases":2871,"primaryCompletion":2872,"completion":2873,"start":2874,"enrollment":2875,"conditions":2876,"interventions":2877},"NCT00460317","MONET1-MOtesanib NSCLC Efficacy and Tolerability Study",[91],"2011-03","2013-08","2007-07",1450,[1971],[2428,2782,2783],{"nctId":2879,"briefTitle":2880,"status":336,"phases":2881,"primaryCompletion":2882,"completion":2883,"start":1705,"enrollment":2884,"conditions":2885,"interventions":2888},"NCT01493505","TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer",[91],"2016-03","2016-12",1015,[2886,2795,2887],"Fallopian Tube Cancer","Peritoneal Cancer",[2807,1280,2808,1109],{"trials":2890,"activeCount":100},[],{"trials":2892,"activeCount":100},[],{"intervention":2894,"totalTrials":2895,"cells":2896},"Rocatinlimab",12,{"EARLY_PHASE1":2897,"PHASE1":2911,"PHASE2":2930,"PHASE3":2943,"PHASE4":3019,"NA":3021},{"trials":2898,"activeCount":100},[2899],{"nctId":2900,"briefTitle":2901,"status":217,"phases":2902,"primaryCompletion":2903,"completion":2904,"start":2905,"enrollment":35,"conditions":2906,"interventions":2908},"NCT05891119","Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis",[88],"2024-08-28","2025-02-12","2023-06-03",[2907],"Atopic Dermatitis",[2909,1930,2910,1849,2894],"Metoprolol","Warfarin",{"trials":2912,"activeCount":100},[2913,2922],{"nctId":2914,"briefTitle":2915,"status":217,"phases":2916,"primaryCompletion":2917,"completion":2918,"start":491,"enrollment":2919,"conditions":2920,"interventions":2921},"NCT06438263","A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants",[89],"2025-05-03","2025-07-02",231,[2907],[2894,2894],{"nctId":2923,"briefTitle":2924,"status":217,"phases":2925,"primaryCompletion":2926,"completion":1223,"start":2927,"enrollment":305,"conditions":2928,"interventions":2929},"NCT06214481","A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese Participants",[89],"2024-05-27","2024-01-23",[2907],[2894],{"trials":2931,"activeCount":204,"soonestReadout":2936},[2932],{"nctId":2933,"briefTitle":2934,"status":164,"phases":2935,"primaryCompletion":2936,"completion":2937,"start":2938,"enrollment":2939,"conditions":2940,"interventions":2942},"NCT06376045","A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma",[90],"2026-10-19","2026-12-11","2024-05-24",317,[2941],"Asthma",[2894],{"trials":2944,"activeCount":985,"soonestReadout":3003},[2945,2955,2963,2971,2981,2989,2999,3010],{"nctId":2946,"briefTitle":2947,"status":217,"phases":2948,"primaryCompletion":2949,"completion":2950,"start":2951,"enrollment":2952,"conditions":2953,"interventions":2954},"NCT05398445","A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)",[91],"2024-11-28","2025-01-13","2022-05-31",769,[2907],[2894],{"nctId":2956,"briefTitle":2957,"status":217,"phases":2958,"primaryCompletion":1368,"completion":1368,"start":2959,"enrollment":2960,"conditions":2961,"interventions":2962},"NCT05633355","A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)",[91],"2023-01-30",187,[2907],[2894],{"nctId":2964,"briefTitle":2965,"status":164,"phases":2966,"primaryCompletion":2967,"completion":2967,"start":1232,"enrollment":2968,"conditions":2969,"interventions":2970},"NCT05882877","A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)",[91],"2026-06-22",2621,[2907],[2894],{"nctId":2972,"briefTitle":2973,"status":217,"phases":2974,"primaryCompletion":2975,"completion":2976,"start":2977,"enrollment":2978,"conditions":2979,"interventions":2980},"NCT05724199","A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and\u002For Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)",[91],"2024-09-15","2024-12-04","2023-02-21",746,[2907],[2894],{"nctId":2982,"briefTitle":2983,"status":217,"phases":2984,"primaryCompletion":1223,"completion":924,"start":2985,"enrollment":2986,"conditions":2987,"interventions":2988},"NCT05651711","A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)",[91],"2022-12-14",726,[2907],[2894],{"nctId":2990,"briefTitle":2991,"status":217,"phases":2992,"primaryCompletion":2993,"completion":2994,"start":2995,"enrollment":2332,"conditions":2996,"interventions":2998},"NCT05899816","A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)",[91],"2024-08-26","2024-11-14","2023-06-07",[2907,2997],"Moderate-to-severe Atopic Dermatitis",[2894],{"nctId":3000,"briefTitle":3001,"status":164,"phases":3002,"primaryCompletion":3003,"completion":3004,"start":3005,"enrollment":3006,"conditions":3007,"interventions":3009},"NCT06527404","A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis",[91],"2026-04-17","2027-01-17","2024-07-18",469,[3008],"Prurigo Nodularis",[2894],{"nctId":3011,"briefTitle":3012,"status":217,"phases":3013,"primaryCompletion":3014,"completion":993,"start":3015,"enrollment":3016,"conditions":3017,"interventions":3018},"NCT05704738","A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)",[91],"2025-02-27","2023-04-20",532,[2907],[2894],{"trials":3020,"activeCount":100},[],{"trials":3022,"activeCount":100},[],{"intervention":1279,"totalTrials":1726,"cells":3024},{"EARLY_PHASE1":3025,"PHASE1":3027,"PHASE2":3041,"PHASE3":3095,"PHASE4":3109,"NA":3111},{"trials":3026,"activeCount":100},[],{"trials":3028,"activeCount":100},[3029,3037],{"nctId":3030,"briefTitle":3031,"status":217,"phases":3032,"primaryCompletion":2661,"completion":1705,"start":3033,"enrollment":17,"conditions":3034,"interventions":3036},"NCT00322400","Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer",[89],"2006-03",[3035],"Locally Recurrent and Metastatic Breast Cancer",[1279,1280,2428],{"nctId":1271,"briefTitle":1272,"status":336,"phases":3038,"primaryCompletion":52,"completion":52,"start":1274,"enrollment":1275,"conditions":3039,"interventions":3040},[89],[1277],[72,1279,1152,1109,1280,1281],{"trials":3042,"activeCount":204,"soonestReadout":1298},[3043,3054,3063,3072,3076,3085],{"nctId":3044,"briefTitle":3045,"status":3046,"phases":3047,"start":3048,"conditions":3049,"interventions":3050},"NCT00006215","Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","UNKNOWN",[90],"1999-10",[2463],[3051,3052,3053],"filgrastim","docetaxel","vinorelbine tartrate",{"nctId":3055,"briefTitle":3056,"status":3046,"phases":3057,"start":3048,"conditions":3058,"interventions":3060},"NCT00005960","Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy",[90],[3059,1265],"Pain",[3051,3061,3052,3062],"cyclophosphamide","doxorubicin hydrochloride",{"nctId":3064,"briefTitle":3065,"status":3046,"phases":3066,"start":3048,"conditions":3067,"interventions":3070},"NCT00005958","Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer",[90],[3068,3069],"Bladder Cancer","Transitional Cell Cancer of the Renal Pelvis and Ureter",[3051,3052,3071],"gemcitabine hydrochloride",{"nctId":2557,"briefTitle":2558,"status":217,"phases":3073,"primaryCompletion":2560,"completion":2561,"start":2562,"enrollment":2563,"conditions":3074,"interventions":3075},[90],[2533],[2468,1322,1279,2468,1279],{"nctId":3077,"briefTitle":3078,"status":217,"phases":3079,"conditions":3080,"interventions":3083},"NCT00115414","Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)",[90],[2794,3081,3082],"Fever","Neutropenia",[2797,3052,3084,3061],"doxorubicin",{"nctId":3086,"briefTitle":3087,"status":164,"phases":3088,"primaryCompletion":1298,"completion":1298,"start":3089,"enrollment":3090,"conditions":3091,"interventions":3093},"NCT05094336","A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)",[89,90],"2022-02-01",329,[3092],"Advanced MTAP-null Solid Tumors",[1305,1279,3094],"Comparator Anvumetostat Test",{"trials":3096,"activeCount":985,"soonestReadout":42},[3097,3101],{"nctId":1519,"briefTitle":1520,"status":108,"phases":3098,"primaryCompletion":1522,"completion":1523,"start":1524,"enrollment":1433,"conditions":3099,"interventions":3100},[91],[1264],[1453,1527,1279,1528],{"nctId":40,"briefTitle":41,"status":164,"phases":3102,"primaryCompletion":42,"completion":3103,"start":3104,"enrollment":3105,"conditions":3106,"interventions":3108},[91],"2026-06-24","2020-06-04",345,[3107],"KRAS p, G12c Mutated \u002FAdvanced Metastatic NSCLC",[43,1279],{"trials":3110,"activeCount":100},[],{"trials":3112,"activeCount":100},[],{"intervention":1503,"totalTrials":160,"cells":3114},{"EARLY_PHASE1":3115,"PHASE1":3117,"PHASE2":3134,"PHASE3":3146,"PHASE4":3152,"NA":3154},{"trials":3116,"activeCount":100},[],{"trials":3118,"activeCount":985,"soonestReadout":1496},[3119,3130],{"nctId":3120,"briefTitle":3121,"status":108,"phases":3122,"primaryCompletion":3123,"completion":3124,"start":3125,"enrollment":3126,"conditions":3127,"interventions":3128},"NCT04221542","Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer",[89],"2030-03-22","2032-03-21","2020-03-04",479,[1265],[3129,1503,1539],"AMG 509",{"nctId":1493,"briefTitle":1494,"status":108,"phases":3131,"primaryCompletion":1496,"completion":1497,"start":1498,"enrollment":13,"conditions":3132,"interventions":3133},[89],[1500],[1453,1502,1503],{"trials":3135,"activeCount":100},[3136],{"nctId":3137,"briefTitle":3138,"status":336,"phases":3139,"primaryCompletion":3140,"completion":3140,"start":3141,"enrollment":3142,"conditions":3143,"interventions":3144},"NCT04631601","Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)",[89,90],"2023-10-23","2021-01-15",65,[1264],[3145,1539,1503,1099],"Acapatamab",{"trials":3147,"activeCount":204,"soonestReadout":1533},[3148],{"nctId":1530,"briefTitle":1531,"status":164,"phases":3149,"primaryCompletion":1533,"completion":1534,"start":1535,"enrollment":1536,"conditions":3150,"interventions":3151},[91],[1264],[1453,1503,1539,1528],{"trials":3153,"activeCount":100},[],{"trials":3155,"activeCount":100},[],{"intervention":3157,"totalTrials":193,"cells":3158},"Nivolumab",{"EARLY_PHASE1":3159,"PHASE1":3161,"PHASE2":3163,"PHASE3":3175,"PHASE4":3195,"NA":3197},{"trials":3160,"activeCount":100},[],{"trials":3162,"activeCount":100},[],{"trials":3164,"activeCount":204,"soonestReadout":86},[3165],{"nctId":84,"briefTitle":85,"status":164,"phases":3166,"primaryCompletion":86,"completion":3167,"start":3168,"enrollment":1400,"conditions":3169,"interventions":3172},[89,90],"2026-08-12","2022-05-17",[3170,3171],"Gastric Cancer","Gastroesophageal Junction Cancer",[72,3173,3174,3157],"CAPOX","SOX",{"trials":3176,"activeCount":985,"soonestReadout":71},[3177,3185],{"nctId":69,"briefTitle":70,"status":164,"phases":3178,"primaryCompletion":71,"completion":3179,"start":3180,"enrollment":353,"conditions":3181,"interventions":3183},[91],"2027-01-29","2022-03-14",[3170,3182],"Gastroesophageal Junction Adenocarcinoma",[72,3157,3184],"Chemotherapy",{"nctId":3186,"briefTitle":3187,"status":164,"phases":3188,"primaryCompletion":3189,"completion":3189,"start":3190,"enrollment":3191,"conditions":3192,"interventions":3193},"NCT06054555","A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma",[91],"2028-01-25","2023-11-02",633,[1402],[3194,3157],"ABP 206",{"trials":3196,"activeCount":100},[],{"trials":3198,"activeCount":100},[],{"intervention":3200,"totalTrials":193,"cells":3201},"Dazodalibep",{"EARLY_PHASE1":3202,"PHASE1":3204,"PHASE2":3206,"PHASE3":3208,"PHASE4":3238,"NA":3240},{"trials":3203,"activeCount":100},[],{"trials":3205,"activeCount":100},[],{"trials":3207,"activeCount":100},[],{"trials":3209,"activeCount":193,"soonestReadout":3214},[3210,3220,3229],{"nctId":3211,"briefTitle":3212,"status":164,"phases":3213,"primaryCompletion":3214,"completion":3214,"start":3215,"enrollment":3216,"conditions":3217,"interventions":3219},"NCT06104124","A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity",[91],"2026-08-19","2024-01-24",651,[3218],"Sjogren's Syndrome",[3200],{"nctId":3221,"briefTitle":3222,"status":108,"phases":3223,"primaryCompletion":3224,"completion":3224,"start":3225,"enrollment":2150,"conditions":3226,"interventions":3228},"NCT06747949","A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)",[91],"2029-12-11","2025-02-25",[3227],"Sjögren's Syndrome",[3200],{"nctId":3230,"briefTitle":3231,"status":164,"phases":3232,"primaryCompletion":3233,"completion":1312,"start":3234,"enrollment":1369,"conditions":3235,"interventions":3237},"NCT06245408","A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State",[91],"2026-10-22","2024-04-08",[3236],"Sjögren's Syndrome (SS)",[3200],{"trials":3239,"activeCount":100},[],{"trials":3241,"activeCount":100},[],{"intervention":3243,"totalTrials":96,"cells":3244},"Olpasiran",{"EARLY_PHASE1":3245,"PHASE1":3247,"PHASE2":3285,"PHASE3":3297,"PHASE4":3325,"NA":3327},{"trials":3246,"activeCount":100},[],{"trials":3248,"activeCount":100},[3249,3258,3268,3275],{"nctId":3250,"briefTitle":3251,"status":217,"phases":3252,"primaryCompletion":3253,"completion":3254,"start":1421,"enrollment":26,"conditions":3255,"interventions":3257},"NCT06411860","A Study to Assess the Effect of Olpasiran on QT\u002FQTc Intervals in Healthy Participants",[89],"2024-11-29","2024-12-11",[3256],"Basic Science",[3243,246],{"nctId":3259,"briefTitle":3260,"status":217,"phases":3261,"primaryCompletion":2256,"completion":3262,"start":3263,"enrollment":3264,"conditions":3265,"interventions":3267},"NCT05489614","A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment",[89],"2023-12-19","2022-09-13",33,[3266],"Renal Impairment",[3243],{"nctId":3269,"briefTitle":3270,"status":217,"phases":3271,"primaryCompletion":3272,"completion":1232,"start":3263,"enrollment":32,"conditions":3273,"interventions":3274},"NCT05481411","A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment",[89],"2023-04-05",[255],[3243],{"nctId":3276,"briefTitle":3277,"status":217,"phases":3278,"primaryCompletion":3279,"completion":3280,"start":3281,"enrollment":253,"conditions":3282,"interventions":3284},"NCT04987320","A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)",[89],"2021-11-12","2022-03-18","2021-07-28",[3283],"Elevated Serum Lipoprotein(a)",[3243],{"trials":3286,"activeCount":100},[3287],{"nctId":3288,"briefTitle":3289,"status":217,"phases":3290,"primaryCompletion":3291,"completion":3292,"start":3293,"enrollment":3294,"conditions":3295,"interventions":3296},"NCT04270760","Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study",[90],"2021-12-27","2022-11-08","2020-07-28",281,[466],[3243],{"trials":3298,"activeCount":193,"soonestReadout":3321},[3299,3308,3317],{"nctId":3300,"briefTitle":3301,"status":108,"phases":3302,"primaryCompletion":3303,"completion":3303,"start":3304,"enrollment":3305,"conditions":3306,"interventions":3307},"NCT07136012","OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events",[91],"2031-10-20","2025-08-22",11000,[466],[3243],{"nctId":3309,"briefTitle":3310,"status":108,"phases":3311,"primaryCompletion":3312,"completion":3312,"start":3313,"enrollment":3314,"conditions":3315,"interventions":3316},"NCT07293260","Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial",[91],"2028-06-15","2026-03-23",406,[466],[3243],{"nctId":3318,"briefTitle":3319,"status":164,"phases":3320,"primaryCompletion":3321,"completion":3321,"start":2985,"enrollment":3322,"conditions":3323,"interventions":3324},"NCT05581303","Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial",[91],"2028-03-31",7297,[1062],[3243],{"trials":3326,"activeCount":100},[],{"trials":3328,"activeCount":100},[3329],{"nctId":3330,"briefTitle":3331,"status":3332,"phases":3333,"conditions":3334,"interventions":3335},"NCT07079267","Olpasiran Expanded Access Program","AVAILABLE",[],[],[3243],{"intervention":3337,"totalTrials":3338,"cells":3339},"Etelcalcetide",11,{"EARLY_PHASE1":3340,"PHASE1":3342,"PHASE2":3360,"PHASE3":3362,"PHASE4":3446,"NA":3448},{"trials":3341,"activeCount":100},[],{"trials":3343,"activeCount":100},[3344,3352],{"nctId":3345,"briefTitle":3346,"status":217,"phases":3347,"primaryCompletion":3348,"completion":3348,"start":1747,"enrollment":3338,"conditions":3349,"interventions":3351},"NCT02833857","A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis",[89],"2018-10-31",[3350],"Chronic Kidney Disease, Secondary Hyperparathyroidism",[3337],{"nctId":3353,"briefTitle":3354,"status":217,"phases":3355,"primaryCompletion":3356,"completion":3356,"start":3357,"enrollment":3264,"conditions":3358,"interventions":3359},"NCT03283098","A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416",[89],"2019-02-04","2018-03-01",[384],[3337],{"trials":3361,"activeCount":100},[],{"trials":3363,"activeCount":985,"soonestReadout":1430},[3364,3373,3385,3394,3403,3409,3418,3427,3436],{"nctId":3365,"briefTitle":3366,"status":217,"phases":3367,"primaryCompletion":3368,"completion":3369,"start":3370,"enrollment":353,"conditions":3371,"interventions":3372},"NCT01788046","Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis",[91],"2014-04-14","2014-05-09","2013-03-12",[342],[3337],{"nctId":3374,"briefTitle":3375,"status":217,"phases":3376,"primaryCompletion":3377,"completion":2065,"start":3378,"enrollment":3379,"conditions":3380,"interventions":3381},"NCT01896232","Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet",[91],"2014-11-12","2013-08-13",683,[384,28],[3337,3382,3383,3384],"Cinacalcet","Oral Placebo","Intravenous Placebo",{"nctId":3386,"briefTitle":3387,"status":108,"phases":3388,"primaryCompletion":3389,"completion":3389,"start":3390,"enrollment":3391,"conditions":3392,"interventions":3393},"NCT03633708","A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis",[91],"2029-01-31","2019-04-29",56,[384,28],[3337],{"nctId":3395,"briefTitle":3396,"status":217,"phases":3397,"primaryCompletion":3398,"completion":3399,"start":3400,"enrollment":752,"conditions":3401,"interventions":3402},"NCT01932970","Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide",[91],"2014-01-14","2017-02-14","2013-08-12",[342],[3337],{"nctId":3404,"briefTitle":3405,"status":108,"phases":3406,"primaryCompletion":1430,"completion":1430,"start":2229,"enrollment":253,"conditions":3407,"interventions":3408},"NCT03969329","A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis",[91],[384],[3337],{"nctId":3410,"briefTitle":3411,"status":217,"phases":3412,"primaryCompletion":3413,"completion":3414,"start":3370,"enrollment":3415,"conditions":3416,"interventions":3417},"NCT01785849","Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis",[91],"2014-05-22","2014-06-12",508,[342],[3337],{"nctId":3419,"briefTitle":3420,"status":217,"phases":3421,"primaryCompletion":3422,"completion":3422,"start":3423,"enrollment":3424,"conditions":3425,"interventions":3426},"NCT03299244","Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)",[91],"2020-04-08","2018-05-15",637,[384,28],[3337,3382],{"nctId":3428,"briefTitle":3429,"status":217,"phases":3430,"primaryCompletion":3431,"completion":3431,"start":3432,"enrollment":3433,"conditions":3434,"interventions":3435},"NCT01785875","Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis",[91],"2015-07-01","2013-07-31",891,[342],[3337],{"nctId":3437,"briefTitle":3438,"status":217,"phases":3439,"primaryCompletion":3440,"completion":3441,"start":3442,"enrollment":3443,"conditions":3444,"interventions":3445},"NCT02102204","Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis",[91],"2016-11-04","2017-06-26","2014-03-25",902,[342],[3337],{"trials":3447,"activeCount":100},[],{"trials":3449,"activeCount":100},[],{"intervention":72,"totalTrials":325,"cells":3451},{"EARLY_PHASE1":3452,"PHASE1":3454,"PHASE2":3460,"PHASE3":3475,"PHASE4":3491,"NA":3493},{"trials":3453,"activeCount":100},[],{"trials":3455,"activeCount":100},[3456],{"nctId":1271,"briefTitle":1272,"status":336,"phases":3457,"primaryCompletion":52,"completion":52,"start":1274,"enrollment":1275,"conditions":3458,"interventions":3459},[89],[1277],[72,1279,1152,1109,1280,1281],{"trials":3461,"activeCount":204,"soonestReadout":86},[3462,3466],{"nctId":84,"briefTitle":85,"status":164,"phases":3463,"primaryCompletion":86,"completion":3167,"start":3168,"enrollment":1400,"conditions":3464,"interventions":3465},[89,90],[3170,3171],[72,3173,3174,3157],{"nctId":3467,"briefTitle":3468,"status":217,"phases":3469,"primaryCompletion":3470,"completion":3470,"start":3471,"enrollment":3472,"conditions":3473,"interventions":3474},"NCT05325866","A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression",[89,90],"2026-01-28","2022-09-23",260,[2441],[72],{"trials":3476,"activeCount":204,"soonestReadout":71},[3477,3481],{"nctId":69,"briefTitle":70,"status":164,"phases":3478,"primaryCompletion":71,"completion":3179,"start":3180,"enrollment":353,"conditions":3479,"interventions":3480},[91],[3170,3182],[72,3157,3184],{"nctId":3482,"briefTitle":3483,"status":217,"phases":3484,"primaryCompletion":3485,"completion":3486,"start":3487,"enrollment":3488,"conditions":3489,"interventions":3490},"NCT05052801","Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression",[91],"2025-06-20","2026-04-26","2022-03-07",547,[3170,3182],[72,2617],{"trials":3492,"activeCount":100},[],{"trials":3494,"activeCount":100},[],{"intervention":1539,"totalTrials":193,"cells":3496},{"EARLY_PHASE1":3497,"PHASE1":3499,"PHASE2":3505,"PHASE3":3511,"PHASE4":3517,"NA":3519},{"trials":3498,"activeCount":100},[],{"trials":3500,"activeCount":204,"soonestReadout":3123},[3501],{"nctId":3120,"briefTitle":3121,"status":108,"phases":3502,"primaryCompletion":3123,"completion":3124,"start":3125,"enrollment":3126,"conditions":3503,"interventions":3504},[89],[1265],[3129,1503,1539],{"trials":3506,"activeCount":100},[3507],{"nctId":3137,"briefTitle":3138,"status":336,"phases":3508,"primaryCompletion":3140,"completion":3140,"start":3141,"enrollment":3142,"conditions":3509,"interventions":3510},[89,90],[1264],[3145,1539,1503,1099],{"trials":3512,"activeCount":204,"soonestReadout":1533},[3513],{"nctId":1530,"briefTitle":1531,"status":164,"phases":3514,"primaryCompletion":1533,"completion":1534,"start":1535,"enrollment":1536,"conditions":3515,"interventions":3516},[91],[1264],[1453,1503,1539,1528],{"trials":3518,"activeCount":100},[],{"trials":3520,"activeCount":100},[],{"intervention":1110,"totalTrials":193,"cells":3522},{"EARLY_PHASE1":3523,"PHASE1":3525,"PHASE2":3531,"PHASE3":3537,"PHASE4":3543,"NA":3545},{"trials":3524,"activeCount":100},[],{"trials":3526,"activeCount":204,"soonestReadout":1104},[3527],{"nctId":1101,"briefTitle":1102,"status":164,"phases":3528,"primaryCompletion":1104,"completion":1104,"start":1105,"enrollment":1106,"conditions":3529,"interventions":3530},[89],[1085],[58,1109,1110,1111,1112],{"trials":3532,"activeCount":100},[3533],{"nctId":2819,"briefTitle":2820,"status":217,"phases":3534,"primaryCompletion":2822,"completion":2823,"start":2824,"enrollment":26,"conditions":3535,"interventions":3536},[89,90],[1226],[2827,1109,1110],{"trials":3538,"activeCount":204,"soonestReadout":1209},[3539],{"nctId":1206,"briefTitle":1207,"status":108,"phases":3540,"primaryCompletion":1209,"completion":1210,"start":1211,"enrollment":1212,"conditions":3541,"interventions":3542},[91],[1214,1215],[58,1112,1109,1110],{"trials":3544,"activeCount":100},[],{"trials":3546,"activeCount":100},[],{"intervention":1528,"totalTrials":985,"cells":3548},{"EARLY_PHASE1":3549,"PHASE1":3551,"PHASE2":3553,"PHASE3":3555,"PHASE4":3565,"NA":3567},{"trials":3550,"activeCount":100},[],{"trials":3552,"activeCount":100},[],{"trials":3554,"activeCount":100},[],{"trials":3556,"activeCount":985,"soonestReadout":1533},[3557,3561],{"nctId":1519,"briefTitle":1520,"status":108,"phases":3558,"primaryCompletion":1522,"completion":1523,"start":1524,"enrollment":1433,"conditions":3559,"interventions":3560},[91],[1264],[1453,1527,1279,1528],{"nctId":1530,"briefTitle":1531,"status":164,"phases":3562,"primaryCompletion":1533,"completion":1534,"start":1535,"enrollment":1536,"conditions":3563,"interventions":3564},[91],[1264],[1453,1503,1539,1528],{"trials":3566,"activeCount":100},[],{"trials":3568,"activeCount":100},[],{"intervention":1425,"totalTrials":985,"cells":3570},{"EARLY_PHASE1":3571,"PHASE1":3573,"PHASE2":3575,"PHASE3":3577,"PHASE4":3587,"NA":3589},{"trials":3572,"activeCount":100},[],{"trials":3574,"activeCount":100},[],{"trials":3576,"activeCount":100},[],{"trials":3578,"activeCount":985,"soonestReadout":1420},[3579,3583],{"nctId":1417,"briefTitle":1418,"status":164,"phases":3580,"primaryCompletion":1420,"completion":1420,"start":1421,"enrollment":678,"conditions":3581,"interventions":3582},[91],[1423],[1425,1152],{"nctId":1438,"briefTitle":1439,"status":164,"phases":3584,"primaryCompletion":1441,"completion":1442,"start":1443,"enrollment":1444,"conditions":3585,"interventions":3586},[91],[1446],[1425,1152,1152],{"trials":3588,"activeCount":100},[],{"trials":3590,"activeCount":100},[],{"intervention":3592,"totalTrials":1593,"cells":3593},"Romosozumab",{"EARLY_PHASE1":3594,"PHASE1":3596,"PHASE2":3654,"PHASE3":3702,"PHASE4":3752,"NA":3762},{"trials":3595,"activeCount":100},[],{"trials":3597,"activeCount":100},[3598,3606,3614,3623,3630,3638,3646],{"nctId":3599,"briefTitle":3600,"status":217,"phases":3601,"primaryCompletion":3602,"completion":3602,"start":707,"enrollment":32,"conditions":3603,"interventions":3605},"NCT04545554","Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta",[89],"2023-03-30",[3604],"Osteogenesis Imperfecta",[3592],{"nctId":3607,"briefTitle":3608,"status":217,"phases":3609,"primaryCompletion":2723,"completion":2723,"start":3610,"enrollment":1337,"conditions":3611,"interventions":3613},"NCT01101061","A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal Japanese and Non-Japanese Women",[89],"2010-05-03",[3612],"Osteopenia",[3592],{"nctId":3615,"briefTitle":3616,"status":217,"phases":3617,"primaryCompletion":3618,"completion":3618,"start":3619,"enrollment":2197,"conditions":3620,"interventions":3622},"NCT01825785","A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)",[89],"2008-12-02","2007-11-14",[3621,3612],"Postmenopausal",[3592],{"nctId":3624,"briefTitle":3625,"status":217,"phases":3626,"primaryCompletion":3627,"completion":3627,"start":2488,"enrollment":13,"conditions":3628,"interventions":3629},"NCT01588509","Transition From Alendronate to Romosozumab (AMG 785)",[89],"2012-11-21",[493],[3592],{"nctId":3631,"briefTitle":3632,"status":217,"phases":3633,"primaryCompletion":3634,"completion":3634,"start":3635,"enrollment":1275,"conditions":3636,"interventions":3637},"NCT01059435","A First-in-human Study Evaluating Romosozumab (AMG 785) in Healthy Men and Postmenopausal Women",[89],"2007-07-06","2006-12-13",[3612],[3592],{"nctId":3639,"briefTitle":3640,"status":217,"phases":3641,"primaryCompletion":3642,"completion":3642,"start":3643,"enrollment":253,"conditions":3644,"interventions":3645},"NCT00950950","A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass",[89],"2010-08-19","2009-08-18",[3612],[3592],{"nctId":3647,"briefTitle":3648,"status":217,"phases":3649,"primaryCompletion":3650,"completion":3650,"start":3651,"enrollment":253,"conditions":3652,"interventions":3653},"NCT01833754","Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis",[89],"2014-02-19","2013-04-22",[493],[3592],{"trials":3655,"activeCount":100},[3656,3672,3683,3693],{"nctId":3657,"briefTitle":3658,"status":217,"phases":3659,"primaryCompletion":3660,"completion":3661,"start":3662,"enrollment":3663,"conditions":3664,"interventions":3667},"NCT00896532","Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density",[90],"2011-02-21","2016-02-18","2009-06-03",419,[3665,3666],"Low Bone Mineral Density","Postmenopausal Osteoporosis",[3668,3669,3592,3670,3671],"Alendronate","Teriparatide","Denosumab","Zoledronic acid",{"nctId":3673,"briefTitle":3674,"status":217,"phases":3675,"primaryCompletion":3676,"completion":3677,"start":3678,"enrollment":3679,"conditions":3680,"interventions":3682},"NCT00907296","Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing",[90],"2012-03-06","2013-05-10","2009-09-02",402,[3681],"Fracture Healing",[3592],{"nctId":3684,"briefTitle":3685,"status":217,"phases":3686,"primaryCompletion":3687,"completion":3688,"start":3689,"enrollment":1173,"conditions":3690,"interventions":3692},"NCT01992159","Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis",[90],"2014-10-09","2015-06-17","2012-10-12",[3691],"Postmenopausal Osteoporosis (PMO)",[3592],{"nctId":3694,"briefTitle":3695,"status":217,"phases":3696,"primaryCompletion":3697,"completion":3677,"start":3698,"enrollment":3699,"conditions":3700,"interventions":3701},"NCT01081678","Study To Assess FRacTure Healing With SclerosTin Antibody - Hip",[90],"2012-06-30","2010-06-20",332,[3681],[3592],{"trials":3703,"activeCount":204,"soonestReadout":3746},[3704,3712,3721,3731,3742],{"nctId":3705,"briefTitle":3706,"status":217,"phases":3707,"primaryCompletion":3708,"completion":265,"start":3709,"enrollment":2490,"conditions":3710,"interventions":3711},"NCT02791516","A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis",[91],"2018-02-12","2017-01-16",[3666],[3592],{"nctId":3713,"briefTitle":3714,"status":217,"phases":3715,"primaryCompletion":3716,"completion":3717,"start":2175,"enrollment":3718,"conditions":3719,"interventions":3720},"NCT01575834","Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis",[91],"2015-12-14","2016-12-28",7180,[3666],[3592,3670],{"nctId":3722,"briefTitle":3723,"status":217,"phases":3724,"primaryCompletion":3725,"completion":3726,"start":3727,"enrollment":2188,"conditions":3728,"interventions":3730},"NCT02186171","A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis",[91],"2016-02-15","2016-04-20","2014-06-16",[3729],"Osteoporosis in Men",[3592],{"nctId":3732,"briefTitle":3733,"status":217,"phases":3734,"primaryCompletion":3735,"completion":3736,"start":3737,"enrollment":3738,"conditions":3739,"interventions":3741},"NCT01631214","Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis",[91],"2017-02-27","2017-06-29","2012-05-04",4093,[3740],"Postmenopausal Women With Osteoporosis",[3592,3668],{"nctId":3743,"briefTitle":3744,"status":164,"phases":3745,"primaryCompletion":3746,"completion":3747,"start":3748,"enrollment":1759,"conditions":3749,"interventions":3750},"NCT05972551","Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta",[91],"2027-05-04","2027-07-30","2024-04-22",[3604],[3592,3751],"Bisphosphonate",{"trials":3753,"activeCount":100},[3754],{"nctId":3755,"briefTitle":3756,"status":217,"phases":3757,"primaryCompletion":3758,"completion":3758,"start":3759,"enrollment":12,"conditions":3760,"interventions":3761},"NCT06079476","A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.",[92],"2025-10-18","2023-10-30",[3666],[3592],{"trials":3763,"activeCount":100},[],{"intervention":1765,"totalTrials":1907,"cells":3765},{"EARLY_PHASE1":3766,"PHASE1":3768,"PHASE2":3770,"PHASE3":3789,"PHASE4":3837,"NA":3912},{"trials":3767,"activeCount":100},[],{"trials":3769,"activeCount":100},[],{"trials":3771,"activeCount":100},[3772,3780],{"nctId":3773,"briefTitle":3774,"status":217,"phases":3775,"conditions":3776,"interventions":3777},"NCT00124111","A Study of Cyclophosphamide\u002FMethotrexate\u002F5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer",[90],[2794],[2797,3061,3778,3779],"methotrexate","5-fluorouracil",{"nctId":3781,"briefTitle":3782,"status":217,"phases":3783,"primaryCompletion":3784,"completion":3784,"start":3785,"enrollment":1173,"conditions":3786,"interventions":3787},"NCT00950989","Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate",[90],"2011-02-11","2009-12-30",[19],[3788,1765],"Brodalumab",{"trials":3790,"activeCount":204,"soonestReadout":3809},[3791,3801,3805,3817,3827],{"nctId":3792,"briefTitle":3793,"status":336,"phases":3794,"primaryCompletion":3795,"completion":3796,"start":3797,"enrollment":32,"conditions":3798,"interventions":3800},"NCT03781375","Etanercept Plus Methotrexate Versus Methotrexate Alone in Children With Polyarticular Course Juvenile Rheumatoid Arthritis",[91],"2002-06-20","2002-06-24","2000-08-24",[3799],"Juvenile Rheumatoid Arthritis",[1268,1765],{"nctId":1754,"briefTitle":1755,"status":217,"phases":3802,"primaryCompletion":1757,"completion":1758,"start":760,"enrollment":1759,"conditions":3803,"interventions":3804},[91],[1761],[117,1656,1763,1764,1765,1766,1767,1768],{"nctId":3806,"briefTitle":3807,"status":108,"phases":3808,"primaryCompletion":3809,"completion":3810,"start":3811,"enrollment":3812,"conditions":3813,"interventions":3815},"NCT07388498","A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout",[91],"2028-05-23","2028-07-18","2026-02-09",270,[3814],"Uncontrolled Gout",[3816,1765],"Pegloticase",{"nctId":3818,"briefTitle":3819,"status":217,"phases":3820,"primaryCompletion":3821,"completion":3822,"start":3823,"enrollment":3824,"conditions":3825,"interventions":3826},"NCT02376790","Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis",[91],"2018-01-09","2018-07-06","2015-03-03",851,[2078],[1268,1765],{"nctId":3828,"briefTitle":3829,"status":217,"phases":3830,"primaryCompletion":3831,"completion":3832,"start":3833,"enrollment":3834,"conditions":3835,"interventions":3836},"NCT01001208","The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis",[91],"2010-12","2011-02","2009-11",478,[22],[1765,1268],{"trials":3838,"activeCount":100},[3839,3851,3864,3874,3885,3894,3903],{"nctId":3840,"briefTitle":3841,"status":217,"phases":3842,"primaryCompletion":3843,"completion":3844,"start":3845,"enrollment":1907,"conditions":3846,"interventions":3848},"NCT03635957","Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout",[92],"2019-10-23","2020-10-26","2018-09-26",[3847],"Gout",[3816,1765,3849,3850],"Standard Gout Flare Prophylaxis","Infusion Reaction (IR) Prophylaxis",{"nctId":3852,"briefTitle":3853,"status":217,"phases":3854,"primaryCompletion":3855,"completion":3856,"start":3857,"enrollment":2302,"conditions":3858,"interventions":3859},"NCT03994731","Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout",[92],"2021-03-17","2022-04-11","2019-06-13",[3847],[3816,3778,3860,3861,3862,3863],"gout flare prophylaxis regimen","fexofenadine","acetaminophen","methylprednisolone",{"nctId":3865,"briefTitle":3866,"status":217,"phases":3867,"primaryCompletion":3868,"completion":3869,"start":3870,"enrollment":3871,"conditions":3872,"interventions":3873},"NCT00654368","CAMEO: Canadian Methotrexate and Etanercept Outcome Study",[92],"2012-12","2013-02","2008-06",258,[19],[1268,1765],{"nctId":3875,"briefTitle":3876,"status":217,"phases":3877,"primaryCompletion":3878,"completion":3879,"start":3880,"enrollment":3881,"conditions":3882,"interventions":3884},"NCT04762498","A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)",[92],"2023-05-18","2023-12-20","2021-01-26",54,[3814,3883],"Chronic Gout",[3816,1765],{"nctId":3886,"briefTitle":3887,"status":336,"phases":3888,"primaryCompletion":3889,"completion":3889,"start":3890,"enrollment":2126,"conditions":3891,"interventions":3893},"NCT01927757","Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab",[92],"2015-06-11","2013-05-06",[3892],"Moderate to Severe Rheumatoid Arthritis",[1268,1765],{"nctId":3895,"briefTitle":3896,"status":217,"phases":3897,"primaryCompletion":3898,"completion":3899,"start":3900,"enrollment":3338,"conditions":3901,"interventions":3902},"NCT04772313","Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy",[92],"2022-08-23","2023-04-24","2021-03-08",[3814],[3816,1765],{"nctId":3904,"briefTitle":3905,"status":217,"phases":3906,"primaryCompletion":1555,"completion":3907,"start":3908,"enrollment":3909,"conditions":3910,"interventions":3911},"NCT06229145","A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout",[92],"2026-03-11","2024-03-18",262,[3847],[3816,1765],{"trials":3913,"activeCount":100},[],{"intervention":3816,"totalTrials":1454,"cells":3915},{"EARLY_PHASE1":3916,"PHASE1":3918,"PHASE2":3920,"PHASE3":3922,"PHASE4":3928,"NA":3960},{"trials":3917,"activeCount":100},[],{"trials":3919,"activeCount":100},[],{"trials":3921,"activeCount":100},[],{"trials":3923,"activeCount":204,"soonestReadout":3809},[3924],{"nctId":3806,"briefTitle":3807,"status":108,"phases":3925,"primaryCompletion":3809,"completion":3810,"start":3811,"enrollment":3812,"conditions":3926,"interventions":3927},[91],[3814],[3816,1765],{"trials":3929,"activeCount":100},[3930,3934,3938,3942,3946,3956],{"nctId":3840,"briefTitle":3841,"status":217,"phases":3931,"primaryCompletion":3843,"completion":3844,"start":3845,"enrollment":1907,"conditions":3932,"interventions":3933},[92],[3847],[3816,1765,3849,3850],{"nctId":3852,"briefTitle":3853,"status":217,"phases":3935,"primaryCompletion":3855,"completion":3856,"start":3857,"enrollment":2302,"conditions":3936,"interventions":3937},[92],[3847],[3816,3778,3860,3861,3862,3863],{"nctId":3875,"briefTitle":3876,"status":217,"phases":3939,"primaryCompletion":3878,"completion":3879,"start":3880,"enrollment":3881,"conditions":3940,"interventions":3941},[92],[3814,3883],[3816,1765],{"nctId":3895,"briefTitle":3896,"status":217,"phases":3943,"primaryCompletion":3898,"completion":3899,"start":3900,"enrollment":3338,"conditions":3944,"interventions":3945},[92],[3814],[3816,1765],{"nctId":3947,"briefTitle":3948,"status":217,"phases":3949,"primaryCompletion":3950,"completion":3951,"start":3952,"enrollment":305,"conditions":3953,"interventions":3955},"NCT04087720","Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant",[92],"2021-07-06","2021-09-07","2019-09-09",[3814,3954],"Kidney Transplant",[3816],{"nctId":3904,"briefTitle":3905,"status":217,"phases":3957,"primaryCompletion":1555,"completion":3907,"start":3908,"enrollment":3909,"conditions":3958,"interventions":3959},[92],[3847],[3816,1765],{"trials":3961,"activeCount":100},[],{"intervention":3194,"totalTrials":985,"cells":3963},{"EARLY_PHASE1":3964,"PHASE1":3966,"PHASE2":3968,"PHASE3":3970,"PHASE4":3988,"NA":3990},{"trials":3965,"activeCount":100},[],{"trials":3967,"activeCount":100},[],{"trials":3969,"activeCount":100},[],{"trials":3971,"activeCount":204,"soonestReadout":3189},[3972,3984],{"nctId":3973,"briefTitle":3974,"status":217,"phases":3975,"primaryCompletion":3976,"completion":3977,"start":3978,"enrollment":3979,"conditions":3980,"interventions":3981},"NCT05907122","A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma",[91],"2025-03-26","2025-10-31","2023-07-26",256,[1402],[3194,3982,3983],"FDA-licensed Nivolumab","EU-authorized Nivolumab",{"nctId":3186,"briefTitle":3187,"status":164,"phases":3985,"primaryCompletion":3189,"completion":3189,"start":3190,"enrollment":3191,"conditions":3986,"interventions":3987},[91],[1402],[3194,3157],{"trials":3989,"activeCount":100},[],{"trials":3991,"activeCount":100},[],{"intervention":3184,"totalTrials":985,"cells":3993},{"EARLY_PHASE1":3994,"PHASE1":3996,"PHASE2":3998,"PHASE3":4013,"PHASE4":4019,"NA":4021},{"trials":3995,"activeCount":100},[],{"trials":3997,"activeCount":100},[],{"trials":3999,"activeCount":100},[4000],{"nctId":4001,"briefTitle":4002,"status":217,"phases":4003,"primaryCompletion":4004,"completion":4004,"start":4005,"enrollment":4006,"conditions":4007,"interventions":4009},"NCT01712009","NOLAN: Naproxen or Loratadine and Neulasta",[90],"2015-03-18","2012-11-01",600,[4008],"Bone Pain in Stage I - III Breast Cancer",[4010,4011,4012,3184],"Naproxen","Loratadine","Pegfilgrastim",{"trials":4014,"activeCount":204,"soonestReadout":71},[4015],{"nctId":69,"briefTitle":70,"status":164,"phases":4016,"primaryCompletion":71,"completion":3179,"start":3180,"enrollment":353,"conditions":4017,"interventions":4018},[91],[3170,3182],[72,3157,3184],{"trials":4020,"activeCount":100},[],{"trials":4022,"activeCount":100},[],{"intervention":77,"totalTrials":985,"cells":4024},{"EARLY_PHASE1":4025,"PHASE1":4027,"PHASE2":4029,"PHASE3":4031,"PHASE4":4052,"NA":4054},{"trials":4026,"activeCount":100},[],{"trials":4028,"activeCount":100},[],{"trials":4030,"activeCount":100},[],{"trials":4032,"activeCount":204,"soonestReadout":76},[4033,4043],{"nctId":74,"briefTitle":75,"status":164,"phases":4034,"primaryCompletion":76,"completion":4035,"start":4036,"enrollment":4037,"conditions":4038,"interventions":4040},[91],"2026-11-15","2019-07-19",457,[4039],"Migraine",[77,4041,4042],"Erenumab Dose 2","Erenumab Dose 3",{"nctId":4044,"briefTitle":4045,"status":217,"phases":4046,"primaryCompletion":1557,"completion":4047,"start":4048,"enrollment":4049,"conditions":4050,"interventions":4051},"NCT03832998","Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine",[91],"2026-01-07","2019-09-05",284,[4039],[77,4041,4042],{"trials":4053,"activeCount":100},[],{"trials":4055,"activeCount":100},[],{"intervention":4041,"totalTrials":985,"cells":4057},{"EARLY_PHASE1":4058,"PHASE1":4060,"PHASE2":4062,"PHASE3":4064,"PHASE4":4074,"NA":4076},{"trials":4059,"activeCount":100},[],{"trials":4061,"activeCount":100},[],{"trials":4063,"activeCount":100},[],{"trials":4065,"activeCount":204,"soonestReadout":76},[4066,4070],{"nctId":74,"briefTitle":75,"status":164,"phases":4067,"primaryCompletion":76,"completion":4035,"start":4036,"enrollment":4037,"conditions":4068,"interventions":4069},[91],[4039],[77,4041,4042],{"nctId":4044,"briefTitle":4045,"status":217,"phases":4071,"primaryCompletion":1557,"completion":4047,"start":4048,"enrollment":4049,"conditions":4072,"interventions":4073},[91],[4039],[77,4041,4042],{"trials":4075,"activeCount":100},[],{"trials":4077,"activeCount":100},[],{"intervention":4042,"totalTrials":985,"cells":4079},{"EARLY_PHASE1":4080,"PHASE1":4082,"PHASE2":4084,"PHASE3":4086,"PHASE4":4096,"NA":4098},{"trials":4081,"activeCount":100},[],{"trials":4083,"activeCount":100},[],{"trials":4085,"activeCount":100},[],{"trials":4087,"activeCount":204,"soonestReadout":76},[4088,4092],{"nctId":74,"briefTitle":75,"status":164,"phases":4089,"primaryCompletion":76,"completion":4035,"start":4036,"enrollment":4037,"conditions":4090,"interventions":4091},[91],[4039],[77,4041,4042],{"nctId":4044,"briefTitle":4045,"status":217,"phases":4093,"primaryCompletion":1557,"completion":4047,"start":4048,"enrollment":4049,"conditions":4094,"interventions":4095},[91],[4039],[77,4041,4042],{"trials":4097,"activeCount":100},[],{"trials":4099,"activeCount":100},[],{"intervention":180,"totalTrials":204,"cells":4101},{"EARLY_PHASE1":4102,"PHASE1":4104,"PHASE2":4106,"PHASE3":4108,"PHASE4":4114,"NA":4116},{"trials":4103,"activeCount":100},[],{"trials":4105,"activeCount":100},[],{"trials":4107,"activeCount":100},[],{"trials":4109,"activeCount":204,"soonestReadout":52},[4110],{"nctId":50,"briefTitle":51,"status":164,"phases":4111,"primaryCompletion":52,"completion":174,"start":175,"enrollment":176,"conditions":4112,"interventions":4113},[91],[178],[53,180],{"trials":4115,"activeCount":100},[],{"trials":4117,"activeCount":100},[],{"intervention":1943,"totalTrials":204,"cells":4119},{"EARLY_PHASE1":4120,"PHASE1":4122,"PHASE2":4124,"PHASE3":4126,"PHASE4":4132,"NA":4134},{"trials":4121,"activeCount":100},[],{"trials":4123,"activeCount":100},[],{"trials":4125,"activeCount":100},[],{"trials":4127,"activeCount":204,"soonestReadout":1937},[4128],{"nctId":1934,"briefTitle":1935,"status":108,"phases":4129,"primaryCompletion":1937,"completion":1938,"start":1939,"enrollment":1940,"conditions":4130,"interventions":4131},[91],[37],[1943,1307,1322,1944],{"trials":4133,"activeCount":100},[],{"trials":4135,"activeCount":100},[],{"intervention":1944,"totalTrials":204,"cells":4137},{"EARLY_PHASE1":4138,"PHASE1":4140,"PHASE2":4142,"PHASE3":4144,"PHASE4":4150,"NA":4152},{"trials":4139,"activeCount":100},[],{"trials":4141,"activeCount":100},[],{"trials":4143,"activeCount":100},[],{"trials":4145,"activeCount":204,"soonestReadout":1937},[4146],{"nctId":1934,"briefTitle":1935,"status":108,"phases":4147,"primaryCompletion":1937,"completion":1938,"start":1939,"enrollment":1940,"conditions":4148,"interventions":4149},[91],[37],[1943,1307,1322,1944],{"trials":4151,"activeCount":100},[],{"trials":4153,"activeCount":100},[],{"intervention":4155,"totalTrials":204,"cells":4156},"ABP 938 8 mg",{"EARLY_PHASE1":4157,"PHASE1":4159,"PHASE2":4161,"PHASE3":4163,"PHASE4":4178,"NA":4180},{"trials":4158,"activeCount":100},[],{"trials":4160,"activeCount":100},[],{"trials":4162,"activeCount":100},[],{"trials":4164,"activeCount":204,"soonestReadout":4169},[4165],{"nctId":4166,"briefTitle":4167,"status":144,"phases":4168,"primaryCompletion":4169,"completion":4170,"start":4171,"enrollment":4172,"conditions":4173,"interventions":4176},"NCT07614776","A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration",[91],"2027-08-03","2028-01-17","2026-06-01",304,[4174,4175],"Neovascular Age-related Macular Degeneration","nAMD",[4155,4177],"Aflibercept (US) 8 mg",{"trials":4179,"activeCount":100},[],{"trials":4181,"activeCount":100},[],{"intervention":4177,"totalTrials":204,"cells":4183},{"EARLY_PHASE1":4184,"PHASE1":4186,"PHASE2":4188,"PHASE3":4190,"PHASE4":4196,"NA":4198},{"trials":4185,"activeCount":100},[],{"trials":4187,"activeCount":100},[],{"trials":4189,"activeCount":100},[],{"trials":4191,"activeCount":204,"soonestReadout":4169},[4192],{"nctId":4166,"briefTitle":4167,"status":144,"phases":4193,"primaryCompletion":4169,"completion":4170,"start":4171,"enrollment":4172,"conditions":4194,"interventions":4195},[91],[4174,4175],[4155,4177],{"trials":4197,"activeCount":100},[],{"trials":4199,"activeCount":100},[],{"intervention":1527,"totalTrials":204,"cells":4201},{"EARLY_PHASE1":4202,"PHASE1":4204,"PHASE2":4206,"PHASE3":4208,"PHASE4":4214,"NA":4216},{"trials":4203,"activeCount":100},[],{"trials":4205,"activeCount":100},[],{"trials":4207,"activeCount":100},[],{"trials":4209,"activeCount":204,"soonestReadout":1522},[4210],{"nctId":1519,"briefTitle":1520,"status":108,"phases":4211,"primaryCompletion":1522,"completion":1523,"start":1524,"enrollment":1433,"conditions":4212,"interventions":4213},[91],[1264],[1453,1527,1279,1528],{"trials":4215,"activeCount":100},[],{"trials":4217,"activeCount":100},[],{"intervention":4219,"totalTrials":204,"cells":4220},"Ocrelizumab",{"EARLY_PHASE1":4221,"PHASE1":4223,"PHASE2":4225,"PHASE3":4227,"PHASE4":4240,"NA":4242},{"trials":4222,"activeCount":100},[],{"trials":4224,"activeCount":100},[],{"trials":4226,"activeCount":100},[],{"trials":4228,"activeCount":204,"soonestReadout":4233},[4229],{"nctId":4230,"briefTitle":4231,"status":108,"phases":4232,"primaryCompletion":4233,"completion":4234,"start":2950,"enrollment":4235,"conditions":4236,"interventions":4238},"NCT06700343","Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)",[91],"2027-01-15","2027-12-17",444,[4237],"Relapsing-remitting Multiple Sclerosis (RRMS)",[4219,4219,4239],"ABP 692",{"trials":4241,"activeCount":100},[],{"trials":4243,"activeCount":100},[],{"intervention":4239,"totalTrials":204,"cells":4245},{"EARLY_PHASE1":4246,"PHASE1":4248,"PHASE2":4250,"PHASE3":4252,"PHASE4":4258,"NA":4260},{"trials":4247,"activeCount":100},[],{"trials":4249,"activeCount":100},[],{"trials":4251,"activeCount":100},[],{"trials":4253,"activeCount":204,"soonestReadout":4233},[4254],{"nctId":4230,"briefTitle":4231,"status":108,"phases":4255,"primaryCompletion":4233,"completion":4234,"start":2950,"enrollment":4235,"conditions":4256,"interventions":4257},[91],[4237],[4219,4219,4239],{"trials":4259,"activeCount":100},[],{"trials":4261,"activeCount":100},[],{"intervention":1780,"totalTrials":204,"cells":4263},{"EARLY_PHASE1":4264,"PHASE1":4266,"PHASE2":4268,"PHASE3":4270,"PHASE4":4276,"NA":4278},{"trials":4265,"activeCount":100},[],{"trials":4267,"activeCount":100},[],{"trials":4269,"activeCount":100},[],{"trials":4271,"activeCount":204,"soonestReadout":1773},[4272],{"nctId":1770,"briefTitle":1771,"status":164,"phases":4273,"primaryCompletion":1773,"completion":1774,"start":1775,"enrollment":1776,"conditions":4274,"interventions":4275},[91],[1778],[117,1780,1781],{"trials":4277,"activeCount":100},[],{"trials":4279,"activeCount":100},[],{"intervention":1781,"totalTrials":204,"cells":4281},{"EARLY_PHASE1":4282,"PHASE1":4284,"PHASE2":4286,"PHASE3":4288,"PHASE4":4294,"NA":4296},{"trials":4283,"activeCount":100},[],{"trials":4285,"activeCount":100},[],{"trials":4287,"activeCount":100},[],{"trials":4289,"activeCount":204,"soonestReadout":1773},[4290],{"nctId":1770,"briefTitle":1771,"status":164,"phases":4291,"primaryCompletion":1773,"completion":1774,"start":1775,"enrollment":1776,"conditions":4292,"interventions":4293},[91],[1778],[117,1780,1781],{"trials":4295,"activeCount":100},[],{"trials":4297,"activeCount":100},[],{"intervention":1804,"totalTrials":204,"cells":4299},{"EARLY_PHASE1":4300,"PHASE1":4302,"PHASE2":4304,"PHASE3":4306,"PHASE4":4312,"NA":4314},{"trials":4301,"activeCount":100},[],{"trials":4303,"activeCount":100},[],{"trials":4305,"activeCount":100},[],{"trials":4307,"activeCount":204,"soonestReadout":1797},[4308],{"nctId":1794,"briefTitle":1795,"status":144,"phases":4309,"primaryCompletion":1797,"completion":1798,"start":1799,"enrollment":1800,"conditions":4310,"interventions":4311},[91],[1802],[117,117,1804],{"trials":4313,"activeCount":100},[],{"trials":4315,"activeCount":100},[],{"intervention":1236,"totalTrials":204,"cells":4317},{"EARLY_PHASE1":4318,"PHASE1":4320,"PHASE2":4322,"PHASE3":4324,"PHASE4":4330,"NA":4332},{"trials":4319,"activeCount":100},[],{"trials":4321,"activeCount":100},[],{"trials":4323,"activeCount":100},[],{"trials":4325,"activeCount":204,"soonestReadout":57},[4326],{"nctId":55,"briefTitle":56,"status":164,"phases":4327,"primaryCompletion":57,"completion":1231,"start":1232,"enrollment":1233,"conditions":4328,"interventions":4329},[91],[1175],[58,1236,1237,1238],{"trials":4331,"activeCount":100},[],{"trials":4333,"activeCount":100},[],{"intervention":1237,"totalTrials":204,"cells":4335},{"EARLY_PHASE1":4336,"PHASE1":4338,"PHASE2":4340,"PHASE3":4342,"PHASE4":4348,"NA":4350},{"trials":4337,"activeCount":100},[],{"trials":4339,"activeCount":100},[],{"trials":4341,"activeCount":100},[],{"trials":4343,"activeCount":204,"soonestReadout":57},[4344],{"nctId":55,"briefTitle":56,"status":164,"phases":4345,"primaryCompletion":57,"completion":1231,"start":1232,"enrollment":1233,"conditions":4346,"interventions":4347},[91],[1175],[58,1236,1237,1238],{"trials":4349,"activeCount":100},[],{"trials":4351,"activeCount":100},[],{"intervention":1238,"totalTrials":204,"cells":4353},{"EARLY_PHASE1":4354,"PHASE1":4356,"PHASE2":4358,"PHASE3":4360,"PHASE4":4366,"NA":4368},{"trials":4355,"activeCount":100},[],{"trials":4357,"activeCount":100},[],{"trials":4359,"activeCount":100},[],{"trials":4361,"activeCount":204,"soonestReadout":57},[4362],{"nctId":55,"briefTitle":56,"status":164,"phases":4363,"primaryCompletion":57,"completion":1231,"start":1232,"enrollment":1233,"conditions":4364,"interventions":4365},[91],[1175],[58,1236,1237,1238],{"trials":4367,"activeCount":100},[],{"trials":4369,"activeCount":100},[],{"intervention":2840,"totalTrials":340,"cells":4371},{"EARLY_PHASE1":4372,"PHASE1":4374,"PHASE2":4376,"PHASE3":4440,"PHASE4":4526,"NA":4538},{"trials":4373,"activeCount":100},[],{"trials":4375,"activeCount":100},[],{"trials":4377,"activeCount":100},[4378,4387,4397,4406,4416,4427,4436],{"nctId":4379,"briefTitle":4380,"status":217,"phases":4381,"primaryCompletion":4382,"completion":4382,"start":4383,"enrollment":1070,"conditions":4384,"interventions":4386},"NCT00117143","Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)",[89,90],"2004-07-19","2002-12-02",[4385],"Thrombocytopenic Purpura",[2840],{"nctId":4388,"briefTitle":4389,"status":131,"phases":4390,"primaryCompletion":3225,"completion":3225,"start":4391,"enrollment":100,"conditions":4392,"interventions":4394},"NCT05323617","Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy",[90],"2023-08-31",[4393],"Severe Aplastic Anemia (SAA)",[2840,4395,4396],"Antithymocyte Globulin","Cyclosporine A",{"nctId":4398,"briefTitle":4399,"status":217,"phases":4400,"primaryCompletion":4401,"completion":4401,"start":4402,"enrollment":20,"conditions":4403,"interventions":4405},"NCT00111475","Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)",[90],"2004-06-17","2002-07-01",[4404],"Idiopathic Thrombocytopenic Purpura",[2840],{"nctId":4407,"briefTitle":4408,"status":217,"phases":4409,"primaryCompletion":4410,"completion":4411,"start":4412,"enrollment":4413,"conditions":4414,"interventions":4415},"NCT01143038","Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim",[90],"2013-09-20","2013-12-26","2010-11-30",75,[4404],[2840],{"nctId":4417,"briefTitle":4418,"status":217,"phases":4419,"primaryCompletion":4420,"completion":4420,"start":4421,"enrollment":1400,"conditions":4422,"interventions":4426},"NCT00303472","Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)",[90],"2008-05","2006-02",[2838,4423,4424,4425],"MDS","Myelodysplastic Syndromes","Refractory Cytopenias",[2840],{"nctId":4428,"briefTitle":4429,"status":217,"phases":4430,"primaryCompletion":4431,"completion":4432,"start":4433,"enrollment":994,"conditions":4434,"interventions":4435},"NCT00614523","Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)",[90],"2011-03-31","2015-11-30","2008-07-21",[4423,4424,2838],[2840],{"nctId":2829,"briefTitle":2830,"status":217,"phases":4437,"primaryCompletion":2541,"completion":2832,"start":2833,"enrollment":2834,"conditions":4438,"interventions":4439},[90],[2463,2836,1971,25,2837,2479,2441,2838],[2840,2467,1109,2468],{"trials":4441,"activeCount":204,"soonestReadout":4521},[4442,4450,4459,4471,4480,4488,4498,4508,4517],{"nctId":4443,"briefTitle":4444,"status":217,"phases":4445,"primaryCompletion":4446,"completion":4446,"start":3785,"enrollment":1617,"conditions":4447,"interventions":4449},"NCT01071954","A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura",[91],"2017-01-12",[4448],"Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP",[2840],{"nctId":4451,"briefTitle":4452,"status":131,"phases":4453,"primaryCompletion":4454,"completion":4454,"start":4455,"enrollment":100,"conditions":4456,"interventions":4458},"NCT03343847","Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.",[91],"2021-07-17","2018-01-27",[4457],"Chemotherapy-induced Thrombocytopenia",[2840],{"nctId":4460,"briefTitle":4461,"status":217,"phases":4462,"primaryCompletion":4463,"completion":4464,"start":4465,"enrollment":4466,"conditions":4467,"interventions":4469},"NCT00415532","Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura",[91],"2008-11-07","2009-05-11","2006-12-01",234,[4404,2838,4468,4385],"Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)",[4470,2840],"Medical Standard of Care for ITP",{"nctId":4472,"briefTitle":4473,"status":217,"phases":4474,"primaryCompletion":4475,"completion":4476,"start":1724,"enrollment":4477,"conditions":4478,"interventions":4479},"NCT03362177","Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer",[91],"2024-01-25","2025-01-09",165,[4457],[2840],{"nctId":4481,"briefTitle":4482,"status":217,"phases":4483,"primaryCompletion":4484,"completion":4484,"start":2475,"enrollment":4485,"conditions":4486,"interventions":4487},"NCT00116688","Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)",[91],"2010-01",313,[2838,4404],[2840],{"nctId":4489,"briefTitle":4490,"status":217,"phases":4491,"primaryCompletion":4492,"completion":4493,"start":4494,"enrollment":4495,"conditions":4496,"interventions":4497},"NCT00508820","An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP",[91],"2011-01-01","2011-03-01","2005-02-01",407,[4404,2838,4385],[2840],{"nctId":4499,"briefTitle":4500,"status":217,"phases":4501,"primaryCompletion":4502,"completion":4503,"start":4504,"enrollment":2219,"conditions":4505,"interventions":4507},"NCT02279173","Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)",[91],"2018-08-30","2019-08-08","2014-12-10",[4506],"Immune Thrombocytopenia",[2840],{"nctId":4509,"briefTitle":4510,"status":217,"phases":4511,"primaryCompletion":4512,"completion":4512,"start":1705,"enrollment":4513,"conditions":4514,"interventions":4516},"NCT01444417","Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients",[91],"2015-02",62,[4404,2838,4515,4468,4385,4506],"Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)",[2840],{"nctId":4518,"briefTitle":4519,"status":164,"phases":4520,"primaryCompletion":4521,"completion":4522,"start":4523,"enrollment":1877,"conditions":4524,"interventions":4525},"NCT03937154","Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer",[91],"2026-03-10","2027-02-23","2020-02-26",[4457],[2840],{"trials":4527,"activeCount":100},[4528],{"nctId":4529,"briefTitle":4530,"status":217,"phases":4531,"primaryCompletion":4532,"completion":3398,"start":4533,"enrollment":4534,"conditions":4535,"interventions":4536},"NCT00907478","Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)",[92],"2014-01-09","2009-08-11",169,[2838,4404],[4537],"romiplostim",{"trials":4539,"activeCount":100},[4540],{"nctId":4541,"briefTitle":4542,"status":217,"phases":4543,"primaryCompletion":4544,"completion":4545,"start":4546,"enrollment":1400,"conditions":4547,"interventions":4549},"NCT00472290","Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)",[93],"2011-07-18","2011-12-26","2007-04-01",[4548,4423,4424,2838],"Hematology",[2840],{"intervention":43,"totalTrials":2895,"cells":4551},{"EARLY_PHASE1":4552,"PHASE1":4554,"PHASE2":4637,"PHASE3":4639,"PHASE4":4645,"NA":4647},{"trials":4553,"activeCount":100},[],{"trials":4555,"activeCount":100},[4556,4564,4571,4579,4588,4596,4604,4612,4620,4628],{"nctId":4557,"briefTitle":4558,"status":217,"phases":4559,"primaryCompletion":750,"completion":4560,"start":4561,"enrollment":1907,"conditions":4562,"interventions":4563},"NCT05581758","A Study to Assess the Effect of Food on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants",[89],"2019-12-09","2019-11-14",[1857],[43],{"nctId":4565,"briefTitle":4566,"status":217,"phases":4567,"primaryCompletion":4568,"completion":4568,"start":2279,"enrollment":231,"conditions":4569,"interventions":4570},"NCT05571163","A Study to Evaluate the Relative Bioavailability of AMG 510 Administered as Tablets and as a Water Dispersion in Healthy Participants",[89],"2020-06-14",[1857],[43],{"nctId":4572,"briefTitle":4573,"status":217,"phases":4574,"primaryCompletion":4575,"completion":4575,"start":4576,"enrollment":1907,"conditions":4577,"interventions":4578},"NCT05581992","Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants",[89],"2020-01-26","2020-01-06",[1857],[43,1849],{"nctId":4580,"briefTitle":4581,"status":217,"phases":4582,"primaryCompletion":4583,"completion":4583,"start":4584,"enrollment":1907,"conditions":4585,"interventions":4586},"NCT05577624","A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy Participants",[89],"2019-12-01","2019-11-05",[1857],[43,4587],"Rifampin",{"nctId":4589,"briefTitle":4590,"status":217,"phases":4591,"primaryCompletion":4592,"completion":4592,"start":4593,"enrollment":1064,"conditions":4594,"interventions":4595},"NCT05578859","A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following a Single Oral Dose in Healthy Male Subjects",[89],"2020-03-24","2020-03-11",[2053],[43],{"nctId":4597,"briefTitle":4598,"status":217,"phases":4599,"primaryCompletion":750,"completion":750,"start":4600,"enrollment":231,"conditions":4601,"interventions":4602},"NCT05550129","Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy Participants",[89],"2019-11-13",[222],[43,4603],"Metformin",{"nctId":4605,"briefTitle":4606,"status":217,"phases":4607,"primaryCompletion":1314,"completion":1314,"start":4608,"enrollment":1907,"conditions":4609,"interventions":4610},"NCT05568082","A Study to Evaluate the Drug-drug Interaction Effect of Itraconazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants",[89],"2019-12-03",[1857],[43,4611],"Itraconazole",{"nctId":4613,"briefTitle":4614,"status":217,"phases":4615,"primaryCompletion":4616,"completion":4616,"start":2206,"enrollment":1907,"conditions":4617,"interventions":4618},"NCT05599828","A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants",[89],"2020-09-13",[1857],[43,1849,4619],"Famotidine",{"nctId":4621,"briefTitle":4622,"status":217,"phases":4623,"primaryCompletion":4624,"completion":4624,"start":4584,"enrollment":1907,"conditions":4625,"interventions":4626},"NCT05598281","Study to Evaluate the Effect of AMG 510 on the Pharmacokinetics (PK) of Digoxin in Healthy Participants",[89],"2019-11-19",[1857],[43,4627],"Digoxin",{"nctId":4629,"briefTitle":4630,"status":217,"phases":4631,"primaryCompletion":4632,"completion":3811,"start":4633,"enrollment":2895,"conditions":4634,"interventions":4636},"NCT04380753","AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).",[89],"2021-12-31","2020-04-28",[4635],"Advanced\u002FMetastatic Solid Tumors With KRAS p.G12C Mutation",[43],{"trials":4638,"activeCount":100},[],{"trials":4640,"activeCount":204,"soonestReadout":42},[4641],{"nctId":40,"briefTitle":41,"status":164,"phases":4642,"primaryCompletion":42,"completion":3103,"start":3104,"enrollment":3105,"conditions":4643,"interventions":4644},[91],[3107],[43,1279],{"trials":4646,"activeCount":100},[],{"trials":4648,"activeCount":100},[4649],{"nctId":4650,"briefTitle":4651,"status":1830,"phases":4652,"conditions":4653,"interventions":4657},"NCT04667234","Expanded Access of Sotorasib",[],[4654,4655,4656],"Non Small-cell Lung Cancer","Locally Advanced Unresectable NSCLC","Locally Advanced Metastatic NSCLC",[43],{"intervention":4659,"totalTrials":3338,"cells":4660},"Teprotumumab",{"EARLY_PHASE1":4661,"PHASE1":4663,"PHASE2":4700,"PHASE3":4715,"PHASE4":4746,"NA":4755},{"trials":4662,"activeCount":100},[],{"trials":4664,"activeCount":100},[4665,4674,4682,4691],{"nctId":4666,"briefTitle":4667,"status":217,"phases":4668,"primaryCompletion":4669,"completion":4669,"start":4670,"enrollment":4671,"conditions":4672,"interventions":4673},"NCT06674941","A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants",[89],"2023-11-14","2023-03-24",44,[222],[4659],{"nctId":4675,"briefTitle":4676,"status":217,"phases":4677,"primaryCompletion":2822,"completion":2822,"start":4678,"enrollment":325,"conditions":4679,"interventions":4681},"NCT02103283","A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)",[89],"2014-10",[4680],"Diabetic Macular Edema",[4659],{"nctId":4683,"briefTitle":4684,"status":217,"phases":4685,"primaryCompletion":4686,"completion":4687,"start":4688,"enrollment":305,"conditions":4689,"interventions":4690},"NCT07142642","A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants",[89],"2025-11-22","2026-01-15","2025-08-26",[222],[4659],{"nctId":4692,"briefTitle":4693,"status":217,"phases":4694,"primaryCompletion":4695,"completion":4696,"start":1846,"enrollment":1070,"conditions":4697,"interventions":4699},"NCT06389578","A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease",[89],"2023-02-28","2023-09-12",[4698],"Thyroid Eye Disease",[4659],{"trials":4701,"activeCount":100},[4702],{"nctId":4703,"briefTitle":4704,"status":217,"phases":4705,"primaryCompletion":2882,"completion":4706,"start":4707,"enrollment":4708,"conditions":4709,"interventions":4712},"NCT01868997","Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease",[90],"2017-02-22","2013-07",88,[4710,4711],"Thyroid Associated Ophthalmopathies","Thyroid-Associated Ophthalmopathy",[4713,4714],"teprotumumab","normal saline",{"trials":4716,"activeCount":204,"soonestReadout":4741},[4717,4726,4737],{"nctId":4718,"briefTitle":4719,"status":217,"phases":4720,"primaryCompletion":4721,"completion":4722,"start":4723,"enrollment":2257,"conditions":4724,"interventions":4725},"NCT03461211","Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study",[91],"2020-06-08","2021-02-17","2018-04-16",[4698],[4659],{"nctId":4727,"briefTitle":4728,"status":217,"phases":4729,"primaryCompletion":4730,"completion":4731,"start":4732,"enrollment":4733,"conditions":4734,"interventions":4736},"NCT03298867","Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study",[91],"2019-02-13","2020-11-30","2017-10-04",83,[4698,4735],"Graves' Orbitopathy",[4659],{"nctId":4738,"briefTitle":4739,"status":164,"phases":4740,"primaryCompletion":4741,"completion":4742,"start":4743,"enrollment":698,"conditions":4744,"interventions":4745},"NCT06248619","A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease",[91],"2026-01-14","2026-09-02","2024-07-05",[4698],[4659],{"trials":4747,"activeCount":100},[4748],{"nctId":4749,"briefTitle":4750,"status":217,"phases":4751,"primaryCompletion":1014,"completion":1014,"start":4752,"enrollment":4485,"conditions":4753,"interventions":4754},"NCT05002998","TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study",[92],"2021-09-16",[4698],[4659],{"trials":4756,"activeCount":100},[4757,4764],{"nctId":4758,"briefTitle":4759,"status":217,"phases":4760,"primaryCompletion":4761,"completion":4761,"start":2918,"enrollment":325,"conditions":4762,"interventions":4763},"NCT07085117","Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients",[],"2025-08-10",[4698],[4659],{"nctId":4765,"briefTitle":4766,"status":1246,"phases":4767,"conditions":4768,"interventions":4769},"NCT04040894","Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease",[],[4698,4735],[4659],{"intervention":4771,"totalTrials":985,"cells":4772},"bisphosphonate",{"EARLY_PHASE1":4773,"PHASE1":4775,"PHASE2":4777,"PHASE3":4779,"PHASE4":4785,"NA":4787},{"trials":4774,"activeCount":100},[],{"trials":4776,"activeCount":100},[],{"trials":4778,"activeCount":100},[],{"trials":4780,"activeCount":204,"soonestReadout":3746},[4781],{"nctId":3743,"briefTitle":3744,"status":164,"phases":4782,"primaryCompletion":3746,"completion":3747,"start":3748,"enrollment":1759,"conditions":4783,"interventions":4784},[91],[3604],[3592,3751],{"trials":4786,"activeCount":100},[],{"trials":4788,"activeCount":100},[4789],{"nctId":4790,"briefTitle":4791,"status":217,"phases":4792,"primaryCompletion":4793,"completion":4793,"start":4794,"enrollment":4795,"conditions":4796,"interventions":4797},"NCT02520362","Denosumab Safety Assessment in Multiple Observational Databases",[],"2023-07-21","2010-05-31",517991,[493],[4798,4771],"denosumab",{"intervention":1305,"totalTrials":325,"cells":4800},{"EARLY_PHASE1":4801,"PHASE1":4803,"PHASE2":4820,"PHASE3":4847,"PHASE4":4849,"NA":4851},{"trials":4802,"activeCount":100},[],{"trials":4804,"activeCount":985,"soonestReadout":1297},[4805,4809],{"nctId":1294,"briefTitle":1295,"status":164,"phases":4806,"primaryCompletion":1297,"completion":1298,"start":1299,"enrollment":1300,"conditions":4807,"interventions":4808},[89],[1302,1303],[1305,1109,1280,1152,1306,1307],{"nctId":4810,"briefTitle":4811,"status":164,"phases":4812,"primaryCompletion":1297,"completion":1298,"start":4813,"enrollment":4814,"conditions":4815,"interventions":4817},"NCT06360354","A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)",[89],"2024-05-29",120,[4816],"Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers",[1305,2467,1281,4818,4819],"Modified FOLFIRINOX","RMC-6236",{"trials":4821,"activeCount":985,"soonestReadout":1297},[4822,4826,4838],{"nctId":3086,"briefTitle":3087,"status":164,"phases":4823,"primaryCompletion":1298,"completion":1298,"start":3089,"enrollment":3090,"conditions":4824,"interventions":4825},[89,90],[3092],[1305,1279,3094],{"nctId":4827,"briefTitle":4828,"status":217,"phases":4829,"primaryCompletion":4830,"completion":4831,"start":4832,"enrollment":2500,"conditions":4833,"interventions":4836},"NCT05975073","A Phase 1\u002F2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors",[89,90],"2026-02-25","2026-03-26","2023-08-01",[4834,4835],"MTAP-null Non-Small-Cell Lung Cancer","MTAP-null Solid Tumors",[1305,4837],"IDE397",{"nctId":4839,"briefTitle":4840,"status":164,"phases":4841,"primaryCompletion":1297,"completion":1298,"start":4842,"enrollment":731,"conditions":4843,"interventions":4845},"NCT06593522","A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)",[90],"2024-12-26",[4844],"MTAP-deleted NSCLC",[4846],"anvumetostat",{"trials":4848,"activeCount":100},[],{"trials":4850,"activeCount":100},[],{"trials":4852,"activeCount":100},[],{"intervention":4854,"totalTrials":985,"cells":4855},"AMG 732",{"EARLY_PHASE1":4856,"PHASE1":4858,"PHASE2":4860,"PHASE3":4880,"PHASE4":4882,"NA":4884},{"trials":4857,"activeCount":100},[],{"trials":4859,"activeCount":100},[],{"trials":4861,"activeCount":985,"soonestReadout":4875},[4862,4871],{"nctId":4863,"briefTitle":4864,"status":108,"phases":4865,"primaryCompletion":4866,"completion":4867,"start":4868,"enrollment":866,"conditions":4869,"interventions":4870},"NCT07438405","An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease",[90],"2028-01-29","2028-07-14","2026-05-07",[4698],[4854],{"nctId":4872,"briefTitle":4873,"status":108,"phases":4874,"primaryCompletion":4875,"completion":4876,"start":4877,"enrollment":4708,"conditions":4878,"interventions":4879},"NCT06401044","A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease",[89,90],"2027-02-22","2027-08-13","2024-05-30",[4698],[4854],{"trials":4881,"activeCount":100},[],{"trials":4883,"activeCount":100},[],{"trials":4885,"activeCount":100},[],{"intervention":1930,"totalTrials":1164,"cells":4887},{"EARLY_PHASE1":4888,"PHASE1":4894,"PHASE2":4935,"PHASE3":4941,"PHASE4":4943,"NA":4945},{"trials":4889,"activeCount":100},[4890],{"nctId":2900,"briefTitle":2901,"status":217,"phases":4891,"primaryCompletion":2903,"completion":2904,"start":2905,"enrollment":35,"conditions":4892,"interventions":4893},[88],[2907],[2909,1930,2910,1849,2894],{"trials":4895,"activeCount":100},[4896,4906,4919,4928],{"nctId":4897,"briefTitle":4898,"status":336,"phases":4899,"primaryCompletion":4900,"completion":4901,"start":1703,"enrollment":380,"conditions":4902,"interventions":4904},"NCT02244112","A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies",[89],"2015-05-15","2019-07-10",[4903],"Advanced Non-Central Nervous System (CNS) Malignancies",[4905,1930],"Oprozomib",{"nctId":4907,"briefTitle":4908,"status":217,"phases":4909,"primaryCompletion":4910,"completion":4911,"start":4912,"enrollment":26,"conditions":4913,"interventions":4915},"NCT06004947","A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications",[89],"2016-03-15","2016-06-10","2016-01-14",[4914],"Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis",[4916,1930,4917,4611,4918],"CCX168","Celecoxib","Rifampicin",{"nctId":4920,"briefTitle":4921,"status":217,"phases":4922,"primaryCompletion":2114,"completion":2114,"start":4923,"enrollment":2527,"conditions":4924,"interventions":4926},"NCT02504476","Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective",[89],"2015-08",[4925],"Schizophrenia or Schizoaffective Disorder",[4927,1930],"AMG 581",{"nctId":4929,"briefTitle":4930,"status":217,"phases":4931,"primaryCompletion":4932,"completion":4932,"start":1627,"enrollment":866,"conditions":4933,"interventions":4934},"NCT01221727","The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam",[89],"2011-07",[3666],[3670,1930],{"trials":4936,"activeCount":204,"soonestReadout":1923},[4937],{"nctId":1920,"briefTitle":1921,"status":164,"phases":4938,"primaryCompletion":1923,"completion":1923,"start":1924,"enrollment":1413,"conditions":4939,"interventions":4940},[89,90],[1926],[1928,1929,1930],{"trials":4942,"activeCount":100},[],{"trials":4944,"activeCount":100},[],{"trials":4946,"activeCount":100},[],{"intervention":3173,"totalTrials":204,"cells":4948},{"EARLY_PHASE1":4949,"PHASE1":4951,"PHASE2":4953,"PHASE3":4959,"PHASE4":4961,"NA":4963},{"trials":4950,"activeCount":100},[],{"trials":4952,"activeCount":100},[],{"trials":4954,"activeCount":204,"soonestReadout":86},[4955],{"nctId":84,"briefTitle":85,"status":164,"phases":4956,"primaryCompletion":86,"completion":3167,"start":3168,"enrollment":1400,"conditions":4957,"interventions":4958},[89,90],[3170,3171],[72,3173,3174,3157],{"trials":4960,"activeCount":100},[],{"trials":4962,"activeCount":100},[],{"trials":4964,"activeCount":100},[],{"intervention":3174,"totalTrials":204,"cells":4966},{"EARLY_PHASE1":4967,"PHASE1":4969,"PHASE2":4971,"PHASE3":4977,"PHASE4":4979,"NA":4981},{"trials":4968,"activeCount":100},[],{"trials":4970,"activeCount":100},[],{"trials":4972,"activeCount":204,"soonestReadout":86},[4973],{"nctId":84,"briefTitle":85,"status":164,"phases":4974,"primaryCompletion":86,"completion":3167,"start":3168,"enrollment":1400,"conditions":4975,"interventions":4976},[89,90],[3170,3171],[72,3173,3174,3157],{"trials":4978,"activeCount":100},[],{"trials":4980,"activeCount":100},[],{"trials":4982,"activeCount":100},[],{"intervention":1929,"totalTrials":204,"cells":4984},{"EARLY_PHASE1":4985,"PHASE1":4987,"PHASE2":4989,"PHASE3":4995,"PHASE4":4997,"NA":4999},{"trials":4986,"activeCount":100},[],{"trials":4988,"activeCount":100},[],{"trials":4990,"activeCount":204,"soonestReadout":1923},[4991],{"nctId":1920,"briefTitle":1921,"status":164,"phases":4992,"primaryCompletion":1923,"completion":1923,"start":1924,"enrollment":1413,"conditions":4993,"interventions":4994},[89,90],[1926],[1928,1929,1930],{"trials":4996,"activeCount":100},[],{"trials":4998,"activeCount":100},[],{"trials":5000,"activeCount":100},[],{"intervention":3094,"totalTrials":204,"cells":5002},{"EARLY_PHASE1":5003,"PHASE1":5005,"PHASE2":5007,"PHASE3":5013,"PHASE4":5015,"NA":5017},{"trials":5004,"activeCount":100},[],{"trials":5006,"activeCount":100},[],{"trials":5008,"activeCount":204,"soonestReadout":1298},[5009],{"nctId":3086,"briefTitle":3087,"status":164,"phases":5010,"primaryCompletion":1298,"completion":1298,"start":3089,"enrollment":3090,"conditions":5011,"interventions":5012},[89,90],[3092],[1305,1279,3094],{"trials":5014,"activeCount":100},[],{"trials":5016,"activeCount":100},[],{"trials":5018,"activeCount":100},[],{"intervention":1111,"totalTrials":193,"cells":5020},{"EARLY_PHASE1":5021,"PHASE1":5023,"PHASE2":5043,"PHASE3":5045,"PHASE4":5047,"NA":5049},{"trials":5022,"activeCount":100},[],{"trials":5024,"activeCount":985,"soonestReadout":1312},[5025,5035,5039],{"nctId":5026,"briefTitle":5027,"status":217,"phases":5028,"primaryCompletion":5029,"completion":5030,"start":5031,"enrollment":439,"conditions":5032,"interventions":5034},"NCT03256344","Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases",[89],"2020-05-26","2021-12-03","2018-03-19",[5033,37],"Metastatic Triple Negative Breast Cancer",[1351,1111],{"nctId":1101,"briefTitle":1102,"status":164,"phases":5036,"primaryCompletion":1104,"completion":1104,"start":1105,"enrollment":1106,"conditions":5037,"interventions":5038},[89],[1085],[58,1109,1110,1111,1112],{"nctId":1309,"briefTitle":1310,"status":164,"phases":5040,"primaryCompletion":1312,"completion":1313,"start":1314,"enrollment":1315,"conditions":5041,"interventions":5042},[89],[1290,1317],[1307,1319,1320,1321,1152,1322,1323,1111,1324,1325,1326,1327,1327,1328,1099,1329],{"trials":5044,"activeCount":100},[],{"trials":5046,"activeCount":100},[],{"trials":5048,"activeCount":100},[],{"trials":5050,"activeCount":100},[],{"intervention":5052,"totalTrials":985,"cells":5053},"Evolocumab Drug Substance A",{"EARLY_PHASE1":5054,"PHASE1":5056,"PHASE2":5076,"PHASE3":5078,"PHASE4":5080,"NA":5082},{"trials":5055,"activeCount":100},[],{"trials":5057,"activeCount":985,"soonestReadout":5072},[5058,5068],{"nctId":5059,"briefTitle":5060,"status":144,"phases":5061,"primaryCompletion":5062,"completion":5062,"start":5063,"enrollment":5064,"conditions":5065,"interventions":5066},"NCT07545226","Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.",[89],"2026-09-08","2026-04-20",400,[1857],[5052,5067],"Evolocumab Drug Substance B",{"nctId":5069,"briefTitle":5070,"status":108,"phases":5071,"primaryCompletion":5072,"completion":5072,"start":5073,"enrollment":5064,"conditions":5074,"interventions":5075},"NCT07422285","Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose",[89],"2026-06-30","2026-01-16",[1857,2046],[5052,5067],{"trials":5077,"activeCount":100},[],{"trials":5079,"activeCount":100},[],{"trials":5081,"activeCount":100},[],{"trials":5083,"activeCount":100},[],{"intervention":5067,"totalTrials":985,"cells":5085},{"EARLY_PHASE1":5086,"PHASE1":5088,"PHASE2":5098,"PHASE3":5100,"PHASE4":5102,"NA":5104},{"trials":5087,"activeCount":100},[],{"trials":5089,"activeCount":985,"soonestReadout":5072},[5090,5094],{"nctId":5059,"briefTitle":5060,"status":144,"phases":5091,"primaryCompletion":5062,"completion":5062,"start":5063,"enrollment":5064,"conditions":5092,"interventions":5093},[89],[1857],[5052,5067],{"nctId":5069,"briefTitle":5070,"status":108,"phases":5095,"primaryCompletion":5072,"completion":5072,"start":5073,"enrollment":5064,"conditions":5096,"interventions":5097},[89],[1857,2046],[5052,5067],{"trials":5099,"activeCount":100},[],{"trials":5101,"activeCount":100},[],{"trials":5103,"activeCount":100},[],{"trials":5105,"activeCount":100},[],{"intervention":1280,"totalTrials":340,"cells":5107},{"EARLY_PHASE1":5108,"PHASE1":5110,"PHASE2":5131,"PHASE3":5181,"PHASE4":5219,"NA":5221},{"trials":5109,"activeCount":100},[],{"trials":5111,"activeCount":204,"soonestReadout":1297},[5112,5116,5120,5124],{"nctId":3030,"briefTitle":3031,"status":217,"phases":5113,"primaryCompletion":2661,"completion":1705,"start":3033,"enrollment":17,"conditions":5114,"interventions":5115},[89],[3035],[1279,1280,2428],{"nctId":1271,"briefTitle":1272,"status":336,"phases":5117,"primaryCompletion":52,"completion":52,"start":1274,"enrollment":1275,"conditions":5118,"interventions":5119},[89],[1277],[72,1279,1152,1109,1280,1281],{"nctId":1294,"briefTitle":1295,"status":164,"phases":5121,"primaryCompletion":1297,"completion":1298,"start":1299,"enrollment":1300,"conditions":5122,"interventions":5123},[89],[1302,1303],[1305,1109,1280,1152,1306,1307],{"nctId":5125,"briefTitle":5126,"status":217,"phases":5127,"primaryCompletion":2873,"completion":5128,"start":1695,"enrollment":1582,"conditions":5129,"interventions":5130},"NCT01992341","AMG 386 Drug-Drug Interaction Study With Paclitaxel",[89],"2014-09",[1290],[2807,1280],{"trials":5132,"activeCount":100},[5133,5143,5147,5156,5160,5164,5173,5177],{"nctId":5134,"briefTitle":5135,"status":336,"phases":5136,"primaryCompletion":2832,"completion":2803,"start":2833,"enrollment":5137,"conditions":5138,"interventions":5141},"NCT00356681","A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer",[90],282,[5139,5140,2794,3035],"Breast Neoplasms","Breast Tumors",[5142,2616,2428,1280],"AMG 706 placebo",{"nctId":2762,"briefTitle":2763,"status":336,"phases":5144,"primaryCompletion":2765,"completion":2766,"start":2767,"enrollment":2768,"conditions":5145,"interventions":5146},[90],[2770],[2616,2428,1280,1109],{"nctId":5148,"briefTitle":5149,"status":217,"phases":5150,"primaryCompletion":5151,"completion":5152,"start":2874,"enrollment":5153,"conditions":5154,"interventions":5155},"NCT00511459","Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients",[90],"2010-08","2014-05",228,[3035],[2808,2807,2616,2807,2807,1280],{"nctId":2773,"briefTitle":2774,"status":217,"phases":5157,"start":2776,"enrollment":2777,"conditions":5158,"interventions":5159},[90],[1971,2779,2463],[2781,2782,2783],{"nctId":2598,"briefTitle":2599,"status":217,"phases":5161,"primaryCompletion":2601,"completion":2601,"start":2602,"enrollment":2257,"conditions":5162,"interventions":5163},[89,90],[2463,1971],[1322,2605,1280,1109],{"nctId":5165,"briefTitle":5166,"status":217,"phases":5167,"primaryCompletion":4533,"completion":4560,"start":5168,"enrollment":5169,"conditions":5170,"interventions":5172},"NCT00479817","Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer",[90],"2007-07-05",161,[2795,2886,5171],"Primary Peritoneal Cancer",[2807,2807,1280,2808],{"nctId":2789,"briefTitle":2790,"status":217,"phases":5174,"primaryCompletion":2475,"completion":2422,"start":2792,"enrollment":731,"conditions":5175,"interventions":5176},[90],[2794,2463,2795],[2783,2782,2797],{"nctId":2810,"briefTitle":2811,"status":217,"phases":5178,"primaryCompletion":2451,"completion":2733,"start":2813,"enrollment":2814,"conditions":5179,"interventions":5180},[90],[1971],[2817,2616,1109,1280],{"trials":5182,"activeCount":100},[5183,5187,5195,5199,5203,5207],{"nctId":2844,"briefTitle":2845,"status":131,"phases":5184,"primaryCompletion":2847,"completion":2847,"start":2848,"enrollment":100,"conditions":5185,"interventions":5186},[91],[2850,2851],[2853,2616,1280,1109],{"nctId":5188,"briefTitle":5189,"status":217,"phases":5190,"primaryCompletion":5191,"completion":2883,"start":1627,"enrollment":5192,"conditions":5193,"interventions":5194},"NCT01204749","TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer",[91],"2013-03",919,[2886,2795,5171],[2807,2808,1280,1280],{"nctId":2855,"briefTitle":2856,"status":217,"phases":5196,"primaryCompletion":2858,"completion":2858,"start":2859,"enrollment":2860,"conditions":5197,"interventions":5198},[91],[2862],[1109,1280,2853,2616],{"nctId":2869,"briefTitle":2870,"status":336,"phases":5200,"primaryCompletion":2872,"completion":2873,"start":2874,"enrollment":2875,"conditions":5201,"interventions":5202},[91],[1971],[2428,2782,2783],{"nctId":2879,"briefTitle":2880,"status":336,"phases":5204,"primaryCompletion":2882,"completion":2883,"start":1705,"enrollment":2884,"conditions":5205,"interventions":5206},[91],[2886,2795,2887],[2807,1280,2808,1109],{"nctId":5208,"briefTitle":5209,"status":217,"phases":5210,"primaryCompletion":5211,"completion":5212,"start":5213,"enrollment":5214,"conditions":5215,"interventions":5216},"NCT01901146","Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer",[91],"2016-05-05","2017-01-27","2013-04-29",725,[2794],[5217,5218,1280],"ABP 980","Trastuzumab",{"trials":5220,"activeCount":100},[],{"trials":5222,"activeCount":100},[],{"intervention":1099,"totalTrials":1454,"cells":5224},{"EARLY_PHASE1":5225,"PHASE1":5227,"PHASE2":5270,"PHASE3":5276,"PHASE4":5278,"NA":5280},{"trials":5226,"activeCount":100},[],{"trials":5228,"activeCount":204,"soonestReadout":1312},[5229,5233,5242,5246,5255,5266],{"nctId":1089,"briefTitle":1090,"status":217,"phases":5230,"primaryCompletion":1092,"completion":1093,"start":1094,"enrollment":1095,"conditions":5231,"interventions":5232},[89],[1097],[58,1099],{"nctId":5234,"briefTitle":5235,"status":217,"phases":5236,"primaryCompletion":5237,"completion":3190,"start":5238,"enrollment":5239,"conditions":5240,"interventions":5241},"NCT03853109","AMG 404 in Patients With Advanced Solid Tumors",[89],"2022-07-19","2019-03-05",171,[1290],[1099],{"nctId":1309,"briefTitle":1310,"status":164,"phases":5243,"primaryCompletion":1312,"completion":1313,"start":1314,"enrollment":1315,"conditions":5244,"interventions":5245},[89],[1290,1317],[1307,1319,1320,1321,1152,1322,1323,1111,1324,1325,1326,1327,1327,1328,1099,1329],{"nctId":5247,"briefTitle":5248,"status":217,"phases":5249,"primaryCompletion":5250,"completion":5250,"start":5251,"enrollment":3338,"conditions":5252,"interventions":5253},"NCT04727554","Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors",[89],"2023-06-05","2021-04-29",[1290],[5254,1099],"AMG 994",{"nctId":5256,"briefTitle":5257,"status":336,"phases":5258,"primaryCompletion":5259,"completion":5260,"start":5261,"enrollment":866,"conditions":5262,"interventions":5264},"NCT03296696","Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma",[89],"2021-07-01","2021-08-28","2018-04-18",[5263],"Glioblastoma or Malignant Glioma",[5265,1099],"AMG 596",{"nctId":1588,"briefTitle":1589,"status":217,"phases":5267,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":1593,"conditions":5268,"interventions":5269},[89],[1595],[117,1099,1597],{"trials":5271,"activeCount":100},[5272],{"nctId":3137,"briefTitle":3138,"status":336,"phases":5273,"primaryCompletion":3140,"completion":3140,"start":3141,"enrollment":3142,"conditions":5274,"interventions":5275},[89,90],[1264],[3145,1539,1503,1099],{"trials":5277,"activeCount":100},[],{"trials":5279,"activeCount":100},[],{"trials":5281,"activeCount":100},[],{"intervention":2467,"totalTrials":160,"cells":5283},{"EARLY_PHASE1":5284,"PHASE1":5286,"PHASE2":5296,"PHASE3":5306,"PHASE4":5308,"NA":5310},{"trials":5285,"activeCount":100},[],{"trials":5287,"activeCount":204,"soonestReadout":1297},[5288,5292],{"nctId":4810,"briefTitle":4811,"status":164,"phases":5289,"primaryCompletion":1297,"completion":1298,"start":4813,"enrollment":4814,"conditions":5290,"interventions":5291},[89],[4816],[1305,2467,1281,4818,4819],{"nctId":2457,"briefTitle":2458,"status":336,"phases":5293,"primaryCompletion":2460,"completion":2461,"start":2422,"enrollment":1160,"conditions":5294,"interventions":5295},[89],[2463,2464,2465],[2428,1322,2467,2468],{"trials":5297,"activeCount":100},[5298,5302],{"nctId":2658,"briefTitle":2659,"status":336,"phases":5299,"primaryCompletion":2661,"completion":2661,"start":2662,"enrollment":193,"conditions":5300,"interventions":5301},[90],[2664,2665,2666,2464],[2467,2481],{"nctId":2829,"briefTitle":2830,"status":217,"phases":5303,"primaryCompletion":2541,"completion":2832,"start":2833,"enrollment":2834,"conditions":5304,"interventions":5305},[90],[2463,2836,1971,25,2837,2479,2441,2838],[2840,2467,1109,2468],{"trials":5307,"activeCount":100},[],{"trials":5309,"activeCount":100},[],{"trials":5311,"activeCount":100},[],{"intervention":1306,"totalTrials":985,"cells":5313},{"EARLY_PHASE1":5314,"PHASE1":5316,"PHASE2":5322,"PHASE3":5328,"PHASE4":5330,"NA":5332},{"trials":5315,"activeCount":100},[],{"trials":5317,"activeCount":204,"soonestReadout":1297},[5318],{"nctId":1294,"briefTitle":1295,"status":164,"phases":5319,"primaryCompletion":1297,"completion":1298,"start":1299,"enrollment":1300,"conditions":5320,"interventions":5321},[89],[1302,1303],[1305,1109,1280,1152,1306,1307],{"trials":5323,"activeCount":100},[5324],{"nctId":2799,"briefTitle":2800,"status":217,"phases":5325,"primaryCompletion":2802,"completion":2802,"start":2803,"enrollment":439,"conditions":5326,"interventions":5327},[89,90],[2805],[2807,2807,2808,1306,1109],{"trials":5329,"activeCount":100},[],{"trials":5331,"activeCount":100},[],{"trials":5333,"activeCount":100},[],{"intervention":246,"totalTrials":160,"cells":5335},{"EARLY_PHASE1":5336,"PHASE1":5338,"PHASE2":5364,"PHASE3":5366,"PHASE4":5368,"NA":5370},{"trials":5337,"activeCount":100},[],{"trials":5339,"activeCount":204,"soonestReadout":892},[5340,5344,5348,5360],{"nctId":3250,"briefTitle":3251,"status":217,"phases":5341,"primaryCompletion":3253,"completion":3254,"start":1421,"enrollment":26,"conditions":5342,"interventions":5343},[89],[3256],[3243,246],{"nctId":889,"briefTitle":890,"status":164,"phases":5345,"primaryCompletion":892,"completion":892,"start":893,"enrollment":894,"conditions":5346,"interventions":5347},[89],[896,897],[67,246],{"nctId":5349,"briefTitle":5350,"status":217,"phases":5351,"primaryCompletion":5352,"completion":5352,"start":5353,"enrollment":5354,"conditions":5355,"interventions":5357},"NCT01135680","Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100",[89],"2010-09","2010-05",98,[5356],"Drug Toxicity",[5358,5359,246,5358,5358],"HPN-100","HPN-100 or Placebo",{"nctId":236,"briefTitle":237,"status":217,"phases":5361,"primaryCompletion":239,"completion":240,"start":241,"enrollment":242,"conditions":5362,"interventions":5363},[89],[244],[208,246],{"trials":5365,"activeCount":100},[],{"trials":5367,"activeCount":100},[],{"trials":5369,"activeCount":100},[],{"trials":5371,"activeCount":100},[],{"intervention":1281,"totalTrials":985,"cells":5373},{"EARLY_PHASE1":5374,"PHASE1":5376,"PHASE2":5386,"PHASE3":5388,"PHASE4":5390,"NA":5392},{"trials":5375,"activeCount":100},[],{"trials":5377,"activeCount":204,"soonestReadout":1297},[5378,5382],{"nctId":1271,"briefTitle":1272,"status":336,"phases":5379,"primaryCompletion":52,"completion":52,"start":1274,"enrollment":1275,"conditions":5380,"interventions":5381},[89],[1277],[72,1279,1152,1109,1280,1281],{"nctId":4810,"briefTitle":4811,"status":164,"phases":5383,"primaryCompletion":1297,"completion":1298,"start":4813,"enrollment":4814,"conditions":5384,"interventions":5385},[89],[4816],[1305,2467,1281,4818,4819],{"trials":5387,"activeCount":100},[],{"trials":5389,"activeCount":100},[],{"trials":5391,"activeCount":100},[],{"trials":5393,"activeCount":100},[],{"intervention":3129,"totalTrials":204,"cells":5395},{"EARLY_PHASE1":5396,"PHASE1":5398,"PHASE2":5404,"PHASE3":5406,"PHASE4":5408,"NA":5410},{"trials":5397,"activeCount":100},[],{"trials":5399,"activeCount":204,"soonestReadout":3123},[5400],{"nctId":3120,"briefTitle":3121,"status":108,"phases":5401,"primaryCompletion":3123,"completion":3124,"start":3125,"enrollment":3126,"conditions":5402,"interventions":5403},[89],[1265],[3129,1503,1539],{"trials":5405,"activeCount":100},[],{"trials":5407,"activeCount":100},[],{"trials":5409,"activeCount":100},[],{"trials":5411,"activeCount":100},[],{"intervention":1087,"totalTrials":204,"cells":5413},{"EARLY_PHASE1":5414,"PHASE1":5416,"PHASE2":5422,"PHASE3":5424,"PHASE4":5426,"NA":5428},{"trials":5415,"activeCount":100},[],{"trials":5417,"activeCount":204,"soonestReadout":1080},[5418],{"nctId":1077,"briefTitle":1078,"status":108,"phases":5419,"primaryCompletion":1080,"completion":1081,"start":1082,"enrollment":1083,"conditions":5420,"interventions":5421},[89],[1085],[58,1087],{"trials":5423,"activeCount":100},[],{"trials":5425,"activeCount":100},[],{"trials":5427,"activeCount":100},[],{"trials":5429,"activeCount":100},[],{"intervention":1292,"totalTrials":204,"cells":5431},{"EARLY_PHASE1":5432,"PHASE1":5434,"PHASE2":5440,"PHASE3":5442,"PHASE4":5444,"NA":5446},{"trials":5433,"activeCount":100},[],{"trials":5435,"activeCount":204,"soonestReadout":1286},[5436],{"nctId":1283,"briefTitle":1284,"status":164,"phases":5437,"primaryCompletion":1286,"completion":1286,"start":1287,"enrollment":1288,"conditions":5438,"interventions":5439},[89],[1290],[1292,1152],{"trials":5441,"activeCount":100},[],{"trials":5443,"activeCount":100},[],{"trials":5445,"activeCount":100},[],{"trials":5447,"activeCount":100},[],{"intervention":5449,"totalTrials":204,"cells":5450},"AMG 127",{"EARLY_PHASE1":5451,"PHASE1":5453,"PHASE2":5465,"PHASE3":5467,"PHASE4":5469,"NA":5471},{"trials":5452,"activeCount":100},[],{"trials":5454,"activeCount":204,"soonestReadout":5459},[5455],{"nctId":5456,"briefTitle":5457,"status":144,"phases":5458,"primaryCompletion":5459,"completion":5459,"start":5460,"enrollment":5461,"conditions":5462,"interventions":5464},"NCT07590193","A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus",[89],"2027-10-02","2026-06-15",162,[5463],"Diabetes Mellitus, Type 2",[5449],{"trials":5466,"activeCount":100},[],{"trials":5468,"activeCount":100},[],{"trials":5470,"activeCount":100},[],{"trials":5472,"activeCount":100},[],{"intervention":5474,"totalTrials":204,"cells":5475},"AMG 691",{"EARLY_PHASE1":5476,"PHASE1":5478,"PHASE2":5488,"PHASE3":5490,"PHASE4":5492,"NA":5494},{"trials":5477,"activeCount":100},[],{"trials":5479,"activeCount":204,"soonestReadout":5484},[5480],{"nctId":5481,"briefTitle":5482,"status":108,"phases":5483,"primaryCompletion":5484,"completion":5484,"start":5485,"enrollment":2372,"conditions":5486,"interventions":5487},"NCT06637371","A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma",[89],"2027-06-07","2024-10-16",[2941],[5474],{"trials":5489,"activeCount":100},[],{"trials":5491,"activeCount":100},[],{"trials":5493,"activeCount":100},[],{"trials":5495,"activeCount":100},[],{"intervention":5497,"totalTrials":204,"cells":5498},"AMG 513",{"EARLY_PHASE1":5499,"PHASE1":5501,"PHASE2":5512,"PHASE3":5514,"PHASE4":5516,"NA":5518},{"trials":5500,"activeCount":100},[],{"trials":5502,"activeCount":204,"soonestReadout":5507},[5503],{"nctId":5504,"briefTitle":5505,"status":108,"phases":5506,"primaryCompletion":5507,"completion":5507,"start":1443,"enrollment":5508,"conditions":5509,"interventions":5511},"NCT06585462","Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity",[89],"2026-10-01",80,[5510],"Cardiometabolic Disease",[5497,5497],{"trials":5513,"activeCount":100},[],{"trials":5515,"activeCount":100},[],{"trials":5517,"activeCount":100},[],{"trials":5519,"activeCount":100},[],{"intervention":1502,"totalTrials":204,"cells":5521},{"EARLY_PHASE1":5522,"PHASE1":5524,"PHASE2":5530,"PHASE3":5532,"PHASE4":5534,"NA":5536},{"trials":5523,"activeCount":100},[],{"trials":5525,"activeCount":204,"soonestReadout":1496},[5526],{"nctId":1493,"briefTitle":1494,"status":108,"phases":5527,"primaryCompletion":1496,"completion":1497,"start":1498,"enrollment":13,"conditions":5528,"interventions":5529},[89],[1500],[1453,1502,1503],{"trials":5531,"activeCount":100},[],{"trials":5533,"activeCount":100},[],{"trials":5535,"activeCount":100},[],{"trials":5537,"activeCount":100},[],{"intervention":1121,"totalTrials":204,"cells":5539},{"EARLY_PHASE1":5540,"PHASE1":5542,"PHASE2":5548,"PHASE3":5550,"PHASE4":5552,"NA":5554},{"trials":5541,"activeCount":100},[],{"trials":5543,"activeCount":204,"soonestReadout":1117},[5544],{"nctId":1114,"briefTitle":1115,"status":164,"phases":5545,"primaryCompletion":1117,"completion":1117,"start":1118,"enrollment":29,"conditions":5546,"interventions":5547},[89],[1097],[1121,58,1112],{"trials":5549,"activeCount":100},[],{"trials":5551,"activeCount":100},[],{"trials":5553,"activeCount":100},[],{"trials":5555,"activeCount":100},[],{"intervention":1319,"totalTrials":204,"cells":5557},{"EARLY_PHASE1":5558,"PHASE1":5560,"PHASE2":5566,"PHASE3":5568,"PHASE4":5570,"NA":5572},{"trials":5559,"activeCount":100},[],{"trials":5561,"activeCount":204,"soonestReadout":1312},[5562],{"nctId":1309,"briefTitle":1310,"status":164,"phases":5563,"primaryCompletion":1312,"completion":1313,"start":1314,"enrollment":1315,"conditions":5564,"interventions":5565},[89],[1290,1317],[1307,1319,1320,1321,1152,1322,1323,1111,1324,1325,1326,1327,1327,1328,1099,1329],{"trials":5567,"activeCount":100},[],{"trials":5569,"activeCount":100},[],{"trials":5571,"activeCount":100},[],{"trials":5573,"activeCount":100},[],{"intervention":1320,"totalTrials":204,"cells":5575},{"EARLY_PHASE1":5576,"PHASE1":5578,"PHASE2":5584,"PHASE3":5586,"PHASE4":5588,"NA":5590},{"trials":5577,"activeCount":100},[],{"trials":5579,"activeCount":204,"soonestReadout":1312},[5580],{"nctId":1309,"briefTitle":1310,"status":164,"phases":5581,"primaryCompletion":1312,"completion":1313,"start":1314,"enrollment":1315,"conditions":5582,"interventions":5583},[89],[1290,1317],[1307,1319,1320,1321,1152,1322,1323,1111,1324,1325,1326,1327,1327,1328,1099,1329],{"trials":5585,"activeCount":100},[],{"trials":5587,"activeCount":100},[],{"trials":5589,"activeCount":100},[],{"trials":5591,"activeCount":100},[],{"intervention":1321,"totalTrials":204,"cells":5593},{"EARLY_PHASE1":5594,"PHASE1":5596,"PHASE2":5602,"PHASE3":5604,"PHASE4":5606,"NA":5608},{"trials":5595,"activeCount":100},[],{"trials":5597,"activeCount":204,"soonestReadout":1312},[5598],{"nctId":1309,"briefTitle":1310,"status":164,"phases":5599,"primaryCompletion":1312,"completion":1313,"start":1314,"enrollment":1315,"conditions":5600,"interventions":5601},[89],[1290,1317],[1307,1319,1320,1321,1152,1322,1323,1111,1324,1325,1326,1327,1327,1328,1099,1329],{"trials":5603,"activeCount":100},[],{"trials":5605,"activeCount":100},[],{"trials":5607,"activeCount":100},[],{"trials":5609,"activeCount":100},[],{"intervention":1323,"totalTrials":204,"cells":5611},{"EARLY_PHASE1":5612,"PHASE1":5614,"PHASE2":5620,"PHASE3":5622,"PHASE4":5624,"NA":5626},{"trials":5613,"activeCount":100},[],{"trials":5615,"activeCount":204,"soonestReadout":1312},[5616],{"nctId":1309,"briefTitle":1310,"status":164,"phases":5617,"primaryCompletion":1312,"completion":1313,"start":1314,"enrollment":1315,"conditions":5618,"interventions":5619},[89],[1290,1317],[1307,1319,1320,1321,1152,1322,1323,1111,1324,1325,1326,1327,1327,1328,1099,1329],{"trials":5621,"activeCount":100},[],{"trials":5623,"activeCount":100},[],{"trials":5625,"activeCount":100},[],{"trials":5627,"activeCount":100},[],{"intervention":1324,"totalTrials":204,"cells":5629},{"EARLY_PHASE1":5630,"PHASE1":5632,"PHASE2":5638,"PHASE3":5640,"PHASE4":5642,"NA":5644},{"trials":5631,"activeCount":100},[],{"trials":5633,"activeCount":204,"soonestReadout":1312},[5634],{"nctId":1309,"briefTitle":1310,"status":164,"phases":5635,"primaryCompletion":1312,"completion":1313,"start":1314,"enrollment":1315,"conditions":5636,"interventions":5637},[89],[1290,1317],[1307,1319,1320,1321,1152,1322,1323,1111,1324,1325,1326,1327,1327,1328,1099,1329],{"trials":5639,"activeCount":100},[],{"trials":5641,"activeCount":100},[],{"trials":5643,"activeCount":100},[],{"trials":5645,"activeCount":100},[],{"intervention":1325,"totalTrials":204,"cells":5647},{"EARLY_PHASE1":5648,"PHASE1":5650,"PHASE2":5656,"PHASE3":5658,"PHASE4":5660,"NA":5662},{"trials":5649,"activeCount":100},[],{"trials":5651,"activeCount":204,"soonestReadout":1312},[5652],{"nctId":1309,"briefTitle":1310,"status":164,"phases":5653,"primaryCompletion":1312,"completion":1313,"start":1314,"enrollment":1315,"conditions":5654,"interventions":5655},[89],[1290,1317],[1307,1319,1320,1321,1152,1322,1323,1111,1324,1325,1326,1327,1327,1328,1099,1329],{"trials":5657,"activeCount":100},[],{"trials":5659,"activeCount":100},[],{"trials":5661,"activeCount":100},[],{"trials":5663,"activeCount":100},[],{"intervention":1326,"totalTrials":204,"cells":5665},{"EARLY_PHASE1":5666,"PHASE1":5668,"PHASE2":5674,"PHASE3":5676,"PHASE4":5678,"NA":5680},{"trials":5667,"activeCount":100},[],{"trials":5669,"activeCount":204,"soonestReadout":1312},[5670],{"nctId":1309,"briefTitle":1310,"status":164,"phases":5671,"primaryCompletion":1312,"completion":1313,"start":1314,"enrollment":1315,"conditions":5672,"interventions":5673},[89],[1290,1317],[1307,1319,1320,1321,1152,1322,1323,1111,1324,1325,1326,1327,1327,1328,1099,1329],{"trials":5675,"activeCount":100},[],{"trials":5677,"activeCount":100},[],{"trials":5679,"activeCount":100},[],{"trials":5681,"activeCount":100},[],{"intervention":1327,"totalTrials":204,"cells":5683},{"EARLY_PHASE1":5684,"PHASE1":5686,"PHASE2":5692,"PHASE3":5694,"PHASE4":5696,"NA":5698},{"trials":5685,"activeCount":100},[],{"trials":5687,"activeCount":204,"soonestReadout":1312},[5688],{"nctId":1309,"briefTitle":1310,"status":164,"phases":5689,"primaryCompletion":1312,"completion":1313,"start":1314,"enrollment":1315,"conditions":5690,"interventions":5691},[89],[1290,1317],[1307,1319,1320,1321,1152,1322,1323,1111,1324,1325,1326,1327,1327,1328,1099,1329],{"trials":5693,"activeCount":100},[],{"trials":5695,"activeCount":100},[],{"trials":5697,"activeCount":100},[],{"trials":5699,"activeCount":100},[],{"intervention":1328,"totalTrials":204,"cells":5701},{"EARLY_PHASE1":5702,"PHASE1":5704,"PHASE2":5710,"PHASE3":5712,"PHASE4":5714,"NA":5716},{"trials":5703,"activeCount":100},[],{"trials":5705,"activeCount":204,"soonestReadout":1312},[5706],{"nctId":1309,"briefTitle":1310,"status":164,"phases":5707,"primaryCompletion":1312,"completion":1313,"start":1314,"enrollment":1315,"conditions":5708,"interventions":5709},[89],[1290,1317],[1307,1319,1320,1321,1152,1322,1323,1111,1324,1325,1326,1327,1327,1328,1099,1329],{"trials":5711,"activeCount":100},[],{"trials":5713,"activeCount":100},[],{"trials":5715,"activeCount":100},[],{"trials":5717,"activeCount":100},[],{"intervention":1329,"totalTrials":204,"cells":5719},{"EARLY_PHASE1":5720,"PHASE1":5722,"PHASE2":5728,"PHASE3":5730,"PHASE4":5732,"NA":5734},{"trials":5721,"activeCount":100},[],{"trials":5723,"activeCount":204,"soonestReadout":1312},[5724],{"nctId":1309,"briefTitle":1310,"status":164,"phases":5725,"primaryCompletion":1312,"completion":1313,"start":1314,"enrollment":1315,"conditions":5726,"interventions":5727},[89],[1290,1317],[1307,1319,1320,1321,1152,1322,1323,1111,1324,1325,1326,1327,1327,1328,1099,1329],{"trials":5729,"activeCount":100},[],{"trials":5731,"activeCount":100},[],{"trials":5733,"activeCount":100},[],{"trials":5735,"activeCount":100},[],{"intervention":4818,"totalTrials":204,"cells":5737},{"EARLY_PHASE1":5738,"PHASE1":5740,"PHASE2":5746,"PHASE3":5748,"PHASE4":5750,"NA":5752},{"trials":5739,"activeCount":100},[],{"trials":5741,"activeCount":204,"soonestReadout":1297},[5742],{"nctId":4810,"briefTitle":4811,"status":164,"phases":5743,"primaryCompletion":1297,"completion":1298,"start":4813,"enrollment":4814,"conditions":5744,"interventions":5745},[89],[4816],[1305,2467,1281,4818,4819],{"trials":5747,"activeCount":100},[],{"trials":5749,"activeCount":100},[],{"trials":5751,"activeCount":100},[],{"trials":5753,"activeCount":100},[],{"intervention":4819,"totalTrials":204,"cells":5755},{"EARLY_PHASE1":5756,"PHASE1":5758,"PHASE2":5764,"PHASE3":5766,"PHASE4":5768,"NA":5770},{"trials":5757,"activeCount":100},[],{"trials":5759,"activeCount":204,"soonestReadout":1297},[5760],{"nctId":4810,"briefTitle":4811,"status":164,"phases":5761,"primaryCompletion":1297,"completion":1298,"start":4813,"enrollment":4814,"conditions":5762,"interventions":5763},[89],[4816],[1305,2467,1281,4818,4819],{"trials":5765,"activeCount":100},[],{"trials":5767,"activeCount":100},[],{"trials":5769,"activeCount":100},[],{"trials":5771,"activeCount":100},[],{"intervention":1373,"totalTrials":204,"cells":5773},{"EARLY_PHASE1":5774,"PHASE1":5776,"PHASE2":5782,"PHASE3":5784,"PHASE4":5786,"NA":5788},{"trials":5775,"activeCount":100},[],{"trials":5777,"activeCount":204,"soonestReadout":1366},[5778],{"nctId":1363,"briefTitle":1364,"status":108,"phases":5779,"primaryCompletion":1366,"completion":1367,"start":1368,"enrollment":1369,"conditions":5780,"interventions":5781},[89],[1371],[1373,1152,1322],{"trials":5783,"activeCount":100},[],{"trials":5785,"activeCount":100},[],{"trials":5787,"activeCount":100},[],{"trials":5789,"activeCount":100},[],{"intervention":5791,"totalTrials":204,"cells":5792},"AMG 436",{"EARLY_PHASE1":5793,"PHASE1":5795,"PHASE2":5806,"PHASE3":5808,"PHASE4":5810,"NA":5812},{"trials":5794,"activeCount":100},[],{"trials":5796,"activeCount":204,"soonestReadout":5801},[5797],{"nctId":5798,"briefTitle":5799,"status":108,"phases":5800,"primaryCompletion":5801,"completion":5801,"start":1475,"enrollment":5802,"conditions":5803,"interventions":5805},"NCT07403721","AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H\u002FdMMR Solid Tumors",[89],"2028-06-28",464,[5804],"Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)",[5791],{"trials":5807,"activeCount":100},[],{"trials":5809,"activeCount":100},[],{"trials":5811,"activeCount":100},[],{"trials":5813,"activeCount":100},[],{"intervention":1513,"totalTrials":204,"cells":5815},{"EARLY_PHASE1":5816,"PHASE1":5818,"PHASE2":5824,"PHASE3":5826,"PHASE4":5828,"NA":5830},{"trials":5817,"activeCount":100},[],{"trials":5819,"activeCount":204,"soonestReadout":1508},[5820],{"nctId":1505,"briefTitle":1506,"status":108,"phases":5821,"primaryCompletion":1508,"completion":1509,"start":1510,"enrollment":23,"conditions":5822,"interventions":5823},[89],[1265],[1453,1513],{"trials":5825,"activeCount":100},[],{"trials":5827,"activeCount":100},[],{"trials":5829,"activeCount":100},[],{"trials":5831,"activeCount":100},[],{"intervention":1140,"totalTrials":204,"cells":5833},{"EARLY_PHASE1":5834,"PHASE1":5836,"PHASE2":5842,"PHASE3":5844,"PHASE4":5846,"NA":5848},{"trials":5835,"activeCount":100},[],{"trials":5837,"activeCount":204,"soonestReadout":1135},[5838],{"nctId":1132,"briefTitle":1133,"status":108,"phases":5839,"primaryCompletion":1135,"completion":1136,"start":1137,"enrollment":579,"conditions":5840,"interventions":5841},[89],[1097],[1140,58,1112],{"trials":5843,"activeCount":100},[],{"trials":5845,"activeCount":100},[],{"trials":5847,"activeCount":100},[],{"trials":5849,"activeCount":100},[],{"intervention":1153,"totalTrials":204,"cells":5851},{"EARLY_PHASE1":5852,"PHASE1":5854,"PHASE2":5860,"PHASE3":5862,"PHASE4":5864,"NA":5866},{"trials":5853,"activeCount":100},[],{"trials":5855,"activeCount":204,"soonestReadout":1145},[5856],{"nctId":1142,"briefTitle":1143,"status":164,"phases":5857,"primaryCompletion":1145,"completion":1146,"start":1147,"enrollment":1148,"conditions":5858,"interventions":5859},[89],[1150],[58,1152,1153],{"trials":5861,"activeCount":100},[],{"trials":5863,"activeCount":100},[],{"trials":5865,"activeCount":100},[],{"trials":5867,"activeCount":100},[],{"intervention":955,"totalTrials":204,"cells":5869},{"EARLY_PHASE1":5870,"PHASE1":5872,"PHASE2":5878,"PHASE3":5880,"PHASE4":5882,"NA":5884},{"trials":5871,"activeCount":100},[],{"trials":5873,"activeCount":204,"soonestReadout":951},[5874],{"nctId":948,"briefTitle":949,"status":108,"phases":5875,"primaryCompletion":951,"completion":951,"start":952,"enrollment":20,"conditions":5876,"interventions":5877},[89],[896,897],[955,67],{"trials":5879,"activeCount":100},[],{"trials":5881,"activeCount":100},[],{"trials":5883,"activeCount":100},[],{"trials":5885,"activeCount":100},[],{"intervention":5887,"totalTrials":985,"cells":5888},"UPLIZNA",{"EARLY_PHASE1":5889,"PHASE1":5891,"PHASE2":5893,"PHASE3":5895,"PHASE4":5897,"NA":5899},{"trials":5890,"activeCount":100},[],{"trials":5892,"activeCount":100},[],{"trials":5894,"activeCount":100},[],{"trials":5896,"activeCount":100},[],{"trials":5898,"activeCount":100},[],{"trials":5900,"activeCount":204,"soonestReadout":5905},[5901,5910],{"nctId":5902,"briefTitle":5903,"status":108,"phases":5904,"primaryCompletion":5905,"completion":5905,"start":5906,"enrollment":13,"conditions":5907,"interventions":5909},"NCT05909761","Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy",[],"2032-10-31","2026-04-15",[126,5908],"Pregnancy Related",[5887],{"nctId":5911,"briefTitle":5912,"status":3332,"phases":5913,"conditions":5914,"interventions":5915},"NCT06590051","AMG 335 Expanded Access Program for IgG4-Related Disease",[],[],[5887],{"intervention":5917,"totalTrials":204,"cells":5918},"erenumab-aooe",{"EARLY_PHASE1":5919,"PHASE1":5921,"PHASE2":5923,"PHASE3":5925,"PHASE4":5927,"NA":5929},{"trials":5920,"activeCount":100},[],{"trials":5922,"activeCount":100},[],{"trials":5924,"activeCount":100},[],{"trials":5926,"activeCount":100},[],{"trials":5928,"activeCount":100},[],{"trials":5930,"activeCount":204,"soonestReadout":5935},[5931],{"nctId":5932,"briefTitle":5933,"status":108,"phases":5934,"primaryCompletion":5935,"completion":5935,"start":2389,"enrollment":5936,"conditions":5937,"interventions":5938},"NCT06150781","Aimovig Pregnancy Exposure Registry",[],"2027-10-28",2842,[4039],[5917],{"intervention":5940,"totalTrials":340,"cells":5941},"Erenumab",{"EARLY_PHASE1":5942,"PHASE1":5944,"PHASE2":6000,"PHASE3":6052,"PHASE4":6083,"NA":6117},{"trials":5943,"activeCount":100},[],{"trials":5945,"activeCount":100},[5946,5956,5964,5973,5981,5990],{"nctId":5947,"briefTitle":5948,"status":217,"phases":5949,"primaryCompletion":5950,"completion":5951,"start":5952,"enrollment":1582,"conditions":5953,"interventions":5954},"NCT02542605","To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients",[89],"2017-09-28","2017-11-08","2015-11-11",[4039],[5940,5955],"PACAP-38 Challenge Agent",{"nctId":5957,"briefTitle":5958,"status":217,"phases":5959,"primaryCompletion":5960,"completion":5960,"start":5961,"enrollment":731,"conditions":5962,"interventions":5963},"NCT01688739","Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients",[89],"2013-03-27","2012-03-13",[4039],[5940],{"nctId":5965,"briefTitle":5966,"status":217,"phases":5967,"primaryCompletion":5968,"completion":5968,"start":5969,"enrollment":2028,"conditions":5970,"interventions":5971},"NCT02741310","Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan",[89],"2016-08-11","2016-02-22",[2053],[5972,5940],"Sumatriptan",{"nctId":5974,"briefTitle":5975,"status":217,"phases":5976,"primaryCompletion":5977,"completion":5977,"start":5978,"enrollment":2197,"conditions":5979,"interventions":5980},"NCT01723514","Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine Patients",[89],"2014-07-10","2012-11-14",[4039],[5940],{"nctId":5982,"briefTitle":5983,"status":217,"phases":5984,"primaryCompletion":5985,"completion":5985,"start":2330,"enrollment":1160,"conditions":5986,"interventions":5988},"NCT02792517","Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females",[89],"2016-09-09",[5987],"Headache, Migraine",[5940,5989],"Ethynil Estradiol\u002FNorgestimate Oral Contraceptive",{"nctId":5991,"briefTitle":5992,"status":217,"phases":5993,"primaryCompletion":5994,"completion":5994,"start":5995,"enrollment":5996,"conditions":5997,"interventions":5999},"NCT01890109","Study of Erenumab (AMG 334) in Women With Hot Flashes",[89],"2014-03-11","2013-05-13",103,[5998],"Vasomotor Symptoms; Hot Flashes",[5940],{"trials":6001,"activeCount":100},[6002,6012,6021,6033,6043],{"nctId":6003,"briefTitle":6004,"status":217,"phases":6005,"primaryCompletion":6006,"completion":6006,"start":6007,"enrollment":6008,"conditions":6009,"interventions":6011},"NCT02174861","A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.",[90],"2017-05-26","2014-06-30",609,[6010],"Treatment for Prevention of Chronic Migraine",[5940],{"nctId":6013,"briefTitle":6014,"status":217,"phases":6015,"primaryCompletion":1810,"completion":6016,"start":6017,"enrollment":698,"conditions":6018,"interventions":6020},"NCT02575833","Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)",[90],"2017-04-13","2015-11-23",[6019],"Stable Angina",[5940],{"nctId":6022,"briefTitle":6023,"status":217,"phases":6024,"primaryCompletion":6025,"completion":6026,"start":6027,"enrollment":6028,"conditions":6029,"interventions":6030},"NCT01952574","Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention",[90],"2014-09-25","2019-11-12","2013-08-06",483,[4039],[5940,6031,6032],"Erenumab PFS","Erenumab AI\u002FPen",{"nctId":6034,"briefTitle":6035,"status":217,"phases":6036,"primaryCompletion":6037,"completion":6038,"start":6039,"enrollment":6040,"conditions":6041,"interventions":6042},"NCT02066415","A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention",[90],"2016-02-24","2016-04-28","2014-03-05",667,[6010],[5940],{"nctId":6044,"briefTitle":6045,"status":217,"phases":6046,"primaryCompletion":2063,"completion":6047,"start":6048,"enrollment":6049,"conditions":6050,"interventions":6051},"NCT02630459","A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention",[90],"2019-06-05","2016-01-06",475,[4039],[5940,5940],{"trials":6053,"activeCount":100},[6054,6064,6074],{"nctId":6055,"briefTitle":6056,"status":217,"phases":6057,"primaryCompletion":6058,"completion":6059,"start":6060,"enrollment":6061,"conditions":6062,"interventions":6063},"NCT02483585","Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention",[91],"2016-07-11","2017-03-20","2015-07-20",577,[4039],[5940],{"nctId":6065,"briefTitle":6066,"status":217,"phases":6067,"primaryCompletion":6068,"completion":6069,"start":6070,"enrollment":6071,"conditions":6072,"interventions":6073},"NCT03812224","A Controlled Trial of Erenumab in Migraine Prevention",[91],"2020-03-16","2020-11-25","2019-04-12",261,[4039],[5940],{"nctId":6075,"briefTitle":6023,"status":217,"phases":6076,"primaryCompletion":6077,"completion":6078,"start":6079,"enrollment":6080,"conditions":6081,"interventions":6082},"NCT02456740",[91],"2016-09-05","2017-06-19","2015-07-17",955,[4039],[5940],{"trials":6084,"activeCount":100},[6085,6092,6101,6110],{"nctId":6086,"briefTitle":6087,"status":217,"phases":6088,"primaryCompletion":971,"completion":971,"start":3844,"enrollment":6089,"conditions":6090,"interventions":6091},"NCT04265755","Biomarker and Genetic Predictors of Erenumab Treatment Response",[92],1406,[4039],[5940],{"nctId":6093,"briefTitle":6094,"status":217,"phases":6095,"primaryCompletion":6096,"completion":6096,"start":6097,"enrollment":6098,"conditions":6099,"interventions":6100},"NCT04252742","Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine",[92],"2023-10-26","2020-09-15",512,[4039],[5940],{"nctId":6102,"briefTitle":6103,"status":217,"phases":6104,"primaryCompletion":6105,"completion":6105,"start":6106,"enrollment":6107,"conditions":6108,"interventions":6109},"NCT04825678","A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine",[92],"2023-09-28","2021-06-11",240,[4039],[5940],{"nctId":6111,"briefTitle":6112,"status":336,"phases":6113,"primaryCompletion":3281,"completion":3281,"start":6114,"enrollment":29,"conditions":6115,"interventions":6116},"NCT03912337","Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine",[92],"2019-12-04",[4039],[5940],{"trials":6118,"activeCount":100},[],{"intervention":5358,"totalTrials":1726,"cells":6120},{"EARLY_PHASE1":6121,"PHASE1":6123,"PHASE2":6149,"PHASE3":6177,"PHASE4":6199,"NA":6209},{"trials":6122,"activeCount":100},[],{"trials":6124,"activeCount":100},[6125,6134,6138],{"nctId":6126,"briefTitle":6127,"status":217,"phases":6128,"completion":2460,"start":6129,"enrollment":26,"conditions":6130,"interventions":6133},"NCT00986895","A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group",[89],"2006-09",[6131,6132],"Hepatic Encephalopathy","Urea Cycle Disorders",[5358],{"nctId":5349,"briefTitle":5350,"status":217,"phases":6135,"primaryCompletion":5352,"completion":5352,"start":5353,"enrollment":5354,"conditions":6136,"interventions":6137},[89],[5356],[5358,5359,246,5358,5358],{"nctId":6139,"briefTitle":6140,"status":217,"phases":6141,"completion":6142,"start":6143,"enrollment":253,"conditions":6144,"interventions":6146},"NCT00977600","A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)",[89],"2005-07","2005-03",[6145],"Healthy",[5358,6147,6148],"Ammonul","Buphenyl",{"trials":6150,"activeCount":100},[6151,6159,6168],{"nctId":6152,"briefTitle":6153,"status":217,"phases":6154,"primaryCompletion":1565,"completion":1565,"start":6155,"enrollment":1593,"conditions":6156,"interventions":6157},"NCT00947544","Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders",[90],"2010-03",[6132],[5358,6158],"NaPBA",{"nctId":6160,"briefTitle":6161,"status":217,"phases":6162,"primaryCompletion":1566,"completion":1566,"start":6163,"enrollment":6164,"conditions":6165,"interventions":6167},"NCT00999167","A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy",[90],"2009-12",189,[6166,6131],"Cirrhosis",[5358],{"nctId":6169,"briefTitle":6170,"status":217,"phases":6171,"primaryCompletion":6172,"completion":2541,"start":6173,"enrollment":1907,"conditions":6174,"interventions":6175},"NCT00551200","Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders",[90],"2008-07","2007-10",[6132],[5358,6176],"BUPHENYL®",{"trials":6178,"activeCount":100},[6179,6186,6193],{"nctId":6180,"briefTitle":6181,"status":217,"phases":6182,"primaryCompletion":5352,"completion":5352,"start":6183,"enrollment":17,"conditions":6184,"interventions":6185},"NCT00992459","Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders",[91],"2009-10",[6132],[5358,6148],{"nctId":6187,"briefTitle":6188,"status":217,"phases":6189,"primaryCompletion":6190,"completion":2733,"start":3833,"enrollment":13,"conditions":6191,"interventions":6192},"NCT00947297","Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)",[91],"2011-09",[6132],[5358],{"nctId":6194,"briefTitle":6195,"status":217,"phases":6196,"primaryCompletion":3869,"completion":5191,"start":4932,"enrollment":1095,"conditions":6197,"interventions":6198},"NCT01347073","Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)",[91],[6132],[5358],{"trials":6200,"activeCount":100},[6201],{"nctId":6202,"briefTitle":6203,"status":217,"phases":6204,"primaryCompletion":6205,"completion":6205,"start":6206,"enrollment":4708,"conditions":6207,"interventions":6208},"NCT01257737","To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)",[92],"2017-02-16","2010-10-04",[6132],[5358],{"trials":6210,"activeCount":100},[],{"intervention":6212,"totalTrials":96,"cells":6213},"Aranesp®",{"EARLY_PHASE1":6214,"PHASE1":6216,"PHASE2":6218,"PHASE3":6227,"PHASE4":6243,"NA":6288},{"trials":6215,"activeCount":100},[],{"trials":6217,"activeCount":100},[],{"trials":6219,"activeCount":100},[6220],{"nctId":6221,"briefTitle":6222,"status":217,"phases":6223,"start":6224,"enrollment":1433,"conditions":6225,"interventions":6226},"NCT00144131","Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy",[90],"2005-08",[16,25],[6212],{"trials":6228,"activeCount":100},[6229,6237],{"nctId":6230,"briefTitle":6231,"status":217,"phases":6232,"start":6233,"enrollment":6234,"conditions":6235,"interventions":6236},"NCT00116701","Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis",[91],"2005-05",200,[383],[6212],{"nctId":6238,"briefTitle":6239,"status":217,"phases":6240,"conditions":6241,"interventions":6242},"NCT00124098","An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)",[91],[383],[6212],{"trials":6244,"activeCount":100},[6245,6251,6257,6263,6270,6278],{"nctId":6246,"briefTitle":6247,"status":217,"phases":6248,"conditions":6249,"interventions":6250},"NCT00117130","Study to Evaluate Effectiveness of Aranesp®",[92],[383],[6212],{"nctId":6252,"briefTitle":6253,"status":217,"phases":6254,"conditions":6255,"interventions":6256},"NCT00117065","Study of Transplant Related Anemia Treated With Aranesp® (STRATA)",[92],[16],[6212],{"nctId":6258,"briefTitle":6259,"status":217,"phases":6260,"conditions":6261,"interventions":6262},"NCT00117078","Aranesp® Monthly Preference Study - 2",[92],[383],[6212],{"nctId":6264,"briefTitle":6265,"status":217,"phases":6266,"conditions":6267,"interventions":6269},"NCT00117104","Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis",[92],[6268],"End Stage Renal Disease",[6212],{"nctId":6271,"briefTitle":6272,"status":217,"phases":6273,"start":6274,"enrollment":5064,"conditions":6275,"interventions":6277},"NCT00111995","Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis",[92],"2002-05",[6276,16],"Chronic Renal Failure",[6212],{"nctId":6279,"briefTitle":6280,"status":217,"phases":6281,"completion":6282,"start":6283,"enrollment":6284,"conditions":6285,"interventions":6287},"NCT00117039","A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia",[92],"2005-04","2004-01",1500,[16,6286],"Neoplasms",[6212],{"trials":6289,"activeCount":100},[],{"intervention":6291,"totalTrials":1064,"cells":6292},"Zoledronic Acid",{"EARLY_PHASE1":6293,"PHASE1":6295,"PHASE2":6297,"PHASE3":6313,"PHASE4":6368,"NA":6380},{"trials":6294,"activeCount":100},[],{"trials":6296,"activeCount":100},[],{"trials":6298,"activeCount":100},[6299,6309],{"nctId":6300,"briefTitle":6301,"status":217,"phases":6302,"primaryCompletion":640,"completion":6303,"start":6304,"enrollment":6305,"conditions":6306,"interventions":6307},"NCT01951586","Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer",[90],"2017-11-28","2013-12-31",226,[1971],[3670,3671,6308],"Standard Chemotherapy",{"nctId":3657,"briefTitle":3658,"status":217,"phases":6310,"primaryCompletion":3660,"completion":3661,"start":3662,"enrollment":3663,"conditions":6311,"interventions":6312},[90],[3665,3666],[3668,3669,3592,3670,3671],{"trials":6314,"activeCount":100},[6315,6325,6337,6348,6359],{"nctId":6316,"briefTitle":6317,"status":217,"phases":6318,"primaryCompletion":2084,"completion":6319,"start":6320,"enrollment":6321,"conditions":6322,"interventions":6324},"NCT00330759","Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.",[91],"2011-10-01","2006-06-01",1779,[6323],"Bone Metastases",[3670,6291],{"nctId":6326,"briefTitle":6327,"status":217,"phases":6328,"primaryCompletion":6329,"completion":6330,"start":6331,"enrollment":6332,"conditions":6333,"interventions":6336},"NCT01345019","Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma",[91],"2016-07-19","2019-03-29","2012-05-17",1718,[25,6334,31,2479,6323,6335],"Hematologic Malignancies","Multiple Myeloma Bone Lesions",[3670,3671,3670],{"nctId":6338,"briefTitle":6339,"status":217,"phases":6340,"primaryCompletion":6341,"completion":6342,"start":6343,"enrollment":6344,"conditions":6345,"interventions":6346},"NCT00556374","Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy",[91],"2014-10-07","2022-07-26","2006-12-18",3420,[2794],[3670,6347,6291],"Non-steroidal aromatase inhibitor therapy",{"nctId":6349,"briefTitle":6350,"status":217,"phases":6351,"primaryCompletion":6352,"completion":6353,"start":6354,"enrollment":6355,"conditions":6356,"interventions":6357},"NCT00321620","Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer",[91],"2009-10-01","2012-02-24","2006-04-01",1904,[6323],[6358,4798],"zoledronic acid",{"nctId":6360,"briefTitle":6361,"status":217,"phases":6362,"primaryCompletion":6363,"completion":6364,"start":6354,"enrollment":6365,"conditions":6366,"interventions":6367},"NCT00321464","A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.",[91],"2009-07-20","2012-04-04",2049,[6323],[3670,6291],{"trials":6369,"activeCount":100},[6370],{"nctId":6371,"briefTitle":6372,"status":217,"phases":6373,"primaryCompletion":6374,"completion":6374,"start":6375,"enrollment":6376,"conditions":6377,"interventions":6379},"NCT01732770","Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis",[92],"2015-01-07","2012-11-07",643,[6378],"Post Menopausal Osteoporosis",[3670,6291],{"trials":6381,"activeCount":100},[],{"intervention":6383,"totalTrials":1164,"cells":6384},"AMG 073",{"EARLY_PHASE1":6385,"PHASE1":6387,"PHASE2":6389,"PHASE3":6408,"PHASE4":6434,"NA":6444},{"trials":6386,"activeCount":100},[],{"trials":6388,"activeCount":100},[],{"trials":6390,"activeCount":100},[6391,6400],{"nctId":6392,"briefTitle":6393,"status":217,"phases":6394,"primaryCompletion":6395,"completion":6395,"start":6396,"enrollment":20,"conditions":6397,"interventions":6399},"NCT00527085","12-month Study of AMG 073 in Renal Osteodystrophy",[90],"2003-08","2001-10",[6398],"Renal Osteodystrophy",[6383],{"nctId":6401,"briefTitle":6402,"status":217,"phases":6403,"start":6404,"enrollment":6405,"conditions":6406,"interventions":6407},"NCT00110929","Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)",[90],"2002-11",850,[6268],[6383],{"trials":6409,"activeCount":100},[6410,6417,6425],{"nctId":6411,"briefTitle":6412,"status":217,"phases":6413,"primaryCompletion":6414,"completion":6414,"start":6274,"enrollment":1083,"conditions":6415,"interventions":6416},"NCT00042653","A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis",[91],"2003-07",[384,6268],[6383],{"nctId":6418,"briefTitle":6419,"status":217,"phases":6420,"primaryCompletion":6421,"completion":6421,"start":6422,"enrollment":5064,"conditions":6423,"interventions":6424},"NCT00037635","A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients",[91],"2003-03","2001-12",[384,6268],[6383],{"nctId":6426,"briefTitle":6427,"status":217,"phases":6428,"primaryCompletion":6429,"completion":6429,"start":6430,"enrollment":6431,"conditions":6432,"interventions":6433},"NCT00527267","Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects",[91],"2003-04","2002-02",320,[382],[6383],{"trials":6435,"activeCount":100},[6436],{"nctId":6437,"briefTitle":6438,"status":217,"phases":6439,"start":6440,"enrollment":17,"conditions":6441,"interventions":6443},"NCT00037518","A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer",[92],"2001-04",[382,6442],"Parathyroid Neoplasms",[6383],{"trials":6445,"activeCount":100},[],{"intervention":6447,"totalTrials":325,"cells":6448},"Anakinra",{"EARLY_PHASE1":6449,"PHASE1":6451,"PHASE2":6453,"PHASE3":6483,"PHASE4":6491,"NA":6499},{"trials":6450,"activeCount":100},[],{"trials":6452,"activeCount":100},[],{"trials":6454,"activeCount":100},[6455,6465,6475],{"nctId":6456,"briefTitle":6457,"status":217,"phases":6458,"completion":6459,"start":6460,"conditions":6461,"interventions":6462},"NCT00037700","Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis",[90],"2002-12","2001-05",[19],[6463,6464],"anakinra","pegsunercept",{"nctId":6466,"briefTitle":6467,"status":336,"phases":6468,"primaryCompletion":6421,"completion":6469,"start":6470,"enrollment":6471,"conditions":6472,"interventions":6473},"NCT00537667","The SPECTRA Study",[90],"2003-06","2001-08",22,[19],[6463,6474],"anakinra and PEG sTNF-R1",{"nctId":6476,"briefTitle":3799,"status":217,"phases":6477,"primaryCompletion":6478,"completion":6478,"start":6479,"enrollment":2476,"conditions":6480,"interventions":6482},"NCT00037648",[90],"2003-11","2000-07",[6481],"Juvenile Chronic Arthritis",[6447],{"trials":6484,"activeCount":100},[6485],{"nctId":6486,"briefTitle":6487,"status":217,"phases":6488,"conditions":6489,"interventions":6490},"NCT00117091","Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA)",[91],[19],[6447],{"trials":6492,"activeCount":100},[6493],{"nctId":6494,"briefTitle":6495,"status":217,"phases":6496,"completion":6478,"conditions":6497,"interventions":6498},"NCT00111410","Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse in Subjects With Rheumatoid Arthritis (RA)",[92],[19],[6447],{"trials":6500,"activeCount":100},[],{"intervention":6502,"totalTrials":193,"cells":6503},"TEPEZZA",{"EARLY_PHASE1":6504,"PHASE1":6506,"PHASE2":6530,"PHASE3":6532,"PHASE4":6534,"NA":6545},{"trials":6505,"activeCount":100},[],{"trials":6507,"activeCount":100},[6508,6520],{"nctId":6509,"briefTitle":6510,"status":217,"phases":6511,"primaryCompletion":6512,"completion":6512,"start":6513,"enrollment":6514,"conditions":6515,"interventions":6518},"NCT06563856","A Study of TEPEZZA Subcutaneous Administration in Healthy Adults",[89],"2021-05-27","2020-09-22",37,[6516,6517],"Bioavailability","Bioequivalence",[6502,6519],"EDP",{"nctId":6521,"briefTitle":6522,"status":336,"phases":6523,"primaryCompletion":6524,"completion":6525,"start":6526,"enrollment":193,"conditions":6527,"interventions":6529},"NCT04478994","A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)",[89],"2022-11-29","2022-12-08","2021-11-17",[6528],"Diffuse Cutaneous Systemic Sclerosis",[6502],{"trials":6531,"activeCount":100},[],{"trials":6533,"activeCount":100},[],{"trials":6535,"activeCount":100},[6536],{"nctId":6537,"briefTitle":6538,"status":217,"phases":6539,"primaryCompletion":6540,"completion":6541,"start":1580,"enrollment":4513,"conditions":6542,"interventions":6544},"NCT04583735","A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease",[92],"2023-03-17","2023-10-12",[4698,6543],"Chronic (Inactive) Thyroid Eye Disease",[6502],{"trials":6546,"activeCount":100},[],{"intervention":6548,"totalTrials":985,"cells":6549},"RAVICTI",{"EARLY_PHASE1":6550,"PHASE1":6552,"PHASE2":6554,"PHASE3":6556,"PHASE4":6558,"NA":6579},{"trials":6551,"activeCount":100},[],{"trials":6553,"activeCount":100},[],{"trials":6555,"activeCount":100},[],{"trials":6557,"activeCount":100},[],{"trials":6559,"activeCount":100},[6560,6570],{"nctId":6561,"briefTitle":6562,"status":217,"phases":6563,"primaryCompletion":6564,"completion":6565,"start":6566,"enrollment":1070,"conditions":6567,"interventions":6569},"NCT03335488","Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)",[92],"2022-07-05","2022-12-20","2018-02-20",[6568],"Urea Cycle Disorder",[6548,6158],{"nctId":6571,"briefTitle":6572,"status":217,"phases":6573,"primaryCompletion":6574,"completion":6575,"start":6576,"enrollment":1545,"conditions":6577,"interventions":6578},"NCT02246218","A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders",[92],"2016-10-17","2017-07-17","2014-12-31",[6568],[6548],{"trials":6580,"activeCount":100},[],{"intervention":6158,"totalTrials":985,"cells":6582},{"EARLY_PHASE1":6583,"PHASE1":6585,"PHASE2":6587,"PHASE3":6593,"PHASE4":6595,"NA":6601},{"trials":6584,"activeCount":100},[],{"trials":6586,"activeCount":100},[],{"trials":6588,"activeCount":100},[6589],{"nctId":6152,"briefTitle":6153,"status":217,"phases":6590,"primaryCompletion":1565,"completion":1565,"start":6155,"enrollment":1593,"conditions":6591,"interventions":6592},[90],[6132],[5358,6158],{"trials":6594,"activeCount":100},[],{"trials":6596,"activeCount":100},[6597],{"nctId":6561,"briefTitle":6562,"status":217,"phases":6598,"primaryCompletion":6564,"completion":6565,"start":6566,"enrollment":1070,"conditions":6599,"interventions":6600},[92],[6568],[6548,6158],{"trials":6602,"activeCount":100},[],{"intervention":6604,"totalTrials":985,"cells":6605},"Vitamin D",{"EARLY_PHASE1":6606,"PHASE1":6608,"PHASE2":6610,"PHASE3":6612,"PHASE4":6614,"NA":6632},{"trials":6607,"activeCount":100},[],{"trials":6609,"activeCount":100},[],{"trials":6611,"activeCount":100},[],{"trials":6613,"activeCount":100},[],{"trials":6615,"activeCount":100},[6616,6625],{"nctId":6617,"briefTitle":6618,"status":217,"phases":6619,"primaryCompletion":6620,"completion":6621,"start":6622,"enrollment":4485,"conditions":6623,"interventions":6624},"NCT00803712","20070360 Incident Dialysis",[92],"2010-12-09","2011-07-05","2009-02-01",[28,384],[3382,6604],{"nctId":6626,"briefTitle":6627,"status":217,"phases":6628,"primaryCompletion":2474,"completion":2833,"start":6224,"enrollment":2066,"conditions":6629,"interventions":6630},"NCT00135304","ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism",[92],[384],[6631,6604],"Sensipar®",{"trials":6633,"activeCount":100},[],{"intervention":6635,"totalTrials":985,"cells":6636},"Ivabradine",{"EARLY_PHASE1":6637,"PHASE1":6639,"PHASE2":6641,"PHASE3":6643,"PHASE4":6654,"NA":6665},{"trials":6638,"activeCount":100},[],{"trials":6640,"activeCount":100},[],{"trials":6642,"activeCount":100},[],{"trials":6644,"activeCount":100},[6645],{"nctId":6646,"briefTitle":6647,"status":131,"phases":6648,"primaryCompletion":6649,"completion":6649,"start":6650,"enrollment":100,"conditions":6651,"interventions":6653},"NCT03619187","An Interventional Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients",[91],"2020-02-19","2018-11-02",[6652],"Heart Transplantation, Elevated Resting Heart Rate",[6635],{"trials":6655,"activeCount":100},[6656],{"nctId":6657,"briefTitle":6658,"status":217,"phases":6659,"primaryCompletion":6660,"completion":6661,"start":5950,"enrollment":866,"conditions":6662,"interventions":6664},"NCT03456856","A Study of Ivabradine in African-American\u002F Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.",[92],"2019-04-19","2019-05-20",[6663],"Heart Failure (HF)",[6635],{"trials":6666,"activeCount":100},[],{"intervention":3862,"totalTrials":985,"cells":6668},{"EARLY_PHASE1":6669,"PHASE1":6671,"PHASE2":6684,"PHASE3":6686,"PHASE4":6688,"NA":6694},{"trials":6670,"activeCount":100},[],{"trials":6672,"activeCount":100},[6673],{"nctId":6674,"briefTitle":6675,"status":217,"phases":6676,"primaryCompletion":6677,"completion":6677,"start":6678,"enrollment":278,"conditions":6679,"interventions":6681},"NCT07429032","The Effect of AMG 133 on Gastric Emptying",[89],"2025-11-26","2025-04-17",[6680],"Overweight or Obesity",[6682,6683],"AMG 133","Acetaminophen",{"trials":6685,"activeCount":100},[],{"trials":6687,"activeCount":100},[],{"trials":6689,"activeCount":100},[6690],{"nctId":3852,"briefTitle":3853,"status":217,"phases":6691,"primaryCompletion":3855,"completion":3856,"start":3857,"enrollment":2302,"conditions":6692,"interventions":6693},[92],[3847],[3816,3778,3860,3861,3862,3863],{"trials":6695,"activeCount":100},[],{"intervention":3863,"totalTrials":985,"cells":6697},{"EARLY_PHASE1":6698,"PHASE1":6700,"PHASE2":6702,"PHASE3":6720,"PHASE4":6722,"NA":6728},{"trials":6699,"activeCount":100},[],{"trials":6701,"activeCount":100},[],{"trials":6703,"activeCount":100},[6704],{"nctId":6705,"briefTitle":6706,"status":217,"phases":6707,"primaryCompletion":6708,"completion":6709,"start":6710,"enrollment":32,"conditions":6711,"interventions":6716},"NCT04046549","A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant",[90],"2022-07-18","2023-03-22","2019-10-30",[6712,6713,6714,6715],"Allografts","Rejection; Transplant, Kidney","Transplant Rejection","Kidney Transplantation",[6717,139,6718,6719],"Belatacept","Thymoglobulin","Methylprednisolone",{"trials":6721,"activeCount":100},[],{"trials":6723,"activeCount":100},[6724],{"nctId":3852,"briefTitle":3853,"status":217,"phases":6725,"primaryCompletion":3855,"completion":3856,"start":3857,"enrollment":2302,"conditions":6726,"interventions":6727},[92],[3847],[3816,3778,3860,3861,3862,3863],{"trials":6729,"activeCount":100},[],{"intervention":6731,"totalTrials":985,"cells":6732},"Neulasta",{"EARLY_PHASE1":6733,"PHASE1":6735,"PHASE2":6737,"PHASE3":6748,"PHASE4":6750,"NA":6761},{"trials":6734,"activeCount":100},[],{"trials":6736,"activeCount":100},[],{"trials":6738,"activeCount":100},[6739],{"nctId":6740,"briefTitle":6741,"status":217,"phases":6742,"primaryCompletion":2460,"completion":6743,"start":6744,"enrollment":5508,"conditions":6745,"interventions":6746},"NCT00261313","ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer",[90],"2007-12","2005-12",[2794],[6731,6747],"Aranesp",{"trials":6749,"activeCount":100},[],{"trials":6751,"activeCount":100},[6752],{"nctId":6753,"briefTitle":6754,"status":217,"phases":6755,"primaryCompletion":6756,"completion":2602,"start":6757,"enrollment":6758,"conditions":6759,"interventions":6760},"NCT00277160","A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>\u002F= 65 Years Old) With Cancer",[92],"2004-11","2002-06",852,[3082,2794,2463,1584,2795],[6731],{"trials":6762,"activeCount":100},[],{"intervention":6764,"totalTrials":985,"cells":6765},"Sensipar",{"EARLY_PHASE1":6766,"PHASE1":6768,"PHASE2":6770,"PHASE3":6780,"PHASE4":6782,"NA":6791},{"trials":6767,"activeCount":100},[],{"trials":6769,"activeCount":100},[],{"trials":6771,"activeCount":100},[6772],{"nctId":6773,"briefTitle":6774,"status":217,"phases":6775,"primaryCompletion":6776,"completion":6776,"start":6777,"enrollment":916,"conditions":6778,"interventions":6779},"NCT00261950","Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease",[90],"2011-05","2006-05",[384],[6764],{"trials":6781,"activeCount":100},[],{"trials":6783,"activeCount":100},[6784],{"nctId":6785,"briefTitle":6786,"status":217,"phases":6787,"completion":6142,"start":6788,"enrollment":317,"conditions":6789,"interventions":6790},"NCT00132431","START: Sensipar Treatment Algorithm to Reach K\u002FDOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism",[92],"2004-07",[383,384,28],[6764],{"trials":6792,"activeCount":100},[],{"intervention":6794,"totalTrials":204,"cells":6795},"pamidronate",{"EARLY_PHASE1":6796,"PHASE1":6798,"PHASE2":6800,"PHASE3":6802,"PHASE4":6804,"NA":6814},{"trials":6797,"activeCount":100},[],{"trials":6799,"activeCount":100},[],{"trials":6801,"activeCount":100},[],{"trials":6803,"activeCount":100},[],{"trials":6805,"activeCount":100},[6806],{"nctId":6807,"briefTitle":6808,"status":131,"phases":6809,"primaryCompletion":1637,"completion":1637,"start":1637,"enrollment":100,"conditions":6810,"interventions":6813},"NCT02101164","Evaluate Time Associated With the Preparation & Administration of Denosumab\u002FPamidronate in Patients With Solid Tumors and Metastatic Bone Disease",[92],[6811,6812],"Solid Tumor","Metastatic Bone Disease",[4798,6794],{"trials":6815,"activeCount":100},[],{"intervention":6817,"totalTrials":204,"cells":6818},"DMARD Therapy",{"EARLY_PHASE1":6819,"PHASE1":6821,"PHASE2":6823,"PHASE3":6825,"PHASE4":6827,"NA":6838},{"trials":6820,"activeCount":100},[],{"trials":6822,"activeCount":100},[],{"trials":6824,"activeCount":100},[],{"trials":6826,"activeCount":100},[],{"trials":6828,"activeCount":100},[6829],{"nctId":6830,"briefTitle":6831,"status":217,"phases":6832,"primaryCompletion":3869,"completion":6833,"start":2872,"enrollment":6834,"conditions":6835,"interventions":6836},"NCT01313208","Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)",[92],"2013-05",210,[19],[6837,6817],"etanercept",{"trials":6839,"activeCount":100},[],{"intervention":3849,"totalTrials":204,"cells":6841},{"EARLY_PHASE1":6842,"PHASE1":6844,"PHASE2":6846,"PHASE3":6848,"PHASE4":6850,"NA":6856},{"trials":6843,"activeCount":100},[],{"trials":6845,"activeCount":100},[],{"trials":6847,"activeCount":100},[],{"trials":6849,"activeCount":100},[],{"trials":6851,"activeCount":100},[6852],{"nctId":3840,"briefTitle":3841,"status":217,"phases":6853,"primaryCompletion":3843,"completion":3844,"start":3845,"enrollment":1907,"conditions":6854,"interventions":6855},[92],[3847],[3816,1765,3849,3850],{"trials":6857,"activeCount":100},[],{"intervention":3850,"totalTrials":204,"cells":6859},{"EARLY_PHASE1":6860,"PHASE1":6862,"PHASE2":6864,"PHASE3":6866,"PHASE4":6868,"NA":6874},{"trials":6861,"activeCount":100},[],{"trials":6863,"activeCount":100},[],{"trials":6865,"activeCount":100},[],{"trials":6867,"activeCount":100},[],{"trials":6869,"activeCount":100},[6870],{"nctId":3840,"briefTitle":3841,"status":217,"phases":6871,"primaryCompletion":3843,"completion":3844,"start":3845,"enrollment":1907,"conditions":6872,"interventions":6873},[92],[3847],[3816,1765,3849,3850],{"trials":6875,"activeCount":100},[],{"intervention":6877,"totalTrials":204,"cells":6878},"Etanerept",{"EARLY_PHASE1":6879,"PHASE1":6881,"PHASE2":6883,"PHASE3":6885,"PHASE4":6887,"NA":6895},{"trials":6880,"activeCount":100},[],{"trials":6882,"activeCount":100},[],{"trials":6884,"activeCount":100},[],{"trials":6886,"activeCount":100},[],{"trials":6888,"activeCount":100},[6889],{"nctId":6890,"briefTitle":6891,"status":217,"phases":6892,"primaryCompletion":4421,"completion":3033,"start":6143,"enrollment":2476,"conditions":6893,"interventions":6894},"NCT00110981","Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of Psoriasis",[92],[22],[6877,1268],{"trials":6896,"activeCount":100},[],{"intervention":3860,"totalTrials":204,"cells":6898},{"EARLY_PHASE1":6899,"PHASE1":6901,"PHASE2":6903,"PHASE3":6905,"PHASE4":6907,"NA":6913},{"trials":6900,"activeCount":100},[],{"trials":6902,"activeCount":100},[],{"trials":6904,"activeCount":100},[],{"trials":6906,"activeCount":100},[],{"trials":6908,"activeCount":100},[6909],{"nctId":3852,"briefTitle":3853,"status":217,"phases":6910,"primaryCompletion":3855,"completion":3856,"start":3857,"enrollment":2302,"conditions":6911,"interventions":6912},[92],[3847],[3816,3778,3860,3861,3862,3863],{"trials":6914,"activeCount":100},[],{"intervention":3861,"totalTrials":204,"cells":6916},{"EARLY_PHASE1":6917,"PHASE1":6919,"PHASE2":6921,"PHASE3":6923,"PHASE4":6925,"NA":6931},{"trials":6918,"activeCount":100},[],{"trials":6920,"activeCount":100},[],{"trials":6922,"activeCount":100},[],{"trials":6924,"activeCount":100},[],{"trials":6926,"activeCount":100},[6927],{"nctId":3852,"briefTitle":3853,"status":217,"phases":6928,"primaryCompletion":3855,"completion":3856,"start":3857,"enrollment":2302,"conditions":6929,"interventions":6930},[92],[3847],[3816,3778,3860,3861,3862,3863],{"trials":6932,"activeCount":100},[],{"intervention":6934,"totalTrials":204,"cells":6935},"Drug: Carfilzomib + Dexamethasone",{"EARLY_PHASE1":6936,"PHASE1":6938,"PHASE2":6940,"PHASE3":6942,"PHASE4":6944,"NA":6957},{"trials":6937,"activeCount":100},[],{"trials":6939,"activeCount":100},[],{"trials":6941,"activeCount":100},[],{"trials":6943,"activeCount":100},[],{"trials":6945,"activeCount":100},[6946],{"nctId":6947,"briefTitle":6948,"status":217,"phases":6949,"primaryCompletion":2196,"completion":6950,"start":6951,"enrollment":6952,"conditions":6953,"interventions":6955},"NCT03934684","Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma",[92],"2025-06-27","2019-09-16",101,[6954],"Relapsed Refractory Multiple Myeloma",[6934,6956],"Drug: Carfilzomib + Lenalidomide + Dexamethasone",{"trials":6958,"activeCount":100},[],{"intervention":6956,"totalTrials":204,"cells":6960},{"EARLY_PHASE1":6961,"PHASE1":6963,"PHASE2":6965,"PHASE3":6967,"PHASE4":6969,"NA":6975},{"trials":6962,"activeCount":100},[],{"trials":6964,"activeCount":100},[],{"trials":6966,"activeCount":100},[],{"trials":6968,"activeCount":100},[],{"trials":6970,"activeCount":100},[6971],{"nctId":6947,"briefTitle":6948,"status":217,"phases":6972,"primaryCompletion":2196,"completion":6950,"start":6951,"enrollment":6952,"conditions":6973,"interventions":6974},[92],[6954],[6934,6956],{"trials":6976,"activeCount":100},[],{"intervention":6978,"totalTrials":204,"cells":6979},"Enbrel",{"EARLY_PHASE1":6980,"PHASE1":6982,"PHASE2":6984,"PHASE3":6986,"PHASE4":6988,"NA":6999},{"trials":6981,"activeCount":100},[],{"trials":6983,"activeCount":100},[],{"trials":6985,"activeCount":100},[],{"trials":6987,"activeCount":100},[],{"trials":6989,"activeCount":100},[6990],{"nctId":6991,"briefTitle":6992,"status":217,"phases":6993,"primaryCompletion":6994,"completion":6994,"start":6995,"enrollment":6996,"conditions":6997,"interventions":6998},"NCT00132418","Study of Enbrel in Rheumatoid Arthritis (RA) Subjects With Comorbid Disorders",[92],"2004-02","2000-04",564,[19],[6978],{"trials":7000,"activeCount":100},[],{"intervention":7002,"totalTrials":204,"cells":7003},"AMG334",{"EARLY_PHASE1":7004,"PHASE1":7006,"PHASE2":7008,"PHASE3":7010,"PHASE4":7012,"NA":7026},{"trials":7005,"activeCount":100},[],{"trials":7007,"activeCount":100},[],{"trials":7009,"activeCount":100},[],{"trials":7011,"activeCount":100},[],{"trials":7013,"activeCount":100},[7014],{"nctId":7015,"briefTitle":7016,"status":217,"phases":7017,"primaryCompletion":7018,"completion":7019,"start":7020,"enrollment":7021,"conditions":7022,"interventions":7024},"NCT03927144","Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients",[92],"2021-10-01","2022-09-30","2019-05-15",621,[7023],"Episodic Migraine",[7002,7025],"Oral Prophylactic",{"trials":7027,"activeCount":100},[],{"intervention":7025,"totalTrials":204,"cells":7029},{"EARLY_PHASE1":7030,"PHASE1":7032,"PHASE2":7034,"PHASE3":7036,"PHASE4":7038,"NA":7044},{"trials":7031,"activeCount":100},[],{"trials":7033,"activeCount":100},[],{"trials":7035,"activeCount":100},[],{"trials":7037,"activeCount":100},[],{"trials":7039,"activeCount":100},[7040],{"nctId":7015,"briefTitle":7016,"status":217,"phases":7041,"primaryCompletion":7018,"completion":7019,"start":7020,"enrollment":7021,"conditions":7042,"interventions":7043},[92],[7023],[7002,7025],{"trials":7045,"activeCount":100},[],{"intervention":7047,"totalTrials":204,"cells":7048},"Neulasta®",{"EARLY_PHASE1":7049,"PHASE1":7051,"PHASE2":7053,"PHASE3":7055,"PHASE4":7057,"NA":7065},{"trials":7050,"activeCount":100},[],{"trials":7052,"activeCount":100},[],{"trials":7054,"activeCount":100},[],{"trials":7056,"activeCount":100},[],{"trials":7058,"activeCount":100},[7059],{"nctId":7060,"briefTitle":7061,"status":217,"phases":7062,"completion":6788,"start":2644,"conditions":7063,"interventions":7064},"NCT00115206","Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy",[92],[1971],[7047],{"trials":7066,"activeCount":100},[],{"intervention":7068,"totalTrials":204,"cells":7069},"Traditional Vitamin D Therapy",{"EARLY_PHASE1":7070,"PHASE1":7072,"PHASE2":7074,"PHASE3":7076,"PHASE4":7078,"NA":7090},{"trials":7071,"activeCount":100},[],{"trials":7073,"activeCount":100},[],{"trials":7075,"activeCount":100},[],{"trials":7077,"activeCount":100},[],{"trials":7079,"activeCount":100},[7080],{"nctId":7081,"briefTitle":7082,"status":217,"phases":7083,"primaryCompletion":7084,"completion":7085,"start":7086,"enrollment":7087,"conditions":7088,"interventions":7089},"NCT01181531","Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis",[92],"2012-07-17","2012-08-14","2010-10-01",312,[342],[7068,3382],{"trials":7091,"activeCount":100},[],{"intervention":7093,"totalTrials":204,"cells":7094},"VIMOVO 250\u002F20",{"EARLY_PHASE1":7095,"PHASE1":7097,"PHASE2":7099,"PHASE3":7101,"PHASE4":7103,"NA":7114},{"trials":7096,"activeCount":100},[],{"trials":7098,"activeCount":100},[],{"trials":7100,"activeCount":100},[],{"trials":7102,"activeCount":100},[],{"trials":7104,"activeCount":100},[7105],{"nctId":7106,"briefTitle":7107,"status":217,"phases":7108,"primaryCompletion":4512,"completion":4512,"start":1566,"enrollment":17,"conditions":7109,"interventions":7111},"NCT01544114","A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)",[92],[7110],"Juvenile Idiopathic Arthritis (JIA)",[7093,7112,7113],"VIMOVO 375\u002F20","VIMOVO 500\u002F20",{"trials":7115,"activeCount":100},[],{"intervention":7112,"totalTrials":204,"cells":7117},{"EARLY_PHASE1":7118,"PHASE1":7120,"PHASE2":7122,"PHASE3":7124,"PHASE4":7126,"NA":7132},{"trials":7119,"activeCount":100},[],{"trials":7121,"activeCount":100},[],{"trials":7123,"activeCount":100},[],{"trials":7125,"activeCount":100},[],{"trials":7127,"activeCount":100},[7128],{"nctId":7106,"briefTitle":7107,"status":217,"phases":7129,"primaryCompletion":4512,"completion":4512,"start":1566,"enrollment":17,"conditions":7130,"interventions":7131},[92],[7110],[7093,7112,7113],{"trials":7133,"activeCount":100},[],{"intervention":7113,"totalTrials":204,"cells":7135},{"EARLY_PHASE1":7136,"PHASE1":7138,"PHASE2":7140,"PHASE3":7142,"PHASE4":7144,"NA":7150},{"trials":7137,"activeCount":100},[],{"trials":7139,"activeCount":100},[],{"trials":7141,"activeCount":100},[],{"trials":7143,"activeCount":100},[],{"trials":7145,"activeCount":100},[7146],{"nctId":7106,"briefTitle":7107,"status":217,"phases":7147,"primaryCompletion":4512,"completion":4512,"start":1566,"enrollment":17,"conditions":7148,"interventions":7149},[92],[7110],[7093,7112,7113],{"trials":7151,"activeCount":100},[],{"intervention":7153,"totalTrials":204,"cells":7154},"Pegloticase with MTX",{"EARLY_PHASE1":7155,"PHASE1":7157,"PHASE2":7159,"PHASE3":7161,"PHASE4":7163,"NA":7174},{"trials":7156,"activeCount":100},[],{"trials":7158,"activeCount":100},[],{"trials":7160,"activeCount":100},[],{"trials":7162,"activeCount":100},[],{"trials":7164,"activeCount":100},[7165],{"nctId":7166,"briefTitle":7167,"status":217,"phases":7168,"primaryCompletion":7169,"completion":7170,"start":1592,"enrollment":2115,"conditions":7171,"interventions":7173},"NCT04511702","Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate",[92],"2024-01-18","2024-03-25",[7172,3847,3814],"Chronic Uncontrolled Gout",[7153],{"trials":7175,"activeCount":100},[],{"intervention":7177,"totalTrials":204,"cells":7178},"800 mg ibuprofen\u002F26.6 mg famotidine",{"EARLY_PHASE1":7179,"PHASE1":7181,"PHASE2":7183,"PHASE3":7185,"PHASE4":7187,"NA":7196},{"trials":7180,"activeCount":100},[],{"trials":7182,"activeCount":100},[],{"trials":7184,"activeCount":100},[],{"trials":7186,"activeCount":100},[],{"trials":7188,"activeCount":100},[7189],{"nctId":7190,"briefTitle":7191,"status":217,"phases":7192,"primaryCompletion":2438,"completion":2438,"start":1566,"enrollment":2895,"conditions":7193,"interventions":7195},"NCT01563185","Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis",[92],[7194],"Juvenile Idiopathic Arthritis",[7177],{"trials":7197,"activeCount":100},[],{"intervention":7199,"totalTrials":204,"cells":7200},"Erenumab 70 mg",{"EARLY_PHASE1":7201,"PHASE1":7203,"PHASE2":7205,"PHASE3":7207,"PHASE4":7209,"NA":7223},{"trials":7202,"activeCount":100},[],{"trials":7204,"activeCount":100},[],{"trials":7206,"activeCount":100},[],{"trials":7208,"activeCount":100},[],{"trials":7210,"activeCount":100},[7211],{"nctId":7212,"briefTitle":7213,"status":217,"phases":7214,"primaryCompletion":7215,"completion":7216,"start":7217,"enrollment":7218,"conditions":7219,"interventions":7221},"NCT03971071","A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache",[92],"2022-12-01","2023-06-13","2019-10-07",620,[7220],"Migraine Headache",[7199,7222],"Erenumab 140 mg",{"trials":7224,"activeCount":100},[],{"intervention":7222,"totalTrials":204,"cells":7226},{"EARLY_PHASE1":7227,"PHASE1":7229,"PHASE2":7231,"PHASE3":7233,"PHASE4":7235,"NA":7241},{"trials":7228,"activeCount":100},[],{"trials":7230,"activeCount":100},[],{"trials":7232,"activeCount":100},[],{"trials":7234,"activeCount":100},[],{"trials":7236,"activeCount":100},[7237],{"nctId":7212,"briefTitle":7213,"status":217,"phases":7238,"primaryCompletion":7215,"completion":7216,"start":7217,"enrollment":7218,"conditions":7239,"interventions":7240},[92],[7220],[7199,7222],{"trials":7242,"activeCount":100},[],{"intervention":7244,"totalTrials":204,"cells":7245},"Peginesatide",{"EARLY_PHASE1":7246,"PHASE1":7248,"PHASE2":7250,"PHASE3":7252,"PHASE4":7254,"NA":7264},{"trials":7247,"activeCount":100},[],{"trials":7249,"activeCount":100},[],{"trials":7251,"activeCount":100},[],{"trials":7253,"activeCount":100},[],{"trials":7255,"activeCount":100},[7256],{"nctId":7257,"briefTitle":7258,"status":336,"phases":7259,"primaryCompletion":5191,"completion":4707,"start":7260,"enrollment":1160,"conditions":7261,"interventions":7262},"NCT01737879","Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis",[92],"2012-10",[16],[7244,7263],"Epoetin alfa",{"trials":7265,"activeCount":100},[],{"intervention":7267,"totalTrials":204,"cells":7268},"Etanercept via Autoinjector A",{"EARLY_PHASE1":7269,"PHASE1":7271,"PHASE2":7273,"PHASE3":7275,"PHASE4":7277,"NA":7289},{"trials":7270,"activeCount":100},[],{"trials":7272,"activeCount":100},[],{"trials":7274,"activeCount":100},[],{"trials":7276,"activeCount":100},[],{"trials":7278,"activeCount":100},[7279],{"nctId":7280,"briefTitle":7281,"status":217,"phases":7282,"primaryCompletion":7283,"completion":7283,"start":7284,"enrollment":7285,"conditions":7286,"interventions":7287},"NCT01875991","Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept",[92],"2014-03-04","2013-06-05",217,[19,2152],[7267,7288],"Etanercept via Autoinjector B",{"trials":7290,"activeCount":100},[],{"intervention":7288,"totalTrials":204,"cells":7292},{"EARLY_PHASE1":7293,"PHASE1":7295,"PHASE2":7297,"PHASE3":7299,"PHASE4":7301,"NA":7307},{"trials":7294,"activeCount":100},[],{"trials":7296,"activeCount":100},[],{"trials":7298,"activeCount":100},[],{"trials":7300,"activeCount":100},[],{"trials":7302,"activeCount":100},[7303],{"nctId":7280,"briefTitle":7281,"status":217,"phases":7304,"primaryCompletion":7283,"completion":7283,"start":7284,"enrollment":7285,"conditions":7305,"interventions":7306},[92],[19,2152],[7267,7288],{"trials":7308,"activeCount":100},[],{"intervention":1656,"totalTrials":1095,"cells":7310},{"EARLY_PHASE1":7311,"PHASE1":7313,"PHASE2":7409,"PHASE3":7464,"PHASE4":7530,"NA":7532},{"trials":7312,"activeCount":100},[],{"trials":7314,"activeCount":100},[7315,7327,7336,7342,7353,7368,7384,7394,7402],{"nctId":7316,"briefTitle":7317,"status":217,"phases":7318,"primaryCompletion":7319,"completion":7319,"start":7320,"enrollment":731,"conditions":7321,"interventions":7323},"NCT02939183","Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma",[89],"2022-10-06","2017-01-17",[7322],"Relapsed or Refractory Multiple Myeloma",[7324,7325,1656,7326],"Immediate Release (IR) Formulation","Gastro-Retentive (GR) Formulation","Pomalidomide",{"nctId":7328,"briefTitle":7329,"status":217,"phases":7330,"primaryCompletion":6183,"completion":6183,"start":7331,"enrollment":2197,"conditions":7332,"interventions":7335},"NCT00150462","Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies",[89],"2005-09",[7333,1584,7334,31],"Waldenstrom's Macroglobulinemia","Hodgkin's Disease",[2827,1656],{"nctId":7337,"briefTitle":7338,"status":217,"phases":7339,"primaryCompletion":2882,"completion":2882,"start":2873,"enrollment":6471,"conditions":7340,"interventions":7341},"NCT01980589","A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects",[89],[31],[2827,296,1656],{"nctId":7343,"briefTitle":7344,"status":336,"phases":7345,"primaryCompletion":7346,"completion":7346,"start":7347,"enrollment":7348,"conditions":7349,"interventions":7351},"NCT03287908","A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",[89],"2023-06-30","2017-11-13",174,[7350],"Relapsed\u002FRefractory Multiple Myeloma",[7352,7326,1656],"AMG 701",{"nctId":7354,"briefTitle":7355,"status":336,"phases":7356,"primaryCompletion":7357,"completion":7357,"start":7358,"enrollment":253,"conditions":7359,"interventions":7365},"NCT03465540","Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies",[89],"2019-07-25","2018-08-17",[31,7360,7361,7362,7363,4423,7364],"Acute Myeloid Leukemia","Non-Hodgkins Lymphoma","Myelodysplastic Syndrome","AML","NHL",[7366,1656,7367],"AMG 397","Azacitidine",{"nctId":7369,"briefTitle":7370,"status":217,"phases":7371,"primaryCompletion":7372,"completion":7372,"start":7373,"enrollment":7374,"conditions":7375,"interventions":7377},"NCT02303821","Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia",[89],"2024-06-28","2015-02-16",141,[7376],"Acute Lymphoblastic Leukemia (ALL)",[2827,1656,7378,1767,7379,7380,7381,7382,296,7383,1764],"Mitoxantrone","Vincristine","Intrathecal (IT) Methotrexate","Intrathecal Triple Therapy","6-Mercaptopurine","Cytarabine",{"nctId":7385,"briefTitle":7386,"status":217,"phases":7387,"primaryCompletion":6833,"completion":7388,"start":4420,"enrollment":7389,"conditions":7390,"interventions":7392},"NCT00603447","Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma",[89],"2016-01",84,[7391],"Relapsed Multiple Myeloma",[2827,7393,1656],"Lenalidomide",{"nctId":7395,"briefTitle":7396,"status":336,"phases":7397,"primaryCompletion":7398,"completion":7398,"start":7399,"enrollment":3264,"conditions":7400,"interventions":7401},"NCT01999335","A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma",[89],"2019-04-25","2014-07-30",[31],[4905,7326,1656],{"nctId":7403,"briefTitle":7404,"status":217,"phases":7405,"primaryCompletion":1650,"completion":1650,"start":7406,"enrollment":9,"conditions":7407,"interventions":7408},"NCT02335983","Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma",[89],"2015-04-30",[31],[2827,7393,1656],{"trials":7410,"activeCount":100},[7411,7420,7424,7432,7440,7448,7456],{"nctId":7412,"briefTitle":7413,"status":217,"phases":7414,"primaryCompletion":7415,"completion":7416,"start":7417,"enrollment":3881,"conditions":7418,"interventions":7419},"NCT04191616","Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet",[90],"2022-11-30","2024-10-01","2020-08-06",[7322],[2827,1656,7326],{"nctId":1646,"briefTitle":1647,"status":217,"phases":7421,"primaryCompletion":1649,"completion":1650,"start":608,"enrollment":1651,"conditions":7422,"interventions":7423},[90],[1653],[117,1655,1656],{"nctId":7425,"briefTitle":7426,"status":336,"phases":7427,"primaryCompletion":7428,"completion":7428,"start":7429,"enrollment":6471,"conditions":7430,"interventions":7431},"NCT01881789","Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma",[89,90],"2019-09-23","2013-10-28",[31],[4905,7393,1656,296],{"nctId":7433,"briefTitle":7434,"status":217,"phases":7435,"primaryCompletion":4678,"completion":772,"start":2570,"enrollment":1106,"conditions":7436,"interventions":7439},"NCT00531284","Phase 1b\u002F2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma",[89,90],[2795,7437,1303,1097,2441,31,7438],"Renal Cancer","Lymphoma",[2827,1656],{"nctId":7441,"briefTitle":7442,"status":336,"phases":7443,"primaryCompletion":7444,"completion":7444,"start":7445,"enrollment":3142,"conditions":7446,"interventions":7447},"NCT01832727","Phase 1b\u002F2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and\u002For Refractory Multiple Myeloma",[89,90],"2019-06-25","2013-07-02",[31],[4905,1656],{"nctId":7449,"briefTitle":7450,"status":336,"phases":7451,"primaryCompletion":7452,"completion":7452,"start":7453,"enrollment":1454,"conditions":7454,"interventions":7455},"NCT03512353","A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers",[90],"2020-01-16","2018-07-05",[7322],[1656,2827],{"nctId":7457,"briefTitle":7458,"status":217,"phases":7459,"primaryCompletion":7460,"completion":3348,"start":7461,"enrollment":1628,"conditions":7462,"interventions":7463},"NCT01677858","A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma",[89,90],"2016-07-22","2012-07-04",[31],[2827,1656],{"trials":7465,"activeCount":100},[7466,7477,7481,7493,7504,7513,7521],{"nctId":7467,"briefTitle":7468,"status":217,"phases":7469,"primaryCompletion":7470,"completion":7471,"start":7472,"enrollment":7473,"conditions":7474,"interventions":7475},"NCT01568866","Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients",[91],"2014-11-10","2018-02-05","2012-06-20",929,[31],[2827,7476,1656],"Bortezomib",{"nctId":1754,"briefTitle":1755,"status":217,"phases":7478,"primaryCompletion":1757,"completion":1758,"start":760,"enrollment":1759,"conditions":7479,"interventions":7480},[91],[1761],[117,1656,1763,1764,1765,1766,1767,1768],{"nctId":7482,"briefTitle":7483,"status":217,"phases":7484,"primaryCompletion":7485,"completion":7486,"start":7487,"enrollment":7488,"conditions":7489,"interventions":7491},"NCT03158688","Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and\u002For Refractory Multiple Myeloma.",[91],"2019-07-14","2022-04-15","2017-06-13",466,[7391,7490],"Refractory Multiple Myeloma",[1656,7492,2827],"Daratumumab",{"nctId":7494,"briefTitle":7495,"status":217,"phases":7496,"primaryCompletion":7497,"completion":7498,"start":7499,"enrollment":7500,"conditions":7501,"interventions":7503},"NCT03029234","Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma",[91],"2018-11-05","2021-06-04","2017-03-31",126,[7502],"Relapsed and Refractory Multiple Myeloma",[1656,2827],{"nctId":7505,"briefTitle":7506,"status":217,"phases":7507,"primaryCompletion":3727,"completion":7508,"start":7509,"enrollment":7510,"conditions":7511,"interventions":7512},"NCT01080391","Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma",[91],"2017-12-05","2010-07-14",792,[7391],[1656,7393,2827],{"nctId":7514,"briefTitle":7515,"status":217,"phases":7516,"primaryCompletion":7517,"completion":1626,"start":7518,"enrollment":3834,"conditions":7519,"interventions":7520},"NCT02412878","Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma",[91],"2017-06-15","2015-09-09",[31],[2827,1656],{"nctId":7522,"briefTitle":7523,"status":217,"phases":7524,"primaryCompletion":7525,"completion":7525,"start":7526,"enrollment":7527,"conditions":7528,"interventions":7529},"NCT03859427","A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",[91],"2023-03-31","2019-05-08",454,[7322],[2827,2827,7393,1656],{"trials":7531,"activeCount":100},[],{"trials":7533,"activeCount":100},[],{"intervention":2428,"totalTrials":124,"cells":7535},{"EARLY_PHASE1":7536,"PHASE1":7538,"PHASE2":7589,"PHASE3":7630,"PHASE4":7636,"NA":7638},{"trials":7537,"activeCount":100},[],{"trials":7539,"activeCount":100},[7540,7544,7552,7560,7564,7570,7578,7582],{"nctId":3030,"briefTitle":3031,"status":217,"phases":7541,"primaryCompletion":2661,"completion":1705,"start":3033,"enrollment":17,"conditions":7542,"interventions":7543},[89],[3035],[1279,1280,2428],{"nctId":7545,"briefTitle":7546,"status":217,"phases":7547,"primaryCompletion":2461,"completion":7548,"start":7331,"enrollment":278,"conditions":7549,"interventions":7551},"NCT01235416","A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors",[89],"2010-02",[7550],"Histologically or Cytologically Documented Solid Tumors",[2428],{"nctId":7553,"briefTitle":7554,"status":217,"phases":7555,"primaryCompletion":4421,"completion":2833,"start":6414,"enrollment":7556,"conditions":7557,"interventions":7558},"NCT00093873","Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors",[89],71,[2478],[7559,2428],"Anti-angiogenesis",{"nctId":2418,"briefTitle":2419,"status":217,"phases":7561,"primaryCompletion":2421,"completion":1685,"start":2422,"enrollment":2363,"conditions":7562,"interventions":7563},[89],[2424,2425],[2427,2428,1322,2429],{"nctId":7565,"briefTitle":7566,"status":217,"phases":7567,"primaryCompletion":1627,"completion":3831,"start":2499,"enrollment":160,"conditions":7568,"interventions":7569},"NCT01386866","Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors",[89],[1290],[2428],{"nctId":7571,"briefTitle":7572,"status":217,"phases":7573,"start":6744,"enrollment":4708,"conditions":7574,"interventions":7575},"NCT00861419","To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.",[89],[1290],[7576,2428,2428,2807,7577,2616,2807],"Sorafenib","Sunitinib",{"nctId":2457,"briefTitle":2458,"status":336,"phases":7579,"primaryCompletion":2460,"completion":2461,"start":2422,"enrollment":1160,"conditions":7580,"interventions":7581},[89],[2463,2464,2465],[2428,1322,2467,2468],{"nctId":7583,"briefTitle":7584,"status":217,"phases":7585,"primaryCompletion":2541,"completion":2451,"start":7586,"enrollment":1300,"conditions":7587,"interventions":7588},"NCT00448786","Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors",[89],"2007-02",[2441],[2428,2428,2428],{"trials":7590,"activeCount":100},[7591,7595,7602,7606,7615,7622],{"nctId":5134,"briefTitle":5135,"status":336,"phases":7592,"primaryCompletion":2832,"completion":2803,"start":2833,"enrollment":5137,"conditions":7593,"interventions":7594},[90],[5139,5140,2794,3035],[5142,2616,2428,1280],{"nctId":7596,"briefTitle":7597,"status":336,"phases":7598,"primaryCompletion":1695,"completion":1695,"start":6744,"enrollment":7599,"conditions":7600,"interventions":7601},"NCT00360867","An Open Label Treatment Extension Study of AMG 706",[90],94,[2441],[2428],{"nctId":2762,"briefTitle":2763,"status":336,"phases":7603,"primaryCompletion":2765,"completion":2766,"start":2767,"enrollment":2768,"conditions":7604,"interventions":7605},[90],[2770],[2616,2428,1280,1109],{"nctId":7607,"briefTitle":7608,"status":217,"phases":7609,"primaryCompletion":2813,"completion":3870,"start":7610,"enrollment":7611,"conditions":7612,"interventions":7614},"NCT00089960","Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)",[90],"2004-10",138,[7613],"Gastrointestinal Cancer",[2428],{"nctId":7616,"briefTitle":7617,"status":217,"phases":7618,"primaryCompletion":2587,"completion":1606,"start":6142,"enrollment":1106,"conditions":7619,"interventions":7621},"NCT00121628","A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer",[90],[7620],"Thyroid Cancer",[2428],{"nctId":7623,"briefTitle":7624,"status":217,"phases":7625,"primaryCompletion":7586,"completion":3868,"start":7626,"enrollment":1582,"conditions":7627,"interventions":7629},"NCT00254267","Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors",[90],"2005-11",[7628],"Advanced Gastrointestinal Stromal Tumor",[2428],{"trials":7631,"activeCount":100},[7632],{"nctId":2869,"briefTitle":2870,"status":336,"phases":7633,"primaryCompletion":2872,"completion":2873,"start":2874,"enrollment":2875,"conditions":7634,"interventions":7635},[91],[1971],[2428,2782,2783],{"trials":7637,"activeCount":100},[],{"trials":7639,"activeCount":100},[],{"intervention":2797,"totalTrials":231,"cells":7641},{"EARLY_PHASE1":7642,"PHASE1":7644,"PHASE2":7646,"PHASE3":7708,"PHASE4":7736,"NA":7738},{"trials":7643,"activeCount":100},[],{"trials":7645,"activeCount":100},[],{"trials":7647,"activeCount":100},[7648,7655,7659,7665,7669,7673,7682,7686,7694,7702],{"nctId":7649,"briefTitle":7650,"status":217,"phases":7651,"completion":6994,"start":2644,"conditions":7652,"interventions":7653},"NCT00117897","Treatment for Subjects With Non-Hodgkin's Lymphoma",[90],[1584],[2797,7654],"Filgrastim",{"nctId":3773,"briefTitle":3774,"status":217,"phases":7656,"conditions":7657,"interventions":7658},[90],[2794],[2797,3061,3778,3779],{"nctId":7660,"briefTitle":7661,"status":217,"phases":7662,"primaryCompletion":6224,"completion":6224,"start":2578,"enrollment":1288,"conditions":7663,"interventions":7664},"NCT00115193","Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma",[90],[1584],[2797,2797],{"nctId":4001,"briefTitle":4002,"status":217,"phases":7666,"primaryCompletion":4004,"completion":4004,"start":4005,"enrollment":4006,"conditions":7667,"interventions":7668},[90],[4008],[4010,4011,4012,3184],{"nctId":3077,"briefTitle":3078,"status":217,"phases":7670,"conditions":7671,"interventions":7672},[90],[2794,3081,3082],[2797,3052,3084,3061],{"nctId":7674,"briefTitle":7675,"status":217,"phases":7676,"primaryCompletion":7677,"completion":7678,"start":7679,"enrollment":1173,"conditions":7680,"interventions":7681},"NCT00094809","Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer",[90],"2006-05-19","2008-01-23","2003-02-01",[2425,34,2424],[4012],{"nctId":2789,"briefTitle":2790,"status":217,"phases":7683,"primaryCompletion":2475,"completion":2422,"start":2792,"enrollment":731,"conditions":7684,"interventions":7685},[90],[2794,2463,2795],[2783,2782,2797],{"nctId":7687,"briefTitle":7688,"status":217,"phases":7689,"primaryCompletion":7690,"completion":2475,"start":6421,"enrollment":7389,"conditions":7691,"interventions":7693},"NCT00114764","Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)",[90],"2004-04",[7692],"Myeloid Leukemia",[3051,2797],{"nctId":7695,"briefTitle":7696,"status":217,"phases":7697,"primaryCompletion":2662,"completion":7698,"start":6995,"enrollment":4671,"conditions":7699,"interventions":7701},"NCT00035620","Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy",[90],"2007-04",[7700,3082],"Sarcoma",[2797,3051],{"nctId":7703,"briefTitle":7704,"status":217,"phases":7705,"conditions":7706,"interventions":7707},"NCT00117455","A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma",[90],[1584],[2797,3051],{"trials":7709,"activeCount":100},[7710,7721,7728],{"nctId":7711,"briefTitle":7712,"status":217,"phases":7713,"primaryCompletion":7714,"completion":7715,"start":7716,"enrollment":7717,"conditions":7718,"interventions":7720},"NCT00911170","PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study",[91],"2012-09-17","2015-01-02","2009-11-03",847,[25,2425,34,3081,7719,37,3082,2424],"Locally Advanced",[4012,2616,6308],{"nctId":7722,"briefTitle":7723,"status":217,"phases":7724,"primaryCompletion":6994,"completion":1567,"start":6430,"enrollment":7725,"conditions":7726,"interventions":7727},"NCT00035594","Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy",[91],928,[3082],[2797],{"nctId":7729,"briefTitle":7730,"status":217,"phases":7731,"completion":7732,"start":7733,"conditions":7734,"interventions":7735},"NCT00117910","Treatment for Elderly Patients With High Risk Breast Cancer",[91],"2004-05","2002-10",[2794],[2797],{"trials":7737,"activeCount":100},[],{"trials":7739,"activeCount":100},[],{"intervention":2616,"totalTrials":231,"cells":7741},{"EARLY_PHASE1":7742,"PHASE1":7744,"PHASE2":7750,"PHASE3":7795,"PHASE4":7813,"NA":7815},{"trials":7743,"activeCount":100},[],{"trials":7745,"activeCount":100},[7746],{"nctId":7571,"briefTitle":7572,"status":217,"phases":7747,"start":6744,"enrollment":4708,"conditions":7748,"interventions":7749},[89],[1290],[7576,2428,2428,2807,7577,2616,2807],{"trials":7751,"activeCount":100},[7752,7756,7760,7764,7768,7779,7783,7787],{"nctId":5134,"briefTitle":5135,"status":336,"phases":7753,"primaryCompletion":2832,"completion":2803,"start":2833,"enrollment":5137,"conditions":7754,"interventions":7755},[90],[5139,5140,2794,3035],[5142,2616,2428,1280],{"nctId":2762,"briefTitle":2763,"status":336,"phases":7757,"primaryCompletion":2765,"completion":2766,"start":2767,"enrollment":2768,"conditions":7758,"interventions":7759},[90],[2770],[2616,2428,1280,1109],{"nctId":5148,"briefTitle":5149,"status":217,"phases":7761,"primaryCompletion":5151,"completion":5152,"start":2874,"enrollment":5153,"conditions":7762,"interventions":7763},[90],[3035],[2808,2807,2616,2807,2807,1280],{"nctId":2607,"briefTitle":2608,"status":217,"phases":7765,"primaryCompletion":2610,"completion":2611,"start":2612,"enrollment":2613,"conditions":7766,"interventions":7767},[90],[2425,34,2424,37],[1322,2616,2617],{"nctId":7769,"briefTitle":7770,"status":217,"phases":7771,"primaryCompletion":7772,"completion":7772,"start":7773,"enrollment":2895,"conditions":7774,"interventions":7776},"NCT01327612","Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)",[90],"2020-02-05","2011-03-03",[1290,7775,34,7719,7438,2532,1971,7700,2441],"Carcinoid",[7777,2503,7778,2616],"Modified FOLFOX6","Ganitumab",{"nctId":2810,"briefTitle":2811,"status":217,"phases":7780,"primaryCompletion":2451,"completion":2733,"start":2813,"enrollment":2814,"conditions":7781,"interventions":7782},[90],[1971],[2817,2616,1109,1280],{"nctId":2627,"briefTitle":2628,"status":217,"phases":7784,"primaryCompletion":2630,"completion":2631,"start":2632,"enrollment":2633,"conditions":7785,"interventions":7786},[90],[25,2425,34,2532,2424,37],[1322,2616,2636,2455,2637],{"nctId":7788,"briefTitle":7789,"status":217,"phases":7790,"primaryCompletion":5151,"completion":6190,"start":6173,"enrollment":7791,"conditions":7792,"interventions":7793},"NCT00625651","Phase 1b\u002F2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer",[89,90],202,[37,2425,34,2424],[7794,7777,2616],"AMG 655",{"trials":7796,"activeCount":100},[7797,7801,7805,7809],{"nctId":7711,"briefTitle":7712,"status":217,"phases":7798,"primaryCompletion":7714,"completion":7715,"start":7716,"enrollment":7717,"conditions":7799,"interventions":7800},[91],[25,2425,34,3081,7719,37,3082,2424],[4012,2616,6308],{"nctId":2844,"briefTitle":2845,"status":131,"phases":7802,"primaryCompletion":2847,"completion":2847,"start":2848,"enrollment":100,"conditions":7803,"interventions":7804},[91],[2850,2851],[2853,2616,1280,1109],{"nctId":2690,"briefTitle":2691,"status":217,"phases":7806,"primaryCompletion":2693,"completion":2085,"start":2694,"enrollment":2695,"conditions":7807,"interventions":7808},[91],[34],[2698,1322,2699,2616],{"nctId":2855,"briefTitle":2856,"status":217,"phases":7810,"primaryCompletion":2858,"completion":2858,"start":2859,"enrollment":2860,"conditions":7811,"interventions":7812},[91],[2862],[1109,1280,2853,2616],{"trials":7814,"activeCount":100},[],{"trials":7816,"activeCount":100},[],{"intervention":2807,"totalTrials":2895,"cells":7818},{"EARLY_PHASE1":7819,"PHASE1":7821,"PHASE2":7846,"PHASE3":7887,"PHASE4":7897,"NA":7899},{"trials":7820,"activeCount":100},[],{"trials":7822,"activeCount":100},[7823,7827,7833,7837],{"nctId":5125,"briefTitle":5126,"status":217,"phases":7824,"primaryCompletion":2873,"completion":5128,"start":1695,"enrollment":1582,"conditions":7825,"interventions":7826},[89],[1290],[2807,1280],{"nctId":7828,"briefTitle":7829,"status":217,"phases":7830,"conditions":7831,"interventions":7832},"NCT00102830","Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors",[89],[2478],[2807],{"nctId":7571,"briefTitle":7572,"status":217,"phases":7834,"start":6744,"enrollment":4708,"conditions":7835,"interventions":7836},[89],[1290],[7576,2428,2428,2807,7577,2616,2807],{"nctId":7838,"briefTitle":7839,"status":217,"phases":7840,"primaryCompletion":7841,"start":7842,"enrollment":1582,"conditions":7843,"interventions":7844},"NCT01331941","A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function",[89],"2013-02-26","2011-09-19",[1290,383,3266],[7845,2807],"AMG 386 + Paclitaxel",{"trials":7847,"activeCount":100},[7848,7857,7861,7872,7876,7880],{"nctId":7849,"briefTitle":7850,"status":217,"phases":7851,"primaryCompletion":5352,"completion":7852,"start":7853,"enrollment":7854,"conditions":7855,"interventions":7856},"NCT00752570","A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma",[90],"2012-06","2008-11",144,[25,2529,2425,34,7613,2531,2532,37,2479,2424],[2807,2808,2429],{"nctId":5148,"briefTitle":5149,"status":217,"phases":7858,"primaryCompletion":5151,"completion":5152,"start":2874,"enrollment":5153,"conditions":7859,"interventions":7860},[90],[3035],[2808,2807,2616,2807,2807,1280],{"nctId":7862,"briefTitle":7863,"status":217,"phases":7864,"primaryCompletion":7865,"completion":7866,"start":7867,"enrollment":13,"conditions":7868,"interventions":7871},"NCT00872014","A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer",[90],"2011-10","2015-06","2009-08",[7869,7870],"Advanced Hepatocellular Carcinoma","Inoperable Hepatocellular Carcinoma",[2807,2807,7576],{"nctId":5165,"briefTitle":5166,"status":217,"phases":7873,"primaryCompletion":4533,"completion":4560,"start":5168,"enrollment":5169,"conditions":7874,"interventions":7875},[90],[2795,2886,5171],[2807,2807,1280,2808],{"nctId":2799,"briefTitle":2800,"status":217,"phases":7877,"primaryCompletion":2802,"completion":2802,"start":2803,"enrollment":439,"conditions":7878,"interventions":7879},[89,90],[2805],[2807,2807,2808,1306,1109],{"nctId":7881,"briefTitle":7882,"status":217,"phases":7883,"primaryCompletion":2421,"completion":781,"start":2540,"enrollment":2302,"conditions":7884,"interventions":7885},"NCT00467025","AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib",[90],[2572],[2807,7576,7886],"AMG 386 placebo IV",{"trials":7888,"activeCount":100},[7889,7893],{"nctId":5188,"briefTitle":5189,"status":217,"phases":7890,"primaryCompletion":5191,"completion":2883,"start":1627,"enrollment":5192,"conditions":7891,"interventions":7892},[91],[2886,2795,5171],[2807,2808,1280,1280],{"nctId":2879,"briefTitle":2880,"status":336,"phases":7894,"primaryCompletion":2882,"completion":2883,"start":1705,"enrollment":2884,"conditions":7895,"interventions":7896},[91],[2886,2795,2887],[2807,1280,2808,1109],{"trials":7898,"activeCount":100},[],{"trials":7900,"activeCount":100},[],{"intervention":2468,"totalTrials":1726,"cells":7902},{"EARLY_PHASE1":7903,"PHASE1":7905,"PHASE2":7911,"PHASE3":7954,"PHASE4":7969,"NA":7971},{"trials":7904,"activeCount":100},[],{"trials":7906,"activeCount":100},[7907],{"nctId":2457,"briefTitle":2458,"status":336,"phases":7908,"primaryCompletion":2460,"completion":2461,"start":2422,"enrollment":1160,"conditions":7909,"interventions":7910},[89],[2463,2464,2465],[2428,1322,2467,2468],{"trials":7912,"activeCount":100},[7913,7917,7921,7925,7935,7939,7950],{"nctId":2485,"briefTitle":2486,"status":217,"phases":7914,"primaryCompletion":2488,"completion":2488,"start":2489,"enrollment":2490,"conditions":7915,"interventions":7916},[90],[2492],[1322,2468,2494],{"nctId":2557,"briefTitle":2558,"status":217,"phases":7918,"primaryCompletion":2560,"completion":2561,"start":2562,"enrollment":2563,"conditions":7919,"interventions":7920},[90],[2533],[2468,1322,1279,2468,1279],{"nctId":2591,"briefTitle":2592,"status":217,"phases":7922,"primaryCompletion":1685,"completion":1604,"start":2594,"enrollment":2302,"conditions":7923,"interventions":7924},[90],[25,2530,2479,2534],[1322,2468],{"nctId":7926,"briefTitle":7927,"status":217,"phases":7928,"primaryCompletion":6155,"completion":7852,"start":6743,"enrollment":5239,"conditions":7929,"interventions":7930},"NCT00583674","Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma",[90],[7613],[7931,7932,7933,2468,7934,2468,7934,2468,7934],"AMG 386 placebo","AMG 386 10mg\u002Fkg","AMG 386 3mg\u002Fkg","Capecitabine",{"nctId":2648,"briefTitle":2649,"status":217,"phases":7936,"primaryCompletion":2651,"completion":2652,"start":2653,"enrollment":2654,"conditions":7937,"interventions":7938},[90],[2530,2534],[2468,1322],{"nctId":7940,"briefTitle":7941,"status":217,"phases":7942,"primaryCompletion":1627,"completion":7943,"start":2832,"enrollment":7944,"conditions":7945,"interventions":7947},"NCT00719550","AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer",[89,90],"2013-06",130,[7946,3170,2465],"Esophagogastric Junction Adenocarcinoma",[7934,7948,7949,2468],"Epirubicin","AMG 102",{"nctId":2829,"briefTitle":2830,"status":217,"phases":7951,"primaryCompletion":2541,"completion":2832,"start":2833,"enrollment":2834,"conditions":7952,"interventions":7953},[90],[2463,2836,1971,25,2837,2479,2441,2838],[2840,2467,1109,2468],{"trials":7955,"activeCount":100},[7956,7963],{"nctId":7957,"briefTitle":7958,"status":336,"phases":7959,"primaryCompletion":7866,"completion":7866,"start":1693,"enrollment":2028,"conditions":7960,"interventions":7961},"NCT02137343","A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer",[91],[3170],[7962,2468,7934],"Rilotumumab",{"nctId":7964,"briefTitle":7965,"status":336,"phases":7966,"primaryCompletion":1637,"completion":4923,"start":7260,"enrollment":6008,"conditions":7967,"interventions":7968},"NCT01697072","First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma",[91],[3170],[7962,7948,2468,7934],{"trials":7970,"activeCount":100},[],{"trials":7972,"activeCount":100},[],{"intervention":3061,"totalTrials":1064,"cells":7974},{"EARLY_PHASE1":7975,"PHASE1":7977,"PHASE2":7987,"PHASE3":8015,"PHASE4":8021,"NA":8023},{"trials":7976,"activeCount":100},[],{"trials":7978,"activeCount":100},[7979,7983],{"nctId":7337,"briefTitle":7338,"status":217,"phases":7980,"primaryCompletion":2882,"completion":2882,"start":2873,"enrollment":6471,"conditions":7981,"interventions":7982},[89],[31],[2827,296,1656],{"nctId":7369,"briefTitle":7370,"status":217,"phases":7984,"primaryCompletion":7372,"completion":7372,"start":7373,"enrollment":7374,"conditions":7985,"interventions":7986},[89],[7376],[2827,1656,7378,1767,7379,7380,7381,7382,296,7383,1764],{"trials":7988,"activeCount":100},[7989,7993,7997,8001,8011],{"nctId":3773,"briefTitle":3774,"status":217,"phases":7990,"conditions":7991,"interventions":7992},[90],[2794],[2797,3061,3778,3779],{"nctId":3055,"briefTitle":3056,"status":3046,"phases":7994,"start":3048,"conditions":7995,"interventions":7996},[90],[3059,1265],[3051,3061,3052,3062],{"nctId":7425,"briefTitle":7426,"status":336,"phases":7998,"primaryCompletion":7428,"completion":7428,"start":7429,"enrollment":6471,"conditions":7999,"interventions":8000},[89,90],[31],[4905,7393,1656,296],{"nctId":8002,"briefTitle":8003,"status":3046,"phases":8004,"start":8005,"conditions":8006,"interventions":8007},"NCT00005959","Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma",[90],"1999-12",[7438],[3051,8008,3061,3062,8009,8010],"rituximab","prednisone","vincristine sulfate",{"nctId":3077,"briefTitle":3078,"status":217,"phases":8012,"conditions":8013,"interventions":8014},[90],[2794,3081,3082],[2797,3052,3084,3061],{"trials":8016,"activeCount":100},[8017],{"nctId":285,"briefTitle":286,"status":217,"phases":8018,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":8019,"interventions":8020},[91],[293],[208,295,296,297,298],{"trials":8022,"activeCount":100},[],{"trials":8024,"activeCount":100},[],{"intervention":553,"totalTrials":1064,"cells":8026},{"EARLY_PHASE1":8027,"PHASE1":8029,"PHASE2":8031,"PHASE3":8041,"PHASE4":8067,"NA":8069},{"trials":8028,"activeCount":100},[],{"trials":8030,"activeCount":100},[],{"trials":8032,"activeCount":100},[8033,8037],{"nctId":545,"briefTitle":546,"status":217,"phases":8034,"primaryCompletion":548,"completion":548,"start":549,"enrollment":550,"conditions":8035,"interventions":8036},[90],[511],[373,553],{"nctId":574,"briefTitle":575,"status":217,"phases":8038,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":8039,"interventions":8040},[90],[511],[373,553],{"trials":8042,"activeCount":100},[8043,8047,8051,8055,8059,8063],{"nctId":624,"briefTitle":625,"status":217,"phases":8044,"primaryCompletion":627,"completion":628,"start":629,"enrollment":630,"conditions":8045,"interventions":8046},[91],[511],[373,553,633,634,224],{"nctId":725,"briefTitle":726,"status":217,"phases":8048,"primaryCompletion":728,"completion":729,"start":730,"enrollment":731,"conditions":8049,"interventions":8050},[91],[562],[373,553],{"nctId":757,"briefTitle":758,"status":217,"phases":8052,"primaryCompletion":760,"completion":761,"start":762,"enrollment":763,"conditions":8053,"interventions":8054},[91],[511],[633,553,373],{"nctId":797,"briefTitle":798,"status":217,"phases":8056,"primaryCompletion":800,"completion":800,"start":801,"enrollment":802,"conditions":8057,"interventions":8058},[91],[562],[373,633,553],{"nctId":827,"briefTitle":828,"status":217,"phases":8060,"primaryCompletion":830,"completion":830,"start":831,"enrollment":832,"conditions":8061,"interventions":8062},[91],[511],[373,553],{"nctId":845,"briefTitle":846,"status":217,"phases":8064,"primaryCompletion":848,"completion":849,"start":850,"enrollment":851,"conditions":8065,"interventions":8066},[91],[511],[373,553],{"trials":8068,"activeCount":100},[],{"trials":8070,"activeCount":100},[],{"intervention":2808,"totalTrials":1454,"cells":8072},{"EARLY_PHASE1":8073,"PHASE1":8075,"PHASE2":8077,"PHASE3":8099,"PHASE4":8109,"NA":8111},{"trials":8074,"activeCount":100},[],{"trials":8076,"activeCount":100},[],{"trials":8078,"activeCount":100},[8079,8083,8087,8091,8095],{"nctId":7849,"briefTitle":7850,"status":217,"phases":8080,"primaryCompletion":5352,"completion":7852,"start":7853,"enrollment":7854,"conditions":8081,"interventions":8082},[90],[25,2529,2425,34,7613,2531,2532,37,2479,2424],[2807,2808,2429],{"nctId":5148,"briefTitle":5149,"status":217,"phases":8084,"primaryCompletion":5151,"completion":5152,"start":2874,"enrollment":5153,"conditions":8085,"interventions":8086},[90],[3035],[2808,2807,2616,2807,2807,1280],{"nctId":5165,"briefTitle":5166,"status":217,"phases":8088,"primaryCompletion":4533,"completion":4560,"start":5168,"enrollment":5169,"conditions":8089,"interventions":8090},[90],[2795,2886,5171],[2807,2807,1280,2808],{"nctId":7926,"briefTitle":7927,"status":217,"phases":8092,"primaryCompletion":6155,"completion":7852,"start":6743,"enrollment":5239,"conditions":8093,"interventions":8094},[90],[7613],[7931,7932,7933,2468,7934,2468,7934,2468,7934],{"nctId":2799,"briefTitle":2800,"status":217,"phases":8096,"primaryCompletion":2802,"completion":2802,"start":2803,"enrollment":439,"conditions":8097,"interventions":8098},[89,90],[2805],[2807,2807,2808,1306,1109],{"trials":8100,"activeCount":100},[8101,8105],{"nctId":5188,"briefTitle":5189,"status":217,"phases":8102,"primaryCompletion":5191,"completion":2883,"start":1627,"enrollment":5192,"conditions":8103,"interventions":8104},[91],[2886,2795,5171],[2807,2808,1280,1280],{"nctId":2879,"briefTitle":2880,"status":336,"phases":8106,"primaryCompletion":2882,"completion":2883,"start":1705,"enrollment":2884,"conditions":8107,"interventions":8108},[91],[2886,2795,2887],[2807,1280,2808,1109],{"trials":8110,"activeCount":100},[],{"trials":8112,"activeCount":100},[],{"intervention":3668,"totalTrials":1454,"cells":8114},{"EARLY_PHASE1":8115,"PHASE1":8117,"PHASE2":8119,"PHASE3":8140,"PHASE4":8168,"NA":8170},{"trials":8116,"activeCount":100},[],{"trials":8118,"activeCount":100},[],{"trials":8120,"activeCount":100},[8121,8128,8132],{"nctId":8122,"briefTitle":8123,"status":217,"phases":8124,"primaryCompletion":7698,"completion":2460,"start":6274,"enrollment":8125,"conditions":8126,"interventions":8127},"NCT00043186","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",[90],412,[3665],[3670,3668],{"nctId":3657,"briefTitle":3658,"status":217,"phases":8129,"primaryCompletion":3660,"completion":3661,"start":3662,"enrollment":3663,"conditions":8130,"interventions":8131},[90],[3665,3666],[3668,3669,3592,3670,3671],{"nctId":8133,"briefTitle":8134,"status":217,"phases":8135,"primaryCompletion":2439,"completion":8136,"start":6777,"enrollment":8137,"conditions":8138,"interventions":8139},"NCT00293813","A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density",[90],"2008-08",247,[3666],[3668,3670],{"trials":8141,"activeCount":100},[8142,8149,8157,8164],{"nctId":8143,"briefTitle":8144,"status":217,"phases":8145,"primaryCompletion":2594,"completion":1638,"start":6777,"enrollment":8146,"conditions":8147,"interventions":8148},"NCT00330460","A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.",[91],1189,[493,3612],[3668,3670],{"nctId":8150,"briefTitle":8151,"status":217,"phases":8152,"primaryCompletion":2439,"completion":6172,"start":6129,"enrollment":8153,"conditions":8154,"interventions":8155},"NCT00377819","Study of Transitioning From Alendronate to Denosumab",[91],504,[3666],[8156,3670],"alendronate",{"nctId":8158,"briefTitle":8159,"status":217,"phases":8160,"primaryCompletion":2550,"completion":509,"start":8161,"enrollment":994,"conditions":8162,"interventions":8163},"NCT00518531","Denosumab Adherence Preference Satisfaction Study",[91],"2007-09-01",[493],[8156,4798],{"nctId":3732,"briefTitle":3733,"status":217,"phases":8165,"primaryCompletion":3735,"completion":3736,"start":3737,"enrollment":3738,"conditions":8166,"interventions":8167},[91],[3740],[3592,3668],{"trials":8169,"activeCount":100},[],{"trials":8171,"activeCount":100},[],{"intervention":8173,"totalTrials":1454,"cells":8174},"AMG 531",{"EARLY_PHASE1":8175,"PHASE1":8177,"PHASE2":8179,"PHASE3":8211,"PHASE4":8236,"NA":8238},{"trials":8176,"activeCount":100},[],{"trials":8178,"activeCount":100},[],{"trials":8180,"activeCount":100},[8181,8189,8195,8201],{"nctId":8182,"briefTitle":8183,"status":217,"phases":8184,"primaryCompletion":4420,"completion":2512,"start":8185,"enrollment":498,"conditions":8186,"interventions":8188},"NCT00283439","A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma",[89,90],"2005-10",[2836,8187,1584,25,2479,2838],"Hodgkin's Lymphoma",[8173],{"nctId":8190,"briefTitle":8191,"status":217,"phases":8192,"primaryCompletion":2451,"completion":7867,"start":2874,"enrollment":6471,"conditions":8193,"interventions":8194},"NCT00515203","Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects",[89,90],[4404,4515,4468],[8173],{"nctId":8196,"briefTitle":8197,"status":217,"phases":8198,"primaryCompletion":2451,"completion":1606,"start":2833,"enrollment":498,"conditions":8199,"interventions":8200},"NCT00418665","A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid",[90],[4424,2838],[8173],{"nctId":8202,"briefTitle":8203,"status":217,"phases":8204,"primaryCompletion":8205,"completion":8205,"start":8206,"enrollment":8207,"conditions":8208,"interventions":8209},"NCT00321711","Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents",[90],"2009-10-19","2006-10-01",69,[4423,4424,2838],[8173,7367,8210],"Decitabine",{"trials":8212,"activeCount":100},[8213,8220,8229],{"nctId":8214,"briefTitle":8215,"status":217,"phases":8216,"primaryCompletion":4465,"completion":4546,"start":8217,"enrollment":4513,"conditions":8218,"interventions":8219},"NCT00102336","AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy",[91],"2005-04-07",[2838,4404],[8173],{"nctId":8221,"briefTitle":8222,"status":217,"phases":8223,"primaryCompletion":8224,"completion":8225,"start":8226,"enrollment":2834,"conditions":8227,"interventions":8228},"NCT00102323","AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy",[91],"2006-09-01","2007-03-01","2005-03-29",[2838,4404],[8173],{"nctId":8230,"briefTitle":8231,"status":217,"phases":8232,"primaryCompletion":8233,"completion":8233,"start":2653,"enrollment":2028,"conditions":8234,"interventions":8235},"NCT00603642","P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura",[91],"2009-04-13",[4404],[8173],{"trials":8237,"activeCount":100},[],{"trials":8239,"activeCount":100},[],{"intervention":2429,"totalTrials":1164,"cells":8241},{"EARLY_PHASE1":8242,"PHASE1":8244,"PHASE2":8250,"PHASE3":8268,"PHASE4":8274,"NA":8276},{"trials":8243,"activeCount":100},[],{"trials":8245,"activeCount":100},[8246],{"nctId":2418,"briefTitle":2419,"status":217,"phases":8247,"primaryCompletion":2421,"completion":1685,"start":2422,"enrollment":2363,"conditions":8248,"interventions":8249},[89],[2424,2425],[2427,2428,1322,2429],{"trials":8251,"activeCount":100},[8252,8256,8260,8264],{"nctId":7849,"briefTitle":7850,"status":217,"phases":8253,"primaryCompletion":5352,"completion":7852,"start":7853,"enrollment":7854,"conditions":8254,"interventions":8255},[90],[25,2529,2425,34,7613,2531,2532,37,2479,2424],[2807,2808,2429],{"nctId":2509,"briefTitle":2510,"status":217,"phases":8257,"primaryCompletion":1638,"completion":2512,"start":2473,"enrollment":2513,"conditions":8258,"interventions":8259},[90],[37,2515,2516,2425,34],[1322,2455,2429,2518,2519],{"nctId":2547,"briefTitle":2548,"status":217,"phases":8261,"primaryCompletion":2550,"completion":2551,"start":2552,"enrollment":2553,"conditions":8262,"interventions":8263},[90],[37],[1322,2429],{"nctId":2583,"briefTitle":2584,"status":217,"phases":8265,"primaryCompletion":2586,"completion":1606,"start":2587,"enrollment":1628,"conditions":8266,"interventions":8267},[90],[2425,34,2424,25,2532,37,2479],[1322,2429],{"trials":8269,"activeCount":100},[8270],{"nctId":2720,"briefTitle":2721,"status":217,"phases":8271,"primaryCompletion":2084,"completion":2723,"start":2724,"enrollment":2725,"conditions":8272,"interventions":8273},[91],[37],[1322,2429],{"trials":8275,"activeCount":100},[],{"trials":8277,"activeCount":100},[],{"intervention":633,"totalTrials":1164,"cells":8279},{"EARLY_PHASE1":8280,"PHASE1":8282,"PHASE2":8284,"PHASE3":8286,"PHASE4":8312,"NA":8314},{"trials":8281,"activeCount":100},[],{"trials":8283,"activeCount":100},[],{"trials":8285,"activeCount":100},[],{"trials":8287,"activeCount":100},[8288,8292,8296,8300,8304,8308],{"nctId":624,"briefTitle":625,"status":217,"phases":8289,"primaryCompletion":627,"completion":628,"start":629,"enrollment":630,"conditions":8290,"interventions":8291},[91],[511],[373,553,633,634,224],{"nctId":692,"briefTitle":693,"status":217,"phases":8293,"primaryCompletion":695,"completion":696,"start":697,"enrollment":698,"conditions":8294,"interventions":8295},[91],[700],[373,633],{"nctId":757,"briefTitle":758,"status":217,"phases":8297,"primaryCompletion":760,"completion":761,"start":762,"enrollment":763,"conditions":8298,"interventions":8299},[91],[511],[633,553,373],{"nctId":778,"briefTitle":779,"status":217,"phases":8301,"primaryCompletion":781,"completion":781,"start":782,"enrollment":783,"conditions":8302,"interventions":8303},[91],[785],[633,373],{"nctId":788,"briefTitle":789,"status":217,"phases":8305,"primaryCompletion":791,"completion":791,"start":719,"enrollment":792,"conditions":8306,"interventions":8307},[91],[794],[373,633],{"nctId":797,"briefTitle":798,"status":217,"phases":8309,"primaryCompletion":800,"completion":800,"start":801,"enrollment":802,"conditions":8310,"interventions":8311},[91],[562],[373,633,553],{"trials":8313,"activeCount":100},[],{"trials":8315,"activeCount":100},[],{"intervention":8317,"totalTrials":1164,"cells":8318},"MP-376",{"EARLY_PHASE1":8319,"PHASE1":8321,"PHASE2":8343,"PHASE3":8361,"PHASE4":8371,"NA":8373},{"trials":8320,"activeCount":100},[],{"trials":8322,"activeCount":100},[8323,8330,8337],{"nctId":8324,"briefTitle":8325,"status":217,"phases":8326,"primaryCompletion":6163,"completion":6163,"start":2661,"enrollment":1545,"conditions":8327,"interventions":8329},"NCT00840333","\"Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients\"",[89],[8328],"Cystic Fibrosis",[8317],{"nctId":8331,"briefTitle":8332,"status":217,"phases":8333,"primaryCompletion":2643,"completion":2643,"start":6172,"enrollment":35,"conditions":8334,"interventions":8336},"NCT00752414","A Phase 1b Study to Evaluate the Safety and PK of MP-376 in Chronic Obstructive Pulmonary Disease (COPD) Patients",[89],[8335],"Chronic Obstructive Pulmonary Disease",[8317],{"nctId":8338,"briefTitle":8339,"status":217,"phases":8340,"primaryCompletion":6743,"completion":6743,"start":2460,"enrollment":23,"conditions":8341,"interventions":8342},"NCT00503490","Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis",[89],[8328],[8317],{"trials":8344,"activeCount":100},[8345,8354],{"nctId":8346,"briefTitle":8347,"status":217,"phases":8348,"primaryCompletion":8349,"completion":8349,"start":3870,"enrollment":8350,"conditions":8351,"interventions":8353},"NCT00677365","Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients",[90],"2009-06",151,[8352],"Cystic Fibrosis (CF)",[8317],{"nctId":8355,"briefTitle":8356,"status":217,"phases":8357,"primaryCompletion":4484,"completion":2421,"start":2643,"enrollment":8358,"conditions":8359,"interventions":8360},"NCT00739648","A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients",[90],322,[8335],[8317],{"trials":8362,"activeCount":100},[8363],{"nctId":8364,"briefTitle":8365,"status":217,"phases":8366,"primaryCompletion":7260,"completion":7943,"start":8367,"enrollment":5137,"conditions":8368,"interventions":8369},"NCT01270347","Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients",[91],"2011-01",[8328],[8317,8370],"TIS",{"trials":8372,"activeCount":100},[],{"trials":8374,"activeCount":100},[],{"intervention":8376,"totalTrials":325,"cells":8377},"Apremilast 20mg",{"EARLY_PHASE1":8378,"PHASE1":8380,"PHASE2":8382,"PHASE3":8396,"PHASE4":8436,"NA":8438},{"trials":8379,"activeCount":100},[],{"trials":8381,"activeCount":100},[],{"trials":8383,"activeCount":100},[8384],{"nctId":8385,"briefTitle":8386,"status":217,"phases":8387,"primaryCompletion":2096,"completion":1734,"start":8388,"enrollment":8389,"conditions":8390,"interventions":8392},"NCT00773734","Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)",[90],"2008-09-01",352,[22,8391],"Plaque-type Psoriasis",[8393,8376,8394,8395,8376],"Apremilast 10mg","Apremilast 30 mg","Apremilast 30mg",{"trials":8397,"activeCount":100},[8398,8408,8417,8427],{"nctId":8399,"briefTitle":8400,"status":217,"phases":8401,"primaryCompletion":8402,"completion":8403,"start":8404,"enrollment":8405,"conditions":8406,"interventions":8407},"NCT01212757","PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis",[91],"2012-07-26","2017-01-25","2010-09-27",488,[2078],[8376,8395],{"nctId":8409,"briefTitle":8410,"status":217,"phases":8411,"primaryCompletion":8412,"completion":8413,"start":6620,"enrollment":8414,"conditions":8415,"interventions":8416},"NCT01307423","Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)",[91],"2013-02-21","2017-08-16",529,[2078],[8376,8395],{"nctId":8418,"briefTitle":8419,"status":217,"phases":8420,"primaryCompletion":8421,"completion":8422,"start":8423,"enrollment":8424,"conditions":8425,"interventions":8426},"NCT01212770","PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis",[91],"2012-08-21","2017-02-09","2010-09-30",505,[2078],[8376,8395],{"nctId":8428,"briefTitle":8429,"status":217,"phases":8430,"primaryCompletion":8431,"completion":8432,"start":8433,"enrollment":8153,"conditions":8434,"interventions":8435},"NCT01172938","Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis",[91],"2012-04-27","2016-10-27","2010-06-02",[2078],[8376,8395],{"trials":8437,"activeCount":100},[],{"trials":8439,"activeCount":100},[],{"intervention":8395,"totalTrials":325,"cells":8441},{"EARLY_PHASE1":8442,"PHASE1":8444,"PHASE2":8446,"PHASE3":8452,"PHASE4":8470,"NA":8472},{"trials":8443,"activeCount":100},[],{"trials":8445,"activeCount":100},[],{"trials":8447,"activeCount":100},[8448],{"nctId":8385,"briefTitle":8386,"status":217,"phases":8449,"primaryCompletion":2096,"completion":1734,"start":8388,"enrollment":8389,"conditions":8450,"interventions":8451},[90],[22,8391],[8393,8376,8394,8395,8376],{"trials":8453,"activeCount":100},[8454,8458,8462,8466],{"nctId":8399,"briefTitle":8400,"status":217,"phases":8455,"primaryCompletion":8402,"completion":8403,"start":8404,"enrollment":8405,"conditions":8456,"interventions":8457},[91],[2078],[8376,8395],{"nctId":8409,"briefTitle":8410,"status":217,"phases":8459,"primaryCompletion":8412,"completion":8413,"start":6620,"enrollment":8414,"conditions":8460,"interventions":8461},[91],[2078],[8376,8395],{"nctId":8418,"briefTitle":8419,"status":217,"phases":8463,"primaryCompletion":8421,"completion":8422,"start":8423,"enrollment":8424,"conditions":8464,"interventions":8465},[91],[2078],[8376,8395],{"nctId":8428,"briefTitle":8429,"status":217,"phases":8467,"primaryCompletion":8431,"completion":8432,"start":8433,"enrollment":8153,"conditions":8468,"interventions":8469},[91],[2078],[8376,8395],{"trials":8471,"activeCount":100},[],{"trials":8473,"activeCount":100},[],{"intervention":295,"totalTrials":325,"cells":8475},{"EARLY_PHASE1":8476,"PHASE1":8478,"PHASE2":8480,"PHASE3":8503,"PHASE4":8517,"NA":8519},{"trials":8477,"activeCount":100},[],{"trials":8479,"activeCount":100},[],{"trials":8481,"activeCount":100},[8482,8486,8495],{"nctId":8002,"briefTitle":8003,"status":3046,"phases":8483,"start":8005,"conditions":8484,"interventions":8485},[90],[7438],[3051,8008,3061,3062,8009,8010],{"nctId":8487,"briefTitle":8488,"status":217,"phases":8489,"primaryCompletion":8490,"completion":1694,"start":8491,"enrollment":96,"conditions":8492,"interventions":8493},"NCT02072863","A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma",[89,90],"2015-01","2014-01",[31],[4905,8494,295],"Melphalan",{"nctId":8496,"briefTitle":8497,"status":217,"phases":8498,"primaryCompletion":8367,"completion":1566,"start":7853,"enrollment":5461,"conditions":8499,"interventions":8502},"NCT00770848","AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer",[89,90],[25,8500,8501,1265],"Castrate-Resistant Prostate Cancer","Mestastatic Prostate Cancer",[7949,7949,7378,295],{"trials":8504,"activeCount":100},[8505,8513],{"nctId":8506,"briefTitle":8507,"status":217,"phases":8508,"primaryCompletion":8509,"completion":3440,"start":8510,"enrollment":6080,"conditions":8511,"interventions":8512},"NCT01818752","Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma",[91],"2016-07-15","2013-07-08",[31],[2827,7476,8494,295],{"nctId":285,"briefTitle":286,"status":217,"phases":8514,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":8515,"interventions":8516},[91],[293],[208,295,296,297,298],{"trials":8518,"activeCount":100},[],{"trials":8520,"activeCount":100},[],{"intervention":8522,"totalTrials":325,"cells":8523},"ABP 501",{"EARLY_PHASE1":8524,"PHASE1":8526,"PHASE2":8537,"PHASE3":8539,"PHASE4":8574,"NA":8576},{"trials":8525,"activeCount":100},[],{"trials":8527,"activeCount":100},[8528],{"nctId":8529,"briefTitle":8530,"status":217,"phases":8531,"primaryCompletion":8532,"completion":8532,"start":822,"enrollment":8533,"conditions":8534,"interventions":8535},"NCT05995691","Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese Participants",[89],"2015-12-04",179,[222],[8522,8536],"Adalimumab",{"trials":8538,"activeCount":100},[],{"trials":8540,"activeCount":100},[8541,8549,8558,8566],{"nctId":8542,"briefTitle":8543,"status":217,"phases":8544,"primaryCompletion":1637,"completion":1637,"start":782,"enrollment":8545,"conditions":8546,"interventions":8548},"NCT01970475","Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis",[91],526,[8547],"Arthritis, Rheumatoid",[8522,8536],{"nctId":8550,"briefTitle":8551,"status":217,"phases":8552,"primaryCompletion":8553,"completion":4004,"start":8554,"enrollment":8555,"conditions":8556,"interventions":8557},"NCT01970488","Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis",[91],"2014-08-14","2013-10-18",350,[22],[8536,8522],{"nctId":8559,"briefTitle":8560,"status":217,"phases":8561,"primaryCompletion":8562,"completion":8562,"start":8563,"enrollment":773,"conditions":8564,"interventions":8565},"NCT02114931","Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis",[91],"2016-04","2014-04",[8547],[8522],{"nctId":8567,"briefTitle":8568,"status":217,"phases":8569,"primaryCompletion":2350,"completion":2350,"start":8570,"enrollment":8571,"conditions":8572,"interventions":8573},"NCT05073315","A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis",[91],"2021-10-04",425,[2152],[8536,8522],{"trials":8575,"activeCount":100},[],{"trials":8577,"activeCount":100},[],{"intervention":7393,"totalTrials":325,"cells":8579},{"EARLY_PHASE1":8580,"PHASE1":8582,"PHASE2":8592,"PHASE3":8598,"PHASE4":8608,"NA":8610},{"trials":8581,"activeCount":100},[],{"trials":8583,"activeCount":100},[8584,8588],{"nctId":7385,"briefTitle":7386,"status":217,"phases":8585,"primaryCompletion":6833,"completion":7388,"start":4420,"enrollment":7389,"conditions":8586,"interventions":8587},[89],[7391],[2827,7393,1656],{"nctId":7403,"briefTitle":7404,"status":217,"phases":8589,"primaryCompletion":1650,"completion":1650,"start":7406,"enrollment":9,"conditions":8590,"interventions":8591},[89],[31],[2827,7393,1656],{"trials":8593,"activeCount":100},[8594],{"nctId":7425,"briefTitle":7426,"status":336,"phases":8595,"primaryCompletion":7428,"completion":7428,"start":7429,"enrollment":6471,"conditions":8596,"interventions":8597},[89,90],[31],[4905,7393,1656,296],{"trials":8599,"activeCount":100},[8600,8604],{"nctId":7505,"briefTitle":7506,"status":217,"phases":8601,"primaryCompletion":3727,"completion":7508,"start":7509,"enrollment":7510,"conditions":8602,"interventions":8603},[91],[7391],[1656,7393,2827],{"nctId":7522,"briefTitle":7523,"status":217,"phases":8605,"primaryCompletion":7525,"completion":7525,"start":7526,"enrollment":7527,"conditions":8606,"interventions":8607},[91],[7322],[2827,2827,7393,1656],{"trials":8609,"activeCount":100},[],{"trials":8611,"activeCount":100},[],{"intervention":297,"totalTrials":160,"cells":8613},{"EARLY_PHASE1":8614,"PHASE1":8616,"PHASE2":8618,"PHASE3":8624,"PHASE4":8648,"NA":8650},{"trials":8615,"activeCount":100},[],{"trials":8617,"activeCount":100},[],{"trials":8619,"activeCount":100},[8620],{"nctId":8002,"briefTitle":8003,"status":3046,"phases":8621,"start":8005,"conditions":8622,"interventions":8623},[90],[7438],[3051,8008,3061,3062,8009,8010],{"trials":8625,"activeCount":100},[8626,8635,8639],{"nctId":8627,"briefTitle":8628,"status":217,"phases":8629,"primaryCompletion":8630,"completion":8630,"start":589,"enrollment":8631,"conditions":8632,"interventions":8633},"NCT02792699","Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab",[91],"2018-10-08",311,[8547],[8634,297,297],"ABP 798",{"nctId":285,"briefTitle":286,"status":217,"phases":8636,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":8637,"interventions":8638},[91],[293],[208,295,296,297,298],{"nctId":8640,"briefTitle":8641,"status":217,"phases":8642,"primaryCompletion":8643,"completion":8643,"start":8644,"enrollment":3979,"conditions":8645,"interventions":8647},"NCT02747043","Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab",[91],"2019-06-28","2016-05-25",[8646],"Lymphoma, Non-Hodgkin",[8634,297],{"trials":8649,"activeCount":100},[],{"trials":8651,"activeCount":100},[],{"intervention":8653,"totalTrials":160,"cells":8654},"AMG 162",{"EARLY_PHASE1":8655,"PHASE1":8657,"PHASE2":8659,"PHASE3":8661,"PHASE4":8699,"NA":8701},{"trials":8656,"activeCount":100},[],{"trials":8658,"activeCount":100},[],{"trials":8660,"activeCount":100},[],{"trials":8662,"activeCount":100},[8663,8672,8678,8687],{"nctId":8664,"briefTitle":8665,"status":217,"phases":8666,"primaryCompletion":8667,"completion":8668,"start":8669,"enrollment":6234,"conditions":8670,"interventions":8671},"NCT00325468","An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density",[91],"2011-03-28","2012-08-02","2006-05-01",[3665],[8653],{"nctId":8673,"briefTitle":8674,"status":217,"phases":8675,"primaryCompletion":2832,"completion":2451,"start":2475,"enrollment":3699,"conditions":8676,"interventions":8677},"NCT00091793","Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis",[91],[3666],[8653],{"nctId":8679,"briefTitle":8680,"status":217,"phases":8681,"primaryCompletion":8682,"completion":8683,"start":2623,"enrollment":8684,"conditions":8685,"interventions":8686},"NCT00089674","AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer",[91],"2008-05-16","2010-05-11",1468,[1265],[8653],{"nctId":8688,"briefTitle":8689,"status":217,"phases":8690,"primaryCompletion":8691,"completion":1566,"start":8692,"enrollment":1582,"conditions":8693,"interventions":8697},"NCT00950911","Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only",[91],"2012-02","2009-07",[8694,8695,8696],"Bone Metastases in Men With Hormone-Refractory Prostate Cancer","Bone Metastases in Subjects With Advanced Breast Cancer","Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma",[8698],"amg 162",{"trials":8700,"activeCount":100},[],{"trials":8702,"activeCount":100},[],{"intervention":8536,"totalTrials":160,"cells":8704},{"EARLY_PHASE1":8705,"PHASE1":8707,"PHASE2":8713,"PHASE3":8715,"PHASE4":8729,"NA":8731},{"trials":8706,"activeCount":100},[],{"trials":8708,"activeCount":100},[8709],{"nctId":8529,"briefTitle":8530,"status":217,"phases":8710,"primaryCompletion":8532,"completion":8532,"start":822,"enrollment":8533,"conditions":8711,"interventions":8712},[89],[222],[8522,8536],{"trials":8714,"activeCount":100},[],{"trials":8716,"activeCount":100},[8717,8721,8725],{"nctId":8542,"briefTitle":8543,"status":217,"phases":8718,"primaryCompletion":1637,"completion":1637,"start":782,"enrollment":8545,"conditions":8719,"interventions":8720},[91],[8547],[8522,8536],{"nctId":8550,"briefTitle":8551,"status":217,"phases":8722,"primaryCompletion":8553,"completion":4004,"start":8554,"enrollment":8555,"conditions":8723,"interventions":8724},[91],[22],[8536,8522],{"nctId":8567,"briefTitle":8568,"status":217,"phases":8726,"primaryCompletion":2350,"completion":2350,"start":8570,"enrollment":8571,"conditions":8727,"interventions":8728},[91],[2152],[8536,8522],{"trials":8730,"activeCount":100},[],{"trials":8732,"activeCount":100},[],{"intervention":7934,"totalTrials":160,"cells":8734},{"EARLY_PHASE1":8735,"PHASE1":8737,"PHASE2":8739,"PHASE3":8749,"PHASE4":8759,"NA":8761},{"trials":8736,"activeCount":100},[],{"trials":8738,"activeCount":100},[],{"trials":8740,"activeCount":100},[8741,8745],{"nctId":7926,"briefTitle":7927,"status":217,"phases":8742,"primaryCompletion":6155,"completion":7852,"start":6743,"enrollment":5239,"conditions":8743,"interventions":8744},[90],[7613],[7931,7932,7933,2468,7934,2468,7934,2468,7934],{"nctId":7940,"briefTitle":7941,"status":217,"phases":8746,"primaryCompletion":1627,"completion":7943,"start":2832,"enrollment":7944,"conditions":8747,"interventions":8748},[89,90],[7946,3170,2465],[7934,7948,7949,2468],{"trials":8750,"activeCount":100},[8751,8755],{"nctId":7957,"briefTitle":7958,"status":336,"phases":8752,"primaryCompletion":7866,"completion":7866,"start":1693,"enrollment":2028,"conditions":8753,"interventions":8754},[91],[3170],[7962,2468,7934],{"nctId":7964,"briefTitle":7965,"status":336,"phases":8756,"primaryCompletion":1637,"completion":4923,"start":7260,"enrollment":6008,"conditions":8757,"interventions":8758},[91],[3170],[7962,7948,2468,7934],{"trials":8760,"activeCount":100},[],{"trials":8762,"activeCount":100},[],{"intervention":8394,"totalTrials":193,"cells":8764},{"EARLY_PHASE1":8765,"PHASE1":8767,"PHASE2":8769,"PHASE3":8785,"PHASE4":8797,"NA":8799},{"trials":8766,"activeCount":100},[],{"trials":8768,"activeCount":100},[],{"trials":8770,"activeCount":100},[8771,8781],{"nctId":8772,"briefTitle":8773,"status":336,"phases":8774,"primaryCompletion":8775,"completion":8776,"start":6620,"enrollment":8777,"conditions":8778,"interventions":8779},"NCT01285310","Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis",[90],"2012-02-21","2012-09-10",237,[19],[8394,8780],"Apremilast 20 mg",{"nctId":8385,"briefTitle":8386,"status":217,"phases":8782,"primaryCompletion":2096,"completion":1734,"start":8388,"enrollment":8389,"conditions":8783,"interventions":8784},[90],[22,8391],[8393,8376,8394,8395,8376],{"trials":8786,"activeCount":100},[8787],{"nctId":8788,"briefTitle":8789,"status":217,"phases":8790,"primaryCompletion":8791,"completion":8792,"start":8793,"enrollment":8794,"conditions":8795,"interventions":8796},"NCT01925768","Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis",[91],"2015-02-25","2016-11-17","2013-09-04",219,[2078],[8394],{"trials":8798,"activeCount":100},[],{"trials":8800,"activeCount":100},[],{"intervention":8802,"totalTrials":193,"cells":8803},"HZT-501",{"EARLY_PHASE1":8804,"PHASE1":8806,"PHASE2":8808,"PHASE3":8810,"PHASE4":8837,"NA":8839},{"trials":8805,"activeCount":100},[],{"trials":8807,"activeCount":100},[],{"trials":8809,"activeCount":100},[],{"trials":8811,"activeCount":100},[8812,8823,8831],{"nctId":8813,"briefTitle":8814,"status":217,"phases":8815,"primaryCompletion":2643,"completion":2643,"start":2570,"enrollment":8533,"conditions":8816,"interventions":8821},"NCT00613106","Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg\u002FFamotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)",[91],[8817,19,8818,8819,8820],"Osteoarthritis","Chronic Low Back Pain","Chronic Regional Pain Syndrome","Chronic Soft Tissue Pain",[8802,8822],"Ibuprofen",{"nctId":8824,"briefTitle":8825,"status":217,"phases":8826,"primaryCompletion":2512,"completion":2643,"start":2601,"enrollment":8827,"conditions":8828,"interventions":8830},"NCT00450658","Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers",[91],627,[8829],"Peptic Ulcer",[8802,8822],{"nctId":8832,"briefTitle":8833,"status":217,"phases":8834,"primaryCompletion":4932,"completion":4932,"start":1636,"enrollment":2476,"conditions":8835,"interventions":8836},"NCT00984815","Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment",[91],[8817,19,8818,8819,8820],[8802],{"trials":8838,"activeCount":100},[],{"trials":8840,"activeCount":100},[],{"intervention":8822,"totalTrials":193,"cells":8842},{"EARLY_PHASE1":8843,"PHASE1":8845,"PHASE2":8847,"PHASE3":8849,"PHASE4":8868,"NA":8870},{"trials":8844,"activeCount":100},[],{"trials":8846,"activeCount":100},[],{"trials":8848,"activeCount":100},[],{"trials":8850,"activeCount":100},[8851,8855,8859],{"nctId":8813,"briefTitle":8814,"status":217,"phases":8852,"primaryCompletion":2643,"completion":2643,"start":2570,"enrollment":8533,"conditions":8853,"interventions":8854},[91],[8817,19,8818,8819,8820],[8802,8822],{"nctId":8824,"briefTitle":8825,"status":217,"phases":8856,"primaryCompletion":2512,"completion":2643,"start":2601,"enrollment":8827,"conditions":8857,"interventions":8858},[91],[8829],[8802,8822],{"nctId":8860,"briefTitle":8861,"status":217,"phases":8862,"primaryCompletion":8136,"completion":2643,"start":2601,"enrollment":8863,"conditions":8864,"interventions":8866},"NCT00450216","Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment",[91],906,[8865],"Ulcer",[8867,8822],"Ibuprofen\u002Ffamotidine",{"trials":8869,"activeCount":100},[],{"trials":8871,"activeCount":100},[],{"intervention":7962,"totalTrials":193,"cells":8873},{"EARLY_PHASE1":8874,"PHASE1":8876,"PHASE2":8888,"PHASE3":8890,"PHASE4":8900,"NA":8902},{"trials":8875,"activeCount":100},[],{"trials":8877,"activeCount":100},[8878],{"nctId":8879,"briefTitle":8880,"status":217,"phases":8881,"primaryCompletion":2873,"completion":2438,"start":8882,"enrollment":35,"conditions":8883,"interventions":8887},"NCT01791374","Phase 1\u002F1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ",[89],"2012-11",[8884,8885,8886],"Part 1- Advanced Solid Tumors","Part 2- Advanced or Metastatic Gastric Cancer","Part 2- Advanced or Metastatic GEJ",[7962,7962],{"trials":8889,"activeCount":100},[],{"trials":8891,"activeCount":100},[8892,8896],{"nctId":7957,"briefTitle":7958,"status":336,"phases":8893,"primaryCompletion":7866,"completion":7866,"start":1693,"enrollment":2028,"conditions":8894,"interventions":8895},[91],[3170],[7962,2468,7934],{"nctId":7964,"briefTitle":7965,"status":336,"phases":8897,"primaryCompletion":1637,"completion":4923,"start":7260,"enrollment":6008,"conditions":8898,"interventions":8899},[91],[3170],[7962,7948,2468,7934],{"trials":8901,"activeCount":100},[],{"trials":8903,"activeCount":100},[],{"intervention":8905,"totalTrials":193,"cells":8906},"Cystagon®",{"EARLY_PHASE1":8907,"PHASE1":8909,"PHASE2":8911,"PHASE3":8921,"PHASE4":8939,"NA":8941},{"trials":8908,"activeCount":100},[],{"trials":8910,"activeCount":100},[],{"trials":8912,"activeCount":100},[8913],{"nctId":8914,"briefTitle":8915,"status":217,"phases":8916,"primaryCompletion":6183,"completion":6183,"start":2499,"enrollment":96,"conditions":8917,"interventions":8919},"NCT00872729","Pilot Study of Safety, Tolerability, Pharmacokinetics\u002FPharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis",[89,90],[8918],"Cystinosis",[8905,8920],"RP103",{"trials":8922,"activeCount":100},[8923,8931],{"nctId":8924,"briefTitle":8925,"status":217,"phases":8926,"primaryCompletion":8927,"completion":1565,"start":2452,"enrollment":380,"conditions":8928,"interventions":8929},"NCT01000961","Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis",[91],"2011-06",[8918],[8905,8930],"Cysteamine Bitartrate Delayed-release",{"nctId":8932,"briefTitle":8933,"status":217,"phases":8934,"primaryCompletion":4512,"completion":8935,"start":8936,"enrollment":1160,"conditions":8937,"interventions":8938},"NCT01733316","Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis",[91],"2017-07-10","2013-01-31",[8918],[8920,8905],{"trials":8940,"activeCount":100},[],{"trials":8942,"activeCount":100},[],{"intervention":8944,"totalTrials":193,"cells":8945},"rHuEPO",{"EARLY_PHASE1":8946,"PHASE1":8948,"PHASE2":8950,"PHASE3":8952,"PHASE4":8979,"NA":8981},{"trials":8947,"activeCount":100},[],{"trials":8949,"activeCount":100},[],{"trials":8951,"activeCount":100},[],{"trials":8953,"activeCount":100},[8954,8963,8972],{"nctId":8955,"briefTitle":8956,"status":217,"phases":8957,"primaryCompletion":6756,"completion":6756,"start":8958,"enrollment":4814,"conditions":8959,"interventions":8961},"NCT00527137","NESP Pediatric Study",[91],"2000-08",[8960,6268],"Pre-dialysis",[8962,8944],"darbepoetin alfa",{"nctId":8964,"briefTitle":8965,"status":217,"phases":8966,"primaryCompletion":6478,"completion":7690,"start":2578,"enrollment":8967,"conditions":8968,"interventions":8970},"NCT00111137","Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy",[91],718,[25,8969],"Non-Myeloid Malignancies",[8944,8971],"Darbepoetin alfa",{"nctId":8973,"briefTitle":8974,"status":217,"phases":8975,"primaryCompletion":8976,"completion":7690,"start":2776,"enrollment":1536,"conditions":8977,"interventions":8978},"NCT00038064","Anemia in Patients With a Non-Myeloid Malignancy",[91],"2003-10",[6286,16],[8971,8944],{"trials":8980,"activeCount":100},[],{"trials":8982,"activeCount":100},[],{"intervention":8984,"totalTrials":193,"cells":8985},"Epoetin alfa DT",{"EARLY_PHASE1":8986,"PHASE1":8988,"PHASE2":8990,"PHASE3":8992,"PHASE4":9016,"NA":9018},{"trials":8987,"activeCount":100},[],{"trials":8989,"activeCount":100},[],{"trials":8991,"activeCount":100},[],{"trials":8993,"activeCount":100},[8994,9001,9009],{"nctId":8995,"briefTitle":8996,"status":336,"phases":8997,"primaryCompletion":2601,"completion":2601,"start":6282,"enrollment":6405,"conditions":8998,"interventions":8999},"NCT00156962","Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)",[91],[28],[8984,9000],"Epoetin alfa RB",{"nctId":9002,"briefTitle":9003,"status":217,"phases":9004,"primaryCompletion":2662,"completion":2662,"start":7331,"enrollment":9005,"conditions":9006,"interventions":9008},"NCT00146224","Efficacy of Epoetin Alfa Deep Tank in Treatment of Anemia in Patients With Chronic Kidney Disease Receiving Hemodialysis",[91],420,[9007],"Nephrology",[9000,8984],{"nctId":9010,"briefTitle":9011,"status":217,"phases":9012,"primaryCompletion":7586,"completion":7586,"start":6282,"enrollment":9013,"conditions":9014,"interventions":9015},"NCT00156949","EPO Deep Tank in Dialysis Subjects",[91],580,[28],[8984],{"trials":9017,"activeCount":100},[],{"trials":9019,"activeCount":100},[],{"intervention":9021,"totalTrials":193,"cells":9022},"Interferon γ-1b",{"EARLY_PHASE1":9023,"PHASE1":9025,"PHASE2":9027,"PHASE3":9029,"PHASE4":9056,"NA":9058},{"trials":9024,"activeCount":100},[],{"trials":9026,"activeCount":100},[],{"trials":9028,"activeCount":100},[],{"trials":9030,"activeCount":100},[9031,9040,9049],{"nctId":9032,"briefTitle":9033,"status":217,"phases":9034,"primaryCompletion":9035,"completion":9035,"start":9036,"enrollment":2476,"conditions":9037,"interventions":9039},"NCT02593773","Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study",[91],"2017-03-21","2015-12-25",[9038],"Friedreich's Ataxia",[9021],{"nctId":9041,"briefTitle":9042,"status":217,"phases":9043,"primaryCompletion":7499,"completion":7499,"start":9044,"enrollment":9045,"conditions":9046,"interventions":9047},"NCT02797080","Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia",[91],"2016-06-28",38,[9038],[9048],"interferon γ-1b",{"nctId":9050,"briefTitle":9051,"status":217,"phases":9052,"primaryCompletion":2732,"completion":2732,"start":7866,"enrollment":9053,"conditions":9054,"interventions":9055},"NCT02415127","Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia",[91],92,[9038],[9021],{"trials":9057,"activeCount":100},[],{"trials":9059,"activeCount":100},[],{"intervention":8920,"totalTrials":193,"cells":9061},{"EARLY_PHASE1":9062,"PHASE1":9064,"PHASE2":9066,"PHASE3":9072,"PHASE4":9086,"NA":9088},{"trials":9063,"activeCount":100},[],{"trials":9065,"activeCount":100},[],{"trials":9067,"activeCount":100},[9068],{"nctId":8914,"briefTitle":8915,"status":217,"phases":9069,"primaryCompletion":6183,"completion":6183,"start":2499,"enrollment":96,"conditions":9070,"interventions":9071},[89,90],[8918],[8905,8920],{"trials":9073,"activeCount":100},[9074,9082],{"nctId":9075,"briefTitle":9076,"status":217,"phases":9077,"primaryCompletion":9078,"completion":9078,"start":9079,"enrollment":1593,"conditions":9080,"interventions":9081},"NCT01744782","Safety\u002FEffectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis",[91],"2016-12-13","2012-12-20",[8918],[8920],{"nctId":8932,"briefTitle":8933,"status":217,"phases":9083,"primaryCompletion":4512,"completion":8935,"start":8936,"enrollment":1160,"conditions":9084,"interventions":9085},[91],[8918],[8920,8905],{"trials":9087,"activeCount":100},[],{"trials":9089,"activeCount":100},[],{"intervention":8634,"totalTrials":985,"cells":9091},{"EARLY_PHASE1":9092,"PHASE1":9094,"PHASE2":9096,"PHASE3":9098,"PHASE4":9108,"NA":9110},{"trials":9093,"activeCount":100},[],{"trials":9095,"activeCount":100},[],{"trials":9097,"activeCount":100},[],{"trials":9099,"activeCount":100},[9100,9104],{"nctId":8627,"briefTitle":8628,"status":217,"phases":9101,"primaryCompletion":8630,"completion":8630,"start":589,"enrollment":8631,"conditions":9102,"interventions":9103},[91],[8547],[8634,297,297],{"nctId":8640,"briefTitle":8641,"status":217,"phases":9105,"primaryCompletion":8643,"completion":8643,"start":8644,"enrollment":3979,"conditions":9106,"interventions":9107},[91],[8646],[8634,297],{"trials":9109,"activeCount":100},[],{"trials":9111,"activeCount":100},[],{"intervention":7476,"totalTrials":985,"cells":9113},{"EARLY_PHASE1":9114,"PHASE1":9116,"PHASE2":9118,"PHASE3":9120,"PHASE4":9130,"NA":9132},{"trials":9115,"activeCount":100},[],{"trials":9117,"activeCount":100},[],{"trials":9119,"activeCount":100},[],{"trials":9121,"activeCount":100},[9122,9126],{"nctId":7467,"briefTitle":7468,"status":217,"phases":9123,"primaryCompletion":7470,"completion":7471,"start":7472,"enrollment":7473,"conditions":9124,"interventions":9125},[91],[31],[2827,7476,1656],{"nctId":8506,"briefTitle":8507,"status":217,"phases":9127,"primaryCompletion":8509,"completion":3440,"start":8510,"enrollment":6080,"conditions":9128,"interventions":9129},[91],[31],[2827,7476,8494,295],{"trials":9131,"activeCount":100},[],{"trials":9133,"activeCount":100},[],{"intervention":6308,"totalTrials":985,"cells":9135},{"EARLY_PHASE1":9136,"PHASE1":9138,"PHASE2":9140,"PHASE3":9146,"PHASE4":9152,"NA":9154},{"trials":9137,"activeCount":100},[],{"trials":9139,"activeCount":100},[],{"trials":9141,"activeCount":100},[9142],{"nctId":6300,"briefTitle":6301,"status":217,"phases":9143,"primaryCompletion":640,"completion":6303,"start":6304,"enrollment":6305,"conditions":9144,"interventions":9145},[90],[1971],[3670,3671,6308],{"trials":9147,"activeCount":100},[9148],{"nctId":7711,"briefTitle":7712,"status":217,"phases":9149,"primaryCompletion":7714,"completion":7715,"start":7716,"enrollment":7717,"conditions":9150,"interventions":9151},[91],[25,2425,34,3081,7719,37,3082,2424],[4012,2616,6308],{"trials":9153,"activeCount":100},[],{"trials":9155,"activeCount":100},[],{"intervention":8494,"totalTrials":985,"cells":9157},{"EARLY_PHASE1":9158,"PHASE1":9160,"PHASE2":9162,"PHASE3":9168,"PHASE4":9174,"NA":9176},{"trials":9159,"activeCount":100},[],{"trials":9161,"activeCount":100},[],{"trials":9163,"activeCount":100},[9164],{"nctId":8487,"briefTitle":8488,"status":217,"phases":9165,"primaryCompletion":8490,"completion":1694,"start":8491,"enrollment":96,"conditions":9166,"interventions":9167},[89,90],[31],[4905,8494,295],{"trials":9169,"activeCount":100},[9170],{"nctId":8506,"briefTitle":8507,"status":217,"phases":9171,"primaryCompletion":8509,"completion":3440,"start":8510,"enrollment":6080,"conditions":9172,"interventions":9173},[91],[31],[2827,7476,8494,295],{"trials":9175,"activeCount":100},[],{"trials":9177,"activeCount":100},[],{"intervention":1764,"totalTrials":985,"cells":9179},{"EARLY_PHASE1":9180,"PHASE1":9182,"PHASE2":9188,"PHASE3":9190,"PHASE4":9196,"NA":9198},{"trials":9181,"activeCount":100},[],{"trials":9183,"activeCount":100},[9184],{"nctId":7369,"briefTitle":7370,"status":217,"phases":9185,"primaryCompletion":7372,"completion":7372,"start":7373,"enrollment":7374,"conditions":9186,"interventions":9187},[89],[7376],[2827,1656,7378,1767,7379,7380,7381,7382,296,7383,1764],{"trials":9189,"activeCount":100},[],{"trials":9191,"activeCount":100},[9192],{"nctId":1754,"briefTitle":1755,"status":217,"phases":9193,"primaryCompletion":1757,"completion":1758,"start":760,"enrollment":1759,"conditions":9194,"interventions":9195},[91],[1761],[117,1656,1763,1764,1765,1766,1767,1768],{"trials":9197,"activeCount":100},[],{"trials":9199,"activeCount":100},[],{"intervention":1767,"totalTrials":985,"cells":9201},{"EARLY_PHASE1":9202,"PHASE1":9204,"PHASE2":9210,"PHASE3":9212,"PHASE4":9218,"NA":9220},{"trials":9203,"activeCount":100},[],{"trials":9205,"activeCount":100},[9206],{"nctId":7369,"briefTitle":7370,"status":217,"phases":9207,"primaryCompletion":7372,"completion":7372,"start":7373,"enrollment":7374,"conditions":9208,"interventions":9209},[89],[7376],[2827,1656,7378,1767,7379,7380,7381,7382,296,7383,1764],{"trials":9211,"activeCount":100},[],{"trials":9213,"activeCount":100},[9214],{"nctId":1754,"briefTitle":1755,"status":217,"phases":9215,"primaryCompletion":1757,"completion":1758,"start":760,"enrollment":1759,"conditions":9216,"interventions":9217},[91],[1761],[117,1656,1763,1764,1765,1766,1767,1768],{"trials":9219,"activeCount":100},[],{"trials":9221,"activeCount":100},[],{"intervention":3669,"totalTrials":985,"cells":9223},{"EARLY_PHASE1":9224,"PHASE1":9226,"PHASE2":9228,"PHASE3":9234,"PHASE4":9245,"NA":9247},{"trials":9225,"activeCount":100},[],{"trials":9227,"activeCount":100},[],{"trials":9229,"activeCount":100},[9230],{"nctId":3657,"briefTitle":3658,"status":217,"phases":9231,"primaryCompletion":3660,"completion":3661,"start":3662,"enrollment":3663,"conditions":9232,"interventions":9233},[90],[3665,3666],[3668,3669,3592,3670,3671],{"trials":9235,"activeCount":100},[9236],{"nctId":9237,"briefTitle":9238,"status":217,"phases":9239,"primaryCompletion":9240,"completion":9240,"start":8936,"enrollment":9241,"conditions":9242,"interventions":9243},"NCT01796301","An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women",[91],"2015-05-14",436,[3666],[9244,3669],"Romozosumab",{"trials":9246,"activeCount":100},[],{"trials":9248,"activeCount":100},[],{"intervention":634,"totalTrials":985,"cells":9250},{"EARLY_PHASE1":9251,"PHASE1":9253,"PHASE2":9259,"PHASE3":9261,"PHASE4":9267,"NA":9269},{"trials":9252,"activeCount":100},[],{"trials":9254,"activeCount":100},[9255],{"nctId":1851,"briefTitle":1852,"status":217,"phases":9256,"primaryCompletion":1854,"completion":1854,"start":1855,"enrollment":231,"conditions":9257,"interventions":9258},[89],[1857],[634,1307],{"trials":9260,"activeCount":100},[],{"trials":9262,"activeCount":100},[9263],{"nctId":624,"briefTitle":625,"status":217,"phases":9264,"primaryCompletion":627,"completion":628,"start":629,"enrollment":630,"conditions":9265,"interventions":9266},[91],[511],[373,553,633,634,224],{"trials":9268,"activeCount":100},[],{"trials":9270,"activeCount":100},[],{"intervention":224,"totalTrials":985,"cells":9272},{"EARLY_PHASE1":9273,"PHASE1":9275,"PHASE2":9281,"PHASE3":9283,"PHASE4":9289,"NA":9291},{"trials":9274,"activeCount":100},[],{"trials":9276,"activeCount":100},[9277],{"nctId":215,"briefTitle":216,"status":217,"phases":9278,"primaryCompletion":219,"completion":219,"start":220,"enrollment":26,"conditions":9279,"interventions":9280},[89],[222],[208,224],{"trials":9282,"activeCount":100},[],{"trials":9284,"activeCount":100},[9285],{"nctId":624,"briefTitle":625,"status":217,"phases":9286,"primaryCompletion":627,"completion":628,"start":629,"enrollment":630,"conditions":9287,"interventions":9288},[91],[511],[373,553,633,634,224],{"trials":9290,"activeCount":100},[],{"trials":9292,"activeCount":100},[],{"intervention":2853,"totalTrials":985,"cells":9294},{"EARLY_PHASE1":9295,"PHASE1":9297,"PHASE2":9299,"PHASE3":9301,"PHASE4":9311,"NA":9313},{"trials":9296,"activeCount":100},[],{"trials":9298,"activeCount":100},[],{"trials":9300,"activeCount":100},[],{"trials":9302,"activeCount":100},[9303,9307],{"nctId":2844,"briefTitle":2845,"status":131,"phases":9304,"primaryCompletion":2847,"completion":2847,"start":2848,"enrollment":100,"conditions":9305,"interventions":9306},[91],[2850,2851],[2853,2616,1280,1109],{"nctId":2855,"briefTitle":2856,"status":217,"phases":9308,"primaryCompletion":2858,"completion":2858,"start":2859,"enrollment":2860,"conditions":9309,"interventions":9310},[91],[2862],[1109,1280,2853,2616],{"trials":9312,"activeCount":100},[],{"trials":9314,"activeCount":100},[],{"intervention":9316,"totalTrials":985,"cells":9317},"Palifermin",{"EARLY_PHASE1":9318,"PHASE1":9320,"PHASE2":9322,"PHASE3":9324,"PHASE4":9342,"NA":9344},{"trials":9319,"activeCount":100},[],{"trials":9321,"activeCount":100},[],{"trials":9323,"activeCount":100},[],{"trials":9325,"activeCount":100},[9326,9334],{"nctId":9327,"briefTitle":9328,"status":217,"phases":9329,"primaryCompletion":2594,"completion":9330,"start":2602,"enrollment":9331,"conditions":9332,"interventions":9333},"NCT00131638","A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer",[91],"2016-07",241,[2530],[9316],{"nctId":9335,"briefTitle":9336,"status":217,"phases":9337,"primaryCompletion":6743,"completion":9338,"start":6224,"enrollment":12,"conditions":9339,"interventions":9340},"NCT00393822","A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer",[90,91],"2014-03",[2425],[9341],"palifermin",{"trials":9343,"activeCount":100},[],{"trials":9345,"activeCount":100},[],{"intervention":9347,"totalTrials":985,"cells":9348},"Evolocumab AI\u002Fpen",{"EARLY_PHASE1":9349,"PHASE1":9351,"PHASE2":9353,"PHASE3":9355,"PHASE4":9375,"NA":9377},{"trials":9350,"activeCount":100},[],{"trials":9352,"activeCount":100},[],{"trials":9354,"activeCount":100},[],{"trials":9356,"activeCount":100},[9357,9366],{"nctId":9358,"briefTitle":9359,"status":217,"phases":9360,"primaryCompletion":9361,"start":641,"enrollment":9362,"conditions":9363,"interventions":9364},"NCT01849497","Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector\u002FPen",[91],"2013-09-02",149,[814,520],[9365,9347],"Evolocumab Pre-filled Syringe",{"nctId":9367,"briefTitle":9368,"status":217,"phases":9369,"primaryCompletion":9370,"start":9371,"enrollment":709,"conditions":9372,"interventions":9373},"NCT01879319","Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector\u002FPen",[91],"2013-11-15","2013-07-11",[814,520],[9374,9347],"Evolocumab AMD",{"trials":9376,"activeCount":100},[],{"trials":9378,"activeCount":100},[],{"intervention":9380,"totalTrials":985,"cells":9381},"ABP 654",{"EARLY_PHASE1":9382,"PHASE1":9384,"PHASE2":9386,"PHASE3":9388,"PHASE4":9408,"NA":9410},{"trials":9383,"activeCount":100},[],{"trials":9385,"activeCount":100},[],{"trials":9387,"activeCount":100},[],{"trials":9389,"activeCount":100},[9390,9400],{"nctId":9391,"briefTitle":9392,"status":217,"phases":9393,"primaryCompletion":9394,"completion":9395,"start":9396,"enrollment":1224,"conditions":9397,"interventions":9398},"NCT04607980","A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis",[91],"2022-01-13","2022-06-03","2020-11-11",[2152],[9380,9399],"Ustekinumab",{"nctId":9401,"briefTitle":9402,"status":217,"phases":9403,"primaryCompletion":4695,"completion":4695,"start":9404,"enrollment":9405,"conditions":9406,"interventions":9407},"NCT04761627","A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis",[91],"2021-03-24",494,[22],[9399,9380],{"trials":9409,"activeCount":100},[],{"trials":9411,"activeCount":100},[],{"intervention":9399,"totalTrials":985,"cells":9413},{"EARLY_PHASE1":9414,"PHASE1":9416,"PHASE2":9418,"PHASE3":9420,"PHASE4":9430,"NA":9432},{"trials":9415,"activeCount":100},[],{"trials":9417,"activeCount":100},[],{"trials":9419,"activeCount":100},[],{"trials":9421,"activeCount":100},[9422,9426],{"nctId":9391,"briefTitle":9392,"status":217,"phases":9423,"primaryCompletion":9394,"completion":9395,"start":9396,"enrollment":1224,"conditions":9424,"interventions":9425},[91],[2152],[9380,9399],{"nctId":9401,"briefTitle":9402,"status":217,"phases":9427,"primaryCompletion":4695,"completion":4695,"start":9404,"enrollment":9405,"conditions":9428,"interventions":9429},[91],[22],[9399,9380],{"trials":9431,"activeCount":100},[],{"trials":9433,"activeCount":100},[],{"intervention":8930,"totalTrials":985,"cells":9435},{"EARLY_PHASE1":9436,"PHASE1":9438,"PHASE2":9440,"PHASE3":9442,"PHASE4":9455,"NA":9457},{"trials":9437,"activeCount":100},[],{"trials":9439,"activeCount":100},[],{"trials":9441,"activeCount":100},[],{"trials":9443,"activeCount":100},[9444,9448],{"nctId":8924,"briefTitle":8925,"status":217,"phases":9445,"primaryCompletion":8927,"completion":1565,"start":2452,"enrollment":380,"conditions":9446,"interventions":9447},[91],[8918],[8905,8930],{"nctId":9449,"briefTitle":9450,"status":217,"phases":9451,"primaryCompletion":3441,"completion":3441,"start":9452,"enrollment":13,"conditions":9453,"interventions":9454},"NCT01197378","Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)",[91],"2010-08-27",[8918],[8930],{"trials":9456,"activeCount":100},[],{"trials":9458,"activeCount":100},[],{"intervention":9000,"totalTrials":985,"cells":9460},{"EARLY_PHASE1":9461,"PHASE1":9463,"PHASE2":9465,"PHASE3":9467,"PHASE4":9477,"NA":9479},{"trials":9462,"activeCount":100},[],{"trials":9464,"activeCount":100},[],{"trials":9466,"activeCount":100},[],{"trials":9468,"activeCount":100},[9469,9473],{"nctId":8995,"briefTitle":8996,"status":336,"phases":9470,"primaryCompletion":2601,"completion":2601,"start":6282,"enrollment":6405,"conditions":9471,"interventions":9472},[91],[28],[8984,9000],{"nctId":9002,"briefTitle":9003,"status":217,"phases":9474,"primaryCompletion":2662,"completion":2662,"start":7331,"enrollment":9005,"conditions":9475,"interventions":9476},[91],[9007],[9000,8984],{"trials":9478,"activeCount":100},[],{"trials":9480,"activeCount":100},[],{"intervention":6148,"totalTrials":985,"cells":9482},{"EARLY_PHASE1":9483,"PHASE1":9485,"PHASE2":9491,"PHASE3":9493,"PHASE4":9499,"NA":9501},{"trials":9484,"activeCount":100},[],{"trials":9486,"activeCount":100},[9487],{"nctId":6139,"briefTitle":6140,"status":217,"phases":9488,"completion":6142,"start":6143,"enrollment":253,"conditions":9489,"interventions":9490},[89],[6145],[5358,6147,6148],{"trials":9492,"activeCount":100},[],{"trials":9494,"activeCount":100},[9495],{"nctId":6180,"briefTitle":6181,"status":217,"phases":9496,"primaryCompletion":5352,"completion":5352,"start":6183,"enrollment":17,"conditions":9497,"interventions":9498},[91],[6132],[5358,6148],{"trials":9500,"activeCount":100},[],{"trials":9502,"activeCount":100},[],{"intervention":9504,"totalTrials":985,"cells":9505},"Rocatinlimab prefilled syringe",{"EARLY_PHASE1":9506,"PHASE1":9508,"PHASE2":9519,"PHASE3":9521,"PHASE4":9533,"NA":9535},{"trials":9507,"activeCount":100},[],{"trials":9509,"activeCount":100},[9510],{"nctId":9511,"briefTitle":9512,"status":217,"phases":9513,"primaryCompletion":9514,"completion":969,"start":9515,"enrollment":6107,"conditions":9516,"interventions":9517},"NCT06268860","A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants",[89],"2024-08-30","2024-02-15",[2907],[9518,9504],"Rocatinlimab vial",{"trials":9520,"activeCount":100},[],{"trials":9522,"activeCount":100},[9523],{"nctId":9524,"briefTitle":9525,"status":217,"phases":9526,"primaryCompletion":9527,"completion":9528,"start":201,"enrollment":8350,"conditions":9529,"interventions":9530},"NCT06224192","A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis",[91],"2025-04-11","2026-03-16",[2907],[9531,9532],"Rocatinlimab Prefilled Syringe","Rocatinlimab AI",{"trials":9534,"activeCount":100},[],{"trials":9536,"activeCount":100},[],{"intervention":9538,"totalTrials":985,"cells":9539},"Cinacalcet HCl",{"EARLY_PHASE1":9540,"PHASE1":9542,"PHASE2":9544,"PHASE3":9546,"PHASE4":9563,"NA":9565},{"trials":9541,"activeCount":100},[],{"trials":9543,"activeCount":100},[],{"trials":9545,"activeCount":100},[],{"trials":9547,"activeCount":100},[9548,9557],{"nctId":9549,"briefTitle":9550,"status":336,"phases":9551,"primaryCompletion":9552,"completion":9552,"start":9553,"enrollment":9554,"conditions":9555,"interventions":9556},"NCT02138838","Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis",[91],"2016-06-23","2014-11-07",55,[3350],[9538],{"nctId":9558,"briefTitle":9559,"status":217,"phases":9560,"start":7610,"enrollment":5064,"conditions":9561,"interventions":9562},"NCT00094484","Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis",[91],[383,28],[9538],{"trials":9564,"activeCount":100},[],{"trials":9566,"activeCount":100},[],{"intervention":2617,"totalTrials":985,"cells":9568},{"EARLY_PHASE1":9569,"PHASE1":9571,"PHASE2":9573,"PHASE3":9579,"PHASE4":9585,"NA":9587},{"trials":9570,"activeCount":100},[],{"trials":9572,"activeCount":100},[],{"trials":9574,"activeCount":100},[9575],{"nctId":2607,"briefTitle":2608,"status":217,"phases":9576,"primaryCompletion":2610,"completion":2611,"start":2612,"enrollment":2613,"conditions":9577,"interventions":9578},[90],[2425,34,2424,37],[1322,2616,2617],{"trials":9580,"activeCount":100},[9581],{"nctId":3482,"briefTitle":3483,"status":217,"phases":9582,"primaryCompletion":3485,"completion":3486,"start":3487,"enrollment":3488,"conditions":9583,"interventions":9584},[91],[3170,3182],[72,2617],{"trials":9586,"activeCount":100},[],{"trials":9588,"activeCount":100},[],{"intervention":7948,"totalTrials":985,"cells":9590},{"EARLY_PHASE1":9591,"PHASE1":9593,"PHASE2":9595,"PHASE3":9601,"PHASE4":9607,"NA":9609},{"trials":9592,"activeCount":100},[],{"trials":9594,"activeCount":100},[],{"trials":9596,"activeCount":100},[9597],{"nctId":7940,"briefTitle":7941,"status":217,"phases":9598,"primaryCompletion":1627,"completion":7943,"start":2832,"enrollment":7944,"conditions":9599,"interventions":9600},[89,90],[7946,3170,2465],[7934,7948,7949,2468],{"trials":9602,"activeCount":100},[9603],{"nctId":7964,"briefTitle":7965,"status":336,"phases":9604,"primaryCompletion":1637,"completion":4923,"start":7260,"enrollment":6008,"conditions":9605,"interventions":9606},[91],[3170],[7962,7948,2468,7934],{"trials":9608,"activeCount":100},[],{"trials":9610,"activeCount":100},[],{"intervention":9612,"totalTrials":985,"cells":9613},"ABP 938",{"EARLY_PHASE1":9614,"PHASE1":9616,"PHASE2":9618,"PHASE3":9620,"PHASE4":9641,"NA":9643},{"trials":9615,"activeCount":100},[],{"trials":9617,"activeCount":100},[],{"trials":9619,"activeCount":100},[],{"trials":9621,"activeCount":100},[9622,9632],{"nctId":9623,"briefTitle":9624,"status":217,"phases":9625,"primaryCompletion":6708,"completion":2959,"start":9626,"enrollment":9627,"conditions":9628,"interventions":9630},"NCT04270747","A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]",[91],"2020-06-22",576,[9629],"Neovascular (Wet) Age-related Macular Degeneration (AMD)",[9612,9631],"Aflibercept",{"nctId":9633,"briefTitle":9634,"status":217,"phases":9635,"primaryCompletion":9636,"completion":4670,"start":9637,"enrollment":1300,"conditions":9638,"interventions":9640},"NCT05704725","A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)",[91],"2023-02-17","2023-01-23",[9639],"Chorioretinal Vascular Disease",[9612,9631],{"trials":9642,"activeCount":100},[],{"trials":9644,"activeCount":100},[],{"intervention":9631,"totalTrials":985,"cells":9646},{"EARLY_PHASE1":9647,"PHASE1":9649,"PHASE2":9651,"PHASE3":9653,"PHASE4":9663,"NA":9665},{"trials":9648,"activeCount":100},[],{"trials":9650,"activeCount":100},[],{"trials":9652,"activeCount":100},[],{"trials":9654,"activeCount":100},[9655,9659],{"nctId":9623,"briefTitle":9624,"status":217,"phases":9656,"primaryCompletion":6708,"completion":2959,"start":9626,"enrollment":9627,"conditions":9657,"interventions":9658},[91],[9629],[9612,9631],{"nctId":9633,"briefTitle":9634,"status":217,"phases":9660,"primaryCompletion":9636,"completion":4670,"start":9637,"enrollment":1300,"conditions":9661,"interventions":9662},[91],[9639],[9612,9631],{"trials":9664,"activeCount":100},[],{"trials":9666,"activeCount":100},[],{"intervention":9668,"totalTrials":204,"cells":9669},"Actonel®",{"EARLY_PHASE1":9670,"PHASE1":9672,"PHASE2":9674,"PHASE3":9676,"PHASE4":9688,"NA":9690},{"trials":9671,"activeCount":100},[],{"trials":9673,"activeCount":100},[],{"trials":9675,"activeCount":100},[],{"trials":9677,"activeCount":100},[9678],{"nctId":9679,"briefTitle":9680,"status":217,"phases":9681,"primaryCompletion":9682,"completion":9683,"start":9684,"enrollment":9685,"conditions":9686,"interventions":9687},"NCT00919711","Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy",[91],"2011-12-21","2012-03-05","2009-09-01",870,[493],[9668,3670],{"trials":9689,"activeCount":100},[],{"trials":9691,"activeCount":100},[],{"intervention":2154,"totalTrials":204,"cells":9693},{"EARLY_PHASE1":9694,"PHASE1":9696,"PHASE2":9698,"PHASE3":9700,"PHASE4":9706,"NA":9708},{"trials":9695,"activeCount":100},[],{"trials":9697,"activeCount":100},[],{"trials":9699,"activeCount":100},[],{"trials":9701,"activeCount":100},[9702],{"nctId":2144,"briefTitle":2145,"status":217,"phases":9703,"primaryCompletion":2147,"completion":2148,"start":2149,"enrollment":2150,"conditions":9704,"interventions":9705},[91],[2152],[82,2154],{"trials":9707,"activeCount":100},[],{"trials":9709,"activeCount":100},[],{"intervention":9711,"totalTrials":204,"cells":9712},"60 mg denosumab",{"EARLY_PHASE1":9713,"PHASE1":9715,"PHASE2":9717,"PHASE3":9719,"PHASE4":9732,"NA":9734},{"trials":9714,"activeCount":100},[],{"trials":9716,"activeCount":100},[],{"trials":9718,"activeCount":100},[],{"trials":9720,"activeCount":100},[9721],{"nctId":9722,"briefTitle":9723,"status":217,"phases":9724,"primaryCompletion":9725,"completion":9726,"start":6352,"enrollment":9727,"conditions":9728,"interventions":9731},"NCT00980174","Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis",[91],"2011-06-21","2012-05-23",242,[9729,3665,9730,3612,493],"Low Bone Mass","Males With Osteoporosis",[9711],{"trials":9733,"activeCount":100},[],{"trials":9735,"activeCount":100},[],{"intervention":1752,"totalTrials":204,"cells":9737},{"EARLY_PHASE1":9738,"PHASE1":9740,"PHASE2":9742,"PHASE3":9744,"PHASE4":9750,"NA":9752},{"trials":9739,"activeCount":100},[],{"trials":9741,"activeCount":100},[],{"trials":9743,"activeCount":100},[],{"trials":9745,"activeCount":100},[9746],{"nctId":1743,"briefTitle":1744,"status":336,"phases":9747,"primaryCompletion":1746,"completion":1747,"start":1736,"enrollment":1748,"conditions":9748,"interventions":9749},[91],[1750],[117,1752],{"trials":9751,"activeCount":100},[],{"trials":9753,"activeCount":100},[],{"intervention":9755,"totalTrials":204,"cells":9756},"darbepoetin alfa SF",{"EARLY_PHASE1":9757,"PHASE1":9759,"PHASE2":9761,"PHASE3":9763,"PHASE4":9772,"NA":9774},{"trials":9758,"activeCount":100},[],{"trials":9760,"activeCount":100},[],{"trials":9762,"activeCount":100},[],{"trials":9764,"activeCount":100},[9765],{"nctId":9766,"briefTitle":9767,"status":217,"phases":9768,"primaryCompletion":2662,"completion":2662,"start":7610,"enrollment":9769,"conditions":9770,"interventions":9771},"NCT00093977","Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease",[91],1100,[383,28],[9755],{"trials":9773,"activeCount":100},[],{"trials":9775,"activeCount":100},[],{"intervention":1763,"totalTrials":204,"cells":9777},{"EARLY_PHASE1":9778,"PHASE1":9780,"PHASE2":9782,"PHASE3":9784,"PHASE4":9790,"NA":9792},{"trials":9779,"activeCount":100},[],{"trials":9781,"activeCount":100},[],{"trials":9783,"activeCount":100},[],{"trials":9785,"activeCount":100},[9786],{"nctId":1754,"briefTitle":1755,"status":217,"phases":9787,"primaryCompletion":1757,"completion":1758,"start":760,"enrollment":1759,"conditions":9788,"interventions":9789},[91],[1761],[117,1656,1763,1764,1765,1766,1767,1768],{"trials":9791,"activeCount":100},[],{"trials":9793,"activeCount":100},[],{"intervention":1766,"totalTrials":204,"cells":9795},{"EARLY_PHASE1":9796,"PHASE1":9798,"PHASE2":9800,"PHASE3":9802,"PHASE4":9808,"NA":9810},{"trials":9797,"activeCount":100},[],{"trials":9799,"activeCount":100},[],{"trials":9801,"activeCount":100},[],{"trials":9803,"activeCount":100},[9804],{"nctId":1754,"briefTitle":1755,"status":217,"phases":9805,"primaryCompletion":1757,"completion":1758,"start":760,"enrollment":1759,"conditions":9806,"interventions":9807},[91],[1761],[117,1656,1763,1764,1765,1766,1767,1768],{"trials":9809,"activeCount":100},[],{"trials":9811,"activeCount":100},[],{"intervention":1768,"totalTrials":204,"cells":9813},{"EARLY_PHASE1":9814,"PHASE1":9816,"PHASE2":9818,"PHASE3":9820,"PHASE4":9826,"NA":9828},{"trials":9815,"activeCount":100},[],{"trials":9817,"activeCount":100},[],{"trials":9819,"activeCount":100},[],{"trials":9821,"activeCount":100},[9822],{"nctId":1754,"briefTitle":1755,"status":217,"phases":9823,"primaryCompletion":1757,"completion":1758,"start":760,"enrollment":1759,"conditions":9824,"interventions":9825},[91],[1761],[117,1656,1763,1764,1765,1766,1767,1768],{"trials":9827,"activeCount":100},[],{"trials":9829,"activeCount":100},[],{"intervention":7492,"totalTrials":204,"cells":9831},{"EARLY_PHASE1":9832,"PHASE1":9834,"PHASE2":9836,"PHASE3":9838,"PHASE4":9844,"NA":9846},{"trials":9833,"activeCount":100},[],{"trials":9835,"activeCount":100},[],{"trials":9837,"activeCount":100},[],{"trials":9839,"activeCount":100},[9840],{"nctId":7482,"briefTitle":7483,"status":217,"phases":9841,"primaryCompletion":7485,"completion":7486,"start":7487,"enrollment":7488,"conditions":9842,"interventions":9843},[91],[7391,7490],[1656,7492,2827],{"trials":9845,"activeCount":100},[],{"trials":9847,"activeCount":100},[],{"intervention":2684,"totalTrials":204,"cells":9849},{"EARLY_PHASE1":9850,"PHASE1":9852,"PHASE2":9854,"PHASE3":9856,"PHASE4":9862,"NA":9864},{"trials":9851,"activeCount":100},[],{"trials":9853,"activeCount":100},[],{"trials":9855,"activeCount":100},[],{"trials":9857,"activeCount":100},[9858],{"nctId":2675,"briefTitle":2676,"status":217,"phases":9859,"primaryCompletion":2678,"completion":2679,"start":2680,"enrollment":2681,"conditions":9860,"interventions":9861},[91],[37],[2684,1322],{"trials":9863,"activeCount":100},[],{"trials":9865,"activeCount":100},[],{"intervention":9867,"totalTrials":204,"cells":9868},"Topical agents",{"EARLY_PHASE1":9869,"PHASE1":9871,"PHASE2":9873,"PHASE3":9875,"PHASE4":9884,"NA":9886},{"trials":9870,"activeCount":100},[],{"trials":9872,"activeCount":100},[],{"trials":9874,"activeCount":100},[],{"trials":9876,"activeCount":100},[9877],{"nctId":9878,"briefTitle":9879,"status":217,"phases":9880,"primaryCompletion":3868,"completion":6833,"start":9881,"enrollment":540,"conditions":9882,"interventions":9883},"NCT01313221","Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis",[91],"2011-04",[22],[6837,9867],{"trials":9885,"activeCount":100},[],{"trials":9887,"activeCount":100},[],{"intervention":9889,"totalTrials":204,"cells":9890},"AMG 162 \u002F Denosumab",{"EARLY_PHASE1":9891,"PHASE1":9893,"PHASE2":9895,"PHASE3":9897,"PHASE4":9908,"NA":9910},{"trials":9892,"activeCount":100},[],{"trials":9894,"activeCount":100},[],{"trials":9896,"activeCount":100},[],{"trials":9898,"activeCount":100},[9899],{"nctId":9900,"briefTitle":9901,"status":217,"phases":9902,"primaryCompletion":9903,"completion":9904,"start":9905,"enrollment":1173,"conditions":9906,"interventions":9907},"NCT00089661","AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer",[91],"2007-05-11","2009-05-27","2004-10-01",[2794,3665,3612],[9889],{"trials":9909,"activeCount":100},[],{"trials":9911,"activeCount":100},[],{"intervention":3982,"totalTrials":204,"cells":9913},{"EARLY_PHASE1":9914,"PHASE1":9916,"PHASE2":9918,"PHASE3":9920,"PHASE4":9926,"NA":9928},{"trials":9915,"activeCount":100},[],{"trials":9917,"activeCount":100},[],{"trials":9919,"activeCount":100},[],{"trials":9921,"activeCount":100},[9922],{"nctId":3973,"briefTitle":3974,"status":217,"phases":9923,"primaryCompletion":3976,"completion":3977,"start":3978,"enrollment":3979,"conditions":9924,"interventions":9925},[91],[1402],[3194,3982,3983],{"trials":9927,"activeCount":100},[],{"trials":9929,"activeCount":100},[],{"intervention":3983,"totalTrials":204,"cells":9931},{"EARLY_PHASE1":9932,"PHASE1":9934,"PHASE2":9936,"PHASE3":9938,"PHASE4":9944,"NA":9946},{"trials":9933,"activeCount":100},[],{"trials":9935,"activeCount":100},[],{"trials":9937,"activeCount":100},[],{"trials":9939,"activeCount":100},[9940],{"nctId":3973,"briefTitle":3974,"status":217,"phases":9941,"primaryCompletion":3976,"completion":3977,"start":3978,"enrollment":3979,"conditions":9942,"interventions":9943},[91],[1402],[3194,3982,3983],{"trials":9945,"activeCount":100},[],{"trials":9947,"activeCount":100},[],{"intervention":1954,"totalTrials":204,"cells":9949},{"EARLY_PHASE1":9950,"PHASE1":9952,"PHASE2":9954,"PHASE3":9956,"PHASE4":9962,"NA":9964},{"trials":9951,"activeCount":100},[],{"trials":9953,"activeCount":100},[],{"trials":9955,"activeCount":100},[],{"trials":9957,"activeCount":100},[9958],{"nctId":1946,"briefTitle":1947,"status":217,"phases":9959,"primaryCompletion":111,"completion":1949,"start":1950,"enrollment":579,"conditions":9960,"interventions":9961},[91],[1952],[1307,1322,1954,1955],{"trials":9963,"activeCount":100},[],{"trials":9965,"activeCount":100},[],{"intervention":1955,"totalTrials":204,"cells":9967},{"EARLY_PHASE1":9968,"PHASE1":9970,"PHASE2":9972,"PHASE3":9974,"PHASE4":9980,"NA":9982},{"trials":9969,"activeCount":100},[],{"trials":9971,"activeCount":100},[],{"trials":9973,"activeCount":100},[],{"trials":9975,"activeCount":100},[9976],{"nctId":1946,"briefTitle":1947,"status":217,"phases":9977,"primaryCompletion":111,"completion":1949,"start":1950,"enrollment":579,"conditions":9978,"interventions":9979},[91],[1952],[1307,1322,1954,1955],{"trials":9981,"activeCount":100},[],{"trials":9983,"activeCount":100},[],{"intervention":3383,"totalTrials":204,"cells":9985},{"EARLY_PHASE1":9986,"PHASE1":9988,"PHASE2":9990,"PHASE3":9992,"PHASE4":9998,"NA":10000},{"trials":9987,"activeCount":100},[],{"trials":9989,"activeCount":100},[],{"trials":9991,"activeCount":100},[],{"trials":9993,"activeCount":100},[9994],{"nctId":3374,"briefTitle":3375,"status":217,"phases":9995,"primaryCompletion":3377,"completion":2065,"start":3378,"enrollment":3379,"conditions":9996,"interventions":9997},[91],[384,28],[3337,3382,3383,3384],{"trials":9999,"activeCount":100},[],{"trials":10001,"activeCount":100},[],{"intervention":3384,"totalTrials":204,"cells":10003},{"EARLY_PHASE1":10004,"PHASE1":10006,"PHASE2":10008,"PHASE3":10010,"PHASE4":10016,"NA":10018},{"trials":10005,"activeCount":100},[],{"trials":10007,"activeCount":100},[],{"trials":10009,"activeCount":100},[],{"trials":10011,"activeCount":100},[10012],{"nctId":3374,"briefTitle":3375,"status":217,"phases":10013,"primaryCompletion":3377,"completion":2065,"start":3378,"enrollment":3379,"conditions":10014,"interventions":10015},[91],[384,28],[3337,3382,3383,3384],{"trials":10017,"activeCount":100},[],{"trials":10019,"activeCount":100},[],{"intervention":8370,"totalTrials":204,"cells":10021},{"EARLY_PHASE1":10022,"PHASE1":10024,"PHASE2":10026,"PHASE3":10028,"PHASE4":10034,"NA":10036},{"trials":10023,"activeCount":100},[],{"trials":10025,"activeCount":100},[],{"trials":10027,"activeCount":100},[],{"trials":10029,"activeCount":100},[10030],{"nctId":8364,"briefTitle":8365,"status":217,"phases":10031,"primaryCompletion":7260,"completion":7943,"start":8367,"enrollment":5137,"conditions":10032,"interventions":10033},[91],[8328],[8317,8370],{"trials":10035,"activeCount":100},[],{"trials":10037,"activeCount":100},[],{"intervention":10039,"totalTrials":204,"cells":10040},"etanercept pre-filled syringe subcutaneous",{"EARLY_PHASE1":10041,"PHASE1":10043,"PHASE2":10045,"PHASE3":10047,"PHASE4":10059,"NA":10061},{"trials":10042,"activeCount":100},[],{"trials":10044,"activeCount":100},[],{"trials":10046,"activeCount":100},[],{"trials":10048,"activeCount":100},[10049],{"nctId":10050,"briefTitle":10051,"status":217,"phases":10052,"primaryCompletion":10053,"completion":10053,"start":10054,"enrollment":10055,"conditions":10056,"interventions":10057},"NCT02373813","Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission",[91],"2019-12-06","2015-02-20",371,[19],[10039,10058],"Oral methotrexate",{"trials":10060,"activeCount":100},[],{"trials":10062,"activeCount":100},[],{"intervention":10058,"totalTrials":204,"cells":10064},{"EARLY_PHASE1":10065,"PHASE1":10067,"PHASE2":10069,"PHASE3":10071,"PHASE4":10077,"NA":10079},{"trials":10066,"activeCount":100},[],{"trials":10068,"activeCount":100},[],{"trials":10070,"activeCount":100},[],{"trials":10072,"activeCount":100},[10073],{"nctId":10050,"briefTitle":10051,"status":217,"phases":10074,"primaryCompletion":10053,"completion":10053,"start":10054,"enrollment":10055,"conditions":10075,"interventions":10076},[91],[19],[10039,10058],{"trials":10078,"activeCount":100},[],{"trials":10080,"activeCount":100},[],{"intervention":10082,"totalTrials":204,"cells":10083},"Ibandronate",{"EARLY_PHASE1":10084,"PHASE1":10086,"PHASE2":10088,"PHASE3":10090,"PHASE4":10099,"NA":10101},{"trials":10085,"activeCount":100},[],{"trials":10087,"activeCount":100},[],{"trials":10089,"activeCount":100},[],{"trials":10091,"activeCount":100},[10092],{"nctId":10093,"briefTitle":10094,"status":217,"phases":10095,"primaryCompletion":2733,"completion":1705,"start":8692,"enrollment":10096,"conditions":10097,"interventions":10098},"NCT00936897","A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates",[91],833,[3666],[10082,3670],{"trials":10100,"activeCount":100},[],{"trials":10102,"activeCount":100},[],{"intervention":4470,"totalTrials":204,"cells":10104},{"EARLY_PHASE1":10105,"PHASE1":10107,"PHASE2":10109,"PHASE3":10111,"PHASE4":10117,"NA":10119},{"trials":10106,"activeCount":100},[],{"trials":10108,"activeCount":100},[],{"trials":10110,"activeCount":100},[],{"trials":10112,"activeCount":100},[10113],{"nctId":4460,"briefTitle":4461,"status":217,"phases":10114,"primaryCompletion":4463,"completion":4464,"start":4465,"enrollment":4466,"conditions":10115,"interventions":10116},[91],[4404,2838,4468,4385],[4470,2840],{"trials":10118,"activeCount":100},[],{"trials":10120,"activeCount":100},[],{"intervention":10122,"totalTrials":204,"cells":10123},"Commercial Formulation Etanercept",{"EARLY_PHASE1":10124,"PHASE1":10126,"PHASE2":10128,"PHASE3":10130,"PHASE4":10143,"NA":10145},{"trials":10125,"activeCount":100},[],{"trials":10127,"activeCount":100},[],{"trials":10129,"activeCount":100},[],{"trials":10131,"activeCount":100},[10132],{"nctId":10133,"briefTitle":10134,"status":217,"phases":10135,"primaryCompletion":10136,"completion":10137,"start":10138,"enrollment":1759,"conditions":10139,"interventions":10141},"NCT02986139","Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis",[91],"2017-09-08","2017-10-09","2016-11-29",[10140],"Arthritis, Rheumatoid; Arthritis, Psoriatic",[10122,10142],"New Formulation Etanercept",{"trials":10144,"activeCount":100},[],{"trials":10146,"activeCount":100},[],{"intervention":10142,"totalTrials":204,"cells":10148},{"EARLY_PHASE1":10149,"PHASE1":10151,"PHASE2":10153,"PHASE3":10155,"PHASE4":10161,"NA":10163},{"trials":10150,"activeCount":100},[],{"trials":10152,"activeCount":100},[],{"trials":10154,"activeCount":100},[],{"trials":10156,"activeCount":100},[10157],{"nctId":10133,"briefTitle":10134,"status":217,"phases":10158,"primaryCompletion":10136,"completion":10137,"start":10138,"enrollment":1759,"conditions":10159,"interventions":10160},[91],[10140],[10122,10142],{"trials":10162,"activeCount":100},[],{"trials":10164,"activeCount":100},[],{"intervention":671,"totalTrials":204,"cells":10166},{"EARLY_PHASE1":10167,"PHASE1":10169,"PHASE2":10171,"PHASE3":10173,"PHASE4":10179,"NA":10181},{"trials":10168,"activeCount":100},[],{"trials":10170,"activeCount":100},[],{"trials":10172,"activeCount":100},[],{"trials":10174,"activeCount":100},[10175],{"nctId":663,"briefTitle":664,"status":217,"phases":10176,"primaryCompletion":666,"completion":666,"start":667,"enrollment":668,"conditions":10177,"interventions":10178},[91],[611],[373,671],{"trials":10180,"activeCount":100},[],{"trials":10182,"activeCount":100},[],{"intervention":10184,"totalTrials":204,"cells":10185},"romosozumab HCP administration with PFS",{"EARLY_PHASE1":10186,"PHASE1":10188,"PHASE2":10190,"PHASE3":10192,"PHASE4":10205,"NA":10207},{"trials":10187,"activeCount":100},[],{"trials":10189,"activeCount":100},[],{"trials":10191,"activeCount":100},[],{"trials":10193,"activeCount":100},[10194],{"nctId":10195,"briefTitle":10196,"status":217,"phases":10197,"primaryCompletion":10198,"completion":10199,"start":10200,"enrollment":10201,"conditions":10202,"interventions":10204},"NCT03432533","A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis",[91],"2019-04-11","2020-01-08","2018-02-06",283,[10203],"Post-Menopausal Osteoporosis",[10184],{"trials":10206,"activeCount":100},[],{"trials":10208,"activeCount":100},[],{"intervention":9365,"totalTrials":204,"cells":10210},{"EARLY_PHASE1":10211,"PHASE1":10213,"PHASE2":10215,"PHASE3":10217,"PHASE4":10223,"NA":10225},{"trials":10212,"activeCount":100},[],{"trials":10214,"activeCount":100},[],{"trials":10216,"activeCount":100},[],{"trials":10218,"activeCount":100},[10219],{"nctId":9358,"briefTitle":9359,"status":217,"phases":10220,"primaryCompletion":9361,"start":641,"enrollment":9362,"conditions":10221,"interventions":10222},[91],[814,520],[9365,9347],{"trials":10224,"activeCount":100},[],{"trials":10226,"activeCount":100},[],{"intervention":10228,"totalTrials":204,"cells":10229},"1=Etanercept",{"EARLY_PHASE1":10230,"PHASE1":10232,"PHASE2":10234,"PHASE3":10236,"PHASE4":10245,"NA":10247},{"trials":10231,"activeCount":100},[],{"trials":10233,"activeCount":100},[],{"trials":10235,"activeCount":100},[],{"trials":10237,"activeCount":100},[10238],{"nctId":10239,"briefTitle":10240,"status":217,"phases":10241,"primaryCompletion":7865,"completion":1685,"start":5352,"enrollment":972,"conditions":10242,"interventions":10243},"NCT01235442","Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis",[91],[22],[10228,10244],"2=Clobetasol propionate foam",{"trials":10246,"activeCount":100},[],{"trials":10248,"activeCount":100},[],{"intervention":10244,"totalTrials":204,"cells":10250},{"EARLY_PHASE1":10251,"PHASE1":10253,"PHASE2":10255,"PHASE3":10257,"PHASE4":10263,"NA":10265},{"trials":10252,"activeCount":100},[],{"trials":10254,"activeCount":100},[],{"trials":10256,"activeCount":100},[],{"trials":10258,"activeCount":100},[10259],{"nctId":10239,"briefTitle":10240,"status":217,"phases":10260,"primaryCompletion":7865,"completion":1685,"start":5352,"enrollment":972,"conditions":10261,"interventions":10262},[91],[22],[10228,10244],{"trials":10264,"activeCount":100},[],{"trials":10266,"activeCount":100},[],{"intervention":10268,"totalTrials":204,"cells":10269},"MR prednisone",{"EARLY_PHASE1":10270,"PHASE1":10272,"PHASE2":10274,"PHASE3":10276,"PHASE4":10284,"NA":10286},{"trials":10271,"activeCount":100},[],{"trials":10273,"activeCount":100},[],{"trials":10275,"activeCount":100},[],{"trials":10277,"activeCount":100},[10278],{"nctId":10279,"briefTitle":10280,"status":217,"phases":10281,"primaryCompletion":2499,"completion":2499,"start":2439,"enrollment":8555,"conditions":10282,"interventions":10283},"NCT00650078","Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis",[91],[19],[10268],{"trials":10285,"activeCount":100},[],{"trials":10287,"activeCount":100},[],{"intervention":10289,"totalTrials":204,"cells":10290},"Etanercept \u002F Autoinjector A",{"EARLY_PHASE1":10291,"PHASE1":10293,"PHASE2":10295,"PHASE3":10297,"PHASE4":10308,"NA":10310},{"trials":10292,"activeCount":100},[],{"trials":10294,"activeCount":100},[],{"trials":10296,"activeCount":100},[],{"trials":10298,"activeCount":100},[10299],{"nctId":10300,"briefTitle":10301,"status":217,"phases":10302,"primaryCompletion":10303,"completion":10304,"start":10305,"enrollment":1288,"conditions":10306,"interventions":10307},"NCT01901185","Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept",[91],"2013-12-18","2013-12-30","2013-06-11",[19,2078],[10289],{"trials":10309,"activeCount":100},[],{"trials":10311,"activeCount":100},[],{"intervention":10313,"totalTrials":204,"cells":10314},"ARM 2",{"EARLY_PHASE1":10315,"PHASE1":10317,"PHASE2":10319,"PHASE3":10321,"PHASE4":10333,"NA":10335},{"trials":10316,"activeCount":100},[],{"trials":10318,"activeCount":100},[],{"trials":10320,"activeCount":100},[],{"trials":10322,"activeCount":100},[10323],{"nctId":10324,"briefTitle":10325,"status":217,"phases":10326,"primaryCompletion":5353,"completion":10327,"start":2540,"enrollment":10328,"conditions":10329,"interventions":10331},"NCT00460265","Study of Panitumumab Efficacy in Patients With Recurrent and\u002For Metastatic Head and Neck Cancer",[91],"2012-05",658,[10330],"Recurrent and\u002For Metastatic Head and Neck Cancer",[10313,10332],"ARM 1",{"trials":10334,"activeCount":100},[],{"trials":10336,"activeCount":100},[],{"intervention":10332,"totalTrials":204,"cells":10338},{"EARLY_PHASE1":10339,"PHASE1":10341,"PHASE2":10343,"PHASE3":10345,"PHASE4":10351,"NA":10353},{"trials":10340,"activeCount":100},[],{"trials":10342,"activeCount":100},[],{"trials":10344,"activeCount":100},[],{"trials":10346,"activeCount":100},[10347],{"nctId":10324,"briefTitle":10325,"status":217,"phases":10348,"primaryCompletion":5353,"completion":10327,"start":2540,"enrollment":10328,"conditions":10349,"interventions":10350},[91],[10330],[10313,10332],{"trials":10352,"activeCount":100},[],{"trials":10354,"activeCount":100},[],{"intervention":298,"totalTrials":204,"cells":10356},{"EARLY_PHASE1":10357,"PHASE1":10359,"PHASE2":10361,"PHASE3":10363,"PHASE4":10369,"NA":10371},{"trials":10358,"activeCount":100},[],{"trials":10360,"activeCount":100},[],{"trials":10362,"activeCount":100},[],{"trials":10364,"activeCount":100},[10365],{"nctId":285,"briefTitle":286,"status":217,"phases":10366,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":10367,"interventions":10368},[91],[293],[208,295,296,297,298],{"trials":10370,"activeCount":100},[],{"trials":10372,"activeCount":100},[],{"intervention":10374,"totalTrials":204,"cells":10375},"50 mg Etanercept",{"EARLY_PHASE1":10376,"PHASE1":10378,"PHASE2":10380,"PHASE3":10382,"PHASE4":10392,"NA":10394},{"trials":10377,"activeCount":100},[],{"trials":10379,"activeCount":100},[],{"trials":10381,"activeCount":100},[],{"trials":10383,"activeCount":100},[10384],{"nctId":10385,"briefTitle":10386,"status":217,"phases":10387,"primaryCompletion":2833,"completion":2601,"start":8185,"enrollment":10388,"conditions":10389,"interventions":10390},"NCT00249041","Enbrel Liquid Immunogenicity Protocol",[91],447,[19],[10374,10391],"Enbrel liquid",{"trials":10393,"activeCount":100},[],{"trials":10395,"activeCount":100},[],{"intervention":10391,"totalTrials":204,"cells":10397},{"EARLY_PHASE1":10398,"PHASE1":10400,"PHASE2":10402,"PHASE3":10404,"PHASE4":10410,"NA":10412},{"trials":10399,"activeCount":100},[],{"trials":10401,"activeCount":100},[],{"trials":10403,"activeCount":100},[],{"trials":10405,"activeCount":100},[10406],{"nctId":10385,"briefTitle":10386,"status":217,"phases":10407,"primaryCompletion":2833,"completion":2601,"start":8185,"enrollment":10388,"conditions":10408,"interventions":10409},[91],[19],[10374,10391],{"trials":10411,"activeCount":100},[],{"trials":10413,"activeCount":100},[],{"intervention":9244,"totalTrials":204,"cells":10415},{"EARLY_PHASE1":10416,"PHASE1":10418,"PHASE2":10420,"PHASE3":10422,"PHASE4":10428,"NA":10430},{"trials":10417,"activeCount":100},[],{"trials":10419,"activeCount":100},[],{"trials":10421,"activeCount":100},[],{"trials":10423,"activeCount":100},[10424],{"nctId":9237,"briefTitle":9238,"status":217,"phases":10425,"primaryCompletion":9240,"completion":9240,"start":8936,"enrollment":9241,"conditions":10426,"interventions":10427},[91],[3666],[9244,3669],{"trials":10429,"activeCount":100},[],{"trials":10431,"activeCount":100},[],{"intervention":2698,"totalTrials":204,"cells":10433},{"EARLY_PHASE1":10434,"PHASE1":10436,"PHASE2":10438,"PHASE3":10440,"PHASE4":10446,"NA":10448},{"trials":10435,"activeCount":100},[],{"trials":10437,"activeCount":100},[],{"trials":10439,"activeCount":100},[],{"trials":10441,"activeCount":100},[10442],{"nctId":2690,"briefTitle":2691,"status":217,"phases":10443,"primaryCompletion":2693,"completion":2085,"start":2694,"enrollment":2695,"conditions":10444,"interventions":10445},[91],[34],[2698,1322,2699,2616],{"trials":10447,"activeCount":100},[],{"trials":10449,"activeCount":100},[],{"intervention":2699,"totalTrials":204,"cells":10451},{"EARLY_PHASE1":10452,"PHASE1":10454,"PHASE2":10456,"PHASE3":10458,"PHASE4":10464,"NA":10466},{"trials":10453,"activeCount":100},[],{"trials":10455,"activeCount":100},[],{"trials":10457,"activeCount":100},[],{"trials":10459,"activeCount":100},[10460],{"nctId":2690,"briefTitle":2691,"status":217,"phases":10461,"primaryCompletion":2693,"completion":2085,"start":2694,"enrollment":2695,"conditions":10462,"interventions":10463},[91],[34],[2698,1322,2699,2616],{"trials":10465,"activeCount":100},[],{"trials":10467,"activeCount":100},[],{"intervention":10469,"totalTrials":204,"cells":10470},"Risendronate",{"EARLY_PHASE1":10471,"PHASE1":10473,"PHASE2":10475,"PHASE3":10477,"PHASE4":10489,"NA":10491},{"trials":10472,"activeCount":100},[],{"trials":10474,"activeCount":100},[],{"trials":10476,"activeCount":100},[],{"trials":10478,"activeCount":100},[10479],{"nctId":10480,"briefTitle":10481,"status":217,"phases":10482,"primaryCompletion":10483,"completion":3736,"start":10484,"enrollment":10485,"conditions":10486,"interventions":10488},"NCT01575873","Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids",[91],"2016-06-21","2012-03-28",795,[10487],"Steroid-induced Osteopor, Glucocorticoid-induced Ostepor",[3670,10469],{"trials":10490,"activeCount":100},[],{"trials":10492,"activeCount":100},[],{"intervention":10494,"totalTrials":204,"cells":10495},"AMG386 plus PLD",{"EARLY_PHASE1":10496,"PHASE1":10498,"PHASE2":10500,"PHASE3":10502,"PHASE4":10514,"NA":10516},{"trials":10497,"activeCount":100},[],{"trials":10499,"activeCount":100},[],{"trials":10501,"activeCount":100},[],{"trials":10503,"activeCount":100},[10504],{"nctId":10505,"briefTitle":10506,"status":336,"phases":10507,"primaryCompletion":10508,"completion":10509,"start":10510,"enrollment":10511,"conditions":10512,"interventions":10513},"NCT01281254","AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)",[91],"2014-08-29","2017-04-19","2011-04-18",223,[2886,2795,5171],[10494],{"trials":10515,"activeCount":100},[],{"trials":10517,"activeCount":100},[],{"intervention":713,"totalTrials":204,"cells":10519},{"EARLY_PHASE1":10520,"PHASE1":10522,"PHASE2":10524,"PHASE3":10526,"PHASE4":10532,"NA":10534},{"trials":10521,"activeCount":100},[],{"trials":10523,"activeCount":100},[],{"trials":10525,"activeCount":100},[],{"trials":10527,"activeCount":100},[10528],{"nctId":703,"briefTitle":704,"status":217,"phases":10529,"primaryCompletion":706,"completion":707,"start":708,"enrollment":709,"conditions":10530,"interventions":10531},[91],[711],[373,713],{"trials":10533,"activeCount":100},[],{"trials":10535,"activeCount":100},[],{"intervention":358,"totalTrials":204,"cells":10537},{"EARLY_PHASE1":10538,"PHASE1":10540,"PHASE2":10542,"PHASE3":10544,"PHASE4":10550,"NA":10552},{"trials":10539,"activeCount":100},[],{"trials":10541,"activeCount":100},[],{"trials":10543,"activeCount":100},[],{"trials":10545,"activeCount":100},[10546],{"nctId":348,"briefTitle":349,"status":217,"phases":10547,"primaryCompletion":351,"completion":351,"start":352,"enrollment":353,"conditions":10548,"interventions":10549},[91],[355],[357,82,358,359,360,361,362],{"trials":10551,"activeCount":100},[],{"trials":10553,"activeCount":100},[],{"intervention":359,"totalTrials":204,"cells":10555},{"EARLY_PHASE1":10556,"PHASE1":10558,"PHASE2":10560,"PHASE3":10562,"PHASE4":10568,"NA":10570},{"trials":10557,"activeCount":100},[],{"trials":10559,"activeCount":100},[],{"trials":10561,"activeCount":100},[],{"trials":10563,"activeCount":100},[10564],{"nctId":348,"briefTitle":349,"status":217,"phases":10565,"primaryCompletion":351,"completion":351,"start":352,"enrollment":353,"conditions":10566,"interventions":10567},[91],[355],[357,82,358,359,360,361,362],{"trials":10569,"activeCount":100},[],{"trials":10571,"activeCount":100},[],{"intervention":360,"totalTrials":204,"cells":10573},{"EARLY_PHASE1":10574,"PHASE1":10576,"PHASE2":10578,"PHASE3":10580,"PHASE4":10586,"NA":10588},{"trials":10575,"activeCount":100},[],{"trials":10577,"activeCount":100},[],{"trials":10579,"activeCount":100},[],{"trials":10581,"activeCount":100},[10582],{"nctId":348,"briefTitle":349,"status":217,"phases":10583,"primaryCompletion":351,"completion":351,"start":352,"enrollment":353,"conditions":10584,"interventions":10585},[91],[355],[357,82,358,359,360,361,362],{"trials":10587,"activeCount":100},[],{"trials":10589,"activeCount":100},[],{"intervention":361,"totalTrials":204,"cells":10591},{"EARLY_PHASE1":10592,"PHASE1":10594,"PHASE2":10596,"PHASE3":10598,"PHASE4":10604,"NA":10606},{"trials":10593,"activeCount":100},[],{"trials":10595,"activeCount":100},[],{"trials":10597,"activeCount":100},[],{"trials":10599,"activeCount":100},[10600],{"nctId":348,"briefTitle":349,"status":217,"phases":10601,"primaryCompletion":351,"completion":351,"start":352,"enrollment":353,"conditions":10602,"interventions":10603},[91],[355],[357,82,358,359,360,361,362],{"trials":10605,"activeCount":100},[],{"trials":10607,"activeCount":100},[],{"intervention":362,"totalTrials":204,"cells":10609},{"EARLY_PHASE1":10610,"PHASE1":10612,"PHASE2":10614,"PHASE3":10616,"PHASE4":10622,"NA":10624},{"trials":10611,"activeCount":100},[],{"trials":10613,"activeCount":100},[],{"trials":10615,"activeCount":100},[],{"trials":10617,"activeCount":100},[10618],{"nctId":348,"briefTitle":349,"status":217,"phases":10619,"primaryCompletion":351,"completion":351,"start":352,"enrollment":353,"conditions":10620,"interventions":10621},[91],[355],[357,82,358,359,360,361,362],{"trials":10623,"activeCount":100},[],{"trials":10625,"activeCount":100},[],{"intervention":10627,"totalTrials":204,"cells":10628},"ABP 710",{"EARLY_PHASE1":10629,"PHASE1":10631,"PHASE2":10633,"PHASE3":10635,"PHASE4":10646,"NA":10648},{"trials":10630,"activeCount":100},[],{"trials":10632,"activeCount":100},[],{"trials":10634,"activeCount":100},[],{"trials":10636,"activeCount":100},[10637],{"nctId":10638,"briefTitle":10639,"status":217,"phases":10640,"primaryCompletion":4723,"completion":2310,"start":10641,"enrollment":10642,"conditions":10643,"interventions":10644},"NCT02937701","Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab",[91],"2016-10-10",558,[8547],[10627,10645],"Infliximab",{"trials":10647,"activeCount":100},[],{"trials":10649,"activeCount":100},[],{"intervention":10645,"totalTrials":204,"cells":10651},{"EARLY_PHASE1":10652,"PHASE1":10654,"PHASE2":10656,"PHASE3":10658,"PHASE4":10664,"NA":10666},{"trials":10653,"activeCount":100},[],{"trials":10655,"activeCount":100},[],{"trials":10657,"activeCount":100},[],{"trials":10659,"activeCount":100},[10660],{"nctId":10638,"briefTitle":10639,"status":217,"phases":10661,"primaryCompletion":4723,"completion":2310,"start":10641,"enrollment":10642,"conditions":10662,"interventions":10663},[91],[8547],[10627,10645],{"trials":10665,"activeCount":100},[],{"trials":10667,"activeCount":100},[],{"intervention":10669,"totalTrials":204,"cells":10670},"Darbepoetin alfa - 2.25 mcg\u002Fkg",{"EARLY_PHASE1":10671,"PHASE1":10673,"PHASE2":10675,"PHASE3":10677,"PHASE4":10687,"NA":10689},{"trials":10672,"activeCount":100},[],{"trials":10674,"activeCount":100},[],{"trials":10676,"activeCount":100},[],{"trials":10678,"activeCount":100},[10679],{"nctId":10680,"briefTitle":10681,"status":217,"phases":10682,"primaryCompletion":2422,"completion":2602,"start":2542,"enrollment":10683,"conditions":10684,"interventions":10685},"NCT00118638","A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy",[91],705,[16,8969],[10669,10686],"Darbepoetin alfa - 500mcg",{"trials":10688,"activeCount":100},[],{"trials":10690,"activeCount":100},[],{"intervention":10686,"totalTrials":204,"cells":10692},{"EARLY_PHASE1":10693,"PHASE1":10695,"PHASE2":10697,"PHASE3":10699,"PHASE4":10705,"NA":10707},{"trials":10694,"activeCount":100},[],{"trials":10696,"activeCount":100},[],{"trials":10698,"activeCount":100},[],{"trials":10700,"activeCount":100},[10701],{"nctId":10680,"briefTitle":10681,"status":217,"phases":10702,"primaryCompletion":2422,"completion":2602,"start":2542,"enrollment":10683,"conditions":10703,"interventions":10704},[91],[16,8969],[10669,10686],{"trials":10706,"activeCount":100},[],{"trials":10708,"activeCount":100},[],{"intervention":10710,"totalTrials":204,"cells":10711},"Apremilast tablet 20 mg",{"EARLY_PHASE1":10712,"PHASE1":10714,"PHASE2":10716,"PHASE3":10718,"PHASE4":10732,"NA":10734},{"trials":10713,"activeCount":100},[],{"trials":10715,"activeCount":100},[],{"trials":10717,"activeCount":100},[],{"trials":10719,"activeCount":100},[10720],{"nctId":10721,"briefTitle":10722,"status":217,"phases":10723,"primaryCompletion":10724,"completion":10725,"start":10726,"enrollment":10727,"conditions":10728,"interventions":10730},"NCT01583374","Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis",[91],"2014-02-24","2018-10-25","2012-05-02",490,[10729],"Ankylosing Spondyloarthritis",[10710,10731],"Apremilast tablet 30 mg BID",{"trials":10733,"activeCount":100},[],{"trials":10735,"activeCount":100},[],{"intervention":10731,"totalTrials":204,"cells":10737},{"EARLY_PHASE1":10738,"PHASE1":10740,"PHASE2":10742,"PHASE3":10744,"PHASE4":10750,"NA":10752},{"trials":10739,"activeCount":100},[],{"trials":10741,"activeCount":100},[],{"trials":10743,"activeCount":100},[],{"trials":10745,"activeCount":100},[10746],{"nctId":10721,"briefTitle":10722,"status":217,"phases":10747,"primaryCompletion":10724,"completion":10725,"start":10726,"enrollment":10727,"conditions":10748,"interventions":10749},[91],[10729],[10710,10731],{"trials":10751,"activeCount":100},[],{"trials":10753,"activeCount":100},[],{"intervention":1792,"totalTrials":204,"cells":10755},{"EARLY_PHASE1":10756,"PHASE1":10758,"PHASE2":10760,"PHASE3":10762,"PHASE4":10768,"NA":10770},{"trials":10757,"activeCount":100},[],{"trials":10759,"activeCount":100},[],{"trials":10761,"activeCount":100},[],{"trials":10763,"activeCount":100},[10764],{"nctId":1783,"briefTitle":1784,"status":217,"phases":10765,"primaryCompletion":1786,"completion":1787,"start":1788,"enrollment":1789,"conditions":10766,"interventions":10767},[91],[1595],[117,1792],{"trials":10769,"activeCount":100},[],{"trials":10771,"activeCount":100},[],{"intervention":10773,"totalTrials":204,"cells":10774},"Recombinant Human Keratinocyte Growth Factor",{"EARLY_PHASE1":10775,"PHASE1":10777,"PHASE2":10779,"PHASE3":10781,"PHASE4":10790,"NA":10792},{"trials":10776,"activeCount":100},[],{"trials":10778,"activeCount":100},[],{"trials":10780,"activeCount":100},[],{"trials":10782,"activeCount":100},[10783],{"nctId":10784,"briefTitle":10785,"status":217,"phases":10786,"conditions":10787,"interventions":10789},"NCT00041665","Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy",[91],[10788],"Stomatitis",[10773],{"trials":10791,"activeCount":100},[],{"trials":10793,"activeCount":100},[],{"intervention":9532,"totalTrials":204,"cells":10795},{"EARLY_PHASE1":10796,"PHASE1":10798,"PHASE2":10800,"PHASE3":10802,"PHASE4":10808,"NA":10810},{"trials":10797,"activeCount":100},[],{"trials":10799,"activeCount":100},[],{"trials":10801,"activeCount":100},[],{"trials":10803,"activeCount":100},[10804],{"nctId":9524,"briefTitle":9525,"status":217,"phases":10805,"primaryCompletion":9527,"completion":9528,"start":201,"enrollment":8350,"conditions":10806,"interventions":10807},[91],[2907],[9531,9532],{"trials":10809,"activeCount":100},[],{"trials":10811,"activeCount":100},[],{"intervention":10813,"totalTrials":204,"cells":10814},"Romosozumab 90 mg\u002FmL",{"EARLY_PHASE1":10815,"PHASE1":10817,"PHASE2":10819,"PHASE3":10821,"PHASE4":10833,"NA":10835},{"trials":10816,"activeCount":100},[],{"trials":10818,"activeCount":100},[],{"trials":10820,"activeCount":100},[],{"trials":10822,"activeCount":100},[10823],{"nctId":10824,"briefTitle":10825,"status":217,"phases":10826,"primaryCompletion":10827,"completion":1412,"start":10828,"enrollment":10829,"conditions":10830,"interventions":10831},"NCT02016716","A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis",[91],"2014-09-08","2013-12-03",294,[3666],[10813,10832],"Romosozumab 70 mg\u002FmL",{"trials":10834,"activeCount":100},[],{"trials":10836,"activeCount":100},[],{"intervention":10832,"totalTrials":204,"cells":10838},{"EARLY_PHASE1":10839,"PHASE1":10841,"PHASE2":10843,"PHASE3":10845,"PHASE4":10851,"NA":10853},{"trials":10840,"activeCount":100},[],{"trials":10842,"activeCount":100},[],{"trials":10844,"activeCount":100},[],{"trials":10846,"activeCount":100},[10847],{"nctId":10824,"briefTitle":10825,"status":217,"phases":10848,"primaryCompletion":10827,"completion":1412,"start":10828,"enrollment":10829,"conditions":10849,"interventions":10850},[91],[3666],[10813,10832],{"trials":10852,"activeCount":100},[],{"trials":10854,"activeCount":100},[],{"intervention":10856,"totalTrials":204,"cells":10857},"Alternative osteoporosis medications",{"EARLY_PHASE1":10858,"PHASE1":10860,"PHASE2":10862,"PHASE3":10864,"PHASE4":10875,"NA":10877},{"trials":10859,"activeCount":100},[],{"trials":10861,"activeCount":100},[],{"trials":10863,"activeCount":100},[],{"trials":10865,"activeCount":100},[10866],{"nctId":10867,"briefTitle":10868,"status":336,"phases":10869,"primaryCompletion":10870,"completion":10870,"start":10871,"enrollment":4413,"conditions":10872,"interventions":10874},"NCT03638128","Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta",[91],"2022-03-28","2018-07-26",[10873],"Osteogenesis Imperfecta (OI)",[3670,10856],{"trials":10876,"activeCount":100},[],{"trials":10878,"activeCount":100},[],{"intervention":10880,"totalTrials":204,"cells":10881},"ABP 959",{"EARLY_PHASE1":10882,"PHASE1":10884,"PHASE2":10886,"PHASE3":10888,"PHASE4":10900,"NA":10902},{"trials":10883,"activeCount":100},[],{"trials":10885,"activeCount":100},[],{"trials":10887,"activeCount":100},[],{"trials":10889,"activeCount":100},[10890],{"nctId":10891,"briefTitle":10892,"status":217,"phases":10893,"primaryCompletion":10894,"completion":10894,"start":10895,"enrollment":1916,"conditions":10896,"interventions":10898},"NCT03818607","A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH",[91],"2022-07-12","2019-01-22",[10897],"Paroxysmal Nocturnal Hemoglobinuria",[10880,10899],"Eculizumab",{"trials":10901,"activeCount":100},[],{"trials":10903,"activeCount":100},[],{"intervention":10899,"totalTrials":204,"cells":10905},{"EARLY_PHASE1":10906,"PHASE1":10908,"PHASE2":10910,"PHASE3":10912,"PHASE4":10918,"NA":10920},{"trials":10907,"activeCount":100},[],{"trials":10909,"activeCount":100},[],{"trials":10911,"activeCount":100},[],{"trials":10913,"activeCount":100},[10914],{"nctId":10891,"briefTitle":10892,"status":217,"phases":10915,"primaryCompletion":10894,"completion":10894,"start":10895,"enrollment":1916,"conditions":10916,"interventions":10917},[91],[10897],[10880,10899],{"trials":10919,"activeCount":100},[],{"trials":10921,"activeCount":100},[],{"intervention":10923,"totalTrials":204,"cells":10924},"Best Supportive Care",{"EARLY_PHASE1":10925,"PHASE1":10927,"PHASE2":10929,"PHASE3":10931,"PHASE4":10939,"NA":10941},{"trials":10926,"activeCount":100},[],{"trials":10928,"activeCount":100},[],{"trials":10930,"activeCount":100},[],{"trials":10932,"activeCount":100},[10933],{"nctId":10934,"briefTitle":10935,"status":217,"phases":10936,"primaryCompletion":1693,"completion":1694,"start":5352,"enrollment":1444,"conditions":10937,"interventions":10938},"NCT01302392","A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma",[91],[31],[2827,10923],{"trials":10940,"activeCount":100},[],{"trials":10942,"activeCount":100},[],{"intervention":9374,"totalTrials":204,"cells":10944},{"EARLY_PHASE1":10945,"PHASE1":10947,"PHASE2":10949,"PHASE3":10951,"PHASE4":10957,"NA":10959},{"trials":10946,"activeCount":100},[],{"trials":10948,"activeCount":100},[],{"trials":10950,"activeCount":100},[],{"trials":10952,"activeCount":100},[10953],{"nctId":9367,"briefTitle":9368,"status":217,"phases":10954,"primaryCompletion":9370,"start":9371,"enrollment":709,"conditions":10955,"interventions":10956},[91],[814,520],[9374,9347],{"trials":10958,"activeCount":100},[],{"trials":10960,"activeCount":100},[],{"intervention":10962,"totalTrials":204,"cells":10963},"Aeroquin",{"EARLY_PHASE1":10964,"PHASE1":10966,"PHASE2":10968,"PHASE3":10970,"PHASE4":10980,"NA":10982},{"trials":10965,"activeCount":100},[],{"trials":10967,"activeCount":100},[],{"trials":10969,"activeCount":100},[],{"trials":10971,"activeCount":100},[10972],{"nctId":10973,"briefTitle":10974,"status":217,"phases":10975,"primaryCompletion":10976,"completion":10976,"start":10977,"enrollment":1212,"conditions":10978,"interventions":10979},"NCT01180634","MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis",[91],"2012-05-07","2010-11-04",[8328],[10962],{"trials":10981,"activeCount":100},[],{"trials":10983,"activeCount":100},[],{"intervention":2709,"totalTrials":204,"cells":10985},{"EARLY_PHASE1":10986,"PHASE1":10988,"PHASE2":10990,"PHASE3":10992,"PHASE4":10998,"NA":11000},{"trials":10987,"activeCount":100},[],{"trials":10989,"activeCount":100},[],{"trials":10991,"activeCount":100},[],{"trials":10993,"activeCount":100},[10994],{"nctId":2701,"briefTitle":2702,"status":217,"phases":10995,"primaryCompletion":2096,"completion":2704,"start":2705,"enrollment":2706,"conditions":10996,"interventions":10997},[91],[37],[1322,2709],{"trials":10999,"activeCount":100},[],{"trials":11001,"activeCount":100},[],{"intervention":8867,"totalTrials":204,"cells":11003},{"EARLY_PHASE1":11004,"PHASE1":11006,"PHASE2":11008,"PHASE3":11010,"PHASE4":11016,"NA":11018},{"trials":11005,"activeCount":100},[],{"trials":11007,"activeCount":100},[],{"trials":11009,"activeCount":100},[],{"trials":11011,"activeCount":100},[11012],{"nctId":8860,"briefTitle":8861,"status":217,"phases":11013,"primaryCompletion":8136,"completion":2643,"start":2601,"enrollment":8863,"conditions":11014,"interventions":11015},[91],[8865],[8867,8822],{"trials":11017,"activeCount":100},[],{"trials":11019,"activeCount":100},[],{"intervention":6347,"totalTrials":204,"cells":11021},{"EARLY_PHASE1":11022,"PHASE1":11024,"PHASE2":11026,"PHASE3":11028,"PHASE4":11034,"NA":11036},{"trials":11023,"activeCount":100},[],{"trials":11025,"activeCount":100},[],{"trials":11027,"activeCount":100},[],{"trials":11029,"activeCount":100},[11030],{"nctId":6338,"briefTitle":6339,"status":217,"phases":11031,"primaryCompletion":6341,"completion":6342,"start":6343,"enrollment":6344,"conditions":11032,"interventions":11033},[91],[2794],[3670,6347,6291],{"trials":11035,"activeCount":100},[],{"trials":11037,"activeCount":100},[],{"intervention":5217,"totalTrials":204,"cells":11039},{"EARLY_PHASE1":11040,"PHASE1":11042,"PHASE2":11044,"PHASE3":11046,"PHASE4":11052,"NA":11054},{"trials":11041,"activeCount":100},[],{"trials":11043,"activeCount":100},[],{"trials":11045,"activeCount":100},[],{"trials":11047,"activeCount":100},[11048],{"nctId":5208,"briefTitle":5209,"status":217,"phases":11049,"primaryCompletion":5211,"completion":5212,"start":5213,"enrollment":5214,"conditions":11050,"interventions":11051},[91],[2794],[5217,5218,1280],{"trials":11053,"activeCount":100},[],{"trials":11055,"activeCount":100},[],{"intervention":5218,"totalTrials":204,"cells":11057},{"EARLY_PHASE1":11058,"PHASE1":11060,"PHASE2":11062,"PHASE3":11064,"PHASE4":11070,"NA":11072},{"trials":11059,"activeCount":100},[],{"trials":11061,"activeCount":100},[],{"trials":11063,"activeCount":100},[],{"trials":11065,"activeCount":100},[11066],{"nctId":5208,"briefTitle":5209,"status":217,"phases":11067,"primaryCompletion":5211,"completion":5212,"start":5213,"enrollment":5214,"conditions":11068,"interventions":11069},[91],[2794],[5217,5218,1280],{"trials":11071,"activeCount":100},[],{"trials":11073,"activeCount":100},[],{"intervention":11075,"totalTrials":204,"cells":11076},"De Novo Administration of Darbepoetin Alfa",{"EARLY_PHASE1":11077,"PHASE1":11079,"PHASE2":11081,"PHASE3":11083,"PHASE4":11091,"NA":11093},{"trials":11078,"activeCount":100},[],{"trials":11080,"activeCount":100},[],{"trials":11082,"activeCount":100},[],{"trials":11084,"activeCount":100},[11085],{"nctId":11086,"briefTitle":11087,"status":217,"phases":11088,"primaryCompletion":6143,"completion":6143,"start":7732,"enrollment":12,"conditions":11089,"interventions":11090},"NCT00112008","Study for Subjects With Chronic Kidney Disease(CKD) Not Receiving Dialysis",[91],[28,383],[11075],{"trials":11092,"activeCount":100},[],{"trials":11094,"activeCount":100},[],{"intervention":2305,"totalTrials":204,"cells":11096},{"EARLY_PHASE1":11097,"PHASE1":11099,"PHASE2":11101,"PHASE3":11103,"PHASE4":11109,"NA":11111},{"trials":11098,"activeCount":100},[],{"trials":11100,"activeCount":100},[],{"trials":11102,"activeCount":100},[],{"trials":11104,"activeCount":100},[11105],{"nctId":2296,"briefTitle":2297,"status":217,"phases":11106,"primaryCompletion":2299,"completion":2300,"start":2301,"enrollment":2302,"conditions":11107,"interventions":11108},[91],[2152],[82,2305],{"trials":11110,"activeCount":100},[],{"trials":11112,"activeCount":100},[],{"intervention":11114,"totalTrials":204,"cells":11115},"Darbepoetin alfa and Epoetin alfa",{"EARLY_PHASE1":11116,"PHASE1":11118,"PHASE2":11120,"PHASE3":11122,"PHASE4":11130,"NA":11132},{"trials":11117,"activeCount":100},[],{"trials":11119,"activeCount":100},[],{"trials":11121,"activeCount":100},[],{"trials":11123,"activeCount":100},[11124],{"nctId":11125,"briefTitle":11126,"status":217,"phases":11127,"conditions":11128,"interventions":11129},"NCT00148421","Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.",[91],[16],[11114],{"trials":11131,"activeCount":100},[],{"trials":11133,"activeCount":100},[],{"intervention":11135,"totalTrials":204,"cells":11136},"Etanercept Liquid",{"EARLY_PHASE1":11137,"PHASE1":11139,"PHASE2":11141,"PHASE3":11143,"PHASE4":11151,"NA":11153},{"trials":11138,"activeCount":100},[],{"trials":11140,"activeCount":100},[],{"trials":11142,"activeCount":100},[],{"trials":11144,"activeCount":100},[11145],{"nctId":11146,"briefTitle":11147,"status":217,"phases":11148,"conditions":11149,"interventions":11150},"NCT00110903","Treatment for Subjects With Active Rheumatoid Arthritis (RA)",[91],[19],[11135],{"trials":11152,"activeCount":100},[],{"trials":11154,"activeCount":100},[],{"intervention":4905,"totalTrials":1064,"cells":11156},{"EARLY_PHASE1":11157,"PHASE1":11159,"PHASE2":11175,"PHASE3":11207,"PHASE4":11209,"NA":11211},{"trials":11158,"activeCount":100},[],{"trials":11160,"activeCount":100},[11161,11165,11171],{"nctId":4897,"briefTitle":4898,"status":336,"phases":11162,"primaryCompletion":4900,"completion":4901,"start":1703,"enrollment":380,"conditions":11163,"interventions":11164},[89],[4903],[4905,1930],{"nctId":11166,"briefTitle":11167,"status":217,"phases":11168,"primaryCompletion":8882,"completion":5191,"start":2421,"enrollment":4671,"conditions":11169,"interventions":11170},"NCT01129349","Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors",[89],[2441],[4905],{"nctId":7395,"briefTitle":7396,"status":336,"phases":11172,"primaryCompletion":7398,"completion":7398,"start":7399,"enrollment":3264,"conditions":11173,"interventions":11174},[89],[31],[4905,7326,1656],{"trials":11176,"activeCount":100},[11177,11181,11185,11196,11200],{"nctId":7425,"briefTitle":7426,"status":336,"phases":11178,"primaryCompletion":7428,"completion":7428,"start":7429,"enrollment":6471,"conditions":11179,"interventions":11180},[89,90],[31],[4905,7393,1656,296],{"nctId":7441,"briefTitle":7442,"status":336,"phases":11182,"primaryCompletion":7444,"completion":7444,"start":7445,"enrollment":3142,"conditions":11183,"interventions":11184},[89,90],[31],[4905,1656],{"nctId":11186,"briefTitle":11187,"status":336,"phases":11188,"primaryCompletion":11189,"completion":11190,"start":11191,"enrollment":6834,"conditions":11192,"interventions":11194},"NCT01416428","Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies",[89,90],"2016-08-08","2019-08-12","2011-10-15",[31,11193],"Waldenstrom Macroglobulinemia",[11195],"oprozomib",{"nctId":8487,"briefTitle":8488,"status":217,"phases":11197,"primaryCompletion":8490,"completion":1694,"start":8491,"enrollment":96,"conditions":11198,"interventions":11199},[89,90],[31],[4905,8494,295],{"nctId":11201,"briefTitle":11202,"status":131,"phases":11203,"primaryCompletion":2438,"completion":2438,"start":11204,"enrollment":100,"conditions":11205,"interventions":11206},"NCT02227914","Phase 1b\u002F2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma",[89,90],"2014-12",[7869],[4905,7576],{"trials":11208,"activeCount":100},[],{"trials":11210,"activeCount":100},[],{"trials":11212,"activeCount":100},[],{"intervention":11214,"totalTrials":1454,"cells":11215},"Efavaleukin alfa",{"EARLY_PHASE1":11216,"PHASE1":11218,"PHASE2":11238,"PHASE3":11283,"PHASE4":11285,"NA":11287},{"trials":11217,"activeCount":100},[],{"trials":11219,"activeCount":100},[11220,11229],{"nctId":11221,"briefTitle":11222,"status":217,"phases":11223,"primaryCompletion":11224,"completion":11224,"start":11225,"enrollment":26,"conditions":11226,"interventions":11228},"NCT04987333","Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants",[89],"2022-10-03","2021-08-09",[11227],"Inflammatory Diseases",[11214],{"nctId":11230,"briefTitle":11231,"status":217,"phases":11232,"primaryCompletion":11233,"completion":11233,"start":11234,"enrollment":1582,"conditions":11235,"interventions":11236},"NCT03451422","Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus",[89],"2021-10-12","2018-04-10",[114],[11237],"Efavaleukin Alfa",{"trials":11239,"activeCount":100},[11240,11247,11257,11266,11274],{"nctId":11241,"briefTitle":11242,"status":336,"phases":11243,"primaryCompletion":304,"completion":304,"start":11244,"enrollment":2332,"conditions":11245,"interventions":11246},"NCT04987307","Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis",[90],"2022-01-31",[2068],[11214],{"nctId":11248,"briefTitle":11249,"status":336,"phases":11250,"primaryCompletion":11251,"completion":11252,"start":11253,"enrollment":439,"conditions":11254,"interventions":11256},"NCT03410056","Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis",[89,90],"2019-12-10","2020-05-13","2018-05-22",[11255],"Rheumatoid Arthritis RA",[11214],{"nctId":11258,"briefTitle":11259,"status":336,"phases":11260,"primaryCompletion":11261,"completion":11261,"start":11262,"enrollment":26,"conditions":11263,"interventions":11265},"NCT03422627","Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease",[89,90],"2022-10-13","2018-04-27",[11264],"Chronic Graft Versus Host Disease cGVHD",[11237],{"nctId":11267,"briefTitle":11268,"status":336,"phases":11269,"primaryCompletion":11270,"completion":11270,"start":11271,"enrollment":32,"conditions":11272,"interventions":11273},"NCT05672199","Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis",[90],"2024-10-31","2023-04-28",[2068],[11214],{"nctId":11275,"briefTitle":11276,"status":336,"phases":11277,"primaryCompletion":11278,"completion":11278,"start":11279,"enrollment":530,"conditions":11280,"interventions":11282},"NCT04680637","Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus",[90],"2023-05-22","2021-05-06",[11281],"Active Systemic Lupus Erythematosus",[11237],{"trials":11284,"activeCount":100},[],{"trials":11286,"activeCount":100},[],{"trials":11288,"activeCount":100},[],{"intervention":4916,"totalTrials":1164,"cells":11290},{"EARLY_PHASE1":11291,"PHASE1":11293,"PHASE2":11326,"PHASE3":11344,"PHASE4":11346,"NA":11348},{"trials":11292,"activeCount":100},[],{"trials":11294,"activeCount":100},[11295,11303,11312,11316],{"nctId":11296,"briefTitle":11297,"status":217,"phases":11298,"primaryCompletion":11299,"completion":8644,"start":11300,"enrollment":1070,"conditions":11301,"interventions":11302},"NCT05988021","A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168",[89],"2016-02-09","2015-12-03",[4914],[4916],{"nctId":11304,"briefTitle":11305,"status":217,"phases":11306,"primaryCompletion":11307,"completion":11308,"start":11309,"enrollment":5508,"conditions":11310,"interventions":11311},"NCT05988008","A Study of CCX168 in Japanese and Caucasian Healthy Adult Males",[89],"2018-01-26","2018-09-20","2017-10-23",[4914],[4916],{"nctId":4907,"briefTitle":4908,"status":217,"phases":11313,"primaryCompletion":4910,"completion":4911,"start":4912,"enrollment":26,"conditions":11314,"interventions":11315},[89],[4914],[4916,1930,4917,4611,4918],{"nctId":11317,"briefTitle":11318,"status":217,"phases":11319,"primaryCompletion":11320,"completion":11321,"start":11322,"enrollment":2197,"conditions":11323,"interventions":11325},"NCT05984251","A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants",[89],"2010-09-19","2011-04-11","2009-12-21",[307,11324],"Systemic Lupus Erythematosus (SLE)",[4916],{"trials":11327,"activeCount":100},[11328,11338],{"nctId":11329,"briefTitle":11330,"status":217,"phases":11331,"primaryCompletion":11332,"completion":11333,"start":11334,"enrollment":1454,"conditions":11335,"interventions":11337},"NCT02384317","Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade",[90],"2015-09-13","2018-06-01","2015-03-27",[11336],"Immunoglobulin A Nephropathy",[4916],{"nctId":11339,"briefTitle":11340,"status":217,"phases":11341,"primaryCompletion":2113,"completion":7388,"start":6190,"enrollment":2490,"conditions":11342,"interventions":11343},"NCT01363388","A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis",[90],[307],[4916],{"trials":11345,"activeCount":100},[],{"trials":11347,"activeCount":100},[],{"trials":11349,"activeCount":100},[],{"intervention":3788,"totalTrials":325,"cells":11351},{"EARLY_PHASE1":11352,"PHASE1":11354,"PHASE2":11356,"PHASE3":11394,"PHASE4":11396,"NA":11398},{"trials":11353,"activeCount":100},[],{"trials":11355,"activeCount":100},[],{"trials":11357,"activeCount":100},[11358,11367,11375,11379,11387],{"nctId":11359,"briefTitle":11360,"status":336,"phases":11361,"primaryCompletion":11362,"completion":11362,"start":11363,"enrollment":2490,"conditions":11364,"interventions":11366},"NCT01199302","Long-term Safety Study of Brodalumab in Adults With Crohn's Disease",[90],"2011-10-18","2011-02-02",[11365],"Crohn's Disease",[3788],{"nctId":11368,"briefTitle":11369,"status":217,"phases":11370,"primaryCompletion":11371,"completion":11371,"start":11372,"enrollment":23,"conditions":11373,"interventions":11374},"NCT00771030","Study to Evaluate the Safety, PK, PD and Efficacy of AMG 827 in Adults With Rheumatoid Arthritis",[89,90],"2010-05-25","2008-10-27",[19],[3788],{"nctId":3781,"briefTitle":3782,"status":217,"phases":11376,"primaryCompletion":3784,"completion":3784,"start":3785,"enrollment":1173,"conditions":11377,"interventions":11378},[90],[19],[3788,1765],{"nctId":11380,"briefTitle":11381,"status":336,"phases":11382,"primaryCompletion":4900,"completion":4900,"start":11383,"enrollment":11384,"conditions":11385,"interventions":11386},"NCT01902290","Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility",[90],"2013-05-22",421,[2941],[3788],{"nctId":11388,"briefTitle":11389,"status":336,"phases":11390,"primaryCompletion":11191,"completion":11191,"start":11391,"enrollment":7944,"conditions":11392,"interventions":11393},"NCT01150890","Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease",[90],"2010-11-09",[11365],[3788],{"trials":11395,"activeCount":100},[],{"trials":11397,"activeCount":100},[],{"trials":11399,"activeCount":100},[],{"intervention":11401,"totalTrials":325,"cells":11402},"CCX140-B",{"EARLY_PHASE1":11403,"PHASE1":11405,"PHASE2":11407,"PHASE3":11449,"PHASE4":11451,"NA":11453},{"trials":11404,"activeCount":100},[],{"trials":11406,"activeCount":100},[],{"trials":11408,"activeCount":100},[11409,11417,11426,11432,11440],{"nctId":11410,"briefTitle":11411,"status":217,"phases":11412,"primaryCompletion":3869,"completion":11413,"start":6190,"enrollment":305,"conditions":11414,"interventions":11416},"NCT01440257","A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria",[90],"2013-09",[11415,907],"Diabetic Nephropathy",[11401],{"nctId":11418,"briefTitle":11419,"status":336,"phases":11420,"primaryCompletion":11421,"completion":11421,"start":11422,"enrollment":325,"conditions":11423,"interventions":11425},"NCT03703908","A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome",[90],"2020-06-24","2018-10-01",[11424],"Focal Segmental Glomerulosclerosis",[11401],{"nctId":11427,"briefTitle":11428,"status":217,"phases":11429,"primaryCompletion":1703,"completion":11204,"start":7865,"enrollment":3699,"conditions":11430,"interventions":11431},"NCT01447147","A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy",[90],[11415,907],[11401,11401],{"nctId":11433,"briefTitle":11434,"status":217,"phases":11435,"primaryCompletion":1606,"completion":1627,"start":4484,"enrollment":11436,"conditions":11437,"interventions":11438},"NCT01028963","A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus",[90],159,[907],[11439,11401,11401],"pioglitazone",{"nctId":11441,"briefTitle":11442,"status":217,"phases":11443,"primaryCompletion":6649,"completion":6649,"start":11444,"enrollment":17,"conditions":11445,"interventions":11448},"NCT03536754","A Study of CCX140-B in Subjects With FSGS",[90],"2018-05-17",[11446,11424,11447],"FSGS","Glomerulosclerosis",[11401,11401,11401],{"trials":11450,"activeCount":100},[],{"trials":11452,"activeCount":100},[],{"trials":11454,"activeCount":100},[],{"intervention":139,"totalTrials":325,"cells":11456},{"EARLY_PHASE1":11457,"PHASE1":11459,"PHASE2":11471,"PHASE3":11498,"PHASE4":11500,"NA":11502},{"trials":11458,"activeCount":100},[],{"trials":11460,"activeCount":100},[11461],{"nctId":11462,"briefTitle":11463,"status":217,"phases":11464,"primaryCompletion":11465,"completion":11466,"start":11467,"enrollment":278,"conditions":11468,"interventions":11470},"NCT02780388","A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis",[89],"2018-05-21","2018-08-09","2016-05-12",[11469],"Adult Onset Rheumatoid Arthritis",[139],{"trials":11472,"activeCount":100},[11473,11477,11485,11489],{"nctId":129,"briefTitle":130,"status":131,"phases":11474,"primaryCompletion":133,"completion":134,"start":135,"enrollment":100,"conditions":11475,"interventions":11476},[90],[137],[48,139,140],{"nctId":11478,"briefTitle":11479,"status":217,"phases":11480,"primaryCompletion":11481,"completion":11481,"start":4560,"enrollment":11482,"conditions":11483,"interventions":11484},"NCT04163991","A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis",[90],"2021-12-28",78,[19],[139],{"nctId":6705,"briefTitle":6706,"status":217,"phases":11486,"primaryCompletion":6708,"completion":6709,"start":6710,"enrollment":32,"conditions":11487,"interventions":11488},[90],[6712,6713,6714,6715],[6717,139,6718,6719],{"nctId":11490,"briefTitle":11491,"status":217,"phases":11492,"primaryCompletion":11493,"completion":11494,"start":4560,"enrollment":11495,"conditions":11496,"interventions":11497},"NCT04129164","A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome",[90],"2022-09-01","2023-03-10",183,[3227],[139],{"trials":11499,"activeCount":100},[],{"trials":11501,"activeCount":100},[],{"trials":11503,"activeCount":100},[],{"intervention":11505,"totalTrials":325,"cells":11506},"Daxdilimab",{"EARLY_PHASE1":11507,"PHASE1":11509,"PHASE2":11511,"PHASE3":11559,"PHASE4":11561,"NA":11563},{"trials":11508,"activeCount":100},[],{"trials":11510,"activeCount":100},[],{"trials":11512,"activeCount":100},[11513,11523,11533,11542,11551],{"nctId":11514,"briefTitle":11515,"status":336,"phases":11516,"primaryCompletion":11517,"completion":11517,"start":11518,"enrollment":11519,"conditions":11520,"interventions":11522},"NCT05540665","Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)",[90],"2024-01-04","2023-04-26",19,[11521],"Lupus Nephritis",[11505,11505],{"nctId":11524,"briefTitle":11525,"status":217,"phases":11526,"primaryCompletion":11527,"completion":11528,"start":11529,"enrollment":866,"conditions":11530,"interventions":11532},"NCT05368103","Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata",[90],"2023-08-07","2024-01-26","2022-04-27",[11531],"Alopecia Areata",[11505],{"nctId":11534,"briefTitle":11535,"status":336,"phases":11536,"primaryCompletion":11537,"completion":11537,"start":11538,"enrollment":1400,"conditions":11539,"interventions":11541},"NCT05591222","Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus",[90],"2025-05-08","2022-12-29",[11540],"Discoid Lupus Erythematosus",[11505],{"nctId":11543,"briefTitle":11544,"status":336,"phases":11545,"primaryCompletion":11546,"completion":11546,"start":11547,"enrollment":11548,"conditions":11549,"interventions":11550},"NCT05430854","Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study",[90],"2023-10-31","2022-06-01",155,[114],[11505],{"nctId":11552,"briefTitle":11553,"status":217,"phases":11554,"primaryCompletion":2918,"completion":2918,"start":11555,"enrollment":2895,"conditions":11556,"interventions":11558},"NCT05669014","A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)",[90],"2023-12-04",[11557],"Idiopathic Inflammatory Myositis",[11505],{"trials":11560,"activeCount":100},[],{"trials":11562,"activeCount":100},[],{"trials":11564,"activeCount":100},[],{"intervention":2781,"totalTrials":325,"cells":11566},{"EARLY_PHASE1":11567,"PHASE1":11569,"PHASE2":11571,"PHASE3":11603,"PHASE4":11605,"NA":11607},{"trials":11568,"activeCount":100},[],{"trials":11570,"activeCount":100},[],{"trials":11572,"activeCount":100},[11573,11581,11585,11591,11597],{"nctId":11574,"briefTitle":11575,"status":217,"phases":11576,"start":11577,"enrollment":11578,"conditions":11579,"interventions":11580},"NCT00111774","Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma",[90],"2002-03",150,[34,2529],[2781],{"nctId":2773,"briefTitle":2774,"status":217,"phases":11582,"start":2776,"enrollment":2777,"conditions":11583,"interventions":11584},[90],[1971,2779,2463],[2781,2782,2783],{"nctId":11586,"briefTitle":11587,"status":217,"phases":11588,"primaryCompletion":2422,"completion":2422,"start":6469,"enrollment":1476,"conditions":11589,"interventions":11590},"NCT00101920","ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)",[90],[1303,2779,2463],[2781],{"nctId":11592,"briefTitle":11593,"status":217,"phases":11594,"conditions":11595,"interventions":11596},"NCT00113776","Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer",[90],[34],[2781],{"nctId":11598,"briefTitle":11599,"status":217,"phases":11600,"start":2473,"enrollment":1476,"conditions":11601,"interventions":11602},"NCT00327119","Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer",[90],[37],[2781],{"trials":11604,"activeCount":100},[],{"trials":11606,"activeCount":100},[],{"trials":11608,"activeCount":100},[],{"intervention":7794,"totalTrials":160,"cells":11610},{"EARLY_PHASE1":11611,"PHASE1":11613,"PHASE2":11625,"PHASE3":11648,"PHASE4":11650,"NA":11652},{"trials":11612,"activeCount":100},[],{"trials":11614,"activeCount":100},[11615],{"nctId":11616,"briefTitle":11617,"status":217,"phases":11618,"primaryCompletion":11619,"completion":1565,"start":2642,"enrollment":3264,"conditions":11620,"interventions":11624},"NCT00791011","Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat",[89],"2010-07",[8187,11621,7438,11622,1584,11623],"Low Grade Lymphoma","Mantle Cell Lymphoma","Diffuse Large Cell Lymphoma",[7794],{"trials":11626,"activeCount":100},[11627,11637,11644],{"nctId":11628,"briefTitle":11629,"status":217,"phases":11630,"primaryCompletion":7867,"completion":2872,"start":2594,"enrollment":11631,"conditions":11632,"interventions":11635},"NCT00626704","Phase 1b\u002F2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma",[89,90],134,[11633,7700,11634],"Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma","Soft Tissue Sarcoma",[7794,11636],"Doxorubicin",{"nctId":11638,"briefTitle":11639,"status":217,"phases":11640,"primaryCompletion":2872,"completion":2872,"start":1638,"enrollment":11641,"conditions":11642,"interventions":11643},"NCT00534027","A Phase 1b\u002F2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer",[89,90],172,[1971],[7794],{"nctId":7788,"briefTitle":7789,"status":217,"phases":11645,"primaryCompletion":5151,"completion":6190,"start":6173,"enrollment":7791,"conditions":11646,"interventions":11647},[89,90],[37,2425,34,2424],[7794,7777,2616],{"trials":11649,"activeCount":100},[],{"trials":11651,"activeCount":100},[],{"trials":11653,"activeCount":100},[],{"intervention":2455,"totalTrials":160,"cells":11655},{"EARLY_PHASE1":11656,"PHASE1":11658,"PHASE2":11664,"PHASE3":11678,"PHASE4":11680,"NA":11682},{"trials":11657,"activeCount":100},[],{"trials":11659,"activeCount":100},[11660],{"nctId":2448,"briefTitle":2449,"status":217,"phases":11661,"primaryCompletion":2451,"completion":2452,"start":2439,"enrollment":2044,"conditions":11662,"interventions":11663},[89],[37],[1322,2455],{"trials":11665,"activeCount":100},[11666,11670,11674],{"nctId":2509,"briefTitle":2510,"status":217,"phases":11667,"primaryCompletion":1638,"completion":2512,"start":2473,"enrollment":2513,"conditions":11668,"interventions":11669},[90],[37,2515,2516,2425,34],[1322,2455,2429,2518,2519],{"nctId":2627,"briefTitle":2628,"status":217,"phases":11671,"primaryCompletion":2630,"completion":2631,"start":2632,"enrollment":2633,"conditions":11672,"interventions":11673},[90],[25,2425,34,2532,2424,37],[1322,2616,2636,2455,2637],{"nctId":2639,"briefTitle":2640,"status":217,"phases":11675,"primaryCompletion":2642,"completion":2643,"start":2644,"enrollment":380,"conditions":11676,"interventions":11677},[90],[34],[2455,1322,2637,2636],{"trials":11679,"activeCount":100},[],{"trials":11681,"activeCount":100},[],{"trials":11683,"activeCount":100},[],{"intervention":7326,"totalTrials":160,"cells":11685},{"EARLY_PHASE1":11686,"PHASE1":11688,"PHASE2":11702,"PHASE3":11708,"PHASE4":11710,"NA":11712},{"trials":11687,"activeCount":100},[],{"trials":11689,"activeCount":100},[11690,11694,11698],{"nctId":7316,"briefTitle":7317,"status":217,"phases":11691,"primaryCompletion":7319,"completion":7319,"start":7320,"enrollment":731,"conditions":11692,"interventions":11693},[89],[7322],[7324,7325,1656,7326],{"nctId":7343,"briefTitle":7344,"status":336,"phases":11695,"primaryCompletion":7346,"completion":7346,"start":7347,"enrollment":7348,"conditions":11696,"interventions":11697},[89],[7350],[7352,7326,1656],{"nctId":7395,"briefTitle":7396,"status":336,"phases":11699,"primaryCompletion":7398,"completion":7398,"start":7399,"enrollment":3264,"conditions":11700,"interventions":11701},[89],[31],[4905,7326,1656],{"trials":11703,"activeCount":100},[11704],{"nctId":7412,"briefTitle":7413,"status":217,"phases":11705,"primaryCompletion":7415,"completion":7416,"start":7417,"enrollment":3881,"conditions":11706,"interventions":11707},[90],[7322],[2827,1656,7326],{"trials":11709,"activeCount":100},[],{"trials":11711,"activeCount":100},[],{"trials":11713,"activeCount":100},[],{"intervention":11715,"totalTrials":160,"cells":11716},"Tezepelumab",{"EARLY_PHASE1":11717,"PHASE1":11719,"PHASE2":11745,"PHASE3":11757,"PHASE4":11759,"NA":11761},{"trials":11718,"activeCount":100},[],{"trials":11720,"activeCount":100},[11721,11729,11737],{"nctId":11722,"briefTitle":11723,"status":217,"phases":11724,"primaryCompletion":11725,"completion":11725,"start":11726,"enrollment":11482,"conditions":11727,"interventions":11728},"NCT00757042","Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic Dermatitis",[89],"2011-01-05","2008-09-18",[2907,222],[11715],{"nctId":11730,"briefTitle":11731,"status":217,"phases":11732,"primaryCompletion":11733,"completion":11733,"start":11734,"enrollment":1300,"conditions":11735,"interventions":11736},"NCT00972179","Safety Study of Tezepelumab (AMG 157) in Healthy Adults",[89],"2011-01-09","2009-09-15",[222],[11715],{"nctId":11738,"briefTitle":11739,"status":217,"phases":11740,"primaryCompletion":11741,"completion":11741,"start":11742,"enrollment":1337,"conditions":11743,"interventions":11744},"NCT01405963","Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma",[89],"2013-04-05","2011-10-31",[2941],[11715],{"trials":11746,"activeCount":100},[11747],{"nctId":11748,"briefTitle":11749,"status":336,"phases":11750,"primaryCompletion":11751,"completion":11752,"start":11753,"enrollment":11754,"conditions":11755,"interventions":11756},"NCT03809663","A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis",[90],"2020-05-12","2020-12-22","2019-03-15",251,[2907],[11715],{"trials":11758,"activeCount":100},[],{"trials":11760,"activeCount":100},[],{"trials":11762,"activeCount":100},[],{"intervention":7367,"totalTrials":160,"cells":11764},{"EARLY_PHASE1":11765,"PHASE1":11767,"PHASE2":11790,"PHASE3":11796,"PHASE4":11798,"NA":11800},{"trials":11766,"activeCount":100},[],{"trials":11768,"activeCount":100},[11769,11777,11781],{"nctId":11770,"briefTitle":11771,"status":336,"phases":11772,"primaryCompletion":2926,"completion":2926,"start":11773,"enrollment":7374,"conditions":11774,"interventions":11775},"NCT02675452","AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia",[89],"2016-06-13",[7322,1359],[11776,7367,4611],"AMG 176",{"nctId":7354,"briefTitle":7355,"status":336,"phases":11778,"primaryCompletion":7357,"completion":7357,"start":7358,"enrollment":253,"conditions":11779,"interventions":11780},[89],[31,7360,7361,7362,7363,4423,7364],[7366,1656,7367],{"nctId":11782,"briefTitle":11783,"status":336,"phases":11784,"primaryCompletion":3262,"completion":3262,"start":11785,"enrollment":1454,"conditions":11786,"interventions":11789},"NCT05209152","AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome \u002FChronic Myelomonocytic Leukemia",[89],"2022-11-14",[11787,11788],"Higher Risk Myelodysplastic Syndrome","Chronic Myelomonocytic Leukemia",[11776,7367],{"trials":11791,"activeCount":100},[11792],{"nctId":8202,"briefTitle":8203,"status":217,"phases":11793,"primaryCompletion":8205,"completion":8205,"start":8206,"enrollment":8207,"conditions":11794,"interventions":11795},[90],[4423,4424,2838],[8173,7367,8210],{"trials":11797,"activeCount":100},[],{"trials":11799,"activeCount":100},[],{"trials":11801,"activeCount":100},[],{"intervention":7576,"totalTrials":160,"cells":11803},{"EARLY_PHASE1":11804,"PHASE1":11806,"PHASE2":11812,"PHASE3":11826,"PHASE4":11828,"NA":11830},{"trials":11805,"activeCount":100},[],{"trials":11807,"activeCount":100},[11808],{"nctId":7571,"briefTitle":7572,"status":217,"phases":11809,"start":6744,"enrollment":4708,"conditions":11810,"interventions":11811},[89],[1290],[7576,2428,2428,2807,7577,2616,2807],{"trials":11813,"activeCount":100},[11814,11818,11822],{"nctId":7862,"briefTitle":7863,"status":217,"phases":11815,"primaryCompletion":7865,"completion":7866,"start":7867,"enrollment":13,"conditions":11816,"interventions":11817},[90],[7869,7870],[2807,2807,7576],{"nctId":11201,"briefTitle":11202,"status":131,"phases":11819,"primaryCompletion":2438,"completion":2438,"start":11204,"enrollment":100,"conditions":11820,"interventions":11821},[89,90],[7869],[4905,7576],{"nctId":7881,"briefTitle":7882,"status":217,"phases":11823,"primaryCompletion":2421,"completion":781,"start":2540,"enrollment":2302,"conditions":11824,"interventions":11825},[90],[2572],[2807,7576,7886],{"trials":11827,"activeCount":100},[],{"trials":11829,"activeCount":100},[],{"trials":11831,"activeCount":100},[],{"intervention":11833,"totalTrials":193,"cells":11834},"CCX282-B",{"EARLY_PHASE1":11835,"PHASE1":11837,"PHASE2":11839,"PHASE3":11862,"PHASE4":11864,"NA":11866},{"trials":11836,"activeCount":100},[],{"trials":11838,"activeCount":100},[],{"trials":11840,"activeCount":100},[11841,11847,11855],{"nctId":11842,"briefTitle":11843,"status":217,"phases":11844,"primaryCompletion":8136,"completion":8349,"start":3033,"enrollment":9241,"conditions":11845,"interventions":11846},"NCT00306215","A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease",[90],[11365],[11833],{"nctId":11848,"briefTitle":11849,"status":217,"phases":11850,"completion":6744,"start":2475,"enrollment":11851,"conditions":11852,"interventions":11854},"NCT00102921","Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease",[90],70,[11853],"Crohn Disease",[11833],{"nctId":11856,"briefTitle":11857,"status":217,"phases":11858,"primaryCompletion":3870,"completion":6172,"start":6173,"enrollment":2126,"conditions":11859,"interventions":11861},"NCT00540657","A Phase II Study of CCX282-B in Patients With Celiac Disease",[90],[11860],"Celiac Disease",[11833],{"trials":11863,"activeCount":100},[],{"trials":11865,"activeCount":100},[],{"trials":11867,"activeCount":100},[],{"intervention":2637,"totalTrials":193,"cells":11869},{"EARLY_PHASE1":11870,"PHASE1":11872,"PHASE2":11874,"PHASE3":11888,"PHASE4":11890,"NA":11892},{"trials":11871,"activeCount":100},[],{"trials":11873,"activeCount":100},[],{"trials":11875,"activeCount":100},[11876,11880,11884],{"nctId":3773,"briefTitle":3774,"status":217,"phases":11877,"conditions":11878,"interventions":11879},[90],[2794],[2797,3061,3778,3779],{"nctId":2627,"briefTitle":2628,"status":217,"phases":11881,"primaryCompletion":2630,"completion":2631,"start":2632,"enrollment":2633,"conditions":11882,"interventions":11883},[90],[25,2425,34,2532,2424,37],[1322,2616,2636,2455,2637],{"nctId":2639,"briefTitle":2640,"status":217,"phases":11885,"primaryCompletion":2642,"completion":2643,"start":2644,"enrollment":380,"conditions":11886,"interventions":11887},[90],[34],[2455,1322,2637,2636],{"trials":11889,"activeCount":100},[],{"trials":11891,"activeCount":100},[],{"trials":11893,"activeCount":100},[],{"intervention":11895,"totalTrials":193,"cells":11896},"AMG 853",{"EARLY_PHASE1":11897,"PHASE1":11899,"PHASE2":11913,"PHASE3":11922,"PHASE4":11924,"NA":11926},{"trials":11898,"activeCount":100},[],{"trials":11900,"activeCount":100},[11901,11907],{"nctId":11902,"briefTitle":11903,"status":217,"phases":11904,"primaryCompletion":5151,"completion":1606,"start":5353,"enrollment":380,"conditions":11905,"interventions":11906},"NCT01124279","Single-dose, Pharmacokinetics of AMG 853 in Healthy Adult Subjects",[89],[222],[11895],{"nctId":11908,"briefTitle":11909,"status":217,"phases":11910,"primaryCompletion":8367,"completion":8367,"start":2452,"enrollment":1095,"conditions":11911,"interventions":11912},"NCT01137565","Safety, Tolerability, and Pharcodynamics of AMG 853 in Adolescents With Asthma",[89],[2941],[11895],{"trials":11914,"activeCount":100},[11915],{"nctId":11916,"briefTitle":11917,"status":217,"phases":11918,"primaryCompletion":3831,"completion":2872,"start":6183,"enrollment":11919,"conditions":11920,"interventions":11921},"NCT01018550","AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma",[90],397,[2941],[11895,11895,11895,11895],{"trials":11923,"activeCount":100},[],{"trials":11925,"activeCount":100},[],{"trials":11927,"activeCount":100},[],{"intervention":11929,"totalTrials":193,"cells":11930},"AMG 337",{"EARLY_PHASE1":11931,"PHASE1":11933,"PHASE2":11945,"PHASE3":11963,"PHASE4":11965,"NA":11967},{"trials":11932,"activeCount":100},[],{"trials":11934,"activeCount":100},[11935],{"nctId":11936,"briefTitle":11937,"status":217,"phases":11938,"primaryCompletion":11939,"completion":9078,"start":11940,"enrollment":1759,"conditions":11941,"interventions":11944},"NCT01253707","A Study of AMG 337 in Subjects With Advanced Solid Tumors",[89],"2015-10-01","2010-12-08",[11942,1290,25,2479,11943,2478],"Advanced Malignancy","Oncology Patients",[11929],{"trials":11946,"activeCount":100},[11947,11954],{"nctId":11948,"briefTitle":11949,"status":336,"phases":11950,"primaryCompletion":1605,"completion":1605,"start":1625,"enrollment":13,"conditions":11951,"interventions":11953},"NCT02016534","Phase 2 Study of AMG 337 in MET Amplified Gastric\u002FEsophageal Adenocarcinoma or Other Solid Tumors",[90],[11952],"Stomach Neoplasms",[11929],{"nctId":11955,"briefTitle":11956,"status":217,"phases":11957,"primaryCompletion":11958,"completion":11959,"start":11960,"enrollment":3338,"conditions":11961,"interventions":11962},"NCT02096666","A Phase 1\u002F2 Study Evaluating AMG 337 in Asian Subjects",[89,90],"2015-11-05","2018-12-07","2014-04-15",[11952],[11929],{"trials":11964,"activeCount":100},[],{"trials":11966,"activeCount":100},[],{"trials":11968,"activeCount":100},[],{"intervention":11970,"totalTrials":193,"cells":11971},"AMG 108",{"EARLY_PHASE1":11972,"PHASE1":11974,"PHASE2":11976,"PHASE3":11999,"PHASE4":12001,"NA":12003},{"trials":11973,"activeCount":100},[],{"trials":11975,"activeCount":100},[],{"trials":11977,"activeCount":100},[11978,11985,11992],{"nctId":11979,"briefTitle":11980,"status":217,"phases":11981,"primaryCompletion":2594,"completion":2642,"start":3033,"enrollment":11982,"conditions":11983,"interventions":11984},"NCT00293826","A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis",[90],813,[19],[11970,11970,11970],{"nctId":11986,"briefTitle":11987,"status":217,"phases":11988,"primaryCompletion":3870,"completion":3870,"start":6129,"enrollment":11989,"conditions":11990,"interventions":11991},"NCT00369473","Long-Term Assessment of Safety and Physical Function With AMG 108 in RA",[90],690,[19],[11970,11970],{"nctId":11993,"briefTitle":11994,"status":131,"phases":11995,"primaryCompletion":8349,"completion":6183,"start":3870,"enrollment":100,"conditions":11996,"interventions":11998},"NCT00661921","A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes Mellitus",[90],[11997],"Diabetes Mellitus",[11970],{"trials":12000,"activeCount":100},[],{"trials":12002,"activeCount":100},[],{"trials":12004,"activeCount":100},[],{"intervention":12006,"totalTrials":193,"cells":12007},"recombinant human erythropoietin",{"EARLY_PHASE1":12008,"PHASE1":12010,"PHASE2":12012,"PHASE3":12037,"PHASE4":12039,"NA":12041},{"trials":12009,"activeCount":100},[],{"trials":12011,"activeCount":100},[],{"trials":12013,"activeCount":100},[12014,12021,12029],{"nctId":12015,"briefTitle":12016,"status":217,"phases":12017,"completion":12018,"start":7733,"conditions":12019,"interventions":12020},"NCT00120679","Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to Chemotherapy",[90],"2003-12",[1971,16],[8962,12006],{"nctId":12022,"briefTitle":12023,"status":217,"phases":12024,"completion":12018,"start":7733,"conditions":12025,"interventions":12028},"NCT00121030","Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy",[90],[12026,12027,16],"Gynecological Malignancies","Genital Neoplasms, Female",[8962,12006],{"nctId":12030,"briefTitle":12031,"status":217,"phases":12032,"completion":12018,"start":7733,"conditions":12033,"interventions":12034},"NCT00120692","Treatment for Patients Suffering From Anemia Due to Chemotherapy",[90],[2794,16],[12035,12036],"Darbepoetin Alfa","Recombinant Human Erythropoietin",{"trials":12038,"activeCount":100},[],{"trials":12040,"activeCount":100},[],{"trials":12042,"activeCount":100},[],{"intervention":12044,"totalTrials":985,"cells":12045},"AMG 102 at 20 mg\u002Fkg",{"EARLY_PHASE1":12046,"PHASE1":12048,"PHASE2":12050,"PHASE3":12067,"PHASE4":12069,"NA":12071},{"trials":12047,"activeCount":100},[],{"trials":12049,"activeCount":100},[],{"trials":12051,"activeCount":100},[12052,12061],{"nctId":12053,"briefTitle":12054,"status":217,"phases":12055,"primaryCompletion":2541,"completion":12056,"start":2587,"enrollment":731,"conditions":12057,"interventions":12059},"NCT00427440","A Phase II Study to Treat Advanced Malignant Glioma",[90],"2013-04",[12058],"Advanced Malignant Glioma",[12044,12060],"AMG 102 at 10 mg\u002Fkg",{"nctId":12062,"briefTitle":12063,"status":217,"phases":12064,"primaryCompletion":2451,"completion":2451,"start":2662,"enrollment":731,"conditions":12065,"interventions":12066},"NCT00422019","A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma",[90],[2572],[12060,12044],{"trials":12068,"activeCount":100},[],{"trials":12070,"activeCount":100},[],{"trials":12072,"activeCount":100},[],{"intervention":12060,"totalTrials":985,"cells":12074},{"EARLY_PHASE1":12075,"PHASE1":12077,"PHASE2":12079,"PHASE3":12089,"PHASE4":12091,"NA":12093},{"trials":12076,"activeCount":100},[],{"trials":12078,"activeCount":100},[],{"trials":12080,"activeCount":100},[12081,12085],{"nctId":12053,"briefTitle":12054,"status":217,"phases":12082,"primaryCompletion":2541,"completion":12056,"start":2587,"enrollment":731,"conditions":12083,"interventions":12084},[90],[12058],[12044,12060],{"nctId":12062,"briefTitle":12063,"status":217,"phases":12086,"primaryCompletion":2451,"completion":2451,"start":2662,"enrollment":731,"conditions":12087,"interventions":12088},[90],[2572],[12060,12044],{"trials":12090,"activeCount":100},[],{"trials":12092,"activeCount":100},[],{"trials":12094,"activeCount":100},[],{"intervention":2503,"totalTrials":985,"cells":12096},{"EARLY_PHASE1":12097,"PHASE1":12099,"PHASE2":12101,"PHASE3":12111,"PHASE4":12113,"NA":12115},{"trials":12098,"activeCount":100},[],{"trials":12100,"activeCount":100},[],{"trials":12102,"activeCount":100},[12103,12107],{"nctId":2496,"briefTitle":2497,"status":217,"phases":12104,"primaryCompletion":2499,"completion":1627,"start":1638,"enrollment":2500,"conditions":12105,"interventions":12106},[89,90],[2425,34,2424,37,2479],[1322,2503],{"nctId":7769,"briefTitle":7770,"status":217,"phases":12108,"primaryCompletion":7772,"completion":7772,"start":7773,"enrollment":2895,"conditions":12109,"interventions":12110},[90],[1290,7775,34,7719,7438,2532,1971,7700,2441],[7777,2503,7778,2616],{"trials":12112,"activeCount":100},[],{"trials":12114,"activeCount":100},[],{"trials":12116,"activeCount":100},[],{"intervention":12118,"totalTrials":985,"cells":12119},"Rozibafusp Alfa",{"EARLY_PHASE1":12120,"PHASE1":12122,"PHASE2":12133,"PHASE3":12143,"PHASE4":12145,"NA":12147},{"trials":12121,"activeCount":100},[],{"trials":12123,"activeCount":100},[12124],{"nctId":12125,"briefTitle":12126,"status":217,"phases":12127,"primaryCompletion":12128,"completion":12129,"start":12130,"enrollment":2028,"conditions":12131,"interventions":12132},"NCT03156023","Multiple Ascending Doses of Rozibafusp Alfa (AMG 570) in Adults With Rheumatoid Arthritis",[89],"2019-10-17","2020-06-12","2017-08-14",[19],[12118],{"trials":12134,"activeCount":100},[12135],{"nctId":12136,"briefTitle":12137,"status":217,"phases":12138,"primaryCompletion":12139,"completion":12139,"start":6649,"enrollment":12140,"conditions":12141,"interventions":12142},"NCT04058028","Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)",[90],"2023-07-25",244,[11324],[12118],{"trials":12144,"activeCount":100},[],{"trials":12146,"activeCount":100},[],{"trials":12148,"activeCount":100},[],{"intervention":3145,"totalTrials":985,"cells":12150},{"EARLY_PHASE1":12151,"PHASE1":12153,"PHASE2":12159,"PHASE3":12165,"PHASE4":12167,"NA":12169},{"trials":12152,"activeCount":100},[],{"trials":12154,"activeCount":100},[12155],{"nctId":1257,"briefTitle":1258,"status":336,"phases":12156,"primaryCompletion":1260,"completion":1260,"start":1261,"enrollment":1262,"conditions":12157,"interventions":12158},[89],[1264,1265],[1267,1152,1268,1269],{"trials":12160,"activeCount":100},[12161],{"nctId":3137,"briefTitle":3138,"status":336,"phases":12162,"primaryCompletion":3140,"completion":3140,"start":3141,"enrollment":3142,"conditions":12163,"interventions":12164},[89,90],[1264],[3145,1539,1503,1099],{"trials":12166,"activeCount":100},[],{"trials":12168,"activeCount":100},[],{"trials":12170,"activeCount":100},[],{"intervention":12172,"totalTrials":985,"cells":12173},"AMG 827",{"EARLY_PHASE1":12174,"PHASE1":12176,"PHASE2":12178,"PHASE3":12195,"PHASE4":12197,"NA":12199},{"trials":12175,"activeCount":100},[],{"trials":12177,"activeCount":100},[],{"trials":12179,"activeCount":100},[12180,12189],{"nctId":12181,"briefTitle":12182,"status":336,"phases":12183,"primaryCompletion":12184,"completion":12184,"start":12185,"enrollment":12186,"conditions":12187,"interventions":12188},"NCT01059448","Safety and Efficacy of AMG 827 in Subjects With RA",[90],"2011-04-05","2010-06-03",211,[19],[12172],{"nctId":12190,"briefTitle":12191,"status":217,"phases":12192,"primaryCompletion":9682,"completion":9682,"start":6206,"enrollment":1444,"conditions":12193,"interventions":12194},"NCT01199289","A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma",[90],[2941],[12172],{"trials":12196,"activeCount":100},[],{"trials":12198,"activeCount":100},[],{"trials":12200,"activeCount":100},[],{"intervention":3062,"totalTrials":985,"cells":12202},{"EARLY_PHASE1":12203,"PHASE1":12205,"PHASE2":12207,"PHASE3":12217,"PHASE4":12219,"NA":12221},{"trials":12204,"activeCount":100},[],{"trials":12206,"activeCount":100},[],{"trials":12208,"activeCount":100},[12209,12213],{"nctId":3055,"briefTitle":3056,"status":3046,"phases":12210,"start":3048,"conditions":12211,"interventions":12212},[90],[3059,1265],[3051,3061,3052,3062],{"nctId":8002,"briefTitle":8003,"status":3046,"phases":12214,"start":8005,"conditions":12215,"interventions":12216},[90],[7438],[3051,8008,3061,3062,8009,8010],{"trials":12218,"activeCount":100},[],{"trials":12220,"activeCount":100},[],{"trials":12222,"activeCount":100},[],{"intervention":12224,"totalTrials":985,"cells":12225},"Liatermin",{"EARLY_PHASE1":12226,"PHASE1":12228,"PHASE2":12237,"PHASE3":12246,"PHASE4":12248,"NA":12250},{"trials":12227,"activeCount":100},[],{"trials":12229,"activeCount":100},[12230],{"nctId":12231,"briefTitle":12232,"status":217,"phases":12233,"start":6421,"conditions":12234,"interventions":12236},"NCT00115427","Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease",[89],[12235],"Idiopathic Parkinson's Disease",[12224],{"trials":12238,"activeCount":100},[12239],{"nctId":12240,"briefTitle":12241,"status":217,"phases":12242,"primaryCompletion":7626,"completion":4421,"start":12018,"enrollment":2028,"conditions":12243,"interventions":12245},"NCT00111982","Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu)Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin",[89,90],[12244],"Parkinson's Disease",[12224],{"trials":12247,"activeCount":100},[],{"trials":12249,"activeCount":100},[],{"trials":12251,"activeCount":100},[],{"intervention":12253,"totalTrials":985,"cells":12254},"Cysteamine Bitartrate",{"EARLY_PHASE1":12255,"PHASE1":12257,"PHASE2":12259,"PHASE3":12277,"PHASE4":12279,"NA":12281},{"trials":12256,"activeCount":100},[],{"trials":12258,"activeCount":100},[],{"trials":12260,"activeCount":100},[12261,12268],{"nctId":12262,"briefTitle":12263,"status":217,"phases":12264,"primaryCompletion":1605,"completion":1605,"start":5152,"enrollment":439,"conditions":12265,"interventions":12267},"NCT02023866","Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease",[90],[12266],"Inherited Mitochondrial Disease, Including Leigh Syndrome",[12253],{"nctId":12269,"briefTitle":12270,"status":336,"phases":12271,"primaryCompletion":12272,"completion":12272,"start":12273,"enrollment":6471,"conditions":12274,"interventions":12276},"NCT02473445","A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease",[90],"2017-03-06","2015-05-19",[12275],"Mitochondrial Diseases",[12253],{"trials":12278,"activeCount":100},[],{"trials":12280,"activeCount":100},[],{"trials":12282,"activeCount":100},[],{"intervention":7577,"totalTrials":985,"cells":12284},{"EARLY_PHASE1":12285,"PHASE1":12287,"PHASE2":12293,"PHASE3":12305,"PHASE4":12307,"NA":12309},{"trials":12286,"activeCount":100},[],{"trials":12288,"activeCount":100},[12289],{"nctId":7571,"briefTitle":7572,"status":217,"phases":12290,"start":6744,"enrollment":4708,"conditions":12291,"interventions":12292},[89],[1290],[7576,2428,2428,2807,7577,2616,2807],{"trials":12294,"activeCount":100},[12295],{"nctId":12296,"briefTitle":12297,"status":217,"phases":12298,"primaryCompletion":12299,"completion":7444,"start":12300,"enrollment":12301,"conditions":12302,"interventions":12303},"NCT00853372","AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib",[90],"2011-08-08","2009-05-28",85,[2572],[7577,12304],"Trebananib",{"trials":12306,"activeCount":100},[],{"trials":12308,"activeCount":100},[],{"trials":12310,"activeCount":100},[],{"intervention":12312,"totalTrials":985,"cells":12313},"Pegsunercept",{"EARLY_PHASE1":12314,"PHASE1":12316,"PHASE2":12318,"PHASE3":12331,"PHASE4":12333,"NA":12335},{"trials":12315,"activeCount":100},[],{"trials":12317,"activeCount":100},[],{"trials":12319,"activeCount":100},[12320,12327],{"nctId":12321,"briefTitle":12322,"status":217,"phases":12323,"start":2792,"enrollment":12324,"conditions":12325,"interventions":12326},"NCT00111423","Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)",[90],216,[19],[12312],{"nctId":6456,"briefTitle":6457,"status":217,"phases":12328,"completion":6459,"start":6460,"conditions":12329,"interventions":12330},[90],[19],[6463,6464],{"trials":12332,"activeCount":100},[],{"trials":12334,"activeCount":100},[],{"trials":12336,"activeCount":100},[],{"intervention":12338,"totalTrials":985,"cells":12339},"VIB7734",{"EARLY_PHASE1":12340,"PHASE1":12342,"PHASE2":12356,"PHASE3":12369,"PHASE4":12371,"NA":12373},{"trials":12341,"activeCount":100},[],{"trials":12343,"activeCount":100},[12344],{"nctId":12345,"briefTitle":12346,"status":217,"phases":12347,"primaryCompletion":12348,"completion":12348,"start":12349,"enrollment":1337,"conditions":12350,"interventions":12355},"NCT03817424","A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis",[89],"2020-07-20","2018-12-13",[114,12351,3218,12352,12353,12354],"Cutaneous Lupus Erythematosus","Systemic Sclerosis","Polymyositis","Dermatomyositis",[12338],{"trials":12357,"activeCount":100},[12358],{"nctId":12359,"briefTitle":12360,"status":217,"phases":12361,"primaryCompletion":12362,"completion":12363,"start":12364,"enrollment":12365,"conditions":12366,"interventions":12368},"NCT04925934","Study of VIB7734 for the Treatment of Moderate to Severely Active SLE",[90],"2023-05-16","2023-06-09","2021-05-28",214,[12367],"Lupus Erythematosus, Systemic",[12338],{"trials":12370,"activeCount":100},[],{"trials":12372,"activeCount":100},[],{"trials":12374,"activeCount":100},[],{"intervention":12376,"totalTrials":985,"cells":12377},"CC-11050",{"EARLY_PHASE1":12378,"PHASE1":12380,"PHASE2":12390,"PHASE3":12400,"PHASE4":12402,"NA":12404},{"trials":12379,"activeCount":100},[],{"trials":12381,"activeCount":100},[12382],{"nctId":12383,"briefTitle":12384,"status":217,"phases":12385,"primaryCompletion":12386,"completion":12386,"start":12387,"enrollment":4671,"conditions":12388,"interventions":12389},"NCT04139226","A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole",[89],"2020-02-27","2019-08-28",[222],[12376],{"trials":12391,"activeCount":100},[12392],{"nctId":12393,"briefTitle":12394,"status":217,"phases":12395,"primaryCompletion":12396,"completion":12397,"start":7086,"enrollment":2197,"conditions":12398,"interventions":12399},"NCT01300208","To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus",[90],"2013-01-01","2013-03-01",[12351],[12376],{"trials":12401,"activeCount":100},[],{"trials":12403,"activeCount":100},[],{"trials":12405,"activeCount":100},[],{"intervention":12407,"totalTrials":985,"cells":12408},"AMG 747",{"EARLY_PHASE1":12409,"PHASE1":12411,"PHASE2":12413,"PHASE3":12428,"PHASE4":12430,"NA":12432},{"trials":12410,"activeCount":100},[],{"trials":12412,"activeCount":100},[],{"trials":12414,"activeCount":100},[12415,12422],{"nctId":12416,"briefTitle":12417,"status":336,"phases":12418,"primaryCompletion":7943,"completion":7943,"start":10327,"enrollment":1789,"conditions":12419,"interventions":12421},"NCT01568216","20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms",[90],[12420],"Schizophrenia",[12407],{"nctId":12423,"briefTitle":12424,"status":336,"phases":12425,"primaryCompletion":7943,"completion":2873,"start":10327,"enrollment":1759,"conditions":12426,"interventions":12427},"NCT01568229","20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)",[90],[12420],[12407],{"trials":12429,"activeCount":100},[],{"trials":12431,"activeCount":100},[],{"trials":12433,"activeCount":100},[],{"intervention":12435,"totalTrials":985,"cells":12436},"ganitumab",{"EARLY_PHASE1":12437,"PHASE1":12439,"PHASE2":12450,"PHASE3":12456,"PHASE4":12458,"NA":12460},{"trials":12438,"activeCount":100},[],{"trials":12440,"activeCount":100},[12441],{"nctId":12442,"briefTitle":12443,"status":217,"phases":12444,"primaryCompletion":2421,"completion":2452,"start":8185,"enrollment":12445,"conditions":12446,"interventions":12449},"NCT00562380","AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma",[89],64,[7438,1265,7700,12447,12448],"Small Intestine Cancer","Unspecified Adult Solid Tumor, Protocol Specific",[12435],{"trials":12451,"activeCount":100},[12452],{"nctId":7769,"briefTitle":7770,"status":217,"phases":12453,"primaryCompletion":7772,"completion":7772,"start":7773,"enrollment":2895,"conditions":12454,"interventions":12455},[90],[1290,7775,34,7719,7438,2532,1971,7700,2441],[7777,2503,7778,2616],{"trials":12457,"activeCount":100},[],{"trials":12459,"activeCount":100},[],{"trials":12461,"activeCount":100},[],{"intervention":12463,"totalTrials":985,"cells":12464},"Abrilumab",{"EARLY_PHASE1":12465,"PHASE1":12467,"PHASE2":12469,"PHASE3":12488,"PHASE4":12490,"NA":12492},{"trials":12466,"activeCount":100},[],{"trials":12468,"activeCount":100},[],{"trials":12470,"activeCount":100},[12471,12480],{"nctId":12472,"briefTitle":12473,"status":217,"phases":12474,"primaryCompletion":12475,"completion":11234,"start":12476,"enrollment":12477,"conditions":12478,"interventions":12479},"NCT01694485","Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis",[90],"2015-07-13","2012-11-16",359,[2068],[12463],{"nctId":12481,"briefTitle":12482,"status":217,"phases":12483,"primaryCompletion":12484,"completion":11234,"start":12485,"enrollment":2137,"conditions":12486,"interventions":12487},"NCT01696396","Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease",[90],"2014-12-26","2012-12-04",[11365],[12463],{"trials":12489,"activeCount":100},[],{"trials":12491,"activeCount":100},[],{"trials":12493,"activeCount":100},[],{"intervention":12495,"totalTrials":985,"cells":12496},"AMG 151",{"EARLY_PHASE1":12497,"PHASE1":12499,"PHASE2":12508,"PHASE3":12517,"PHASE4":12519,"NA":12521},{"trials":12498,"activeCount":100},[],{"trials":12500,"activeCount":100},[12501],{"nctId":12502,"briefTitle":12503,"status":336,"phases":12504,"primaryCompletion":12505,"completion":12505,"start":8882,"enrollment":325,"conditions":12506,"interventions":12507},"NCT01755442","Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects",[89],"2013-01",[11997],[12495],{"trials":12509,"activeCount":100},[12510],{"nctId":12511,"briefTitle":12512,"status":217,"phases":12513,"primaryCompletion":7260,"completion":3868,"start":6190,"enrollment":12514,"conditions":12515,"interventions":12516},"NCT01464437","AMG 151 Amgen Protocol Number 20100761",[90],236,[11997],[12495,4603,12495,12495,12495,12495,12495],{"trials":12518,"activeCount":100},[],{"trials":12520,"activeCount":100},[],{"trials":12522,"activeCount":100},[],{"intervention":12524,"totalTrials":985,"cells":12525},"HZN-825",{"EARLY_PHASE1":12526,"PHASE1":12528,"PHASE2":12530,"PHASE3":12550,"PHASE4":12552,"NA":12554},{"trials":12527,"activeCount":100},[],{"trials":12529,"activeCount":100},[],{"trials":12531,"activeCount":100},[12532,12541],{"nctId":12533,"briefTitle":12534,"status":336,"phases":12535,"primaryCompletion":1158,"completion":12536,"start":12537,"enrollment":2654,"conditions":12538,"interventions":12540},"NCT05032066","A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis",[90],"2025-01-02","2022-01-20",[12539],"Idiopathic Pulmonary Fibrosis",[12524],{"nctId":12542,"briefTitle":12543,"status":336,"phases":12544,"primaryCompletion":12545,"completion":12545,"start":12546,"enrollment":7348,"conditions":12547,"interventions":12549},"NCT05626751","An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)",[90],"2025-02-24","2022-11-04",[6528,12548],"Sclerosis, Systemic",[12524],{"trials":12551,"activeCount":100},[],{"trials":12553,"activeCount":100},[],{"trials":12555,"activeCount":100},[],{"intervention":3084,"totalTrials":985,"cells":12557},{"EARLY_PHASE1":12558,"PHASE1":12560,"PHASE2":12562,"PHASE3":12572,"PHASE4":12574,"NA":12576},{"trials":12559,"activeCount":100},[],{"trials":12561,"activeCount":100},[],{"trials":12563,"activeCount":100},[12564,12568],{"nctId":3077,"briefTitle":3078,"status":217,"phases":12565,"conditions":12566,"interventions":12567},[90],[2794,3081,3082],[2797,3052,3084,3061],{"nctId":11628,"briefTitle":11629,"status":217,"phases":12569,"primaryCompletion":7867,"completion":2872,"start":2594,"enrollment":11631,"conditions":12570,"interventions":12571},[89,90],[11633,7700,11634],[7794,11636],{"trials":12573,"activeCount":100},[],{"trials":12575,"activeCount":100},[],{"trials":12577,"activeCount":100},[],{"intervention":7378,"totalTrials":985,"cells":12579},{"EARLY_PHASE1":12580,"PHASE1":12582,"PHASE2":12588,"PHASE3":12594,"PHASE4":12596,"NA":12598},{"trials":12581,"activeCount":100},[],{"trials":12583,"activeCount":100},[12584],{"nctId":7369,"briefTitle":7370,"status":217,"phases":12585,"primaryCompletion":7372,"completion":7372,"start":7373,"enrollment":7374,"conditions":12586,"interventions":12587},[89],[7376],[2827,1656,7378,1767,7379,7380,7381,7382,296,7383,1764],{"trials":12589,"activeCount":100},[12590],{"nctId":8496,"briefTitle":8497,"status":217,"phases":12591,"primaryCompletion":8367,"completion":1566,"start":7853,"enrollment":5461,"conditions":12592,"interventions":12593},[89,90],[25,8500,8501,1265],[7949,7949,7378,295],{"trials":12595,"activeCount":100},[],{"trials":12597,"activeCount":100},[],{"trials":12599,"activeCount":100},[],{"intervention":7777,"totalTrials":985,"cells":12601},{"EARLY_PHASE1":12602,"PHASE1":12604,"PHASE2":12606,"PHASE3":12616,"PHASE4":12618,"NA":12620},{"trials":12603,"activeCount":100},[],{"trials":12605,"activeCount":100},[],{"trials":12607,"activeCount":100},[12608,12612],{"nctId":7769,"briefTitle":7770,"status":217,"phases":12609,"primaryCompletion":7772,"completion":7772,"start":7773,"enrollment":2895,"conditions":12610,"interventions":12611},[90],[1290,7775,34,7719,7438,2532,1971,7700,2441],[7777,2503,7778,2616],{"nctId":7788,"briefTitle":7789,"status":217,"phases":12613,"primaryCompletion":5151,"completion":6190,"start":6173,"enrollment":7791,"conditions":12614,"interventions":12615},[89,90],[37,2425,34,2424],[7794,7777,2616],{"trials":12617,"activeCount":100},[],{"trials":12619,"activeCount":100},[],{"trials":12621,"activeCount":100},[],{"intervention":4603,"totalTrials":985,"cells":12623},{"EARLY_PHASE1":12624,"PHASE1":12626,"PHASE2":12632,"PHASE3":12638,"PHASE4":12640,"NA":12642},{"trials":12625,"activeCount":100},[],{"trials":12627,"activeCount":100},[12628],{"nctId":4597,"briefTitle":4598,"status":217,"phases":12629,"primaryCompletion":750,"completion":750,"start":4600,"enrollment":231,"conditions":12630,"interventions":12631},[89],[222],[43,4603],{"trials":12633,"activeCount":100},[12634],{"nctId":12511,"briefTitle":12512,"status":217,"phases":12635,"primaryCompletion":7260,"completion":3868,"start":6190,"enrollment":12514,"conditions":12636,"interventions":12637},[90],[11997],[12495,4603,12495,12495,12495,12495,12495],{"trials":12639,"activeCount":100},[],{"trials":12641,"activeCount":100},[],{"trials":12643,"activeCount":100},[],{"intervention":2636,"totalTrials":985,"cells":12645},{"EARLY_PHASE1":12646,"PHASE1":12648,"PHASE2":12650,"PHASE3":12660,"PHASE4":12662,"NA":12664},{"trials":12647,"activeCount":100},[],{"trials":12649,"activeCount":100},[],{"trials":12651,"activeCount":100},[12652,12656],{"nctId":2627,"briefTitle":2628,"status":217,"phases":12653,"primaryCompletion":2630,"completion":2631,"start":2632,"enrollment":2633,"conditions":12654,"interventions":12655},[90],[25,2425,34,2532,2424,37],[1322,2616,2636,2455,2637],{"nctId":2639,"briefTitle":2640,"status":217,"phases":12657,"primaryCompletion":2642,"completion":2643,"start":2644,"enrollment":380,"conditions":12658,"interventions":12659},[90],[34],[2455,1322,2637,2636],{"trials":12661,"activeCount":100},[],{"trials":12663,"activeCount":100},[],{"trials":12665,"activeCount":100},[],{"intervention":7949,"totalTrials":985,"cells":12667},{"EARLY_PHASE1":12668,"PHASE1":12670,"PHASE2":12672,"PHASE3":12682,"PHASE4":12684,"NA":12686},{"trials":12669,"activeCount":100},[],{"trials":12671,"activeCount":100},[],{"trials":12673,"activeCount":100},[12674,12678],{"nctId":8496,"briefTitle":8497,"status":217,"phases":12675,"primaryCompletion":8367,"completion":1566,"start":7853,"enrollment":5461,"conditions":12676,"interventions":12677},[89,90],[25,8500,8501,1265],[7949,7949,7378,295],{"nctId":7940,"briefTitle":7941,"status":217,"phases":12679,"primaryCompletion":1627,"completion":7943,"start":2832,"enrollment":7944,"conditions":12680,"interventions":12681},[89,90],[7946,3170,2465],[7934,7948,7949,2468],{"trials":12683,"activeCount":100},[],{"trials":12685,"activeCount":100},[],{"trials":12687,"activeCount":100},[],{"intervention":12689,"totalTrials":985,"cells":12690},"AMG 223",{"EARLY_PHASE1":12691,"PHASE1":12693,"PHASE2":12702,"PHASE3":12712,"PHASE4":12714,"NA":12716},{"trials":12692,"activeCount":100},[],{"trials":12694,"activeCount":100},[12695],{"nctId":12696,"briefTitle":12697,"status":217,"phases":12698,"primaryCompletion":8136,"completion":1636,"start":4420,"enrollment":1617,"conditions":12699,"interventions":12700},"NCT00756860","A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®)",[89],[222],[12689,12701],"Renagel®",{"trials":12703,"activeCount":100},[12704],{"nctId":12705,"briefTitle":12706,"status":217,"phases":12707,"primaryCompletion":7853,"completion":2832,"start":2439,"enrollment":12708,"conditions":12709,"interventions":12711},"NCT00530114","Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia",[90],167,[6268,28,12710,383],"Hyperphosphatemic",[12689],{"trials":12713,"activeCount":100},[],{"trials":12715,"activeCount":100},[],{"trials":12717,"activeCount":100},[],{"intervention":2494,"totalTrials":204,"cells":12719},{"EARLY_PHASE1":12720,"PHASE1":12722,"PHASE2":12724,"PHASE3":12730,"PHASE4":12732,"NA":12734},{"trials":12721,"activeCount":100},[],{"trials":12723,"activeCount":100},[],{"trials":12725,"activeCount":100},[12726],{"nctId":2485,"briefTitle":2486,"status":217,"phases":12727,"primaryCompletion":2488,"completion":2488,"start":2489,"enrollment":2490,"conditions":12728,"interventions":12729},[90],[2492],[1322,2468,2494],{"trials":12731,"activeCount":100},[],{"trials":12733,"activeCount":100},[],{"trials":12735,"activeCount":100},[],{"intervention":12737,"totalTrials":204,"cells":12738},"AMG 317 75 mg",{"EARLY_PHASE1":12739,"PHASE1":12741,"PHASE2":12743,"PHASE3":12753,"PHASE4":12755,"NA":12757},{"trials":12740,"activeCount":100},[],{"trials":12742,"activeCount":100},[],{"trials":12744,"activeCount":100},[12745],{"nctId":12746,"briefTitle":12747,"status":217,"phases":12748,"primaryCompletion":2512,"completion":2832,"start":2601,"enrollment":10829,"conditions":12749,"interventions":12750},"NCT00436670","Phase II Study to Evaluate the Efficacy of AMG 317",[90],[2941],[12737,12751,12752],"AMG 317 150 mg","AMG 317 300 mg",{"trials":12754,"activeCount":100},[],{"trials":12756,"activeCount":100},[],{"trials":12758,"activeCount":100},[],{"intervention":12751,"totalTrials":204,"cells":12760},{"EARLY_PHASE1":12761,"PHASE1":12763,"PHASE2":12765,"PHASE3":12771,"PHASE4":12773,"NA":12775},{"trials":12762,"activeCount":100},[],{"trials":12764,"activeCount":100},[],{"trials":12766,"activeCount":100},[12767],{"nctId":12746,"briefTitle":12747,"status":217,"phases":12768,"primaryCompletion":2512,"completion":2832,"start":2601,"enrollment":10829,"conditions":12769,"interventions":12770},[90],[2941],[12737,12751,12752],{"trials":12772,"activeCount":100},[],{"trials":12774,"activeCount":100},[],{"trials":12776,"activeCount":100},[],{"intervention":12752,"totalTrials":204,"cells":12778},{"EARLY_PHASE1":12779,"PHASE1":12781,"PHASE2":12783,"PHASE3":12789,"PHASE4":12791,"NA":12793},{"trials":12780,"activeCount":100},[],{"trials":12782,"activeCount":100},[],{"trials":12784,"activeCount":100},[12785],{"nctId":12746,"briefTitle":12747,"status":217,"phases":12786,"primaryCompletion":2512,"completion":2832,"start":2601,"enrollment":10829,"conditions":12787,"interventions":12788},[90],[2941],[12737,12751,12752],{"trials":12790,"activeCount":100},[],{"trials":12792,"activeCount":100},[],{"trials":12794,"activeCount":100},[],{"intervention":5142,"totalTrials":204,"cells":12796},{"EARLY_PHASE1":12797,"PHASE1":12799,"PHASE2":12801,"PHASE3":12807,"PHASE4":12809,"NA":12811},{"trials":12798,"activeCount":100},[],{"trials":12800,"activeCount":100},[],{"trials":12802,"activeCount":100},[12803],{"nctId":5134,"briefTitle":5135,"status":336,"phases":12804,"primaryCompletion":2832,"completion":2803,"start":2833,"enrollment":5137,"conditions":12805,"interventions":12806},[90],[5139,5140,2794,3035],[5142,2616,2428,1280],{"trials":12808,"activeCount":100},[],{"trials":12810,"activeCount":100},[],{"trials":12812,"activeCount":100},[],{"intervention":8780,"totalTrials":204,"cells":12814},{"EARLY_PHASE1":12815,"PHASE1":12817,"PHASE2":12819,"PHASE3":12825,"PHASE4":12827,"NA":12829},{"trials":12816,"activeCount":100},[],{"trials":12818,"activeCount":100},[],{"trials":12820,"activeCount":100},[12821],{"nctId":8772,"briefTitle":8773,"status":336,"phases":12822,"primaryCompletion":8775,"completion":8776,"start":6620,"enrollment":8777,"conditions":12823,"interventions":12824},[90],[19],[8394,8780],{"trials":12826,"activeCount":100},[],{"trials":12828,"activeCount":100},[],{"trials":12830,"activeCount":100},[],{"intervention":2518,"totalTrials":204,"cells":12832},{"EARLY_PHASE1":12833,"PHASE1":12835,"PHASE2":12837,"PHASE3":12843,"PHASE4":12845,"NA":12847},{"trials":12834,"activeCount":100},[],{"trials":12836,"activeCount":100},[],{"trials":12838,"activeCount":100},[12839],{"nctId":2509,"briefTitle":2510,"status":217,"phases":12840,"primaryCompletion":1638,"completion":2512,"start":2473,"enrollment":2513,"conditions":12841,"interventions":12842},[90],[37,2515,2516,2425,34],[1322,2455,2429,2518,2519],{"trials":12844,"activeCount":100},[],{"trials":12846,"activeCount":100},[],{"trials":12848,"activeCount":100},[],{"intervention":2519,"totalTrials":204,"cells":12850},{"EARLY_PHASE1":12851,"PHASE1":12853,"PHASE2":12855,"PHASE3":12861,"PHASE4":12863,"NA":12865},{"trials":12852,"activeCount":100},[],{"trials":12854,"activeCount":100},[],{"trials":12856,"activeCount":100},[12857],{"nctId":2509,"briefTitle":2510,"status":217,"phases":12858,"primaryCompletion":1638,"completion":2512,"start":2473,"enrollment":2513,"conditions":12859,"interventions":12860},[90],[37,2515,2516,2425,34],[1322,2455,2429,2518,2519],{"trials":12862,"activeCount":100},[],{"trials":12864,"activeCount":100},[],{"trials":12866,"activeCount":100},[],{"intervention":12868,"totalTrials":204,"cells":12869},"Tezepelumab Dose 1",{"EARLY_PHASE1":12870,"PHASE1":12872,"PHASE2":12874,"PHASE3":12887,"PHASE4":12889,"NA":12891},{"trials":12871,"activeCount":100},[],{"trials":12873,"activeCount":100},[],{"trials":12875,"activeCount":100},[12876],{"nctId":12877,"briefTitle":12878,"status":217,"phases":12879,"primaryCompletion":6565,"completion":12880,"start":12881,"enrollment":11495,"conditions":12882,"interventions":12884},"NCT04833855","Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria",[90],"2023-04-13","2021-04-15",[12883],"Chronic Spontaneous Urticaria",[12868,12885,12886],"Tezepelumab Dose 2","Omalizumab",{"trials":12888,"activeCount":100},[],{"trials":12890,"activeCount":100},[],{"trials":12892,"activeCount":100},[],{"intervention":12885,"totalTrials":204,"cells":12894},{"EARLY_PHASE1":12895,"PHASE1":12897,"PHASE2":12899,"PHASE3":12905,"PHASE4":12907,"NA":12909},{"trials":12896,"activeCount":100},[],{"trials":12898,"activeCount":100},[],{"trials":12900,"activeCount":100},[12901],{"nctId":12877,"briefTitle":12878,"status":217,"phases":12902,"primaryCompletion":6565,"completion":12880,"start":12881,"enrollment":11495,"conditions":12903,"interventions":12904},[90],[12883],[12868,12885,12886],{"trials":12906,"activeCount":100},[],{"trials":12908,"activeCount":100},[],{"trials":12910,"activeCount":100},[],{"intervention":12886,"totalTrials":204,"cells":12912},{"EARLY_PHASE1":12913,"PHASE1":12915,"PHASE2":12917,"PHASE3":12923,"PHASE4":12925,"NA":12927},{"trials":12914,"activeCount":100},[],{"trials":12916,"activeCount":100},[],{"trials":12918,"activeCount":100},[12919],{"nctId":12877,"briefTitle":12878,"status":217,"phases":12920,"primaryCompletion":6565,"completion":12880,"start":12881,"enrollment":11495,"conditions":12921,"interventions":12922},[90],[12883],[12868,12885,12886],{"trials":12924,"activeCount":100},[],{"trials":12926,"activeCount":100},[],{"trials":12928,"activeCount":100},[],{"intervention":12930,"totalTrials":204,"cells":12931},"Intra-articular metHuIL-1ra",{"EARLY_PHASE1":12932,"PHASE1":12934,"PHASE2":12936,"PHASE3":12945,"PHASE4":12947,"NA":12949},{"trials":12933,"activeCount":100},[],{"trials":12935,"activeCount":100},[],{"trials":12937,"activeCount":100},[12938],{"nctId":12939,"briefTitle":12940,"status":217,"phases":12941,"primaryCompletion":12942,"completion":12942,"start":1567,"enrollment":4477,"conditions":12943,"interventions":12944},"NCT00110916","Treatment for Patients With Osteoarthritis (OA) of the Knee",[90],"2005-02",[8817],[12930],{"trials":12946,"activeCount":100},[],{"trials":12948,"activeCount":100},[],{"trials":12950,"activeCount":100},[],{"intervention":12952,"totalTrials":204,"cells":12953},"Systemic AMG 108",{"EARLY_PHASE1":12954,"PHASE1":12956,"PHASE2":12958,"PHASE3":12967,"PHASE4":12969,"NA":12971},{"trials":12955,"activeCount":100},[],{"trials":12957,"activeCount":100},[],{"trials":12959,"activeCount":100},[12960],{"nctId":12961,"briefTitle":12962,"status":217,"phases":12963,"primaryCompletion":12964,"completion":7626,"start":12942,"enrollment":579,"conditions":12965,"interventions":12966},"NCT00110942","Treatment for Patients With Osteoarthritis (OA)",[90],"2005-06",[8817],[12952],{"trials":12968,"activeCount":100},[],{"trials":12970,"activeCount":100},[],{"trials":12972,"activeCount":100},[],{"intervention":3053,"totalTrials":204,"cells":12974},{"EARLY_PHASE1":12975,"PHASE1":12977,"PHASE2":12979,"PHASE3":12985,"PHASE4":12987,"NA":12989},{"trials":12976,"activeCount":100},[],{"trials":12978,"activeCount":100},[],{"trials":12980,"activeCount":100},[12981],{"nctId":3044,"briefTitle":3045,"status":3046,"phases":12982,"start":3048,"conditions":12983,"interventions":12984},[90],[2463],[3051,3052,3053],{"trials":12986,"activeCount":100},[],{"trials":12988,"activeCount":100},[],{"trials":12990,"activeCount":100},[],{"intervention":3071,"totalTrials":204,"cells":12992},{"EARLY_PHASE1":12993,"PHASE1":12995,"PHASE2":12997,"PHASE3":13003,"PHASE4":13005,"NA":13007},{"trials":12994,"activeCount":100},[],{"trials":12996,"activeCount":100},[],{"trials":12998,"activeCount":100},[12999],{"nctId":3064,"briefTitle":3065,"status":3046,"phases":13000,"start":3048,"conditions":13001,"interventions":13002},[90],[3068,3069],[3051,3052,3071],{"trials":13004,"activeCount":100},[],{"trials":13006,"activeCount":100},[],{"trials":13008,"activeCount":100},[],{"intervention":13010,"totalTrials":204,"cells":13011},"Darbepoetin alfa SC",{"EARLY_PHASE1":13012,"PHASE1":13014,"PHASE2":13016,"PHASE3":13025,"PHASE4":13027,"NA":13029},{"trials":13013,"activeCount":100},[],{"trials":13015,"activeCount":100},[],{"trials":13017,"activeCount":100},[13018],{"nctId":13019,"briefTitle":13020,"status":217,"phases":13021,"primaryCompletion":6459,"completion":6429,"start":6422,"enrollment":4814,"conditions":13022,"interventions":13023},"NCT00035607","Chemotherapy Related Anemia",[90],[16,8969],[13010,13024],"Darbepoetin alfa IV",{"trials":13026,"activeCount":100},[],{"trials":13028,"activeCount":100},[],{"trials":13030,"activeCount":100},[],{"intervention":13024,"totalTrials":204,"cells":13032},{"EARLY_PHASE1":13033,"PHASE1":13035,"PHASE2":13037,"PHASE3":13043,"PHASE4":13045,"NA":13047},{"trials":13034,"activeCount":100},[],{"trials":13036,"activeCount":100},[],{"trials":13038,"activeCount":100},[13039],{"nctId":13019,"briefTitle":13020,"status":217,"phases":13040,"primaryCompletion":6459,"completion":6429,"start":6422,"enrollment":4814,"conditions":13041,"interventions":13042},[90],[16,8969],[13010,13024],{"trials":13044,"activeCount":100},[],{"trials":13046,"activeCount":100},[],{"trials":13048,"activeCount":100},[],{"intervention":13050,"totalTrials":204,"cells":13051},"AMG 114",{"EARLY_PHASE1":13052,"PHASE1":13054,"PHASE2":13056,"PHASE3":13064,"PHASE4":13066,"NA":13068},{"trials":13053,"activeCount":100},[],{"trials":13055,"activeCount":100},[],{"trials":13057,"activeCount":100},[13058],{"nctId":13059,"briefTitle":13060,"status":336,"phases":13061,"conditions":13062,"interventions":13063},"NCT00119600","A Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy",[89,90],[16,25],[13050],{"trials":13065,"activeCount":100},[],{"trials":13067,"activeCount":100},[],{"trials":13069,"activeCount":100},[],{"intervention":13071,"totalTrials":204,"cells":13072},"epratuzumab",{"EARLY_PHASE1":13073,"PHASE1":13075,"PHASE2":13077,"PHASE3":13085,"PHASE4":13087,"NA":13089},{"trials":13074,"activeCount":100},[],{"trials":13076,"activeCount":100},[],{"trials":13078,"activeCount":100},[13079],{"nctId":13080,"briefTitle":13081,"status":217,"phases":13082,"conditions":13083,"interventions":13084},"NCT00044902","Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)",[90],[1584],[13071],{"trials":13086,"activeCount":100},[],{"trials":13088,"activeCount":100},[],{"trials":13090,"activeCount":100},[],{"intervention":6031,"totalTrials":204,"cells":13092},{"EARLY_PHASE1":13093,"PHASE1":13095,"PHASE2":13097,"PHASE3":13103,"PHASE4":13105,"NA":13107},{"trials":13094,"activeCount":100},[],{"trials":13096,"activeCount":100},[],{"trials":13098,"activeCount":100},[13099],{"nctId":6022,"briefTitle":6023,"status":217,"phases":13100,"primaryCompletion":6025,"completion":6026,"start":6027,"enrollment":6028,"conditions":13101,"interventions":13102},[90],[4039],[5940,6031,6032],{"trials":13104,"activeCount":100},[],{"trials":13106,"activeCount":100},[],{"trials":13108,"activeCount":100},[],{"intervention":6032,"totalTrials":204,"cells":13110},{"EARLY_PHASE1":13111,"PHASE1":13113,"PHASE2":13115,"PHASE3":13121,"PHASE4":13123,"NA":13125},{"trials":13112,"activeCount":100},[],{"trials":13114,"activeCount":100},[],{"trials":13116,"activeCount":100},[13117],{"nctId":6022,"briefTitle":6023,"status":217,"phases":13118,"primaryCompletion":6025,"completion":6026,"start":6027,"enrollment":6028,"conditions":13119,"interventions":13120},[90],[4039],[5940,6031,6032],{"trials":13122,"activeCount":100},[],{"trials":13124,"activeCount":100},[],{"trials":13126,"activeCount":100},[],{"intervention":1655,"totalTrials":204,"cells":13128},{"EARLY_PHASE1":13129,"PHASE1":13131,"PHASE2":13133,"PHASE3":13139,"PHASE4":13141,"NA":13143},{"trials":13130,"activeCount":100},[],{"trials":13132,"activeCount":100},[],{"trials":13134,"activeCount":100},[13135],{"nctId":1646,"briefTitle":1647,"status":217,"phases":13136,"primaryCompletion":1649,"completion":1650,"start":608,"enrollment":1651,"conditions":13137,"interventions":13138},[90],[1653],[117,1655,1656],{"trials":13140,"activeCount":100},[],{"trials":13142,"activeCount":100},[],{"trials":13144,"activeCount":100},[],{"intervention":13146,"totalTrials":204,"cells":13147},"AMG 719",{"EARLY_PHASE1":13148,"PHASE1":13150,"PHASE2":13152,"PHASE3":13162,"PHASE4":13164,"NA":13166},{"trials":13149,"activeCount":100},[],{"trials":13151,"activeCount":100},[],{"trials":13153,"activeCount":100},[13154],{"nctId":13155,"briefTitle":13156,"status":217,"phases":13157,"primaryCompletion":7732,"completion":7732,"start":13158,"enrollment":2500,"conditions":13159,"interventions":13160},"NCT00038298","A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate",[90],"2002-04",[19],[13146,13161,13146],"AGM 719",{"trials":13163,"activeCount":100},[],{"trials":13165,"activeCount":100},[],{"trials":13167,"activeCount":100},[],{"intervention":13161,"totalTrials":204,"cells":13169},{"EARLY_PHASE1":13170,"PHASE1":13172,"PHASE2":13174,"PHASE3":13180,"PHASE4":13182,"NA":13184},{"trials":13171,"activeCount":100},[],{"trials":13173,"activeCount":100},[],{"trials":13175,"activeCount":100},[13176],{"nctId":13155,"briefTitle":13156,"status":217,"phases":13177,"primaryCompletion":7732,"completion":7732,"start":13158,"enrollment":2500,"conditions":13178,"interventions":13179},[90],[19],[13146,13161,13146],{"trials":13181,"activeCount":100},[],{"trials":13183,"activeCount":100},[],{"trials":13185,"activeCount":100},[],{"intervention":13187,"totalTrials":204,"cells":13188},"AMG 745 0.3 mg\u002Fkg",{"EARLY_PHASE1":13189,"PHASE1":13191,"PHASE2":13193,"PHASE3":13204,"PHASE4":13206,"NA":13208},{"trials":13190,"activeCount":100},[],{"trials":13192,"activeCount":100},[],{"trials":13194,"activeCount":100},[13195],{"nctId":13196,"briefTitle":13197,"status":131,"phases":13198,"primaryCompletion":6776,"completion":1565,"start":2421,"enrollment":100,"conditions":13199,"interventions":13201},"NCT00975104","AMG 745 in Subjects With Age-associated Muscle Loss",[90],[13200],"Age-associated Muscle Loss",[13187,13202,13203],"AMG 745 1.0 mg\u002Fkg","AMG 745 3.0 mg\u002Fkg",{"trials":13205,"activeCount":100},[],{"trials":13207,"activeCount":100},[],{"trials":13209,"activeCount":100},[],{"intervention":13202,"totalTrials":204,"cells":13211},{"EARLY_PHASE1":13212,"PHASE1":13214,"PHASE2":13216,"PHASE3":13222,"PHASE4":13224,"NA":13226},{"trials":13213,"activeCount":100},[],{"trials":13215,"activeCount":100},[],{"trials":13217,"activeCount":100},[13218],{"nctId":13196,"briefTitle":13197,"status":131,"phases":13219,"primaryCompletion":6776,"completion":1565,"start":2421,"enrollment":100,"conditions":13220,"interventions":13221},[90],[13200],[13187,13202,13203],{"trials":13223,"activeCount":100},[],{"trials":13225,"activeCount":100},[],{"trials":13227,"activeCount":100},[],{"intervention":13203,"totalTrials":204,"cells":13229},{"EARLY_PHASE1":13230,"PHASE1":13232,"PHASE2":13234,"PHASE3":13240,"PHASE4":13242,"NA":13244},{"trials":13231,"activeCount":100},[],{"trials":13233,"activeCount":100},[],{"trials":13235,"activeCount":100},[13236],{"nctId":13196,"briefTitle":13197,"status":131,"phases":13237,"primaryCompletion":6776,"completion":1565,"start":2421,"enrollment":100,"conditions":13238,"interventions":13239},[90],[13200],[13187,13202,13203],{"trials":13241,"activeCount":100},[],{"trials":13243,"activeCount":100},[],{"trials":13245,"activeCount":100},[],{"intervention":140,"totalTrials":204,"cells":13247},{"EARLY_PHASE1":13248,"PHASE1":13250,"PHASE2":13252,"PHASE3":13258,"PHASE4":13260,"NA":13262},{"trials":13249,"activeCount":100},[],{"trials":13251,"activeCount":100},[],{"trials":13253,"activeCount":100},[13254],{"nctId":129,"briefTitle":130,"status":131,"phases":13255,"primaryCompletion":133,"completion":134,"start":135,"enrollment":100,"conditions":13256,"interventions":13257},[90],[137],[48,139,140],{"trials":13259,"activeCount":100},[],{"trials":13261,"activeCount":100},[],{"trials":13263,"activeCount":100},[],{"intervention":13265,"totalTrials":204,"cells":13266},"Previous denosumab",{"EARLY_PHASE1":13267,"PHASE1":13269,"PHASE2":13271,"PHASE3":13279,"PHASE4":13281,"NA":13283},{"trials":13268,"activeCount":100},[],{"trials":13270,"activeCount":100},[],{"trials":13272,"activeCount":100},[13273],{"nctId":13274,"briefTitle":13275,"status":217,"phases":13276,"primaryCompletion":2452,"completion":5151,"start":8349,"enrollment":124,"conditions":13277,"interventions":13278},"NCT00887965","A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab",[90],[9729,3665,493,3666],[13265],{"trials":13280,"activeCount":100},[],{"trials":13282,"activeCount":100},[],{"trials":13284,"activeCount":100},[],{"intervention":13286,"totalTrials":204,"cells":13287},"CCX-354-C",{"EARLY_PHASE1":13288,"PHASE1":13290,"PHASE2":13292,"PHASE3":13301,"PHASE4":13303,"NA":13305},{"trials":13289,"activeCount":100},[],{"trials":13291,"activeCount":100},[],{"trials":13293,"activeCount":100},[13294],{"nctId":13295,"briefTitle":13296,"status":217,"phases":13297,"primaryCompletion":4932,"completion":4932,"start":5352,"enrollment":11436,"conditions":13298,"interventions":13299},"NCT01242917","A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy",[90],[19],[13286,13300],"CCX354-C",{"trials":13302,"activeCount":100},[],{"trials":13304,"activeCount":100},[],{"trials":13306,"activeCount":100},[],{"intervention":13300,"totalTrials":204,"cells":13308},{"EARLY_PHASE1":13309,"PHASE1":13311,"PHASE2":13313,"PHASE3":13319,"PHASE4":13321,"NA":13323},{"trials":13310,"activeCount":100},[],{"trials":13312,"activeCount":100},[],{"trials":13314,"activeCount":100},[13315],{"nctId":13295,"briefTitle":13296,"status":217,"phases":13316,"primaryCompletion":4932,"completion":4932,"start":5352,"enrollment":11436,"conditions":13317,"interventions":13318},[90],[19],[13286,13300],{"trials":13320,"activeCount":100},[],{"trials":13322,"activeCount":100},[],{"trials":13324,"activeCount":100},[],{"intervention":12304,"totalTrials":204,"cells":13326},{"EARLY_PHASE1":13327,"PHASE1":13329,"PHASE2":13331,"PHASE3":13337,"PHASE4":13339,"NA":13341},{"trials":13328,"activeCount":100},[],{"trials":13330,"activeCount":100},[],{"trials":13332,"activeCount":100},[13333],{"nctId":12296,"briefTitle":12297,"status":217,"phases":13334,"primaryCompletion":12299,"completion":7444,"start":12300,"enrollment":12301,"conditions":13335,"interventions":13336},[90],[2572],[7577,12304],{"trials":13338,"activeCount":100},[],{"trials":13340,"activeCount":100},[],{"trials":13342,"activeCount":100},[],{"intervention":4010,"totalTrials":204,"cells":13344},{"EARLY_PHASE1":13345,"PHASE1":13347,"PHASE2":13349,"PHASE3":13355,"PHASE4":13357,"NA":13359},{"trials":13346,"activeCount":100},[],{"trials":13348,"activeCount":100},[],{"trials":13350,"activeCount":100},[13351],{"nctId":4001,"briefTitle":4002,"status":217,"phases":13352,"primaryCompletion":4004,"completion":4004,"start":4005,"enrollment":4006,"conditions":13353,"interventions":13354},[90],[4008],[4010,4011,4012,3184],{"trials":13356,"activeCount":100},[],{"trials":13358,"activeCount":100},[],{"trials":13360,"activeCount":100},[],{"intervention":4011,"totalTrials":204,"cells":13362},{"EARLY_PHASE1":13363,"PHASE1":13365,"PHASE2":13367,"PHASE3":13373,"PHASE4":13375,"NA":13377},{"trials":13364,"activeCount":100},[],{"trials":13366,"activeCount":100},[],{"trials":13368,"activeCount":100},[13369],{"nctId":4001,"briefTitle":4002,"status":217,"phases":13370,"primaryCompletion":4004,"completion":4004,"start":4005,"enrollment":4006,"conditions":13371,"interventions":13372},[90],[4008],[4010,4011,4012,3184],{"trials":13374,"activeCount":100},[],{"trials":13376,"activeCount":100},[],{"trials":13378,"activeCount":100},[],{"intervention":4395,"totalTrials":204,"cells":13380},{"EARLY_PHASE1":13381,"PHASE1":13383,"PHASE2":13385,"PHASE3":13391,"PHASE4":13393,"NA":13395},{"trials":13382,"activeCount":100},[],{"trials":13384,"activeCount":100},[],{"trials":13386,"activeCount":100},[13387],{"nctId":4388,"briefTitle":4389,"status":131,"phases":13388,"primaryCompletion":3225,"completion":3225,"start":4391,"enrollment":100,"conditions":13389,"interventions":13390},[90],[4393],[2840,4395,4396],{"trials":13392,"activeCount":100},[],{"trials":13394,"activeCount":100},[],{"trials":13396,"activeCount":100},[],{"intervention":4396,"totalTrials":204,"cells":13398},{"EARLY_PHASE1":13399,"PHASE1":13401,"PHASE2":13403,"PHASE3":13409,"PHASE4":13411,"NA":13413},{"trials":13400,"activeCount":100},[],{"trials":13402,"activeCount":100},[],{"trials":13404,"activeCount":100},[13405],{"nctId":4388,"briefTitle":4389,"status":131,"phases":13406,"primaryCompletion":3225,"completion":3225,"start":4391,"enrollment":100,"conditions":13407,"interventions":13408},[90],[4393],[2840,4395,4396],{"trials":13410,"activeCount":100},[],{"trials":13412,"activeCount":100},[],{"trials":13414,"activeCount":100},[],{"intervention":13416,"totalTrials":204,"cells":13417},"Antizol",{"EARLY_PHASE1":13418,"PHASE1":13420,"PHASE2":13422,"PHASE3":13431,"PHASE4":13433,"NA":13435},{"trials":13419,"activeCount":100},[],{"trials":13421,"activeCount":100},[],{"trials":13423,"activeCount":100},[13424],{"nctId":13425,"briefTitle":13426,"status":217,"phases":13427,"primaryCompletion":3870,"completion":3870,"start":2461,"enrollment":26,"conditions":13428,"interventions":13430},"NCT00661141","Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism",[90],[13429],"Aldehyde Dehydrogenase-2 (ALDH2) Deficiency",[13416],{"trials":13432,"activeCount":100},[],{"trials":13434,"activeCount":100},[],{"trials":13436,"activeCount":100},[],{"intervention":8010,"totalTrials":204,"cells":13438},{"EARLY_PHASE1":13439,"PHASE1":13441,"PHASE2":13443,"PHASE3":13449,"PHASE4":13451,"NA":13453},{"trials":13440,"activeCount":100},[],{"trials":13442,"activeCount":100},[],{"trials":13444,"activeCount":100},[13445],{"nctId":8002,"briefTitle":8003,"status":3046,"phases":13446,"start":8005,"conditions":13447,"interventions":13448},[90],[7438],[3051,8008,3061,3062,8009,8010],{"trials":13450,"activeCount":100},[],{"trials":13452,"activeCount":100},[],{"trials":13454,"activeCount":100},[],{"intervention":13456,"totalTrials":204,"cells":13457},"100 mg AMG 162",{"EARLY_PHASE1":13458,"PHASE1":13460,"PHASE2":13462,"PHASE3":13473,"PHASE4":13475,"NA":13477},{"trials":13459,"activeCount":100},[],{"trials":13461,"activeCount":100},[],{"trials":13463,"activeCount":100},[13464],{"nctId":13465,"briefTitle":13466,"status":217,"phases":13467,"primaryCompletion":2460,"completion":2594,"start":13468,"enrollment":1262,"conditions":13469,"interventions":13470},"NCT00306189","A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects",[90],"2006-01",[493],[13456,13471,13472],"60 mg AMG 162","14 mg AMG 162",{"trials":13474,"activeCount":100},[],{"trials":13476,"activeCount":100},[],{"trials":13478,"activeCount":100},[],{"intervention":13471,"totalTrials":204,"cells":13480},{"EARLY_PHASE1":13481,"PHASE1":13483,"PHASE2":13485,"PHASE3":13491,"PHASE4":13493,"NA":13495},{"trials":13482,"activeCount":100},[],{"trials":13484,"activeCount":100},[],{"trials":13486,"activeCount":100},[13487],{"nctId":13465,"briefTitle":13466,"status":217,"phases":13488,"primaryCompletion":2460,"completion":2594,"start":13468,"enrollment":1262,"conditions":13489,"interventions":13490},[90],[493],[13456,13471,13472],{"trials":13492,"activeCount":100},[],{"trials":13494,"activeCount":100},[],{"trials":13496,"activeCount":100},[],{"intervention":13472,"totalTrials":204,"cells":13498},{"EARLY_PHASE1":13499,"PHASE1":13501,"PHASE2":13503,"PHASE3":13509,"PHASE4":13511,"NA":13513},{"trials":13500,"activeCount":100},[],{"trials":13502,"activeCount":100},[],{"trials":13504,"activeCount":100},[13505],{"nctId":13465,"briefTitle":13466,"status":217,"phases":13506,"primaryCompletion":2460,"completion":2594,"start":13468,"enrollment":1262,"conditions":13507,"interventions":13508},[90],[493],[13456,13471,13472],{"trials":13510,"activeCount":100},[],{"trials":13512,"activeCount":100},[],{"trials":13514,"activeCount":100},[],{"intervention":13516,"totalTrials":204,"cells":13517},"Lodotra",{"EARLY_PHASE1":13518,"PHASE1":13520,"PHASE2":13522,"PHASE3":13531,"PHASE4":13533,"NA":13535},{"trials":13519,"activeCount":100},[],{"trials":13521,"activeCount":100},[],{"trials":13523,"activeCount":100},[13524],{"nctId":13525,"briefTitle":13526,"status":217,"phases":13527,"primaryCompletion":6155,"completion":5353,"start":3870,"enrollment":2895,"conditions":13528,"interventions":13529},"NCT00686335","A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma",[90],[2941],[13516,13530],"Cortancyl",{"trials":13532,"activeCount":100},[],{"trials":13534,"activeCount":100},[],{"trials":13536,"activeCount":100},[],{"intervention":13530,"totalTrials":204,"cells":13538},{"EARLY_PHASE1":13539,"PHASE1":13541,"PHASE2":13543,"PHASE3":13549,"PHASE4":13551,"NA":13553},{"trials":13540,"activeCount":100},[],{"trials":13542,"activeCount":100},[],{"trials":13544,"activeCount":100},[13545],{"nctId":13525,"briefTitle":13526,"status":217,"phases":13546,"primaryCompletion":6155,"completion":5353,"start":3870,"enrollment":2895,"conditions":13547,"interventions":13548},[90],[2941],[13516,13530],{"trials":13550,"activeCount":100},[],{"trials":13552,"activeCount":100},[],{"trials":13554,"activeCount":100},[],{"intervention":13556,"totalTrials":204,"cells":13557},"Ipilimumab",{"EARLY_PHASE1":13558,"PHASE1":13560,"PHASE2":13562,"PHASE3":13571,"PHASE4":13573,"NA":13575},{"trials":13559,"activeCount":100},[],{"trials":13561,"activeCount":100},[],{"trials":13563,"activeCount":100},[13564],{"nctId":13565,"briefTitle":13566,"status":217,"phases":13567,"primaryCompletion":13568,"completion":264,"start":600,"enrollment":7285,"conditions":13569,"interventions":13570},"NCT01740297","Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma",[89,90],"2016-08-23",[1402],[1404,13556],{"trials":13572,"activeCount":100},[],{"trials":13574,"activeCount":100},[],{"trials":13576,"activeCount":100},[],{"intervention":344,"totalTrials":204,"cells":13578},{"EARLY_PHASE1":13579,"PHASE1":13581,"PHASE2":13583,"PHASE3":13589,"PHASE4":13591,"NA":13593},{"trials":13580,"activeCount":100},[],{"trials":13582,"activeCount":100},[],{"trials":13584,"activeCount":100},[13585],{"nctId":334,"briefTitle":335,"status":336,"phases":13586,"primaryCompletion":338,"completion":338,"start":339,"enrollment":340,"conditions":13587,"interventions":13588},[90],[28,342],[344,321],{"trials":13590,"activeCount":100},[],{"trials":13592,"activeCount":100},[],{"trials":13594,"activeCount":100},[],{"intervention":13596,"totalTrials":204,"cells":13597},"CCX 354-C",{"EARLY_PHASE1":13598,"PHASE1":13600,"PHASE2":13602,"PHASE3":13610,"PHASE4":13612,"NA":13614},{"trials":13599,"activeCount":100},[],{"trials":13601,"activeCount":100},[],{"trials":13603,"activeCount":100},[13604],{"nctId":13605,"briefTitle":13606,"status":217,"phases":13607,"primaryCompletion":11619,"completion":11619,"start":6163,"enrollment":253,"conditions":13608,"interventions":13609},"NCT01027728","Study to Evaluate Safety and Efficacy of CCX 354-C in Subjects With Rheumatoid Arthritis",[89,90],[19],[13596],{"trials":13611,"activeCount":100},[],{"trials":13613,"activeCount":100},[],{"trials":13615,"activeCount":100},[],{"intervention":4714,"totalTrials":204,"cells":13617},{"EARLY_PHASE1":13618,"PHASE1":13620,"PHASE2":13622,"PHASE3":13628,"PHASE4":13630,"NA":13632},{"trials":13619,"activeCount":100},[],{"trials":13621,"activeCount":100},[],{"trials":13623,"activeCount":100},[13624],{"nctId":4703,"briefTitle":4704,"status":217,"phases":13625,"primaryCompletion":2882,"completion":4706,"start":4707,"enrollment":4708,"conditions":13626,"interventions":13627},[90],[4710,4711],[4713,4714],{"trials":13629,"activeCount":100},[],{"trials":13631,"activeCount":100},[],{"trials":13633,"activeCount":100},[],{"intervention":6474,"totalTrials":204,"cells":13635},{"EARLY_PHASE1":13636,"PHASE1":13638,"PHASE2":13640,"PHASE3":13646,"PHASE4":13648,"NA":13650},{"trials":13637,"activeCount":100},[],{"trials":13639,"activeCount":100},[],{"trials":13641,"activeCount":100},[13642],{"nctId":6466,"briefTitle":6467,"status":336,"phases":13643,"primaryCompletion":6421,"completion":6469,"start":6470,"enrollment":6471,"conditions":13644,"interventions":13645},[90],[19],[6463,6474],{"trials":13647,"activeCount":100},[],{"trials":13649,"activeCount":100},[],{"trials":13651,"activeCount":100},[],{"intervention":2605,"totalTrials":204,"cells":13653},{"EARLY_PHASE1":13654,"PHASE1":13656,"PHASE2":13658,"PHASE3":13664,"PHASE4":13666,"NA":13668},{"trials":13655,"activeCount":100},[],{"trials":13657,"activeCount":100},[],{"trials":13659,"activeCount":100},[13660],{"nctId":2598,"briefTitle":2599,"status":217,"phases":13661,"primaryCompletion":2601,"completion":2601,"start":2602,"enrollment":2257,"conditions":13662,"interventions":13663},[89,90],[2463,1971],[1322,2605,1280,1109],{"trials":13665,"activeCount":100},[],{"trials":13667,"activeCount":100},[],{"trials":13669,"activeCount":100},[],{"intervention":13671,"totalTrials":204,"cells":13672},"CCX168 10 mg, twice daily, plus cyclophosphamide\u002Frituximab plus glucocorticoids",{"EARLY_PHASE1":13673,"PHASE1":13675,"PHASE2":13677,"PHASE3":13689,"PHASE4":13691,"NA":13693},{"trials":13674,"activeCount":100},[],{"trials":13676,"activeCount":100},[],{"trials":13678,"activeCount":100},[13679],{"nctId":13680,"briefTitle":13681,"status":217,"phases":13682,"primaryCompletion":13683,"completion":6329,"start":13684,"enrollment":1916,"conditions":13685,"interventions":13687},"NCT02222155","Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis",[90],"2016-04-24","2015-02-04",[13686],"ANCA-associated Vasculitis",[13671,13688],"CCX168 30 mg, twice daily, cyclophosphamide\u002Frituximab plus glucocorticoids",{"trials":13690,"activeCount":100},[],{"trials":13692,"activeCount":100},[],{"trials":13694,"activeCount":100},[],{"intervention":13688,"totalTrials":204,"cells":13696},{"EARLY_PHASE1":13697,"PHASE1":13699,"PHASE2":13701,"PHASE3":13707,"PHASE4":13709,"NA":13711},{"trials":13698,"activeCount":100},[],{"trials":13700,"activeCount":100},[],{"trials":13702,"activeCount":100},[13703],{"nctId":13680,"briefTitle":13681,"status":217,"phases":13704,"primaryCompletion":13683,"completion":6329,"start":13684,"enrollment":1916,"conditions":13705,"interventions":13706},[90],[13686],[13671,13688],{"trials":13708,"activeCount":100},[],{"trials":13710,"activeCount":100},[],{"trials":13712,"activeCount":100},[],{"intervention":13714,"totalTrials":204,"cells":13715},"HZN-825 BID",{"EARLY_PHASE1":13716,"PHASE1":13718,"PHASE2":13720,"PHASE3":13731,"PHASE4":13733,"NA":13735},{"trials":13717,"activeCount":100},[],{"trials":13719,"activeCount":100},[],{"trials":13721,"activeCount":100},[13722],{"nctId":13723,"briefTitle":13724,"status":336,"phases":13725,"primaryCompletion":12545,"completion":12545,"start":13726,"enrollment":13727,"conditions":13728,"interventions":13729},"NCT04781543","A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis",[90],"2021-11-05",301,[6528,12548],[13714,13730],"HZN-825 QD",{"trials":13732,"activeCount":100},[],{"trials":13734,"activeCount":100},[],{"trials":13736,"activeCount":100},[],{"intervention":13730,"totalTrials":204,"cells":13738},{"EARLY_PHASE1":13739,"PHASE1":13741,"PHASE2":13743,"PHASE3":13749,"PHASE4":13751,"NA":13753},{"trials":13740,"activeCount":100},[],{"trials":13742,"activeCount":100},[],{"trials":13744,"activeCount":100},[13745],{"nctId":13723,"briefTitle":13724,"status":336,"phases":13746,"primaryCompletion":12545,"completion":12545,"start":13726,"enrollment":13727,"conditions":13747,"interventions":13748},[90],[6528,12548],[13714,13730],{"trials":13750,"activeCount":100},[],{"trials":13752,"activeCount":100},[],{"trials":13754,"activeCount":100},[],{"intervention":13756,"totalTrials":204,"cells":13757},"HZN-1116",{"EARLY_PHASE1":13758,"PHASE1":13760,"PHASE2":13762,"PHASE3":13772,"PHASE4":13774,"NA":13776},{"trials":13759,"activeCount":100},[],{"trials":13761,"activeCount":100},[],{"trials":13763,"activeCount":100},[13764],{"nctId":13765,"briefTitle":13766,"status":336,"phases":13767,"primaryCompletion":1466,"completion":1466,"start":13768,"enrollment":13769,"conditions":13770,"interventions":13771},"NCT06312020","A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome",[90],"2024-05-09",209,[3218],[13756],{"trials":13773,"activeCount":100},[],{"trials":13775,"activeCount":100},[],{"trials":13777,"activeCount":100},[],{"intervention":7932,"totalTrials":204,"cells":13779},{"EARLY_PHASE1":13780,"PHASE1":13782,"PHASE2":13784,"PHASE3":13790,"PHASE4":13792,"NA":13794},{"trials":13781,"activeCount":100},[],{"trials":13783,"activeCount":100},[],{"trials":13785,"activeCount":100},[13786],{"nctId":7926,"briefTitle":7927,"status":217,"phases":13787,"primaryCompletion":6155,"completion":7852,"start":6743,"enrollment":5239,"conditions":13788,"interventions":13789},[90],[7613],[7931,7932,7933,2468,7934,2468,7934,2468,7934],{"trials":13791,"activeCount":100},[],{"trials":13793,"activeCount":100},[],{"trials":13795,"activeCount":100},[],{"intervention":7933,"totalTrials":204,"cells":13797},{"EARLY_PHASE1":13798,"PHASE1":13800,"PHASE2":13802,"PHASE3":13808,"PHASE4":13810,"NA":13812},{"trials":13799,"activeCount":100},[],{"trials":13801,"activeCount":100},[],{"trials":13803,"activeCount":100},[13804],{"nctId":7926,"briefTitle":7927,"status":217,"phases":13805,"primaryCompletion":6155,"completion":7852,"start":6743,"enrollment":5239,"conditions":13806,"interventions":13807},[90],[7613],[7931,7932,7933,2468,7934,2468,7934,2468,7934],{"trials":13809,"activeCount":100},[],{"trials":13811,"activeCount":100},[],{"trials":13813,"activeCount":100},[],{"intervention":6176,"totalTrials":204,"cells":13815},{"EARLY_PHASE1":13816,"PHASE1":13818,"PHASE2":13820,"PHASE3":13826,"PHASE4":13828,"NA":13830},{"trials":13817,"activeCount":100},[],{"trials":13819,"activeCount":100},[],{"trials":13821,"activeCount":100},[13822],{"nctId":6169,"briefTitle":6170,"status":217,"phases":13823,"primaryCompletion":6172,"completion":2541,"start":6173,"enrollment":1907,"conditions":13824,"interventions":13825},[90],[6132],[5358,6176],{"trials":13827,"activeCount":100},[],{"trials":13829,"activeCount":100},[],{"trials":13831,"activeCount":100},[],{"intervention":2817,"totalTrials":204,"cells":13833},{"EARLY_PHASE1":13834,"PHASE1":13836,"PHASE2":13838,"PHASE3":13844,"PHASE4":13846,"NA":13848},{"trials":13835,"activeCount":100},[],{"trials":13837,"activeCount":100},[],{"trials":13839,"activeCount":100},[13840],{"nctId":2810,"briefTitle":2811,"status":217,"phases":13841,"primaryCompletion":2451,"completion":2733,"start":2813,"enrollment":2814,"conditions":13842,"interventions":13843},[90],[1971],[2817,2616,1109,1280],{"trials":13845,"activeCount":100},[],{"trials":13847,"activeCount":100},[],{"trials":13849,"activeCount":100},[],{"intervention":13851,"totalTrials":204,"cells":13852},"CC10004",{"EARLY_PHASE1":13853,"PHASE1":13855,"PHASE2":13857,"PHASE3":13868,"PHASE4":13870,"NA":13872},{"trials":13854,"activeCount":100},[],{"trials":13856,"activeCount":100},[],{"trials":13858,"activeCount":100},[13859],{"nctId":13860,"briefTitle":13861,"status":217,"phases":13862,"primaryCompletion":13863,"completion":13864,"start":13865,"enrollment":11519,"conditions":13866,"interventions":13867},"NCT00604682","Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis",[90],"2005-10-01","2005-12-01","2005-01-01",[22],[13851],{"trials":13869,"activeCount":100},[],{"trials":13871,"activeCount":100},[],{"trials":13873,"activeCount":100},[],{"intervention":13875,"totalTrials":204,"cells":13876},"sodium phenylacetate and sodium benzoate injection 10% \u002F 10%",{"EARLY_PHASE1":13877,"PHASE1":13879,"PHASE2":13881,"PHASE3":13889,"PHASE4":13891,"NA":13893},{"trials":13878,"activeCount":100},[],{"trials":13880,"activeCount":100},[],{"trials":13882,"activeCount":100},[13883],{"nctId":13884,"briefTitle":13885,"status":336,"phases":13886,"primaryCompletion":2512,"completion":2512,"start":6743,"enrollment":204,"conditions":13887,"interventions":13888},"NCT00597909","Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy",[90],[6131],[13875,13875],{"trials":13890,"activeCount":100},[],{"trials":13892,"activeCount":100},[],{"trials":13894,"activeCount":100},[],{"intervention":13896,"totalTrials":204,"cells":13897},"Brodalumab 210 mg",{"EARLY_PHASE1":13898,"PHASE1":13900,"PHASE2":13902,"PHASE3":13912,"PHASE4":13914,"NA":13916},{"trials":13899,"activeCount":100},[],{"trials":13901,"activeCount":100},[],{"trials":13903,"activeCount":100},[13904],{"nctId":13905,"briefTitle":13906,"status":131,"phases":13907,"primaryCompletion":13908,"completion":13908,"start":13908,"enrollment":100,"conditions":13909,"interventions":13911},"NCT02429882","Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis",[90],"2015-05",[13910],"Axial Spondyloarthritis",[13896],{"trials":13913,"activeCount":100},[],{"trials":13915,"activeCount":100},[],{"trials":13917,"activeCount":100},[],{"intervention":6717,"totalTrials":204,"cells":13919},{"EARLY_PHASE1":13920,"PHASE1":13922,"PHASE2":13924,"PHASE3":13930,"PHASE4":13932,"NA":13934},{"trials":13921,"activeCount":100},[],{"trials":13923,"activeCount":100},[],{"trials":13925,"activeCount":100},[13926],{"nctId":6705,"briefTitle":6706,"status":217,"phases":13927,"primaryCompletion":6708,"completion":6709,"start":6710,"enrollment":32,"conditions":13928,"interventions":13929},[90],[6712,6713,6714,6715],[6717,139,6718,6719],{"trials":13931,"activeCount":100},[],{"trials":13933,"activeCount":100},[],{"trials":13935,"activeCount":100},[],{"intervention":6718,"totalTrials":204,"cells":13937},{"EARLY_PHASE1":13938,"PHASE1":13940,"PHASE2":13942,"PHASE3":13948,"PHASE4":13950,"NA":13952},{"trials":13939,"activeCount":100},[],{"trials":13941,"activeCount":100},[],{"trials":13943,"activeCount":100},[13944],{"nctId":6705,"briefTitle":6706,"status":217,"phases":13945,"primaryCompletion":6708,"completion":6709,"start":6710,"enrollment":32,"conditions":13946,"interventions":13947},[90],[6712,6713,6714,6715],[6717,139,6718,6719],{"trials":13949,"activeCount":100},[],{"trials":13951,"activeCount":100},[],{"trials":13953,"activeCount":100},[],{"intervention":8393,"totalTrials":204,"cells":13955},{"EARLY_PHASE1":13956,"PHASE1":13958,"PHASE2":13960,"PHASE3":13966,"PHASE4":13968,"NA":13970},{"trials":13957,"activeCount":100},[],{"trials":13959,"activeCount":100},[],{"trials":13961,"activeCount":100},[13962],{"nctId":8385,"briefTitle":8386,"status":217,"phases":13963,"primaryCompletion":2096,"completion":1734,"start":8388,"enrollment":8389,"conditions":13964,"interventions":13965},[90],[22,8391],[8393,8376,8394,8395,8376],{"trials":13967,"activeCount":100},[],{"trials":13969,"activeCount":100},[],{"trials":13971,"activeCount":100},[],{"intervention":13973,"totalTrials":204,"cells":13974},"Adecatumumab",{"EARLY_PHASE1":13975,"PHASE1":13977,"PHASE2":13979,"PHASE3":13989,"PHASE4":13991,"NA":13993},{"trials":13976,"activeCount":100},[],{"trials":13978,"activeCount":100},[],{"trials":13980,"activeCount":100},[13981],{"nctId":13982,"briefTitle":13983,"status":217,"phases":13984,"primaryCompletion":4932,"completion":2733,"start":2451,"enrollment":1582,"conditions":13985,"interventions":13986},"NCT00866944","Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases",[90],[1390,34],[13973,13987,13988],"Adecatumumab and FOLFOX","FOLFOX 4",{"trials":13990,"activeCount":100},[],{"trials":13992,"activeCount":100},[],{"trials":13994,"activeCount":100},[],{"intervention":13987,"totalTrials":204,"cells":13996},{"EARLY_PHASE1":13997,"PHASE1":13999,"PHASE2":14001,"PHASE3":14007,"PHASE4":14009,"NA":14011},{"trials":13998,"activeCount":100},[],{"trials":14000,"activeCount":100},[],{"trials":14002,"activeCount":100},[14003],{"nctId":13982,"briefTitle":13983,"status":217,"phases":14004,"primaryCompletion":4932,"completion":2733,"start":2451,"enrollment":1582,"conditions":14005,"interventions":14006},[90],[1390,34],[13973,13987,13988],{"trials":14008,"activeCount":100},[],{"trials":14010,"activeCount":100},[],{"trials":14012,"activeCount":100},[],{"intervention":13988,"totalTrials":204,"cells":14014},{"EARLY_PHASE1":14015,"PHASE1":14017,"PHASE2":14019,"PHASE3":14025,"PHASE4":14027,"NA":14029},{"trials":14016,"activeCount":100},[],{"trials":14018,"activeCount":100},[],{"trials":14020,"activeCount":100},[14021],{"nctId":13982,"briefTitle":13983,"status":217,"phases":14022,"primaryCompletion":4932,"completion":2733,"start":2451,"enrollment":1582,"conditions":14023,"interventions":14024},[90],[1390,34],[13973,13987,13988],{"trials":14026,"activeCount":100},[],{"trials":14028,"activeCount":100},[],{"trials":14030,"activeCount":100},[],{"intervention":11439,"totalTrials":204,"cells":14032},{"EARLY_PHASE1":14033,"PHASE1":14035,"PHASE2":14037,"PHASE3":14043,"PHASE4":14045,"NA":14047},{"trials":14034,"activeCount":100},[],{"trials":14036,"activeCount":100},[],{"trials":14038,"activeCount":100},[14039],{"nctId":11433,"briefTitle":11434,"status":217,"phases":14040,"primaryCompletion":1606,"completion":1627,"start":4484,"enrollment":11436,"conditions":14041,"interventions":14042},[90],[907],[11439,11401,11401],{"trials":14044,"activeCount":100},[],{"trials":14046,"activeCount":100},[],{"trials":14048,"activeCount":100},[],{"intervention":14050,"totalTrials":204,"cells":14051},"AMG 162 180 mg (SC) q 12 weeks",{"EARLY_PHASE1":14052,"PHASE1":14054,"PHASE2":14056,"PHASE3":14066,"PHASE4":14068,"NA":14070},{"trials":14053,"activeCount":100},[],{"trials":14055,"activeCount":100},[],{"trials":14057,"activeCount":100},[14058],{"nctId":14059,"briefTitle":14060,"status":217,"phases":14061,"primaryCompletion":1638,"completion":6155,"start":2602,"enrollment":1759,"conditions":14062,"interventions":14063},"NCT00104650","Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates",[90],[8694,8695,8696],[14050,14064,14065],"IV Bisphosphonate q 4 weeks","AMG 162- 180 mg q 4 weeks",{"trials":14067,"activeCount":100},[],{"trials":14069,"activeCount":100},[],{"trials":14071,"activeCount":100},[],{"intervention":14064,"totalTrials":204,"cells":14073},{"EARLY_PHASE1":14074,"PHASE1":14076,"PHASE2":14078,"PHASE3":14084,"PHASE4":14086,"NA":14088},{"trials":14075,"activeCount":100},[],{"trials":14077,"activeCount":100},[],{"trials":14079,"activeCount":100},[14080],{"nctId":14059,"briefTitle":14060,"status":217,"phases":14081,"primaryCompletion":1638,"completion":6155,"start":2602,"enrollment":1759,"conditions":14082,"interventions":14083},[90],[8694,8695,8696],[14050,14064,14065],{"trials":14085,"activeCount":100},[],{"trials":14087,"activeCount":100},[],{"trials":14089,"activeCount":100},[],{"intervention":14065,"totalTrials":204,"cells":14091},{"EARLY_PHASE1":14092,"PHASE1":14094,"PHASE2":14096,"PHASE3":14102,"PHASE4":14104,"NA":14106},{"trials":14093,"activeCount":100},[],{"trials":14095,"activeCount":100},[],{"trials":14097,"activeCount":100},[14098],{"nctId":14059,"briefTitle":14060,"status":217,"phases":14099,"primaryCompletion":1638,"completion":6155,"start":2602,"enrollment":1759,"conditions":14100,"interventions":14101},[90],[8694,8695,8696],[14050,14064,14065],{"trials":14103,"activeCount":100},[],{"trials":14105,"activeCount":100},[],{"trials":14107,"activeCount":100},[],{"intervention":14109,"totalTrials":204,"cells":14110},"IV iron dextran",{"EARLY_PHASE1":14111,"PHASE1":14113,"PHASE2":14115,"PHASE3":14124,"PHASE4":14126,"NA":14128},{"trials":14112,"activeCount":100},[],{"trials":14114,"activeCount":100},[],{"trials":14116,"activeCount":100},[14117],{"nctId":14118,"briefTitle":14119,"status":217,"phases":14120,"primaryCompletion":6743,"completion":2439,"start":2833,"enrollment":14121,"conditions":14122,"interventions":14123},"NCT00401544","Darbepoetin Alfa With or Without Intravenous (IV) Iron",[90],243,[16,8969],[8962,14109],{"trials":14125,"activeCount":100},[],{"trials":14127,"activeCount":100},[],{"trials":14129,"activeCount":100},[],{"intervention":4837,"totalTrials":204,"cells":14131},{"EARLY_PHASE1":14132,"PHASE1":14134,"PHASE2":14136,"PHASE3":14142,"PHASE4":14144,"NA":14146},{"trials":14133,"activeCount":100},[],{"trials":14135,"activeCount":100},[],{"trials":14137,"activeCount":100},[14138],{"nctId":4827,"briefTitle":4828,"status":217,"phases":14139,"primaryCompletion":4830,"completion":4831,"start":4832,"enrollment":2500,"conditions":14140,"interventions":14141},[89,90],[4834,4835],[1305,4837],{"trials":14143,"activeCount":100},[],{"trials":14145,"activeCount":100},[],{"trials":14147,"activeCount":100},[],{"intervention":14149,"totalTrials":204,"cells":14150},"AMG 301",{"EARLY_PHASE1":14151,"PHASE1":14153,"PHASE2":14155,"PHASE3":14167,"PHASE4":14169,"NA":14171},{"trials":14152,"activeCount":100},[],{"trials":14154,"activeCount":100},[],{"trials":14156,"activeCount":100},[14157],{"nctId":14158,"briefTitle":14159,"status":217,"phases":14160,"primaryCompletion":14161,"completion":3356,"start":14162,"enrollment":14163,"conditions":14164,"interventions":14166},"NCT03238781","Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention",[90],"2018-10-16","2017-09-06",343,[14165],"Chronic Migraine or Episodic Migraine",[14149],{"trials":14168,"activeCount":100},[],{"trials":14170,"activeCount":100},[],{"trials":14172,"activeCount":100},[],{"intervention":14174,"totalTrials":204,"cells":14175},"Novel Erythropoiesis Stimulating Protein",{"EARLY_PHASE1":14176,"PHASE1":14178,"PHASE2":14180,"PHASE3":14189,"PHASE4":14191,"NA":14193},{"trials":14177,"activeCount":100},[],{"trials":14179,"activeCount":100},[],{"trials":14181,"activeCount":100},[14182],{"nctId":14183,"briefTitle":14184,"status":217,"phases":14185,"primaryCompletion":11577,"completion":6757,"start":14186,"enrollment":1748,"conditions":14187,"interventions":14188},"NCT00540384","Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy",[89,90],"1999-07",[16,2441],[14174],{"trials":14190,"activeCount":100},[],{"trials":14192,"activeCount":100},[],{"trials":14194,"activeCount":100},[],{"intervention":7886,"totalTrials":204,"cells":14196},{"EARLY_PHASE1":14197,"PHASE1":14199,"PHASE2":14201,"PHASE3":14207,"PHASE4":14209,"NA":14211},{"trials":14198,"activeCount":100},[],{"trials":14200,"activeCount":100},[],{"trials":14202,"activeCount":100},[14203],{"nctId":7881,"briefTitle":7882,"status":217,"phases":14204,"primaryCompletion":2421,"completion":781,"start":2540,"enrollment":2302,"conditions":14205,"interventions":14206},[90],[2572],[2807,7576,7886],{"trials":14208,"activeCount":100},[],{"trials":14210,"activeCount":100},[],{"trials":14212,"activeCount":100},[],{"intervention":8210,"totalTrials":204,"cells":14214},{"EARLY_PHASE1":14215,"PHASE1":14217,"PHASE2":14219,"PHASE3":14225,"PHASE4":14227,"NA":14229},{"trials":14216,"activeCount":100},[],{"trials":14218,"activeCount":100},[],{"trials":14220,"activeCount":100},[14221],{"nctId":8202,"briefTitle":8203,"status":217,"phases":14222,"primaryCompletion":8205,"completion":8205,"start":8206,"enrollment":8207,"conditions":14223,"interventions":14224},[90],[4423,4424,2838],[8173,7367,8210],{"trials":14226,"activeCount":100},[],{"trials":14228,"activeCount":100},[],{"trials":14230,"activeCount":100},[],{"intervention":14232,"totalTrials":204,"cells":14233},"pegfilgrastim 12 mg",{"EARLY_PHASE1":14234,"PHASE1":14236,"PHASE2":14238,"PHASE3":14247,"PHASE4":14249,"NA":14251},{"trials":14235,"activeCount":100},[],{"trials":14237,"activeCount":100},[],{"trials":14239,"activeCount":100},[14240],{"nctId":14241,"briefTitle":14242,"status":217,"phases":14243,"primaryCompletion":2542,"completion":7610,"start":6429,"enrollment":1160,"conditions":14244,"interventions":14245},"NCT00066092","Pegfilgrastim PBPC Mobilization Study",[90],[7438,8187,1584,4548,2479],[14232,3051,14246],"pegfilgrastim 6 mg",{"trials":14248,"activeCount":100},[],{"trials":14250,"activeCount":100},[],{"trials":14252,"activeCount":100},[],{"intervention":14246,"totalTrials":204,"cells":14254},{"EARLY_PHASE1":14255,"PHASE1":14257,"PHASE2":14259,"PHASE3":14265,"PHASE4":14267,"NA":14269},{"trials":14256,"activeCount":100},[],{"trials":14258,"activeCount":100},[],{"trials":14260,"activeCount":100},[14261],{"nctId":14241,"briefTitle":14242,"status":217,"phases":14262,"primaryCompletion":2542,"completion":7610,"start":6429,"enrollment":1160,"conditions":14263,"interventions":14264},[90],[7438,8187,1584,4548,2479],[14232,3051,14246],{"trials":14266,"activeCount":100},[],{"trials":14268,"activeCount":100},[],{"trials":14270,"activeCount":100},[],{"intervention":14272,"totalTrials":204,"cells":14273},"IV Bisphosphonates",{"EARLY_PHASE1":14274,"PHASE1":14276,"PHASE2":14278,"PHASE3":14288,"PHASE4":14290,"NA":14292},{"trials":14275,"activeCount":100},[],{"trials":14277,"activeCount":100},[],{"trials":14279,"activeCount":100},[14280],{"nctId":14281,"briefTitle":14282,"status":217,"phases":14283,"primaryCompletion":7626,"completion":2474,"start":14284,"enrollment":14285,"conditions":14286,"interventions":14287},"NCT00091832","Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer",[90],"2004-09",255,[2794,2531,8695],[3670,14272],{"trials":14289,"activeCount":100},[],{"trials":14291,"activeCount":100},[],{"trials":14293,"activeCount":100},[],{"intervention":6682,"totalTrials":1164,"cells":14295},{"EARLY_PHASE1":14296,"PHASE1":14298,"PHASE2":14344,"PHASE3":14346,"PHASE4":14348,"NA":14350},{"trials":14297,"activeCount":100},[],{"trials":14299,"activeCount":100},[14300,14307,14311,14319,14327,14337],{"nctId":14301,"briefTitle":14302,"status":217,"phases":14303,"primaryCompletion":14304,"completion":14304,"start":2380,"enrollment":2028,"conditions":14305,"interventions":14306},"NCT05056246","Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants",[89],"2022-04-08",[1857],[6682],{"nctId":6674,"briefTitle":6675,"status":217,"phases":14308,"primaryCompletion":6677,"completion":6677,"start":6678,"enrollment":278,"conditions":14309,"interventions":14310},[89],[6680],[6682,6683],{"nctId":14312,"briefTitle":14313,"status":217,"phases":14314,"primaryCompletion":14315,"completion":14315,"start":14316,"enrollment":4814,"conditions":14317,"interventions":14318},"NCT06976372","A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity",[89],"2024-12-27","2024-08-20",[896,897],[6682],{"nctId":14320,"briefTitle":14321,"status":217,"phases":14322,"primaryCompletion":14323,"completion":14323,"start":14324,"enrollment":439,"conditions":14325,"interventions":14326},"NCT07428525","A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function",[89],"2026-02-26","2025-03-14",[255],[6682],{"nctId":14328,"briefTitle":14329,"status":217,"phases":14330,"primaryCompletion":14331,"completion":14331,"start":14332,"enrollment":14333,"conditions":14334,"interventions":14335},"NCT07310563","A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity",[89],"2025-05-09","2024-12-10",59,[896,897],[6682,14336],"Ondansetron",{"nctId":14338,"briefTitle":14339,"status":217,"phases":14340,"primaryCompletion":86,"completion":86,"start":14341,"enrollment":4671,"conditions":14342,"interventions":14343},"NCT07429045","A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body",[89],"2025-03-11",[936],[6682],{"trials":14345,"activeCount":100},[],{"trials":14347,"activeCount":100},[],{"trials":14349,"activeCount":100},[],{"trials":14351,"activeCount":100},[],{"intervention":1849,"totalTrials":160,"cells":14353},{"EARLY_PHASE1":14354,"PHASE1":14360,"PHASE2":14374,"PHASE3":14376,"PHASE4":14378,"NA":14380},{"trials":14355,"activeCount":100},[14356],{"nctId":2900,"briefTitle":2901,"status":217,"phases":14357,"primaryCompletion":2903,"completion":2904,"start":2905,"enrollment":35,"conditions":14358,"interventions":14359},[88],[2907],[2909,1930,2910,1849,2894],{"trials":14361,"activeCount":100},[14362,14366,14370],{"nctId":1842,"briefTitle":1843,"status":217,"phases":14363,"primaryCompletion":1845,"completion":1845,"start":1846,"enrollment":1070,"conditions":14364,"interventions":14365},[89],[222],[1849,1307],{"nctId":4572,"briefTitle":4573,"status":217,"phases":14367,"primaryCompletion":4575,"completion":4575,"start":4576,"enrollment":1907,"conditions":14368,"interventions":14369},[89],[1857],[43,1849],{"nctId":4613,"briefTitle":4614,"status":217,"phases":14371,"primaryCompletion":4616,"completion":4616,"start":2206,"enrollment":1907,"conditions":14372,"interventions":14373},[89],[1857],[43,1849,4619],{"trials":14375,"activeCount":100},[],{"trials":14377,"activeCount":100},[],{"trials":14379,"activeCount":100},[],{"trials":14381,"activeCount":100},[],{"intervention":14383,"totalTrials":160,"cells":14384},"AMG 557",{"EARLY_PHASE1":14385,"PHASE1":14387,"PHASE2":14417,"PHASE3":14419,"PHASE4":14421,"NA":14423},{"trials":14386,"activeCount":100},[],{"trials":14388,"activeCount":100},[14389,14395,14401,14408],{"nctId":14390,"briefTitle":14391,"status":217,"phases":14392,"primaryCompletion":10327,"completion":10327,"start":2541,"enrollment":242,"conditions":14393,"interventions":14394},"NCT00774943","A Study of AMG 557 in Adults With Systemic Lupus Erythematosus",[89],[114],[14383],{"nctId":14396,"briefTitle":14397,"status":217,"phases":14398,"primaryCompletion":6190,"completion":2733,"start":2587,"enrollment":278,"conditions":14399,"interventions":14400},"NCT02391259","A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus",[89],[114],[14383],{"nctId":14402,"briefTitle":14403,"status":217,"phases":14404,"primaryCompletion":2882,"completion":2882,"start":7852,"enrollment":305,"conditions":14405,"interventions":14407},"NCT01683695","Safety Study of AMG 557 in Subjects With Lupus Arthritis",[89],[14406],"Lupus Arthritis, Systemic Lupus Erythematosus",[14383],{"nctId":14409,"briefTitle":14410,"status":336,"phases":14411,"primaryCompletion":5191,"completion":5191,"start":7865,"enrollment":204,"conditions":14412,"interventions":14415},"NCT01389895","Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus",[89],[14413,14414],"Cutaneous Lupus","Lupus",[14383,14416],"AMG 557 Placebo",{"trials":14418,"activeCount":100},[],{"trials":14420,"activeCount":100},[],{"trials":14422,"activeCount":100},[],{"trials":14424,"activeCount":100},[],{"intervention":4611,"totalTrials":193,"cells":14426},{"EARLY_PHASE1":14427,"PHASE1":14429,"PHASE2":14443,"PHASE3":14445,"PHASE4":14447,"NA":14449},{"trials":14428,"activeCount":100},[],{"trials":14430,"activeCount":100},[14431,14435,14439],{"nctId":11770,"briefTitle":11771,"status":336,"phases":14432,"primaryCompletion":2926,"completion":2926,"start":11773,"enrollment":7374,"conditions":14433,"interventions":14434},[89],[7322,1359],[11776,7367,4611],{"nctId":4907,"briefTitle":4908,"status":217,"phases":14436,"primaryCompletion":4910,"completion":4911,"start":4912,"enrollment":26,"conditions":14437,"interventions":14438},[89],[4914],[4916,1930,4917,4611,4918],{"nctId":4605,"briefTitle":4606,"status":217,"phases":14440,"primaryCompletion":1314,"completion":1314,"start":4608,"enrollment":1907,"conditions":14441,"interventions":14442},[89],[1857],[43,4611],{"trials":14444,"activeCount":100},[],{"trials":14446,"activeCount":100},[],{"trials":14448,"activeCount":100},[],{"trials":14450,"activeCount":100},[],{"intervention":14452,"totalTrials":985,"cells":14453},"AMG 811",{"EARLY_PHASE1":14454,"PHASE1":14456,"PHASE2":14472,"PHASE3":14474,"PHASE4":14476,"NA":14478},{"trials":14455,"activeCount":100},[],{"trials":14457,"activeCount":100},[14458,14465],{"nctId":14459,"briefTitle":14460,"status":217,"phases":14461,"primaryCompletion":781,"completion":1703,"start":2451,"enrollment":3391,"conditions":14462,"interventions":14464},"NCT00818948","Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis",[89],[14463,114],"Nephritis",[14452],{"nctId":14466,"briefTitle":14467,"status":217,"phases":14468,"primaryCompletion":6155,"completion":2452,"start":6743,"enrollment":14469,"conditions":14470,"interventions":14471},"NCT02291588","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus",[89],26,[114],[14452],{"trials":14473,"activeCount":100},[],{"trials":14475,"activeCount":100},[],{"trials":14477,"activeCount":100},[],{"trials":14479,"activeCount":100},[],{"intervention":14481,"totalTrials":985,"cells":14482},"Arm 1- Dose Escalation",{"EARLY_PHASE1":14483,"PHASE1":14485,"PHASE2":14506,"PHASE3":14508,"PHASE4":14510,"NA":14512},{"trials":14484,"activeCount":100},[],{"trials":14486,"activeCount":100},[14487,14497],{"nctId":14488,"briefTitle":14489,"status":217,"phases":14490,"primaryCompletion":14491,"completion":14491,"start":14492,"enrollment":1582,"conditions":14493,"interventions":14495},"NCT01380756","Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia",[89],"2014-09-04","2011-10-04",[25,6334,14494,7692],"Leukemia",[14481,14496],"Arm 2- Dose Expansion",{"nctId":14498,"briefTitle":14499,"status":217,"phases":14500,"primaryCompletion":6576,"completion":14501,"start":14502,"enrollment":2513,"conditions":14503,"interventions":14504},"NCT00858377","A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors",[89],"2019-04-03","2009-08-10",[11942,1290,25,2441,2478],[14481,14505],"Arm 1- Dose Expansion",{"trials":14507,"activeCount":100},[],{"trials":14509,"activeCount":100},[],{"trials":14511,"activeCount":100},[],{"trials":14513,"activeCount":100},[],{"intervention":1361,"totalTrials":985,"cells":14515},{"EARLY_PHASE1":14516,"PHASE1":14518,"PHASE2":14534,"PHASE3":14536,"PHASE4":14538,"NA":14540},{"trials":14517,"activeCount":100},[],{"trials":14519,"activeCount":100},[14520,14530],{"nctId":14521,"briefTitle":14522,"status":336,"phases":14523,"primaryCompletion":14524,"completion":14524,"start":14525,"enrollment":2513,"conditions":14526,"interventions":14529},"NCT02520427","A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies",[89],"2022-01-09","2015-08-31",[14527,14528,7362],"Relapsed\u002FRefractory AML","Minimal Residual Disease Positive AML",[1361],{"nctId":1353,"briefTitle":1354,"status":336,"phases":14531,"primaryCompletion":1356,"completion":1356,"start":1357,"enrollment":204,"conditions":14532,"interventions":14533},[89],[1359],[1361,1152],{"trials":14535,"activeCount":100},[],{"trials":14537,"activeCount":100},[],{"trials":14539,"activeCount":100},[],{"trials":14541,"activeCount":100},[],{"intervention":4927,"totalTrials":985,"cells":14543},{"EARLY_PHASE1":14544,"PHASE1":14546,"PHASE2":14558,"PHASE3":14560,"PHASE4":14562,"NA":14564},{"trials":14545,"activeCount":100},[],{"trials":14547,"activeCount":100},[14548,14554],{"nctId":14549,"briefTitle":14550,"status":217,"phases":14551,"primaryCompletion":2113,"completion":2113,"start":4923,"enrollment":11851,"conditions":14552,"interventions":14553},"NCT02567370","Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581",[89],[4925],[4927],{"nctId":4920,"briefTitle":4921,"status":217,"phases":14555,"primaryCompletion":2114,"completion":2114,"start":4923,"enrollment":2527,"conditions":14556,"interventions":14557},[89],[4925],[4927,1930],{"trials":14559,"activeCount":100},[],{"trials":14561,"activeCount":100},[],{"trials":14563,"activeCount":100},[],{"trials":14565,"activeCount":100},[],{"intervention":14567,"totalTrials":985,"cells":14568},"Amg 181",{"EARLY_PHASE1":14569,"PHASE1":14571,"PHASE2":14586,"PHASE3":14588,"PHASE4":14590,"NA":14592},{"trials":14570,"activeCount":100},[],{"trials":14572,"activeCount":100},[14573,14579],{"nctId":14574,"briefTitle":14575,"status":336,"phases":14576,"primaryCompletion":12505,"completion":5191,"start":11619,"enrollment":1400,"conditions":14577,"interventions":14578},"NCT01164904","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis",[89],[2068],[14567],{"nctId":14580,"briefTitle":14581,"status":217,"phases":14582,"primaryCompletion":8563,"completion":5152,"start":3832,"enrollment":380,"conditions":14583,"interventions":14584},"NCT01290042","Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.",[89],[2068,11365],[14585],"AMG 181",{"trials":14587,"activeCount":100},[],{"trials":14589,"activeCount":100},[],{"trials":14591,"activeCount":100},[],{"trials":14593,"activeCount":100},[],{"intervention":14595,"totalTrials":985,"cells":14596},"AMG 167",{"EARLY_PHASE1":14597,"PHASE1":14599,"PHASE2":14613,"PHASE3":14615,"PHASE4":14617,"NA":14619},{"trials":14598,"activeCount":100},[],{"trials":14600,"activeCount":100},[14601,14607],{"nctId":14602,"briefTitle":14603,"status":217,"phases":14604,"primaryCompletion":8691,"completion":8691,"start":2452,"enrollment":1275,"conditions":14605,"interventions":14606},"NCT01101048","An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density",[89],[3612],[14595],{"nctId":14608,"briefTitle":14609,"status":217,"phases":14610,"primaryCompletion":3833,"completion":3833,"start":2499,"enrollment":8207,"conditions":14611,"interventions":14612},"NCT00902356","A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women",[89],[3612],[14595],{"trials":14614,"activeCount":100},[],{"trials":14616,"activeCount":100},[],{"trials":14618,"activeCount":100},[],{"trials":14620,"activeCount":100},[],{"intervention":14622,"totalTrials":985,"cells":14623},"AMG 282",{"EARLY_PHASE1":14624,"PHASE1":14626,"PHASE2":14641,"PHASE3":14643,"PHASE4":14645,"NA":14647},{"trials":14625,"activeCount":100},[],{"trials":14627,"activeCount":100},[14628,14634],{"nctId":14629,"briefTitle":14630,"status":217,"phases":14631,"primaryCompletion":2882,"completion":2882,"start":2873,"enrollment":11851,"conditions":14632,"interventions":14633},"NCT01928368","A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.",[89],[2941],[14622],{"nctId":14635,"briefTitle":14636,"status":217,"phases":14637,"primaryCompletion":1704,"completion":1704,"start":1693,"enrollment":1160,"conditions":14638,"interventions":14640},"NCT02170337","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps",[89],[14639],"Chronic Rhinosinusitis With Nasal Polyps",[14622],{"trials":14642,"activeCount":100},[],{"trials":14644,"activeCount":100},[],{"trials":14646,"activeCount":100},[],{"trials":14648,"activeCount":100},[],{"intervention":11776,"totalTrials":985,"cells":14650},{"EARLY_PHASE1":14651,"PHASE1":14653,"PHASE2":14663,"PHASE3":14665,"PHASE4":14667,"NA":14669},{"trials":14652,"activeCount":100},[],{"trials":14654,"activeCount":100},[14655,14659],{"nctId":11770,"briefTitle":11771,"status":336,"phases":14656,"primaryCompletion":2926,"completion":2926,"start":11773,"enrollment":7374,"conditions":14657,"interventions":14658},[89],[7322,1359],[11776,7367,4611],{"nctId":11782,"briefTitle":11783,"status":336,"phases":14660,"primaryCompletion":3262,"completion":3262,"start":11785,"enrollment":1454,"conditions":14661,"interventions":14662},[89],[11787,11788],[11776,7367],{"trials":14664,"activeCount":100},[],{"trials":14666,"activeCount":100},[],{"trials":14668,"activeCount":100},[],{"trials":14670,"activeCount":100},[],{"intervention":14672,"totalTrials":985,"cells":14673},"AMG 403",{"EARLY_PHASE1":14674,"PHASE1":14676,"PHASE2":14691,"PHASE3":14693,"PHASE4":14695,"NA":14697},{"trials":14675,"activeCount":100},[],{"trials":14677,"activeCount":100},[14678,14685],{"nctId":14679,"briefTitle":14680,"status":217,"phases":14681,"primaryCompletion":13468,"completion":3033,"start":2602,"enrollment":2257,"conditions":14682,"interventions":14684},"NCT02348879","A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403 in Healthy Subject",[89],[14683],"Chronic Pain",[14672],{"nctId":14686,"briefTitle":14687,"status":217,"phases":14688,"primaryCompletion":1638,"completion":2439,"start":2833,"enrollment":253,"conditions":14689,"interventions":14690},"NCT02318407","A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee Pain",[89],[8817],[14672],{"trials":14692,"activeCount":100},[],{"trials":14694,"activeCount":100},[],{"trials":14696,"activeCount":100},[],{"trials":14698,"activeCount":100},[],{"intervention":14700,"totalTrials":985,"cells":14701},"AMG 623",{"EARLY_PHASE1":14702,"PHASE1":14704,"PHASE2":14719,"PHASE3":14721,"PHASE4":14723,"NA":14725},{"trials":14703,"activeCount":100},[],{"trials":14705,"activeCount":100},[14706,14713],{"nctId":14707,"briefTitle":14708,"status":217,"phases":14709,"primaryCompletion":14710,"completion":6173,"start":6233,"enrollment":12445,"conditions":14711,"interventions":14712},"NCT02411136","A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus",[89],"2007-08",[114],[14700],{"nctId":14714,"briefTitle":14715,"status":217,"phases":14716,"primaryCompletion":7698,"completion":2460,"start":7610,"enrollment":3391,"conditions":14717,"interventions":14718},"NCT02443506","A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose of AMG 623 in Subjects With Systemic Lupus Erythematosus",[89],[114],[14700],{"trials":14720,"activeCount":100},[],{"trials":14722,"activeCount":100},[],{"trials":14724,"activeCount":100},[],{"trials":14726,"activeCount":100},[],{"intervention":4587,"totalTrials":985,"cells":14728},{"EARLY_PHASE1":14729,"PHASE1":14731,"PHASE2":14741,"PHASE3":14743,"PHASE4":14745,"NA":14747},{"trials":14730,"activeCount":100},[],{"trials":14732,"activeCount":100},[14733,14737],{"nctId":4580,"briefTitle":4581,"status":217,"phases":14734,"primaryCompletion":4583,"completion":4583,"start":4584,"enrollment":1907,"conditions":14735,"interventions":14736},[89],[1857],[43,4587],{"nctId":2049,"briefTitle":2050,"status":217,"phases":14738,"primaryCompletion":2018,"completion":2018,"start":2019,"enrollment":35,"conditions":14739,"interventions":14740},[89],[2053],[82,2055,2056],{"trials":14742,"activeCount":100},[],{"trials":14744,"activeCount":100},[],{"trials":14746,"activeCount":100},[],{"trials":14748,"activeCount":100},[],{"intervention":14750,"totalTrials":985,"cells":14751},"AMG 333",{"EARLY_PHASE1":14752,"PHASE1":14754,"PHASE2":14768,"PHASE3":14770,"PHASE4":14772,"NA":14774},{"trials":14753,"activeCount":100},[],{"trials":14755,"activeCount":100},[14756,14762],{"nctId":14757,"briefTitle":14758,"status":336,"phases":14759,"primaryCompletion":4678,"completion":11204,"start":5152,"enrollment":1070,"conditions":14760,"interventions":14761},"NCT02132429","Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects",[89],[4039],[14750],{"nctId":14763,"briefTitle":14764,"status":217,"phases":14765,"primaryCompletion":5128,"completion":1637,"start":782,"enrollment":1275,"conditions":14766,"interventions":14767},"NCT01953341","Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines",[89],[4039],[14750],{"trials":14769,"activeCount":100},[],{"trials":14771,"activeCount":100},[],{"trials":14773,"activeCount":100},[],{"trials":14775,"activeCount":100},[],{"intervention":14777,"totalTrials":985,"cells":14778},"AMG 592",{"EARLY_PHASE1":14779,"PHASE1":14781,"PHASE2":14801,"PHASE3":14803,"PHASE4":14805,"NA":14807},{"trials":14780,"activeCount":100},[],{"trials":14782,"activeCount":100},[14783,14793],{"nctId":14784,"briefTitle":14785,"status":217,"phases":14786,"primaryCompletion":14787,"completion":14788,"start":14789,"enrollment":12445,"conditions":14790,"interventions":14792},"NCT05873907","A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants",[89],"2017-06-16","2017-07-28","2015-10-19",[14791],"Chronic Graft-versus-host Disease (cGVHD)",[14777],{"nctId":14794,"briefTitle":14795,"status":217,"phases":14796,"primaryCompletion":10198,"completion":10198,"start":14797,"enrollment":340,"conditions":14798,"interventions":14800},"NCT05885451","A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese Participants",[89],"2019-01-29",[14799],"Chronic Graft-versus-Host Disease (cGVHD)",[14777],{"trials":14802,"activeCount":100},[],{"trials":14804,"activeCount":100},[],{"trials":14806,"activeCount":100},[],{"trials":14808,"activeCount":100},[],{"intervention":14810,"totalTrials":985,"cells":14811},"AMG 876",{"EARLY_PHASE1":14812,"PHASE1":14814,"PHASE2":14828,"PHASE3":14830,"PHASE4":14832,"NA":14834},{"trials":14813,"activeCount":100},[],{"trials":14815,"activeCount":100},[14816,14822],{"nctId":14817,"briefTitle":14818,"status":336,"phases":14819,"primaryCompletion":1637,"completion":2438,"start":5191,"enrollment":2476,"conditions":14820,"interventions":14821},"NCT01856881","Multiple Ascending Dose Study in Subjects With Type 2 Diabetes",[89],[11997],[14810],{"nctId":14823,"briefTitle":14824,"status":336,"phases":14825,"primaryCompletion":1695,"completion":7260,"start":2733,"enrollment":1651,"conditions":14826,"interventions":14827},"NCT01492465","Single Ascending Dose Trial in Patients With Type 2 Diabetes",[89],[11997],[14810],{"trials":14829,"activeCount":100},[],{"trials":14831,"activeCount":100},[],{"trials":14833,"activeCount":100},[],{"trials":14835,"activeCount":100},[],{"intervention":14837,"totalTrials":985,"cells":14838},"AMG 357",{"EARLY_PHASE1":14839,"PHASE1":14841,"PHASE2":14857,"PHASE3":14859,"PHASE4":14861,"NA":14863},{"trials":14840,"activeCount":100},[],{"trials":14842,"activeCount":100},[14843,14850],{"nctId":14844,"briefTitle":14845,"status":217,"phases":14846,"primaryCompletion":5128,"completion":4678,"start":7260,"enrollment":242,"conditions":14847,"interventions":14849},"NCT01695876","A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects",[89],[14848],"Inflammatory Disease",[14837],{"nctId":14851,"briefTitle":14852,"status":336,"phases":14853,"primaryCompletion":2114,"completion":2114,"start":14854,"enrollment":26,"conditions":14855,"interventions":14856},"NCT02499315","Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis",[89],"2015-04",[19],[14837],{"trials":14858,"activeCount":100},[],{"trials":14860,"activeCount":100},[],{"trials":14862,"activeCount":100},[],{"trials":14864,"activeCount":100},[],{"intervention":5955,"totalTrials":204,"cells":14866},{"EARLY_PHASE1":14867,"PHASE1":14869,"PHASE2":14875,"PHASE3":14877,"PHASE4":14879,"NA":14881},{"trials":14868,"activeCount":100},[],{"trials":14870,"activeCount":100},[14871],{"nctId":5947,"briefTitle":5948,"status":217,"phases":14872,"primaryCompletion":5950,"completion":5951,"start":5952,"enrollment":1582,"conditions":14873,"interventions":14874},[89],[4039],[5940,5955],{"trials":14876,"activeCount":100},[],{"trials":14878,"activeCount":100},[],{"trials":14880,"activeCount":100},[],{"trials":14882,"activeCount":100},[],{"intervention":14884,"totalTrials":204,"cells":14885},"VIB1116",{"EARLY_PHASE1":14886,"PHASE1":14888,"PHASE2":14898,"PHASE3":14900,"PHASE4":14902,"NA":14904},{"trials":14887,"activeCount":100},[],{"trials":14889,"activeCount":100},[14890],{"nctId":14891,"briefTitle":14892,"status":217,"phases":14893,"primaryCompletion":123,"completion":123,"start":3950,"enrollment":14894,"conditions":14895,"interventions":14897},"NCT04948099","A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases",[89],73,[14896],"Dendritic Cell -Mediated Rheumatic Diseases",[14884],{"trials":14899,"activeCount":100},[],{"trials":14901,"activeCount":100},[],{"trials":14903,"activeCount":100},[],{"trials":14905,"activeCount":100},[],{"intervention":14496,"totalTrials":204,"cells":14907},{"EARLY_PHASE1":14908,"PHASE1":14910,"PHASE2":14916,"PHASE3":14918,"PHASE4":14920,"NA":14922},{"trials":14909,"activeCount":100},[],{"trials":14911,"activeCount":100},[14912],{"nctId":14488,"briefTitle":14489,"status":217,"phases":14913,"primaryCompletion":14491,"completion":14491,"start":14492,"enrollment":1582,"conditions":14914,"interventions":14915},[89],[25,6334,14494,7692],[14481,14496],{"trials":14917,"activeCount":100},[],{"trials":14919,"activeCount":100},[],{"trials":14921,"activeCount":100},[],{"trials":14923,"activeCount":100},[],{"intervention":14925,"totalTrials":204,"cells":14926},"AMG 986",{"EARLY_PHASE1":14927,"PHASE1":14929,"PHASE2":14940,"PHASE3":14942,"PHASE4":14944,"NA":14946},{"trials":14928,"activeCount":100},[],{"trials":14930,"activeCount":100},[14931],{"nctId":14932,"briefTitle":14933,"status":217,"phases":14934,"primaryCompletion":14935,"completion":718,"start":14936,"enrollment":2895,"conditions":14937,"interventions":14939},"NCT03318809","Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal Function",[89],"2018-03-12","2017-12-12",[14938],"Heart Failure",[14925],{"trials":14941,"activeCount":100},[],{"trials":14943,"activeCount":100},[],{"trials":14945,"activeCount":100},[],{"trials":14947,"activeCount":100},[],{"intervention":14949,"totalTrials":204,"cells":14950},"AMG 910",{"EARLY_PHASE1":14951,"PHASE1":14953,"PHASE2":14964,"PHASE3":14966,"PHASE4":14968,"NA":14970},{"trials":14952,"activeCount":100},[],{"trials":14954,"activeCount":100},[14955],{"nctId":14956,"briefTitle":14957,"status":336,"phases":14958,"primaryCompletion":14959,"completion":14959,"start":14960,"enrollment":124,"conditions":14961,"interventions":14963},"NCT04260191","Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma",[89],"2022-06-02","2020-06-29",[14962],"Gastric and Gastroesophageal Junction Adenocarcinoma",[14949],{"trials":14965,"activeCount":100},[],{"trials":14967,"activeCount":100},[],{"trials":14969,"activeCount":100},[],{"trials":14971,"activeCount":100},[],{"intervention":14505,"totalTrials":204,"cells":14973},{"EARLY_PHASE1":14974,"PHASE1":14976,"PHASE2":14982,"PHASE3":14984,"PHASE4":14986,"NA":14988},{"trials":14975,"activeCount":100},[],{"trials":14977,"activeCount":100},[14978],{"nctId":14498,"briefTitle":14499,"status":217,"phases":14979,"primaryCompletion":6576,"completion":14501,"start":14502,"enrollment":2513,"conditions":14980,"interventions":14981},[89],[11942,1290,25,2441,2478],[14481,14505],{"trials":14983,"activeCount":100},[],{"trials":14985,"activeCount":100},[],{"trials":14987,"activeCount":100},[],{"trials":14989,"activeCount":100},[],{"intervention":7324,"totalTrials":204,"cells":14991},{"EARLY_PHASE1":14992,"PHASE1":14994,"PHASE2":15000,"PHASE3":15002,"PHASE4":15004,"NA":15006},{"trials":14993,"activeCount":100},[],{"trials":14995,"activeCount":100},[14996],{"nctId":7316,"briefTitle":7317,"status":217,"phases":14997,"primaryCompletion":7319,"completion":7319,"start":7320,"enrollment":731,"conditions":14998,"interventions":14999},[89],[7322],[7324,7325,1656,7326],{"trials":15001,"activeCount":100},[],{"trials":15003,"activeCount":100},[],{"trials":15005,"activeCount":100},[],{"trials":15007,"activeCount":100},[],{"intervention":7325,"totalTrials":204,"cells":15009},{"EARLY_PHASE1":15010,"PHASE1":15012,"PHASE2":15018,"PHASE3":15020,"PHASE4":15022,"NA":15024},{"trials":15011,"activeCount":100},[],{"trials":15013,"activeCount":100},[15014],{"nctId":7316,"briefTitle":7317,"status":217,"phases":15015,"primaryCompletion":7319,"completion":7319,"start":7320,"enrollment":731,"conditions":15016,"interventions":15017},[89],[7322],[7324,7325,1656,7326],{"trials":15019,"activeCount":100},[],{"trials":15021,"activeCount":100},[],{"trials":15023,"activeCount":100},[],{"trials":15025,"activeCount":100},[],{"intervention":1269,"totalTrials":204,"cells":15027},{"EARLY_PHASE1":15028,"PHASE1":15030,"PHASE2":15036,"PHASE3":15038,"PHASE4":15040,"NA":15042},{"trials":15029,"activeCount":100},[],{"trials":15031,"activeCount":100},[15032],{"nctId":1257,"briefTitle":1258,"status":336,"phases":15033,"primaryCompletion":1260,"completion":1260,"start":1261,"enrollment":1262,"conditions":15034,"interventions":15035},[89],[1264,1265],[1267,1152,1268,1269],{"trials":15037,"activeCount":100},[],{"trials":15039,"activeCount":100},[],{"trials":15041,"activeCount":100},[],{"trials":15043,"activeCount":100},[],{"intervention":15045,"totalTrials":204,"cells":15046},"AMG 954\u002FPanitumumab",{"EARLY_PHASE1":15047,"PHASE1":15049,"PHASE2":15057,"PHASE3":15059,"PHASE4":15061,"NA":15063},{"trials":15048,"activeCount":100},[],{"trials":15050,"activeCount":100},[15051],{"nctId":15052,"briefTitle":15053,"status":131,"phases":15054,"completion":2642,"start":3033,"enrollment":100,"conditions":15055,"interventions":15056},"NCT00352950","Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer",[89],[2479,1971],[15045],{"trials":15058,"activeCount":100},[],{"trials":15060,"activeCount":100},[],{"trials":15062,"activeCount":100},[],{"trials":15064,"activeCount":100},[],{"intervention":15066,"totalTrials":204,"cells":15067},"AMG 529",{"EARLY_PHASE1":15068,"PHASE1":15070,"PHASE2":15081,"PHASE3":15083,"PHASE4":15085,"NA":15087},{"trials":15069,"activeCount":100},[],{"trials":15071,"activeCount":100},[15072],{"nctId":15073,"briefTitle":15074,"status":217,"phases":15075,"primaryCompletion":15076,"completion":15076,"start":15077,"enrollment":2197,"conditions":15078,"interventions":15080},"NCT03170193","AMG 529 First in Human Study",[89],"2017-11-17","2017-05-15",[15079],"Cardiovascular",[15066],{"trials":15082,"activeCount":100},[],{"trials":15084,"activeCount":100},[],{"trials":15086,"activeCount":100},[],{"trials":15088,"activeCount":100},[],{"intervention":15090,"totalTrials":204,"cells":15091},"AMG 378",{"EARLY_PHASE1":15092,"PHASE1":15094,"PHASE2":15104,"PHASE3":15106,"PHASE4":15108,"NA":15110},{"trials":15093,"activeCount":100},[],{"trials":15095,"activeCount":100},[15096],{"nctId":15097,"briefTitle":15098,"status":336,"phases":15099,"primaryCompletion":15100,"completion":15100,"start":15101,"enrollment":2197,"conditions":15102,"interventions":15103},"NCT06910709","Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants",[89],"2025-12-02","2025-04-08",[222],[15090],{"trials":15105,"activeCount":100},[],{"trials":15107,"activeCount":100},[],{"trials":15109,"activeCount":100},[],{"trials":15111,"activeCount":100},[],{"intervention":15113,"totalTrials":204,"cells":15114},"AMG 579",{"EARLY_PHASE1":15115,"PHASE1":15117,"PHASE2":15125,"PHASE3":15127,"PHASE4":15129,"NA":15131},{"trials":15116,"activeCount":100},[],{"trials":15118,"activeCount":100},[15119],{"nctId":15120,"briefTitle":15121,"status":336,"phases":15122,"primaryCompletion":7852,"completion":7852,"start":6190,"enrollment":1476,"conditions":15123,"interventions":15124},"NCT01568203","First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia",[89],[12420],[15113],{"trials":15126,"activeCount":100},[],{"trials":15128,"activeCount":100},[],{"trials":15130,"activeCount":100},[],{"trials":15132,"activeCount":100},[],{"intervention":15134,"totalTrials":204,"cells":15135},"AMG 609",{"EARLY_PHASE1":15136,"PHASE1":15138,"PHASE2":15149,"PHASE3":15151,"PHASE4":15153,"NA":15155},{"trials":15137,"activeCount":100},[],{"trials":15139,"activeCount":100},[15140],{"nctId":15141,"briefTitle":15142,"status":217,"phases":15143,"primaryCompletion":15144,"completion":15144,"start":15145,"enrollment":1651,"conditions":15146,"interventions":15148},"NCT04857606","Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease",[89],"2023-07-19","2021-05-24",[15147],"Non-alcoholic Fatty Liver Disease",[15134],{"trials":15150,"activeCount":100},[],{"trials":15152,"activeCount":100},[],{"trials":15154,"activeCount":100},[],{"trials":15156,"activeCount":100},[],{"intervention":15158,"totalTrials":204,"cells":15159},"AMG 171",{"EARLY_PHASE1":15160,"PHASE1":15162,"PHASE2":15171,"PHASE3":15173,"PHASE4":15175,"NA":15177},{"trials":15161,"activeCount":100},[],{"trials":15163,"activeCount":100},[15164],{"nctId":15165,"briefTitle":15166,"status":336,"phases":15167,"primaryCompletion":2380,"completion":2380,"start":15168,"enrollment":13,"conditions":15169,"interventions":15170},"NCT04199351","Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity",[89],"2019-12-13",[897],[15158],{"trials":15172,"activeCount":100},[],{"trials":15174,"activeCount":100},[],{"trials":15176,"activeCount":100},[],{"trials":15178,"activeCount":100},[],{"intervention":2031,"totalTrials":204,"cells":15180},{"EARLY_PHASE1":15181,"PHASE1":15183,"PHASE2":15189,"PHASE3":15191,"PHASE4":15193,"NA":15195},{"trials":15182,"activeCount":100},[],{"trials":15184,"activeCount":100},[15185],{"nctId":2024,"briefTitle":2025,"status":217,"phases":15186,"primaryCompletion":730,"completion":730,"start":2027,"enrollment":2028,"conditions":15187,"interventions":15188},[89],[222],[82,2031],{"trials":15190,"activeCount":100},[],{"trials":15192,"activeCount":100},[],{"trials":15194,"activeCount":100},[],{"trials":15196,"activeCount":100},[],{"intervention":15198,"totalTrials":204,"cells":15199},"AMG 256",{"EARLY_PHASE1":15200,"PHASE1":15202,"PHASE2":15211,"PHASE3":15213,"PHASE4":15215,"NA":15217},{"trials":15201,"activeCount":100},[],{"trials":15203,"activeCount":100},[15204],{"nctId":15205,"briefTitle":15206,"status":217,"phases":15207,"primaryCompletion":15208,"completion":15208,"start":6097,"enrollment":2028,"conditions":15209,"interventions":15210},"NCT04362748","Study of AMG 256 in Adult Subjects With Advanced Solid Tumors",[89],"2023-09-21",[1290],[15198],{"trials":15212,"activeCount":100},[],{"trials":15214,"activeCount":100},[],{"trials":15216,"activeCount":100},[],{"trials":15218,"activeCount":100},[],{"intervention":15220,"totalTrials":204,"cells":15221},"ABP 501-HCF",{"EARLY_PHASE1":15222,"PHASE1":15224,"PHASE2":15236,"PHASE3":15238,"PHASE4":15240,"NA":15242},{"trials":15223,"activeCount":100},[],{"trials":15225,"activeCount":100},[15226],{"nctId":15227,"briefTitle":15228,"status":217,"phases":15229,"primaryCompletion":15230,"completion":15230,"start":15231,"enrollment":15232,"conditions":15233,"interventions":15234},"NCT05909852","A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg\u002F0.4 mL (ABP 501-HCF) and ABP 501 40 mg\u002F0.8 ml (ABP 501-LCF) in Healthy Adult Participants",[89],"2021-11-24","2021-07-23",372,[8536],[15220,15235],"ABP 501-LCF",{"trials":15237,"activeCount":100},[],{"trials":15239,"activeCount":100},[],{"trials":15241,"activeCount":100},[],{"trials":15243,"activeCount":100},[],{"intervention":15235,"totalTrials":204,"cells":15245},{"EARLY_PHASE1":15246,"PHASE1":15248,"PHASE2":15254,"PHASE3":15256,"PHASE4":15258,"NA":15260},{"trials":15247,"activeCount":100},[],{"trials":15249,"activeCount":100},[15250],{"nctId":15227,"briefTitle":15228,"status":217,"phases":15251,"primaryCompletion":15230,"completion":15230,"start":15231,"enrollment":15232,"conditions":15252,"interventions":15253},[89],[8536],[15220,15235],{"trials":15255,"activeCount":100},[],{"trials":15257,"activeCount":100},[],{"trials":15259,"activeCount":100},[],{"trials":15261,"activeCount":100},[],{"intervention":15263,"totalTrials":204,"cells":15264},"AMG 595",{"EARLY_PHASE1":15265,"PHASE1":15267,"PHASE2":15277,"PHASE3":15279,"PHASE4":15281,"NA":15283},{"trials":15266,"activeCount":100},[],{"trials":15268,"activeCount":100},[15269],{"nctId":15270,"briefTitle":15271,"status":217,"phases":15272,"primaryCompletion":8562,"completion":8562,"start":8691,"enrollment":26,"conditions":15273,"interventions":15276},"NCT01475006","AMG 595 First-in-Human in Recurrent Gliomas",[89],[12058,15274,15275],"Anaplastic Astrocytomas","Glioblastoma Multiforme",[15263],{"trials":15278,"activeCount":100},[],{"trials":15280,"activeCount":100},[],{"trials":15282,"activeCount":100},[],{"trials":15284,"activeCount":100},[],{"intervention":15286,"totalTrials":204,"cells":15287},"AMG 761",{"EARLY_PHASE1":15288,"PHASE1":15290,"PHASE2":15298,"PHASE3":15300,"PHASE4":15302,"NA":15304},{"trials":15289,"activeCount":100},[],{"trials":15291,"activeCount":100},[15292],{"nctId":15293,"briefTitle":15294,"status":336,"phases":15295,"primaryCompletion":8491,"completion":1625,"start":1685,"enrollment":1454,"conditions":15296,"interventions":15297},"NCT01514981","AMG 761 in Adults With Asthma",[89],[2941],[15286],{"trials":15299,"activeCount":100},[],{"trials":15301,"activeCount":100},[],{"trials":15303,"activeCount":100},[],{"trials":15305,"activeCount":100},[],{"intervention":15307,"totalTrials":204,"cells":15308},"AMG 427",{"EARLY_PHASE1":15309,"PHASE1":15311,"PHASE2":15321,"PHASE3":15323,"PHASE4":15325,"NA":15327},{"trials":15310,"activeCount":100},[],{"trials":15312,"activeCount":100},[15313],{"nctId":15314,"briefTitle":15315,"status":336,"phases":15316,"primaryCompletion":2977,"completion":2977,"start":15317,"enrollment":12445,"conditions":15318,"interventions":15320},"NCT03541369","Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed\u002FRefractory Acute Myeloid Leukemia",[89],"2018-09-14",[15319],"Relapsed\u002FRefractory Acute Myeloid Leukemia (AML)",[15307],{"trials":15322,"activeCount":100},[],{"trials":15324,"activeCount":100},[],{"trials":15326,"activeCount":100},[],{"trials":15328,"activeCount":100},[],{"intervention":15330,"totalTrials":204,"cells":15331},"AMG 786",{"EARLY_PHASE1":15332,"PHASE1":15334,"PHASE2":15343,"PHASE3":15345,"PHASE4":15347,"NA":15349},{"trials":15333,"activeCount":100},[],{"trials":15335,"activeCount":100},[15336],{"nctId":15337,"briefTitle":15338,"status":217,"phases":15339,"primaryCompletion":15340,"completion":15340,"start":6342,"enrollment":3142,"conditions":15341,"interventions":15342},"NCT05406115","Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity",[89],"2023-08-21",[897],[15330],{"trials":15344,"activeCount":100},[],{"trials":15346,"activeCount":100},[],{"trials":15348,"activeCount":100},[],{"trials":15350,"activeCount":100},[],{"intervention":15352,"totalTrials":204,"cells":15353},"AMG 208",{"EARLY_PHASE1":15354,"PHASE1":15356,"PHASE2":15364,"PHASE3":15366,"PHASE4":15368,"NA":15370},{"trials":15355,"activeCount":100},[],{"trials":15357,"activeCount":100},[15358],{"nctId":15359,"briefTitle":15360,"status":217,"phases":15361,"primaryCompletion":3869,"completion":11204,"start":2541,"enrollment":3881,"conditions":15362,"interventions":15363},"NCT00813384","A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors",[89],[25,2479,2478,11942,1290,11943],[15352],{"trials":15365,"activeCount":100},[],{"trials":15367,"activeCount":100},[],{"trials":15369,"activeCount":100},[],{"trials":15371,"activeCount":100},[],{"intervention":15373,"totalTrials":204,"cells":15374},"Denosumab CP4",{"EARLY_PHASE1":15375,"PHASE1":15377,"PHASE2":15386,"PHASE3":15388,"PHASE4":15390,"NA":15392},{"trials":15376,"activeCount":100},[],{"trials":15378,"activeCount":100},[15379],{"nctId":15380,"briefTitle":15381,"status":217,"phases":15382,"primaryCompletion":1703,"completion":1703,"start":1625,"enrollment":1864,"conditions":15383,"interventions":15384},"NCT02053753","Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product",[89],[2021],[15373,15385],"Denosumab CP2",{"trials":15387,"activeCount":100},[],{"trials":15389,"activeCount":100},[],{"trials":15391,"activeCount":100},[],{"trials":15393,"activeCount":100},[],{"intervention":15385,"totalTrials":204,"cells":15395},{"EARLY_PHASE1":15396,"PHASE1":15398,"PHASE2":15404,"PHASE3":15406,"PHASE4":15408,"NA":15410},{"trials":15397,"activeCount":100},[],{"trials":15399,"activeCount":100},[15400],{"nctId":15380,"briefTitle":15381,"status":217,"phases":15401,"primaryCompletion":1703,"completion":1703,"start":1625,"enrollment":1864,"conditions":15402,"interventions":15403},[89],[2021],[15373,15385],{"trials":15405,"activeCount":100},[],{"trials":15407,"activeCount":100},[],{"trials":15409,"activeCount":100},[],{"trials":15411,"activeCount":100},[],{"intervention":15413,"totalTrials":204,"cells":15414},"AMG 119",{"EARLY_PHASE1":15415,"PHASE1":15417,"PHASE2":15428,"PHASE3":15430,"PHASE4":15432,"NA":15434},{"trials":15416,"activeCount":100},[],{"trials":15418,"activeCount":100},[15419],{"nctId":15420,"briefTitle":15421,"status":15422,"phases":15423,"primaryCompletion":15424,"completion":15424,"start":15425,"enrollment":1164,"conditions":15426,"interventions":15427},"NCT03392064","A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC","SUSPENDED",[89],"2028-01-14","2018-09-10",[1097],[15413],{"trials":15429,"activeCount":100},[],{"trials":15431,"activeCount":100},[],{"trials":15433,"activeCount":100},[],{"trials":15435,"activeCount":100},[],{"intervention":15437,"totalTrials":204,"cells":15438},"AMG 553",{"EARLY_PHASE1":15439,"PHASE1":15441,"PHASE2":15452,"PHASE3":15454,"PHASE4":15456,"NA":15458},{"trials":15440,"activeCount":100},[],{"trials":15442,"activeCount":100},[15443],{"nctId":15444,"briefTitle":15445,"status":131,"phases":15446,"primaryCompletion":15447,"completion":15447,"start":15448,"enrollment":100,"conditions":15449,"interventions":15451},"NCT03904069","Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed\u002FRefractory AML",[89],"2030-08-07","2023-03-13",[15450],"Relapsed\u002FRefractory Acute Myeloid Leukemia",[15437],{"trials":15453,"activeCount":100},[],{"trials":15455,"activeCount":100},[],{"trials":15457,"activeCount":100},[],{"trials":15459,"activeCount":100},[],{"intervention":7559,"totalTrials":204,"cells":15461},{"EARLY_PHASE1":15462,"PHASE1":15464,"PHASE2":15470,"PHASE3":15472,"PHASE4":15474,"NA":15476},{"trials":15463,"activeCount":100},[],{"trials":15465,"activeCount":100},[15466],{"nctId":7553,"briefTitle":7554,"status":217,"phases":15467,"primaryCompletion":4421,"completion":2833,"start":6414,"enrollment":7556,"conditions":15468,"interventions":15469},[89],[2478],[7559,2428],{"trials":15471,"activeCount":100},[],{"trials":15473,"activeCount":100},[],{"trials":15475,"activeCount":100},[],{"trials":15477,"activeCount":100},[],{"intervention":4917,"totalTrials":204,"cells":15479},{"EARLY_PHASE1":15480,"PHASE1":15482,"PHASE2":15488,"PHASE3":15490,"PHASE4":15492,"NA":15494},{"trials":15481,"activeCount":100},[],{"trials":15483,"activeCount":100},[15484],{"nctId":4907,"briefTitle":4908,"status":217,"phases":15485,"primaryCompletion":4910,"completion":4911,"start":4912,"enrollment":26,"conditions":15486,"interventions":15487},[89],[4914],[4916,1930,4917,4611,4918],{"trials":15489,"activeCount":100},[],{"trials":15491,"activeCount":100},[],{"trials":15493,"activeCount":100},[],{"trials":15495,"activeCount":100},[],{"intervention":4918,"totalTrials":204,"cells":15497},{"EARLY_PHASE1":15498,"PHASE1":15500,"PHASE2":15506,"PHASE3":15508,"PHASE4":15510,"NA":15512},{"trials":15499,"activeCount":100},[],{"trials":15501,"activeCount":100},[15502],{"nctId":4907,"briefTitle":4908,"status":217,"phases":15503,"primaryCompletion":4910,"completion":4911,"start":4912,"enrollment":26,"conditions":15504,"interventions":15505},[89],[4914],[4916,1930,4917,4611,4918],{"trials":15507,"activeCount":100},[],{"trials":15509,"activeCount":100},[],{"trials":15511,"activeCount":100},[],{"trials":15513,"activeCount":100},[],{"intervention":15515,"totalTrials":204,"cells":15516},"AMG 172",{"EARLY_PHASE1":15517,"PHASE1":15519,"PHASE2":15531,"PHASE3":15533,"PHASE4":15535,"NA":15537},{"trials":15518,"activeCount":100},[],{"trials":15520,"activeCount":100},[15521],{"nctId":15522,"briefTitle":15523,"status":217,"phases":15524,"primaryCompletion":1637,"completion":8490,"start":1705,"enrollment":6514,"conditions":15525,"interventions":15530},"NCT01497821","AMG 172 First in Human Study in Patients With Kidney Cancer",[89],[15526,15527,15528,15529],"Renal Cell Adenocarcinoma","Clear Cell Renal Carcinoma","Clear Cell Renal Cell Carcinoma","Renal Cell Carcinoma",[15515],{"trials":15532,"activeCount":100},[],{"trials":15534,"activeCount":100},[],{"trials":15536,"activeCount":100},[],{"trials":15538,"activeCount":100},[],{"intervention":5359,"totalTrials":204,"cells":15540},{"EARLY_PHASE1":15541,"PHASE1":15543,"PHASE2":15549,"PHASE3":15551,"PHASE4":15553,"NA":15555},{"trials":15542,"activeCount":100},[],{"trials":15544,"activeCount":100},[15545],{"nctId":5349,"briefTitle":5350,"status":217,"phases":15546,"primaryCompletion":5352,"completion":5352,"start":5353,"enrollment":5354,"conditions":15547,"interventions":15548},[89],[5356],[5358,5359,246,5358,5358],{"trials":15550,"activeCount":100},[],{"trials":15552,"activeCount":100},[],{"trials":15554,"activeCount":100},[],{"trials":15556,"activeCount":100},[],{"intervention":15558,"totalTrials":204,"cells":15559},"AMG811",{"EARLY_PHASE1":15560,"PHASE1":15562,"PHASE2":15573,"PHASE3":15575,"PHASE4":15577,"NA":15579},{"trials":15561,"activeCount":100},[],{"trials":15563,"activeCount":100},[15564],{"nctId":15565,"briefTitle":15566,"status":336,"phases":15567,"primaryCompletion":15568,"completion":5191,"start":5151,"enrollment":1070,"conditions":15569,"interventions":15571},"NCT01164917","Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus",[89],"2012-09",[14413,15570,14414,114],"Discoid Lupus",[15558,15572],"AMG811 Placebo",{"trials":15574,"activeCount":100},[],{"trials":15576,"activeCount":100},[],{"trials":15578,"activeCount":100},[],{"trials":15580,"activeCount":100},[],{"intervention":15572,"totalTrials":204,"cells":15582},{"EARLY_PHASE1":15583,"PHASE1":15585,"PHASE2":15591,"PHASE3":15593,"PHASE4":15595,"NA":15597},{"trials":15584,"activeCount":100},[],{"trials":15586,"activeCount":100},[15587],{"nctId":15565,"briefTitle":15566,"status":336,"phases":15588,"primaryCompletion":15568,"completion":5191,"start":5151,"enrollment":1070,"conditions":15589,"interventions":15590},[89],[14413,15570,14414,114],[15558,15572],{"trials":15592,"activeCount":100},[],{"trials":15594,"activeCount":100},[],{"trials":15596,"activeCount":100},[],{"trials":15598,"activeCount":100},[],{"intervention":15600,"totalTrials":204,"cells":15601},"AMG 386, paclitaxel and carboplatin",{"EARLY_PHASE1":15602,"PHASE1":15604,"PHASE2":15612,"PHASE3":15614,"PHASE4":15616,"NA":15618},{"trials":15603,"activeCount":100},[],{"trials":15605,"activeCount":100},[15606],{"nctId":15607,"briefTitle":15608,"status":217,"phases":15609,"primaryCompletion":7260,"completion":8490,"start":1627,"enrollment":1545,"conditions":15610,"interventions":15611},"NCT01253681","Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer",[89],[2529,2886,2795,5171],[15600],{"trials":15613,"activeCount":100},[],{"trials":15615,"activeCount":100},[],{"trials":15617,"activeCount":100},[],{"trials":15619,"activeCount":100},[],{"intervention":15621,"totalTrials":204,"cells":15622},"AMG 570",{"EARLY_PHASE1":15623,"PHASE1":15625,"PHASE2":15636,"PHASE3":15638,"PHASE4":15640,"NA":15642},{"trials":15624,"activeCount":100},[],{"trials":15626,"activeCount":100},[15627],{"nctId":15628,"briefTitle":15629,"status":217,"phases":15630,"primaryCompletion":15631,"completion":15632,"start":15633,"enrollment":3391,"conditions":15634,"interventions":15635},"NCT02618967","Single Ascending Dose Study of AMG 570 in Healthy Subjects",[89],"2018-09-06","2018-12-03","2016-03-28",[114],[15621],{"trials":15637,"activeCount":100},[],{"trials":15639,"activeCount":100},[],{"trials":15641,"activeCount":100},[],{"trials":15643,"activeCount":100},[],{"intervention":5972,"totalTrials":204,"cells":15645},{"EARLY_PHASE1":15646,"PHASE1":15648,"PHASE2":15654,"PHASE3":15656,"PHASE4":15658,"NA":15660},{"trials":15647,"activeCount":100},[],{"trials":15649,"activeCount":100},[15650],{"nctId":5965,"briefTitle":5966,"status":217,"phases":15651,"primaryCompletion":5968,"completion":5968,"start":5969,"enrollment":2028,"conditions":15652,"interventions":15653},[89],[2053],[5972,5940],{"trials":15655,"activeCount":100},[],{"trials":15657,"activeCount":100},[],{"trials":15659,"activeCount":100},[],{"trials":15661,"activeCount":100},[],{"intervention":6519,"totalTrials":204,"cells":15663},{"EARLY_PHASE1":15664,"PHASE1":15666,"PHASE2":15672,"PHASE3":15674,"PHASE4":15676,"NA":15678},{"trials":15665,"activeCount":100},[],{"trials":15667,"activeCount":100},[15668],{"nctId":6509,"briefTitle":6510,"status":217,"phases":15669,"primaryCompletion":6512,"completion":6512,"start":6513,"enrollment":6514,"conditions":15670,"interventions":15671},[89],[6516,6517],[6502,6519],{"trials":15673,"activeCount":100},[],{"trials":15675,"activeCount":100},[],{"trials":15677,"activeCount":100},[],{"trials":15679,"activeCount":100},[],{"intervention":15681,"totalTrials":204,"cells":15682},"AMG 986 IV",{"EARLY_PHASE1":15683,"PHASE1":15685,"PHASE2":15697,"PHASE3":15699,"PHASE4":15701,"NA":15703},{"trials":15684,"activeCount":100},[],{"trials":15686,"activeCount":100},[15687],{"nctId":15688,"briefTitle":15689,"status":336,"phases":15690,"primaryCompletion":15691,"completion":15691,"start":15692,"enrollment":15693,"conditions":15694,"interventions":15695},"NCT03276728","Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients",[89],"2019-04-18","2016-08-12",182,[14938,2021],[15681,15696],"AMG 986 PO",{"trials":15698,"activeCount":100},[],{"trials":15700,"activeCount":100},[],{"trials":15702,"activeCount":100},[],{"trials":15704,"activeCount":100},[],{"intervention":15696,"totalTrials":204,"cells":15706},{"EARLY_PHASE1":15707,"PHASE1":15709,"PHASE2":15715,"PHASE3":15717,"PHASE4":15719,"NA":15721},{"trials":15708,"activeCount":100},[],{"trials":15710,"activeCount":100},[15711],{"nctId":15688,"briefTitle":15689,"status":336,"phases":15712,"primaryCompletion":15691,"completion":15691,"start":15692,"enrollment":15693,"conditions":15713,"interventions":15714},[89],[14938,2021],[15681,15696],{"trials":15716,"activeCount":100},[],{"trials":15718,"activeCount":100},[],{"trials":15720,"activeCount":100},[],{"trials":15722,"activeCount":100},[],{"intervention":2427,"totalTrials":204,"cells":15724},{"EARLY_PHASE1":15725,"PHASE1":15727,"PHASE2":15733,"PHASE3":15735,"PHASE4":15737,"NA":15739},{"trials":15726,"activeCount":100},[],{"trials":15728,"activeCount":100},[15729],{"nctId":2418,"briefTitle":2419,"status":217,"phases":15730,"primaryCompletion":2421,"completion":1685,"start":2422,"enrollment":2363,"conditions":15731,"interventions":15732},[89],[2424,2425],[2427,2428,1322,2429],{"trials":15734,"activeCount":100},[],{"trials":15736,"activeCount":100},[],{"trials":15738,"activeCount":100},[],{"trials":15740,"activeCount":100},[],{"intervention":15742,"totalTrials":204,"cells":15743},"AMG 305",{"EARLY_PHASE1":15744,"PHASE1":15746,"PHASE2":15755,"PHASE3":15757,"PHASE4":15759,"NA":15761},{"trials":15745,"activeCount":100},[],{"trials":15747,"activeCount":100},[15748],{"nctId":15749,"briefTitle":15750,"status":217,"phases":15751,"primaryCompletion":15752,"completion":15752,"start":7216,"enrollment":6514,"conditions":15753,"interventions":15754},"NCT05800964","Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors",[89],"2026-01-22",[1290],[15742],{"trials":15756,"activeCount":100},[],{"trials":15758,"activeCount":100},[],{"trials":15760,"activeCount":100},[],{"trials":15762,"activeCount":100},[],{"intervention":7366,"totalTrials":204,"cells":15764},{"EARLY_PHASE1":15765,"PHASE1":15767,"PHASE2":15773,"PHASE3":15775,"PHASE4":15777,"NA":15779},{"trials":15766,"activeCount":100},[],{"trials":15768,"activeCount":100},[15769],{"nctId":7354,"briefTitle":7355,"status":336,"phases":15770,"primaryCompletion":7357,"completion":7357,"start":7358,"enrollment":253,"conditions":15771,"interventions":15772},[89],[31,7360,7361,7362,7363,4423,7364],[7366,1656,7367],{"trials":15774,"activeCount":100},[],{"trials":15776,"activeCount":100},[],{"trials":15778,"activeCount":100},[],{"trials":15780,"activeCount":100},[],{"intervention":9518,"totalTrials":204,"cells":15782},{"EARLY_PHASE1":15783,"PHASE1":15785,"PHASE2":15791,"PHASE3":15793,"PHASE4":15795,"NA":15797},{"trials":15784,"activeCount":100},[],{"trials":15786,"activeCount":100},[15787],{"nctId":9511,"briefTitle":9512,"status":217,"phases":15788,"primaryCompletion":9514,"completion":969,"start":9515,"enrollment":6107,"conditions":15789,"interventions":15790},[89],[2907],[9518,9504],{"trials":15792,"activeCount":100},[],{"trials":15794,"activeCount":100},[],{"trials":15796,"activeCount":100},[],{"trials":15798,"activeCount":100},[],{"intervention":15800,"totalTrials":204,"cells":15801},"AMG 334 Dose 1",{"EARLY_PHASE1":15802,"PHASE1":15804,"PHASE2":15816,"PHASE3":15818,"PHASE4":15820,"NA":15822},{"trials":15803,"activeCount":100},[],{"trials":15805,"activeCount":100},[15806],{"nctId":15807,"briefTitle":15808,"status":217,"phases":15809,"primaryCompletion":15810,"completion":15810,"start":15811,"enrollment":2500,"conditions":15812,"interventions":15813},"NCT03499119","AMG 334 20160172 Pediatric Migraine PK Study.",[89],"2021-11-23","2018-05-04",[4039],[15800,15814,15815],"AMG 334 Dose 2","AMG 334 Dose 3",{"trials":15817,"activeCount":100},[],{"trials":15819,"activeCount":100},[],{"trials":15821,"activeCount":100},[],{"trials":15823,"activeCount":100},[],{"intervention":15814,"totalTrials":204,"cells":15825},{"EARLY_PHASE1":15826,"PHASE1":15828,"PHASE2":15834,"PHASE3":15836,"PHASE4":15838,"NA":15840},{"trials":15827,"activeCount":100},[],{"trials":15829,"activeCount":100},[15830],{"nctId":15807,"briefTitle":15808,"status":217,"phases":15831,"primaryCompletion":15810,"completion":15810,"start":15811,"enrollment":2500,"conditions":15832,"interventions":15833},[89],[4039],[15800,15814,15815],{"trials":15835,"activeCount":100},[],{"trials":15837,"activeCount":100},[],{"trials":15839,"activeCount":100},[],{"trials":15841,"activeCount":100},[],{"intervention":15815,"totalTrials":204,"cells":15843},{"EARLY_PHASE1":15844,"PHASE1":15846,"PHASE2":15852,"PHASE3":15854,"PHASE4":15856,"NA":15858},{"trials":15845,"activeCount":100},[],{"trials":15847,"activeCount":100},[15848],{"nctId":15807,"briefTitle":15808,"status":217,"phases":15849,"primaryCompletion":15810,"completion":15810,"start":15811,"enrollment":2500,"conditions":15850,"interventions":15851},[89],[4039],[15800,15814,15815],{"trials":15853,"activeCount":100},[],{"trials":15855,"activeCount":100},[],{"trials":15857,"activeCount":100},[],{"trials":15859,"activeCount":100},[],{"intervention":15861,"totalTrials":204,"cells":15862},"Apremilast IR",{"EARLY_PHASE1":15863,"PHASE1":15865,"PHASE2":15875,"PHASE3":15877,"PHASE4":15879,"NA":15881},{"trials":15864,"activeCount":100},[],{"trials":15866,"activeCount":100},[15867],{"nctId":15868,"briefTitle":15869,"status":217,"phases":15870,"primaryCompletion":2148,"completion":2148,"start":15871,"enrollment":7854,"conditions":15872,"interventions":15873},"NCT02777554","A Study to Evaluate the Pharmacokinetic Exposure of 2 Formulations of Apremilast in Healthy Adults",[89],"2016-08-17",[222],[15861,15874],"Apremilast XL",{"trials":15876,"activeCount":100},[],{"trials":15878,"activeCount":100},[],{"trials":15880,"activeCount":100},[],{"trials":15882,"activeCount":100},[],{"intervention":15874,"totalTrials":204,"cells":15884},{"EARLY_PHASE1":15885,"PHASE1":15887,"PHASE2":15893,"PHASE3":15895,"PHASE4":15897,"NA":15899},{"trials":15886,"activeCount":100},[],{"trials":15888,"activeCount":100},[15889],{"nctId":15868,"briefTitle":15869,"status":217,"phases":15890,"primaryCompletion":2148,"completion":2148,"start":15871,"enrollment":7854,"conditions":15891,"interventions":15892},[89],[222],[15861,15874],{"trials":15894,"activeCount":100},[],{"trials":15896,"activeCount":100},[],{"trials":15898,"activeCount":100},[],{"trials":15900,"activeCount":100},[],{"intervention":7379,"totalTrials":204,"cells":15902},{"EARLY_PHASE1":15903,"PHASE1":15905,"PHASE2":15911,"PHASE3":15913,"PHASE4":15915,"NA":15917},{"trials":15904,"activeCount":100},[],{"trials":15906,"activeCount":100},[15907],{"nctId":7369,"briefTitle":7370,"status":217,"phases":15908,"primaryCompletion":7372,"completion":7372,"start":7373,"enrollment":7374,"conditions":15909,"interventions":15910},[89],[7376],[2827,1656,7378,1767,7379,7380,7381,7382,296,7383,1764],{"trials":15912,"activeCount":100},[],{"trials":15914,"activeCount":100},[],{"trials":15916,"activeCount":100},[],{"trials":15918,"activeCount":100},[],{"intervention":7380,"totalTrials":204,"cells":15920},{"EARLY_PHASE1":15921,"PHASE1":15923,"PHASE2":15929,"PHASE3":15931,"PHASE4":15933,"NA":15935},{"trials":15922,"activeCount":100},[],{"trials":15924,"activeCount":100},[15925],{"nctId":7369,"briefTitle":7370,"status":217,"phases":15926,"primaryCompletion":7372,"completion":7372,"start":7373,"enrollment":7374,"conditions":15927,"interventions":15928},[89],[7376],[2827,1656,7378,1767,7379,7380,7381,7382,296,7383,1764],{"trials":15930,"activeCount":100},[],{"trials":15932,"activeCount":100},[],{"trials":15934,"activeCount":100},[],{"trials":15936,"activeCount":100},[],{"intervention":7381,"totalTrials":204,"cells":15938},{"EARLY_PHASE1":15939,"PHASE1":15941,"PHASE2":15947,"PHASE3":15949,"PHASE4":15951,"NA":15953},{"trials":15940,"activeCount":100},[],{"trials":15942,"activeCount":100},[15943],{"nctId":7369,"briefTitle":7370,"status":217,"phases":15944,"primaryCompletion":7372,"completion":7372,"start":7373,"enrollment":7374,"conditions":15945,"interventions":15946},[89],[7376],[2827,1656,7378,1767,7379,7380,7381,7382,296,7383,1764],{"trials":15948,"activeCount":100},[],{"trials":15950,"activeCount":100},[],{"trials":15952,"activeCount":100},[],{"trials":15954,"activeCount":100},[],{"intervention":7382,"totalTrials":204,"cells":15956},{"EARLY_PHASE1":15957,"PHASE1":15959,"PHASE2":15965,"PHASE3":15967,"PHASE4":15969,"NA":15971},{"trials":15958,"activeCount":100},[],{"trials":15960,"activeCount":100},[15961],{"nctId":7369,"briefTitle":7370,"status":217,"phases":15962,"primaryCompletion":7372,"completion":7372,"start":7373,"enrollment":7374,"conditions":15963,"interventions":15964},[89],[7376],[2827,1656,7378,1767,7379,7380,7381,7382,296,7383,1764],{"trials":15966,"activeCount":100},[],{"trials":15968,"activeCount":100},[],{"trials":15970,"activeCount":100},[],{"trials":15972,"activeCount":100},[],{"intervention":7383,"totalTrials":204,"cells":15974},{"EARLY_PHASE1":15975,"PHASE1":15977,"PHASE2":15983,"PHASE3":15985,"PHASE4":15987,"NA":15989},{"trials":15976,"activeCount":100},[],{"trials":15978,"activeCount":100},[15979],{"nctId":7369,"briefTitle":7370,"status":217,"phases":15980,"primaryCompletion":7372,"completion":7372,"start":7373,"enrollment":7374,"conditions":15981,"interventions":15982},[89],[7376],[2827,1656,7378,1767,7379,7380,7381,7382,296,7383,1764],{"trials":15984,"activeCount":100},[],{"trials":15986,"activeCount":100},[],{"trials":15988,"activeCount":100},[],{"trials":15990,"activeCount":100},[],{"intervention":15992,"totalTrials":204,"cells":15993},"AMG 780",{"EARLY_PHASE1":15994,"PHASE1":15996,"PHASE2":16005,"PHASE3":16007,"PHASE4":16009,"NA":16011},{"trials":15995,"activeCount":100},[],{"trials":15997,"activeCount":100},[15998],{"nctId":15999,"briefTitle":16000,"status":336,"phases":16001,"primaryCompletion":16002,"completion":8563,"start":2452,"enrollment":4671,"conditions":16003,"interventions":16004},"NCT01137552","A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors",[89],"2013-12",[1290],[15992],{"trials":16006,"activeCount":100},[],{"trials":16008,"activeCount":100},[],{"trials":16010,"activeCount":100},[],{"trials":16012,"activeCount":100},[],{"intervention":16014,"totalTrials":204,"cells":16015},"FPA144",{"EARLY_PHASE1":16016,"PHASE1":16018,"PHASE2":16029,"PHASE3":16031,"PHASE4":16033,"NA":16035},{"trials":16017,"activeCount":100},[],{"trials":16019,"activeCount":100},[16020],{"nctId":16021,"briefTitle":16022,"status":217,"phases":16023,"primaryCompletion":16024,"completion":16024,"start":16025,"enrollment":1164,"conditions":16026,"interventions":16028},"NCT05913115","A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer",[89],"2018-06-19","2017-06-12",[16027],"Gastric or Gastroesophageal Cancer",[16014],{"trials":16030,"activeCount":100},[],{"trials":16032,"activeCount":100},[],{"trials":16034,"activeCount":100},[],{"trials":16036,"activeCount":100},[],{"intervention":16038,"totalTrials":204,"cells":16039},"AMG 827 or Placebo",{"EARLY_PHASE1":16040,"PHASE1":16042,"PHASE2":16050,"PHASE3":16052,"PHASE4":16054,"NA":16056},{"trials":16041,"activeCount":100},[],{"trials":16043,"activeCount":100},[16044],{"nctId":16045,"briefTitle":16046,"status":131,"phases":16047,"primaryCompletion":7852,"completion":7852,"start":8927,"enrollment":100,"conditions":16048,"interventions":16049},"NCT01395485","Safety, Tolerability, and Pharmacokinetics of AMG 827 in Adolescents With Asthma",[89],[2941],[16038],{"trials":16051,"activeCount":100},[],{"trials":16053,"activeCount":100},[],{"trials":16055,"activeCount":100},[],{"trials":16057,"activeCount":100},[],{"intervention":16059,"totalTrials":204,"cells":16060},"MEDI7734",{"EARLY_PHASE1":16061,"PHASE1":16063,"PHASE2":16074,"PHASE3":16076,"PHASE4":16078,"NA":16080},{"trials":16062,"activeCount":100},[],{"trials":16064,"activeCount":100},[16065],{"nctId":16066,"briefTitle":16067,"status":217,"phases":16068,"primaryCompletion":11309,"completion":16069,"start":16070,"enrollment":439,"conditions":16071,"interventions":16073},"NCT02780674","A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases",[89],"2017-11-27","2016-08-26",[16072],"Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc",[16059],{"trials":16075,"activeCount":100},[],{"trials":16077,"activeCount":100},[],{"trials":16079,"activeCount":100},[],{"trials":16081,"activeCount":100},[],{"intervention":5254,"totalTrials":204,"cells":16083},{"EARLY_PHASE1":16084,"PHASE1":16086,"PHASE2":16092,"PHASE3":16094,"PHASE4":16096,"NA":16098},{"trials":16085,"activeCount":100},[],{"trials":16087,"activeCount":100},[16088],{"nctId":5247,"briefTitle":5248,"status":217,"phases":16089,"primaryCompletion":5250,"completion":5250,"start":5251,"enrollment":3338,"conditions":16090,"interventions":16091},[89],[1290],[5254,1099],{"trials":16093,"activeCount":100},[],{"trials":16095,"activeCount":100},[],{"trials":16097,"activeCount":100},[],{"trials":16099,"activeCount":100},[],{"intervention":16101,"totalTrials":204,"cells":16102},"AMG 562",{"EARLY_PHASE1":16103,"PHASE1":16105,"PHASE2":16118,"PHASE3":16120,"PHASE4":16122,"NA":16124},{"trials":16104,"activeCount":100},[],{"trials":16106,"activeCount":100},[16107],{"nctId":16108,"briefTitle":16109,"status":336,"phases":16110,"primaryCompletion":16111,"completion":16111,"start":16112,"enrollment":1726,"conditions":16113,"interventions":16117},"NCT03571828","Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r\u002Fr Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma",[89],"2022-01-12","2018-10-29",[16114,16115,16116],"Diffuse Large B-cell Lymphoma(DLBCL)","Mantle Cell Lymphoma (MCL)","Follicular Lymphoma (FL)",[16101],{"trials":16119,"activeCount":100},[],{"trials":16121,"activeCount":100},[],{"trials":16123,"activeCount":100},[],{"trials":16125,"activeCount":100},[],{"intervention":5265,"totalTrials":204,"cells":16127},{"EARLY_PHASE1":16128,"PHASE1":16130,"PHASE2":16136,"PHASE3":16138,"PHASE4":16140,"NA":16142},{"trials":16129,"activeCount":100},[],{"trials":16131,"activeCount":100},[16132],{"nctId":5256,"briefTitle":5257,"status":336,"phases":16133,"primaryCompletion":5259,"completion":5260,"start":5261,"enrollment":866,"conditions":16134,"interventions":16135},[89],[5263],[5265,1099],{"trials":16137,"activeCount":100},[],{"trials":16139,"activeCount":100},[],{"trials":16141,"activeCount":100},[],{"trials":16143,"activeCount":100},[],{"intervention":16145,"totalTrials":204,"cells":16146},"AMG 811 or Placebo",{"EARLY_PHASE1":16147,"PHASE1":16149,"PHASE2":16157,"PHASE3":16159,"PHASE4":16161,"NA":16163},{"trials":16148,"activeCount":100},[],{"trials":16150,"activeCount":100},[16151],{"nctId":16152,"briefTitle":16153,"status":217,"phases":16154,"primaryCompletion":7260,"completion":7260,"start":1565,"enrollment":96,"conditions":16155,"interventions":16156},"NCT01510951","Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis",[89],[22],[16145],{"trials":16158,"activeCount":100},[],{"trials":16160,"activeCount":100},[],{"trials":16162,"activeCount":100},[],{"trials":16164,"activeCount":100},[],{"intervention":16166,"totalTrials":204,"cells":16167},"AMG 211",{"EARLY_PHASE1":16168,"PHASE1":16170,"PHASE2":16181,"PHASE3":16183,"PHASE4":16185,"NA":16187},{"trials":16169,"activeCount":100},[],{"trials":16171,"activeCount":100},[16172],{"nctId":16173,"briefTitle":16174,"status":336,"phases":16175,"primaryCompletion":16176,"completion":3821,"start":16177,"enrollment":20,"conditions":16178,"interventions":16180},"NCT02291614","A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer",[89],"2017-11-06","2014-11-27",[16179],"GI Adenocarcinoma",[16166],{"trials":16182,"activeCount":100},[],{"trials":16184,"activeCount":100},[],{"trials":16186,"activeCount":100},[],{"trials":16188,"activeCount":100},[],{"intervention":16190,"totalTrials":204,"cells":16191},"[14C]CCX168",{"EARLY_PHASE1":16192,"PHASE1":16194,"PHASE2":16204,"PHASE3":16206,"PHASE4":16208,"NA":16210},{"trials":16193,"activeCount":100},[],{"trials":16195,"activeCount":100},[16196],{"nctId":16197,"briefTitle":16198,"status":217,"phases":16199,"primaryCompletion":16200,"completion":16200,"start":16201,"enrollment":1164,"conditions":16202,"interventions":16203},"NCT06004960","A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants",[89],"2014-12-05","2014-10-20",[4914],[16190],{"trials":16205,"activeCount":100},[],{"trials":16207,"activeCount":100},[],{"trials":16209,"activeCount":100},[],{"trials":16211,"activeCount":100},[],{"intervention":6147,"totalTrials":204,"cells":16213},{"EARLY_PHASE1":16214,"PHASE1":16216,"PHASE2":16222,"PHASE3":16224,"PHASE4":16226,"NA":16228},{"trials":16215,"activeCount":100},[],{"trials":16217,"activeCount":100},[16218],{"nctId":6139,"briefTitle":6140,"status":217,"phases":16219,"completion":6142,"start":6143,"enrollment":253,"conditions":16220,"interventions":16221},[89],[6145],[5358,6147,6148],{"trials":16223,"activeCount":100},[],{"trials":16225,"activeCount":100},[],{"trials":16227,"activeCount":100},[],{"trials":16229,"activeCount":100},[],{"intervention":16231,"totalTrials":204,"cells":16232},"CCX872-B",{"EARLY_PHASE1":16233,"PHASE1":16235,"PHASE2":16244,"PHASE3":16246,"PHASE4":16248,"NA":16250},{"trials":16234,"activeCount":100},[],{"trials":16236,"activeCount":100},[16237],{"nctId":16238,"briefTitle":16239,"status":217,"phases":16240,"primaryCompletion":16241,"completion":16241,"start":4512,"enrollment":3881,"conditions":16242,"interventions":16243},"NCT02345408","Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma",[89],"2020-05-06",[2464],[16231],{"trials":16245,"activeCount":100},[],{"trials":16247,"activeCount":100},[],{"trials":16249,"activeCount":100},[],{"trials":16251,"activeCount":100},[],{"intervention":16253,"totalTrials":204,"cells":16254},"AMG 228",{"EARLY_PHASE1":16255,"PHASE1":16257,"PHASE2":16269,"PHASE3":16271,"PHASE4":16273,"NA":16275},{"trials":16256,"activeCount":100},[],{"trials":16258,"activeCount":100},[16259],{"nctId":16260,"briefTitle":16261,"status":336,"phases":16262,"primaryCompletion":16263,"completion":16263,"start":16264,"enrollment":866,"conditions":16265,"interventions":16268},"NCT02437916","Safety Study of AMG 228 to Treat Solid Tumors",[89],"2016-12-12","2015-04-21",[11942,1290,25,2479,11943,2478,1402,1303,16266,16267,34],"Squamous Cell Carcinoma of the Head and Neck","Transitional Cell Carinoma of Bladder",[16253],{"trials":16270,"activeCount":100},[],{"trials":16272,"activeCount":100},[],{"trials":16274,"activeCount":100},[],{"trials":16276,"activeCount":100},[],{"intervention":16278,"totalTrials":204,"cells":16279},"A1: AMG 386 10 mg\u002Fkg + Liposomal doxorubicin",{"EARLY_PHASE1":16280,"PHASE1":16282,"PHASE2":16293,"PHASE3":16295,"PHASE4":16297,"NA":16299},{"trials":16281,"activeCount":100},[],{"trials":16283,"activeCount":100},[16284],{"nctId":16285,"briefTitle":16286,"status":217,"phases":16287,"primaryCompletion":1705,"completion":7866,"start":2586,"enrollment":5996,"conditions":16288,"interventions":16289},"NCT00770536","AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR",[89],[25,2529,2886,12026,2531,2479,2795,2441,2478],[16278,16290,16291,16292],"A3: AMG 386 15mg\u002Fkg + Liposomal doxorubicin","B1: AMG 386 10 mg\u002Fkg + Topotecan","B3: AMG 386 15mg\u002Fkg + Topotecan",{"trials":16294,"activeCount":100},[],{"trials":16296,"activeCount":100},[],{"trials":16298,"activeCount":100},[],{"trials":16300,"activeCount":100},[],{"intervention":16290,"totalTrials":204,"cells":16302},{"EARLY_PHASE1":16303,"PHASE1":16305,"PHASE2":16311,"PHASE3":16313,"PHASE4":16315,"NA":16317},{"trials":16304,"activeCount":100},[],{"trials":16306,"activeCount":100},[16307],{"nctId":16285,"briefTitle":16286,"status":217,"phases":16308,"primaryCompletion":1705,"completion":7866,"start":2586,"enrollment":5996,"conditions":16309,"interventions":16310},[89],[25,2529,2886,12026,2531,2479,2795,2441,2478],[16278,16290,16291,16292],{"trials":16312,"activeCount":100},[],{"trials":16314,"activeCount":100},[],{"trials":16316,"activeCount":100},[],{"trials":16318,"activeCount":100},[],{"intervention":16291,"totalTrials":204,"cells":16320},{"EARLY_PHASE1":16321,"PHASE1":16323,"PHASE2":16329,"PHASE3":16331,"PHASE4":16333,"NA":16335},{"trials":16322,"activeCount":100},[],{"trials":16324,"activeCount":100},[16325],{"nctId":16285,"briefTitle":16286,"status":217,"phases":16326,"primaryCompletion":1705,"completion":7866,"start":2586,"enrollment":5996,"conditions":16327,"interventions":16328},[89],[25,2529,2886,12026,2531,2479,2795,2441,2478],[16278,16290,16291,16292],{"trials":16330,"activeCount":100},[],{"trials":16332,"activeCount":100},[],{"trials":16334,"activeCount":100},[],{"trials":16336,"activeCount":100},[],{"intervention":16292,"totalTrials":204,"cells":16338},{"EARLY_PHASE1":16339,"PHASE1":16341,"PHASE2":16347,"PHASE3":16349,"PHASE4":16351,"NA":16353},{"trials":16340,"activeCount":100},[],{"trials":16342,"activeCount":100},[16343],{"nctId":16285,"briefTitle":16286,"status":217,"phases":16344,"primaryCompletion":1705,"completion":7866,"start":2586,"enrollment":5996,"conditions":16345,"interventions":16346},[89],[25,2529,2886,12026,2531,2479,2795,2441,2478],[16278,16290,16291,16292],{"trials":16348,"activeCount":100},[],{"trials":16350,"activeCount":100},[],{"trials":16352,"activeCount":100},[],{"trials":16354,"activeCount":100},[],{"intervention":16356,"totalTrials":204,"cells":16357},"Apremilast Immediate Release",{"EARLY_PHASE1":16358,"PHASE1":16360,"PHASE2":16382,"PHASE3":16384,"PHASE4":16386,"NA":16388},{"trials":16359,"activeCount":100},[],{"trials":16361,"activeCount":100},[16362],{"nctId":16363,"briefTitle":16364,"status":217,"phases":16365,"primaryCompletion":16366,"completion":16366,"start":16367,"enrollment":5508,"conditions":16368,"interventions":16369},"NCT02236988","Study to Evaluate Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast in Healthy Men",[89],"2014-09-11","2014-01-07",[222],[16356,16370,16371,16372,16373,16374,16375,16376,16377,16378,16379,16380,16381],"Apremilast Modified Release 1","Apremilast Modified Release 2","Apremilast Modified Release 3","Apremilast Modified Release 4","Apremilast Modified Release 5","Apremilast Modified Release 6","Apremilast Modified Release 8","Apremilast Modified Release 9","Apremilast Modified Release 11","Apremilast Modified Release 12","Apremilast Modified Release 13","Apremilast Modified Release 14",{"trials":16383,"activeCount":100},[],{"trials":16385,"activeCount":100},[],{"trials":16387,"activeCount":100},[],{"trials":16389,"activeCount":100},[],{"intervention":16370,"totalTrials":204,"cells":16391},{"EARLY_PHASE1":16392,"PHASE1":16394,"PHASE2":16400,"PHASE3":16402,"PHASE4":16404,"NA":16406},{"trials":16393,"activeCount":100},[],{"trials":16395,"activeCount":100},[16396],{"nctId":16363,"briefTitle":16364,"status":217,"phases":16397,"primaryCompletion":16366,"completion":16366,"start":16367,"enrollment":5508,"conditions":16398,"interventions":16399},[89],[222],[16356,16370,16371,16372,16373,16374,16375,16376,16377,16378,16379,16380,16381],{"trials":16401,"activeCount":100},[],{"trials":16403,"activeCount":100},[],{"trials":16405,"activeCount":100},[],{"trials":16407,"activeCount":100},[],{"intervention":16371,"totalTrials":204,"cells":16409},{"EARLY_PHASE1":16410,"PHASE1":16412,"PHASE2":16418,"PHASE3":16420,"PHASE4":16422,"NA":16424},{"trials":16411,"activeCount":100},[],{"trials":16413,"activeCount":100},[16414],{"nctId":16363,"briefTitle":16364,"status":217,"phases":16415,"primaryCompletion":16366,"completion":16366,"start":16367,"enrollment":5508,"conditions":16416,"interventions":16417},[89],[222],[16356,16370,16371,16372,16373,16374,16375,16376,16377,16378,16379,16380,16381],{"trials":16419,"activeCount":100},[],{"trials":16421,"activeCount":100},[],{"trials":16423,"activeCount":100},[],{"trials":16425,"activeCount":100},[],{"intervention":16372,"totalTrials":204,"cells":16427},{"EARLY_PHASE1":16428,"PHASE1":16430,"PHASE2":16436,"PHASE3":16438,"PHASE4":16440,"NA":16442},{"trials":16429,"activeCount":100},[],{"trials":16431,"activeCount":100},[16432],{"nctId":16363,"briefTitle":16364,"status":217,"phases":16433,"primaryCompletion":16366,"completion":16366,"start":16367,"enrollment":5508,"conditions":16434,"interventions":16435},[89],[222],[16356,16370,16371,16372,16373,16374,16375,16376,16377,16378,16379,16380,16381],{"trials":16437,"activeCount":100},[],{"trials":16439,"activeCount":100},[],{"trials":16441,"activeCount":100},[],{"trials":16443,"activeCount":100},[],{"intervention":16373,"totalTrials":204,"cells":16445},{"EARLY_PHASE1":16446,"PHASE1":16448,"PHASE2":16454,"PHASE3":16456,"PHASE4":16458,"NA":16460},{"trials":16447,"activeCount":100},[],{"trials":16449,"activeCount":100},[16450],{"nctId":16363,"briefTitle":16364,"status":217,"phases":16451,"primaryCompletion":16366,"completion":16366,"start":16367,"enrollment":5508,"conditions":16452,"interventions":16453},[89],[222],[16356,16370,16371,16372,16373,16374,16375,16376,16377,16378,16379,16380,16381],{"trials":16455,"activeCount":100},[],{"trials":16457,"activeCount":100},[],{"trials":16459,"activeCount":100},[],{"trials":16461,"activeCount":100},[],{"intervention":16374,"totalTrials":204,"cells":16463},{"EARLY_PHASE1":16464,"PHASE1":16466,"PHASE2":16472,"PHASE3":16474,"PHASE4":16476,"NA":16478},{"trials":16465,"activeCount":100},[],{"trials":16467,"activeCount":100},[16468],{"nctId":16363,"briefTitle":16364,"status":217,"phases":16469,"primaryCompletion":16366,"completion":16366,"start":16367,"enrollment":5508,"conditions":16470,"interventions":16471},[89],[222],[16356,16370,16371,16372,16373,16374,16375,16376,16377,16378,16379,16380,16381],{"trials":16473,"activeCount":100},[],{"trials":16475,"activeCount":100},[],{"trials":16477,"activeCount":100},[],{"trials":16479,"activeCount":100},[],{"intervention":16375,"totalTrials":204,"cells":16481},{"EARLY_PHASE1":16482,"PHASE1":16484,"PHASE2":16490,"PHASE3":16492,"PHASE4":16494,"NA":16496},{"trials":16483,"activeCount":100},[],{"trials":16485,"activeCount":100},[16486],{"nctId":16363,"briefTitle":16364,"status":217,"phases":16487,"primaryCompletion":16366,"completion":16366,"start":16367,"enrollment":5508,"conditions":16488,"interventions":16489},[89],[222],[16356,16370,16371,16372,16373,16374,16375,16376,16377,16378,16379,16380,16381],{"trials":16491,"activeCount":100},[],{"trials":16493,"activeCount":100},[],{"trials":16495,"activeCount":100},[],{"trials":16497,"activeCount":100},[],{"intervention":16376,"totalTrials":204,"cells":16499},{"EARLY_PHASE1":16500,"PHASE1":16502,"PHASE2":16508,"PHASE3":16510,"PHASE4":16512,"NA":16514},{"trials":16501,"activeCount":100},[],{"trials":16503,"activeCount":100},[16504],{"nctId":16363,"briefTitle":16364,"status":217,"phases":16505,"primaryCompletion":16366,"completion":16366,"start":16367,"enrollment":5508,"conditions":16506,"interventions":16507},[89],[222],[16356,16370,16371,16372,16373,16374,16375,16376,16377,16378,16379,16380,16381],{"trials":16509,"activeCount":100},[],{"trials":16511,"activeCount":100},[],{"trials":16513,"activeCount":100},[],{"trials":16515,"activeCount":100},[],{"intervention":16377,"totalTrials":204,"cells":16517},{"EARLY_PHASE1":16518,"PHASE1":16520,"PHASE2":16526,"PHASE3":16528,"PHASE4":16530,"NA":16532},{"trials":16519,"activeCount":100},[],{"trials":16521,"activeCount":100},[16522],{"nctId":16363,"briefTitle":16364,"status":217,"phases":16523,"primaryCompletion":16366,"completion":16366,"start":16367,"enrollment":5508,"conditions":16524,"interventions":16525},[89],[222],[16356,16370,16371,16372,16373,16374,16375,16376,16377,16378,16379,16380,16381],{"trials":16527,"activeCount":100},[],{"trials":16529,"activeCount":100},[],{"trials":16531,"activeCount":100},[],{"trials":16533,"activeCount":100},[],{"intervention":16378,"totalTrials":204,"cells":16535},{"EARLY_PHASE1":16536,"PHASE1":16538,"PHASE2":16544,"PHASE3":16546,"PHASE4":16548,"NA":16550},{"trials":16537,"activeCount":100},[],{"trials":16539,"activeCount":100},[16540],{"nctId":16363,"briefTitle":16364,"status":217,"phases":16541,"primaryCompletion":16366,"completion":16366,"start":16367,"enrollment":5508,"conditions":16542,"interventions":16543},[89],[222],[16356,16370,16371,16372,16373,16374,16375,16376,16377,16378,16379,16380,16381],{"trials":16545,"activeCount":100},[],{"trials":16547,"activeCount":100},[],{"trials":16549,"activeCount":100},[],{"trials":16551,"activeCount":100},[],{"intervention":16379,"totalTrials":204,"cells":16553},{"EARLY_PHASE1":16554,"PHASE1":16556,"PHASE2":16562,"PHASE3":16564,"PHASE4":16566,"NA":16568},{"trials":16555,"activeCount":100},[],{"trials":16557,"activeCount":100},[16558],{"nctId":16363,"briefTitle":16364,"status":217,"phases":16559,"primaryCompletion":16366,"completion":16366,"start":16367,"enrollment":5508,"conditions":16560,"interventions":16561},[89],[222],[16356,16370,16371,16372,16373,16374,16375,16376,16377,16378,16379,16380,16381],{"trials":16563,"activeCount":100},[],{"trials":16565,"activeCount":100},[],{"trials":16567,"activeCount":100},[],{"trials":16569,"activeCount":100},[],{"intervention":16380,"totalTrials":204,"cells":16571},{"EARLY_PHASE1":16572,"PHASE1":16574,"PHASE2":16580,"PHASE3":16582,"PHASE4":16584,"NA":16586},{"trials":16573,"activeCount":100},[],{"trials":16575,"activeCount":100},[16576],{"nctId":16363,"briefTitle":16364,"status":217,"phases":16577,"primaryCompletion":16366,"completion":16366,"start":16367,"enrollment":5508,"conditions":16578,"interventions":16579},[89],[222],[16356,16370,16371,16372,16373,16374,16375,16376,16377,16378,16379,16380,16381],{"trials":16581,"activeCount":100},[],{"trials":16583,"activeCount":100},[],{"trials":16585,"activeCount":100},[],{"trials":16587,"activeCount":100},[],{"intervention":16381,"totalTrials":204,"cells":16589},{"EARLY_PHASE1":16590,"PHASE1":16592,"PHASE2":16598,"PHASE3":16600,"PHASE4":16602,"NA":16604},{"trials":16591,"activeCount":100},[],{"trials":16593,"activeCount":100},[16594],{"nctId":16363,"briefTitle":16364,"status":217,"phases":16595,"primaryCompletion":16366,"completion":16366,"start":16367,"enrollment":5508,"conditions":16596,"interventions":16597},[89],[222],[16356,16370,16371,16372,16373,16374,16375,16376,16377,16378,16379,16380,16381],{"trials":16599,"activeCount":100},[],{"trials":16601,"activeCount":100},[],{"trials":16603,"activeCount":100},[],{"trials":16605,"activeCount":100},[],{"intervention":16607,"totalTrials":204,"cells":16608},"AMG 794",{"EARLY_PHASE1":16609,"PHASE1":16611,"PHASE2":16623,"PHASE3":16625,"PHASE4":16627,"NA":16629},{"trials":16610,"activeCount":100},[],{"trials":16612,"activeCount":100},[16613],{"nctId":16614,"briefTitle":16615,"status":336,"phases":16616,"primaryCompletion":3262,"completion":16617,"start":4695,"enrollment":193,"conditions":16618,"interventions":16622},"NCT05317078","A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications",[89],"2024-04-01",[16619,16620,16621],"Non-squamous Non-small Cell Lung Cancer","Epithelial Ovarian Cancer","Claudin 6-positive Advanced\u002FMetastatic Malignant Solid Tumors",[16607],{"trials":16624,"activeCount":100},[],{"trials":16626,"activeCount":100},[],{"trials":16628,"activeCount":100},[],{"trials":16630,"activeCount":100},[],{"intervention":14336,"totalTrials":204,"cells":16632},{"EARLY_PHASE1":16633,"PHASE1":16635,"PHASE2":16641,"PHASE3":16643,"PHASE4":16645,"NA":16647},{"trials":16634,"activeCount":100},[],{"trials":16636,"activeCount":100},[16637],{"nctId":14328,"briefTitle":14329,"status":217,"phases":16638,"primaryCompletion":14331,"completion":14331,"start":14332,"enrollment":14333,"conditions":16639,"interventions":16640},[89],[896,897],[6682,14336],{"trials":16642,"activeCount":100},[],{"trials":16644,"activeCount":100},[],{"trials":16646,"activeCount":100},[],{"trials":16648,"activeCount":100},[],{"intervention":7845,"totalTrials":204,"cells":16650},{"EARLY_PHASE1":16651,"PHASE1":16653,"PHASE2":16659,"PHASE3":16661,"PHASE4":16663,"NA":16665},{"trials":16652,"activeCount":100},[],{"trials":16654,"activeCount":100},[16655],{"nctId":7838,"briefTitle":7839,"status":217,"phases":16656,"primaryCompletion":7841,"start":7842,"enrollment":1582,"conditions":16657,"interventions":16658},[89],[1290,383,3266],[7845,2807],{"trials":16660,"activeCount":100},[],{"trials":16662,"activeCount":100},[],{"trials":16664,"activeCount":100},[],{"trials":16666,"activeCount":100},[],{"intervention":4619,"totalTrials":204,"cells":16668},{"EARLY_PHASE1":16669,"PHASE1":16671,"PHASE2":16677,"PHASE3":16679,"PHASE4":16681,"NA":16683},{"trials":16670,"activeCount":100},[],{"trials":16672,"activeCount":100},[16673],{"nctId":4613,"briefTitle":4614,"status":217,"phases":16674,"primaryCompletion":4616,"completion":4616,"start":2206,"enrollment":1907,"conditions":16675,"interventions":16676},[89],[1857],[43,1849,4619],{"trials":16678,"activeCount":100},[],{"trials":16680,"activeCount":100},[],{"trials":16682,"activeCount":100},[],{"trials":16684,"activeCount":100},[],{"intervention":2056,"totalTrials":204,"cells":16686},{"EARLY_PHASE1":16687,"PHASE1":16689,"PHASE2":16695,"PHASE3":16697,"PHASE4":16699,"NA":16701},{"trials":16688,"activeCount":100},[],{"trials":16690,"activeCount":100},[16691],{"nctId":2049,"briefTitle":2050,"status":217,"phases":16692,"primaryCompletion":2018,"completion":2018,"start":2019,"enrollment":35,"conditions":16693,"interventions":16694},[89],[2053],[82,2055,2056],{"trials":16696,"activeCount":100},[],{"trials":16698,"activeCount":100},[],{"trials":16700,"activeCount":100},[],{"trials":16702,"activeCount":100},[],{"intervention":16704,"totalTrials":204,"cells":16705},"AMG 557 or PLACEBO",{"EARLY_PHASE1":16706,"PHASE1":16708,"PHASE2":16716,"PHASE3":16718,"PHASE4":16720,"NA":16722},{"trials":16707,"activeCount":100},[],{"trials":16709,"activeCount":100},[16710],{"nctId":16711,"briefTitle":16712,"status":336,"phases":16713,"primaryCompletion":6833,"completion":7943,"start":2733,"enrollment":1164,"conditions":16714,"interventions":16715},"NCT01493518","Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis",[89],[22],[16704],{"trials":16717,"activeCount":100},[],{"trials":16719,"activeCount":100},[],{"trials":16721,"activeCount":100},[],{"trials":16723,"activeCount":100},[],{"intervention":5989,"totalTrials":204,"cells":16725},{"EARLY_PHASE1":16726,"PHASE1":16728,"PHASE2":16734,"PHASE3":16736,"PHASE4":16738,"NA":16740},{"trials":16727,"activeCount":100},[],{"trials":16729,"activeCount":100},[16730],{"nctId":5982,"briefTitle":5983,"status":217,"phases":16731,"primaryCompletion":5985,"completion":5985,"start":2330,"enrollment":1160,"conditions":16732,"interventions":16733},[89],[5987],[5940,5989],{"trials":16735,"activeCount":100},[],{"trials":16737,"activeCount":100},[],{"trials":16739,"activeCount":100},[],{"trials":16741,"activeCount":100},[],{"intervention":16743,"totalTrials":204,"cells":16744},"VIB9600",{"EARLY_PHASE1":16745,"PHASE1":16747,"PHASE2":16759,"PHASE3":16761,"PHASE4":16763,"NA":16765},{"trials":16746,"activeCount":100},[],{"trials":16748,"activeCount":100},[16749],{"nctId":16750,"briefTitle":16751,"status":336,"phases":16752,"primaryCompletion":16753,"completion":16753,"start":16754,"enrollment":253,"conditions":16755,"interventions":16757},"NCT03621605","A Phase1 Study of VIB9600",[89],"2019-04-08","2018-08-14",[16756],"Safety Issues",[16743,16758],"Placebos",{"trials":16760,"activeCount":100},[],{"trials":16762,"activeCount":100},[],{"trials":16764,"activeCount":100},[],{"trials":16766,"activeCount":100},[],{"intervention":16758,"totalTrials":204,"cells":16768},{"EARLY_PHASE1":16769,"PHASE1":16771,"PHASE2":16777,"PHASE3":16779,"PHASE4":16781,"NA":16783},{"trials":16770,"activeCount":100},[],{"trials":16772,"activeCount":100},[16773],{"nctId":16750,"briefTitle":16751,"status":336,"phases":16774,"primaryCompletion":16753,"completion":16753,"start":16754,"enrollment":253,"conditions":16775,"interventions":16776},[89],[16756],[16743,16758],{"trials":16778,"activeCount":100},[],{"trials":16780,"activeCount":100},[],{"trials":16782,"activeCount":100},[],{"trials":16784,"activeCount":100},[],{"intervention":16786,"totalTrials":204,"cells":16787},"AMG 420",{"EARLY_PHASE1":16788,"PHASE1":16790,"PHASE2":16801,"PHASE3":16803,"PHASE4":16805,"NA":16807},{"trials":16789,"activeCount":100},[],{"trials":16791,"activeCount":100},[16792],{"nctId":16793,"briefTitle":16794,"status":336,"phases":16795,"primaryCompletion":16796,"completion":16796,"start":16797,"enrollment":1095,"conditions":16798,"interventions":16800},"NCT03836053","Assessment of AMG 420 in Subjects With Relapsed and\u002For Refractory Multiple Myeloma",[89],"2022-04-21","2019-03-04",[16799],"Relapsed and\u002For Refractory Multiple Myeloma",[16786],{"trials":16802,"activeCount":100},[],{"trials":16804,"activeCount":100},[],{"trials":16806,"activeCount":100},[],{"trials":16808,"activeCount":100},[],{"intervention":4627,"totalTrials":204,"cells":16810},{"EARLY_PHASE1":16811,"PHASE1":16813,"PHASE2":16819,"PHASE3":16821,"PHASE4":16823,"NA":16825},{"trials":16812,"activeCount":100},[],{"trials":16814,"activeCount":100},[16815],{"nctId":4621,"briefTitle":4622,"status":217,"phases":16816,"primaryCompletion":4624,"completion":4624,"start":4584,"enrollment":1907,"conditions":16817,"interventions":16818},[89],[1857],[43,4627],{"trials":16820,"activeCount":100},[],{"trials":16822,"activeCount":100},[],{"trials":16824,"activeCount":100},[],{"trials":16826,"activeCount":100},[],{"intervention":16828,"totalTrials":204,"cells":16829},"MT110",{"EARLY_PHASE1":16830,"PHASE1":16832,"PHASE2":16840,"PHASE3":16842,"PHASE4":16844,"NA":16846},{"trials":16831,"activeCount":100},[],{"trials":16833,"activeCount":100},[16834],{"nctId":16835,"briefTitle":16836,"status":217,"phases":16837,"primaryCompletion":8491,"completion":8490,"start":2439,"enrollment":3142,"conditions":16838,"interventions":16839},"NCT00635596","Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer",[89],[2441],[16828],{"trials":16841,"activeCount":100},[],{"trials":16843,"activeCount":100},[],{"trials":16845,"activeCount":100},[],{"trials":16847,"activeCount":100},[],{"intervention":16849,"totalTrials":204,"cells":16850},"AMG 890",{"EARLY_PHASE1":16851,"PHASE1":16853,"PHASE2":16864,"PHASE3":16866,"PHASE4":16868,"NA":16870},{"trials":16852,"activeCount":100},[],{"trials":16854,"activeCount":100},[16855],{"nctId":16856,"briefTitle":16857,"status":217,"phases":16858,"primaryCompletion":16859,"completion":16859,"start":16860,"enrollment":16861,"conditions":16862,"interventions":16863},"NCT03626662","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)",[89],"2023-04-18","2018-07-30",79,[466],[16849],{"trials":16865,"activeCount":100},[],{"trials":16867,"activeCount":100},[],{"trials":16869,"activeCount":100},[],{"trials":16871,"activeCount":100},[],{"intervention":12701,"totalTrials":204,"cells":16873},{"EARLY_PHASE1":16874,"PHASE1":16876,"PHASE2":16882,"PHASE3":16884,"PHASE4":16886,"NA":16888},{"trials":16875,"activeCount":100},[],{"trials":16877,"activeCount":100},[16878],{"nctId":12696,"briefTitle":12697,"status":217,"phases":16879,"primaryCompletion":8136,"completion":1636,"start":4420,"enrollment":1617,"conditions":16880,"interventions":16881},[89],[222],[12689,12701],{"trials":16883,"activeCount":100},[],{"trials":16885,"activeCount":100},[],{"trials":16887,"activeCount":100},[],{"trials":16889,"activeCount":100},[],{"intervention":16891,"totalTrials":204,"cells":16892},"AMG 386 30 mg\u002Fkg, Paclitaxel and Trastuzumab",{"EARLY_PHASE1":16893,"PHASE1":16895,"PHASE2":16908,"PHASE3":16910,"PHASE4":16912,"NA":16914},{"trials":16894,"activeCount":100},[],{"trials":16896,"activeCount":100},[16897],{"nctId":16898,"briefTitle":16899,"status":217,"phases":16900,"primaryCompletion":16901,"completion":14789,"start":16902,"enrollment":3142,"conditions":16903,"interventions":16904},"NCT00807859","Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer",[89],"2014-02-27","2009-03-09",[2794,5139,5140,25,3035,2531,2532,2479,2441,2478],[16891,16905,16906,16907],"AMG 386 30 mg\u002Fkg, Capecitabine and Lapatinib","AMG 386 10 mgkg, Paclitaxel and Trastuzumab","AMG 386 10 mg\u002Fkg, Capecitabine and Lapatinib",{"trials":16909,"activeCount":100},[],{"trials":16911,"activeCount":100},[],{"trials":16913,"activeCount":100},[],{"trials":16915,"activeCount":100},[],{"intervention":16905,"totalTrials":204,"cells":16917},{"EARLY_PHASE1":16918,"PHASE1":16920,"PHASE2":16926,"PHASE3":16928,"PHASE4":16930,"NA":16932},{"trials":16919,"activeCount":100},[],{"trials":16921,"activeCount":100},[16922],{"nctId":16898,"briefTitle":16899,"status":217,"phases":16923,"primaryCompletion":16901,"completion":14789,"start":16902,"enrollment":3142,"conditions":16924,"interventions":16925},[89],[2794,5139,5140,25,3035,2531,2532,2479,2441,2478],[16891,16905,16906,16907],{"trials":16927,"activeCount":100},[],{"trials":16929,"activeCount":100},[],{"trials":16931,"activeCount":100},[],{"trials":16933,"activeCount":100},[],{"intervention":16906,"totalTrials":204,"cells":16935},{"EARLY_PHASE1":16936,"PHASE1":16938,"PHASE2":16944,"PHASE3":16946,"PHASE4":16948,"NA":16950},{"trials":16937,"activeCount":100},[],{"trials":16939,"activeCount":100},[16940],{"nctId":16898,"briefTitle":16899,"status":217,"phases":16941,"primaryCompletion":16901,"completion":14789,"start":16902,"enrollment":3142,"conditions":16942,"interventions":16943},[89],[2794,5139,5140,25,3035,2531,2532,2479,2441,2478],[16891,16905,16906,16907],{"trials":16945,"activeCount":100},[],{"trials":16947,"activeCount":100},[],{"trials":16949,"activeCount":100},[],{"trials":16951,"activeCount":100},[],{"intervention":16907,"totalTrials":204,"cells":16953},{"EARLY_PHASE1":16954,"PHASE1":16956,"PHASE2":16962,"PHASE3":16964,"PHASE4":16966,"NA":16968},{"trials":16955,"activeCount":100},[],{"trials":16957,"activeCount":100},[16958],{"nctId":16898,"briefTitle":16899,"status":217,"phases":16959,"primaryCompletion":16901,"completion":14789,"start":16902,"enrollment":3142,"conditions":16960,"interventions":16961},[89],[2794,5139,5140,25,3035,2531,2532,2479,2441,2478],[16891,16905,16906,16907],{"trials":16963,"activeCount":100},[],{"trials":16965,"activeCount":100},[],{"trials":16967,"activeCount":100},[],{"trials":16969,"activeCount":100},[],{"intervention":16971,"totalTrials":204,"cells":16972},"AMG 319",{"EARLY_PHASE1":16973,"PHASE1":16975,"PHASE2":16985,"PHASE3":16987,"PHASE4":16989,"NA":16991},{"trials":16974,"activeCount":100},[],{"trials":16976,"activeCount":100},[16977],{"nctId":16978,"briefTitle":16979,"status":217,"phases":16980,"primaryCompletion":782,"completion":2883,"start":9881,"enrollment":2044,"conditions":16981,"interventions":16984},"NCT01300026","AMG 319 Lymphoid Malignancy FIH",[89],[25,16982,11623,6334,4548,14494,11621,7438,11622,1584,2479,11943,16983,2478],"Chronic Lymphocytic Leukemia","T Cell Lymphoma",[16971],{"trials":16986,"activeCount":100},[],{"trials":16988,"activeCount":100},[],{"trials":16990,"activeCount":100},[],{"trials":16992,"activeCount":100},[],{"intervention":16994,"totalTrials":204,"cells":16995},"AMG 199",{"EARLY_PHASE1":16996,"PHASE1":16998,"PHASE2":17009,"PHASE3":17011,"PHASE4":17013,"NA":17015},{"trials":16997,"activeCount":100},[],{"trials":16999,"activeCount":100},[17000],{"nctId":17001,"briefTitle":17002,"status":336,"phases":17003,"primaryCompletion":17004,"completion":17004,"start":17005,"enrollment":242,"conditions":17006,"interventions":17008},"NCT04117958","Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers",[89],"2023-06-01","2020-01-20",[17007],"MUC17-positive Solid Tumors",[16994],{"trials":17010,"activeCount":100},[],{"trials":17012,"activeCount":100},[],{"trials":17014,"activeCount":100},[],{"trials":17016,"activeCount":100},[],{"intervention":17018,"totalTrials":204,"cells":17019},"AMG 160",{"EARLY_PHASE1":17020,"PHASE1":17022,"PHASE2":17034,"PHASE3":17036,"PHASE4":17038,"NA":17040},{"trials":17021,"activeCount":100},[],{"trials":17023,"activeCount":100},[17024],{"nctId":17025,"briefTitle":17026,"status":336,"phases":17027,"primaryCompletion":17028,"completion":17029,"start":17030,"enrollment":193,"conditions":17031,"interventions":17033},"NCT04822298","Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer",[89],"2021-12-08","2022-01-26","2021-08-31",[1303,17032],"NSCLC",[17018],{"trials":17035,"activeCount":100},[],{"trials":17037,"activeCount":100},[],{"trials":17039,"activeCount":100},[],{"trials":17041,"activeCount":100},[],{"intervention":17043,"totalTrials":204,"cells":17044},"AMG 340",{"EARLY_PHASE1":17045,"PHASE1":17047,"PHASE2":17056,"PHASE3":17058,"PHASE4":17060,"NA":17062},{"trials":17046,"activeCount":100},[],{"trials":17048,"activeCount":100},[17049],{"nctId":17050,"briefTitle":17051,"status":336,"phases":17052,"primaryCompletion":17053,"completion":17053,"start":5251,"enrollment":1916,"conditions":17054,"interventions":17055},"NCT04740034","A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma",[89],"2024-06-24",[1264],[17043],{"trials":17057,"activeCount":100},[],{"trials":17059,"activeCount":100},[],{"trials":17061,"activeCount":100},[],{"trials":17063,"activeCount":100},[],{"intervention":1597,"totalTrials":204,"cells":17065},{"EARLY_PHASE1":17066,"PHASE1":17068,"PHASE2":17074,"PHASE3":17076,"PHASE4":17078,"NA":17080},{"trials":17067,"activeCount":100},[],{"trials":17069,"activeCount":100},[17070],{"nctId":1588,"briefTitle":1589,"status":217,"phases":17071,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":1593,"conditions":17072,"interventions":17073},[89],[1595],[117,1099,1597],{"trials":17075,"activeCount":100},[],{"trials":17077,"activeCount":100},[],{"trials":17079,"activeCount":100},[],{"trials":17081,"activeCount":100},[],{"intervention":17083,"totalTrials":204,"cells":17084},"AMG 598",{"EARLY_PHASE1":17085,"PHASE1":17087,"PHASE2":17098,"PHASE3":17100,"PHASE4":17102,"NA":17104},{"trials":17086,"activeCount":100},[],{"trials":17088,"activeCount":100},[17089],{"nctId":17090,"briefTitle":17091,"status":217,"phases":17092,"primaryCompletion":17093,"completion":17093,"start":17094,"enrollment":1476,"conditions":17095,"interventions":17096},"NCT03757130","Multiple Ascending Dose Study of AMG 598 in Adults With Obesity",[89],"2019-12-16","2018-11-26",[897],[17083,17097],"Liraglutide",{"trials":17099,"activeCount":100},[],{"trials":17101,"activeCount":100},[],{"trials":17103,"activeCount":100},[],{"trials":17105,"activeCount":100},[],{"intervention":17097,"totalTrials":204,"cells":17107},{"EARLY_PHASE1":17108,"PHASE1":17110,"PHASE2":17116,"PHASE3":17118,"PHASE4":17120,"NA":17122},{"trials":17109,"activeCount":100},[],{"trials":17111,"activeCount":100},[17112],{"nctId":17090,"briefTitle":17091,"status":217,"phases":17113,"primaryCompletion":17093,"completion":17093,"start":17094,"enrollment":1476,"conditions":17114,"interventions":17115},[89],[897],[17083,17097],{"trials":17117,"activeCount":100},[],{"trials":17119,"activeCount":100},[],{"trials":17121,"activeCount":100},[],{"trials":17123,"activeCount":100},[],{"intervention":14416,"totalTrials":204,"cells":17125},{"EARLY_PHASE1":17126,"PHASE1":17128,"PHASE2":17134,"PHASE3":17136,"PHASE4":17138,"NA":17140},{"trials":17127,"activeCount":100},[],{"trials":17129,"activeCount":100},[17130],{"nctId":14409,"briefTitle":14410,"status":336,"phases":17131,"primaryCompletion":5191,"completion":5191,"start":7865,"enrollment":204,"conditions":17132,"interventions":17133},[89],[14413,14414],[14383,14416],{"trials":17135,"activeCount":100},[],{"trials":17137,"activeCount":100},[],{"trials":17139,"activeCount":100},[],{"trials":17141,"activeCount":100},[],{"intervention":17143,"totalTrials":204,"cells":17144},"[¹⁴C]Etelcalcetide",{"EARLY_PHASE1":17145,"PHASE1":17147,"PHASE2":17158,"PHASE3":17160,"PHASE4":17162,"NA":17164},{"trials":17146,"activeCount":100},[],{"trials":17148,"activeCount":100},[17149],{"nctId":17150,"briefTitle":17151,"status":217,"phases":17152,"primaryCompletion":11960,"completion":17153,"start":17154,"enrollment":1164,"conditions":17155,"interventions":17157},"NCT02054572","Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis",[89],"2014-08-15","2014-02-07",[17156],"Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis",[17143],{"trials":17159,"activeCount":100},[],{"trials":17161,"activeCount":100},[],{"trials":17163,"activeCount":100},[],{"trials":17165,"activeCount":100},[],{"intervention":17167,"totalTrials":204,"cells":17168},"AMG 224",{"EARLY_PHASE1":17169,"PHASE1":17171,"PHASE2":17181,"PHASE3":17183,"PHASE4":17185,"NA":17187},{"trials":17170,"activeCount":100},[],{"trials":17172,"activeCount":100},[17173],{"nctId":17174,"briefTitle":17175,"status":217,"phases":17176,"primaryCompletion":17177,"completion":16796,"start":17178,"enrollment":1916,"conditions":17179,"interventions":17180},"NCT02561962","A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma",[89],"2018-11-30","2015-11-20",[31],[17167],{"trials":17182,"activeCount":100},[],{"trials":17184,"activeCount":100},[],{"trials":17186,"activeCount":100},[],{"trials":17188,"activeCount":100},[],{"intervention":17190,"totalTrials":204,"cells":17191},"Emerfetamab",{"EARLY_PHASE1":17192,"PHASE1":17202,"PHASE2":17204,"PHASE3":17206,"PHASE4":17208,"NA":17210},{"trials":17193,"activeCount":100},[17194],{"nctId":17195,"briefTitle":17196,"status":336,"phases":17197,"primaryCompletion":17198,"completion":17198,"start":17199,"enrollment":17,"conditions":17200,"interventions":17201},"NCT03224819","Study of Emerfetamab (AMG 673) in Adults With Relapsed\u002FRefractory Acute Myeloid Leukemia (AML)",[88],"2020-12-28","2017-09-07",[7360],[17190],{"trials":17203,"activeCount":100},[],{"trials":17205,"activeCount":100},[],{"trials":17207,"activeCount":100},[],{"trials":17209,"activeCount":100},[],{"trials":17211,"activeCount":100},[],{"intervention":2909,"totalTrials":204,"cells":17213},{"EARLY_PHASE1":17214,"PHASE1":17220,"PHASE2":17222,"PHASE3":17224,"PHASE4":17226,"NA":17228},{"trials":17215,"activeCount":100},[17216],{"nctId":2900,"briefTitle":2901,"status":217,"phases":17217,"primaryCompletion":2903,"completion":2904,"start":2905,"enrollment":35,"conditions":17218,"interventions":17219},[88],[2907],[2909,1930,2910,1849,2894],{"trials":17221,"activeCount":100},[],{"trials":17223,"activeCount":100},[],{"trials":17225,"activeCount":100},[],{"trials":17227,"activeCount":100},[],{"trials":17229,"activeCount":100},[],{"intervention":2910,"totalTrials":204,"cells":17231},{"EARLY_PHASE1":17232,"PHASE1":17238,"PHASE2":17240,"PHASE3":17242,"PHASE4":17244,"NA":17246},{"trials":17233,"activeCount":100},[17234],{"nctId":2900,"briefTitle":2901,"status":217,"phases":17235,"primaryCompletion":2903,"completion":2904,"start":2905,"enrollment":35,"conditions":17236,"interventions":17237},[88],[2907],[2909,1930,2910,1849,2894],{"trials":17239,"activeCount":100},[],{"trials":17241,"activeCount":100},[],{"trials":17243,"activeCount":100},[],{"trials":17245,"activeCount":100},[],{"trials":17247,"activeCount":100},[],{"intervention":3670,"totalTrials":1651,"cells":17249},{"EARLY_PHASE1":17250,"PHASE1":17252,"PHASE2":17292,"PHASE3":17363,"PHASE4":17522,"NA":17539},{"trials":17251,"activeCount":100},[],{"trials":17253,"activeCount":100},[17254,17260,17266,17274,17280,17288],{"nctId":17255,"briefTitle":17256,"status":217,"phases":17257,"primaryCompletion":11413,"completion":11413,"start":7943,"enrollment":2895,"conditions":17258,"interventions":17259},"NCT01869686","Study to Evaluate the Concentration of Denosumab in Seminal Fluid in Healthy Men After a Single Subcutaneous Dose",[89],[2021],[3670],{"nctId":17261,"briefTitle":17262,"status":336,"phases":17263,"primaryCompletion":7388,"completion":7388,"start":2872,"enrollment":11519,"conditions":17264,"interventions":17265},"NCT01294397","Effects of Denosumab on the Pharmacokinetics of Etanercept",[89],[3621,3612,19,493],[1268,3670],{"nctId":17267,"briefTitle":17268,"status":217,"phases":17269,"primaryCompletion":1693,"completion":1693,"start":8563,"enrollment":17270,"conditions":17271,"interventions":17273},"NCT02099461","Effect of Denosumab on Cellular Biomarkers in the Human Breast",[89],82,[17272],"Healthy Volunteer, Female, Breast",[3670],{"nctId":17275,"briefTitle":17276,"status":217,"phases":17277,"primaryCompletion":12505,"completion":5191,"start":2733,"enrollment":26,"conditions":17278,"interventions":17279},"NCT01464931","Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis",[89],[3266],[3670],{"nctId":17281,"briefTitle":17282,"status":217,"phases":17283,"primaryCompletion":17284,"completion":17284,"start":17285,"enrollment":20,"conditions":17286,"interventions":17287},"NCT03822078","Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women",[89],"2004-12-24","2003-09-30",[493],[3670],{"nctId":4929,"briefTitle":4930,"status":217,"phases":17289,"primaryCompletion":4932,"completion":4932,"start":1627,"enrollment":866,"conditions":17290,"interventions":17291},[89],[3666],[3670,1930],{"trials":17293,"activeCount":100},[17294,17303,17315,17319,17323,17327,17337,17341,17349,17359],{"nctId":17295,"briefTitle":17296,"status":217,"phases":17297,"primaryCompletion":14710,"completion":1685,"start":7626,"enrollment":17298,"conditions":17299,"interventions":17301},"NCT00259740","Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab",[90],96,[17300],"Relapsed or Plateau-Phase Multiple Myeloma",[17302],"DENOSUMAB",{"nctId":17304,"briefTitle":17305,"status":217,"phases":17306,"primaryCompletion":17307,"completion":17308,"start":17309,"enrollment":3264,"conditions":17310,"interventions":17314},"NCT00896454","Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium",[90],"2012-09-13","2013-08-21","2009-11-16",[2794,17311,2425,17312,2530,17313,2463,7438,2532,31,6442,7437,7620,8187,1584,1971],"Hypercalcemia of Malignancy","Endocrine Cancer","Kidney Cancer",[4798],{"nctId":8122,"briefTitle":8123,"status":217,"phases":17316,"primaryCompletion":7698,"completion":2460,"start":6274,"enrollment":8125,"conditions":17317,"interventions":17318},[90],[3665],[3670,3668],{"nctId":6300,"briefTitle":6301,"status":217,"phases":17320,"primaryCompletion":640,"completion":6303,"start":6304,"enrollment":6305,"conditions":17321,"interventions":17322},[90],[1971],[3670,3671,6308],{"nctId":3657,"briefTitle":3658,"status":217,"phases":17324,"primaryCompletion":3660,"completion":3661,"start":3662,"enrollment":3663,"conditions":17325,"interventions":17326},[90],[3665,3666],[3668,3669,3592,3670,3671],{"nctId":17328,"briefTitle":17329,"status":217,"phases":17330,"primaryCompletion":17331,"completion":17332,"start":17333,"enrollment":6514,"conditions":17334,"interventions":17336},"NCT00396279","Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone",[90],"2008-04-07","2011-02-01","2006-07-10",[17335,441],"GCT",[3670],{"nctId":8133,"briefTitle":8134,"status":217,"phases":17338,"primaryCompletion":2439,"completion":8136,"start":6777,"enrollment":8137,"conditions":17339,"interventions":17340},[90],[3666],[3668,3670],{"nctId":17342,"briefTitle":17343,"status":217,"phases":17344,"primaryCompletion":4546,"completion":4546,"start":17345,"enrollment":17346,"conditions":17347,"interventions":17348},"NCT00095498","Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis",[90],"2004-08-11",227,[19],[4798],{"nctId":17350,"briefTitle":17351,"status":217,"phases":17352,"primaryCompletion":11444,"completion":11444,"start":17353,"enrollment":17354,"conditions":17355,"interventions":17358},"NCT00680992","Study of Denosumab in Subjects With Giant Cell Tumor of Bone",[90],"2008-09-09",535,[25,17356,441,17357],"Giant Cell Tumors","Benign Giant Cell Tumors",[3670],{"nctId":14281,"briefTitle":14282,"status":217,"phases":17360,"primaryCompletion":7626,"completion":2474,"start":14284,"enrollment":14285,"conditions":17361,"interventions":17362},[90],[2794,2531,8695],[3670,14272],{"trials":17364,"activeCount":100},[17365,17369,17377,17385,17389,17393,17401,17407,17411,17419,17423,17430,17434,17440,17449,17453,17462,17466,17470,17478,17482,17486,17497,17506,17510,17518],{"nctId":9679,"briefTitle":9680,"status":217,"phases":17366,"primaryCompletion":9682,"completion":9683,"start":9684,"enrollment":9685,"conditions":17367,"interventions":17368},[91],[493],[9668,3670],{"nctId":17370,"briefTitle":17371,"status":217,"phases":17372,"primaryCompletion":11467,"completion":11467,"start":17373,"enrollment":2952,"conditions":17374,"interventions":17376},"NCT00925600","Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss",[91],"2009-11-30",[25,17375,3665,3612,493,1265],"Cataract",[3670],{"nctId":17378,"briefTitle":17379,"status":217,"phases":17380,"primaryCompletion":17381,"completion":17381,"start":5152,"enrollment":17382,"conditions":17383,"interventions":17384},"NCT02157948","A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis",[91],"2015-07",394,[3666],[3670,3670],{"nctId":10093,"briefTitle":10094,"status":217,"phases":17386,"primaryCompletion":2733,"completion":1705,"start":8692,"enrollment":10096,"conditions":17387,"interventions":17388},[91],[3666],[10082,3670],{"nctId":3713,"briefTitle":3714,"status":217,"phases":17390,"primaryCompletion":3716,"completion":3717,"start":2175,"enrollment":3718,"conditions":17391,"interventions":17392},[91],[3666],[3592,3670],{"nctId":17394,"briefTitle":17395,"status":336,"phases":17396,"primaryCompletion":17397,"completion":17397,"start":17398,"enrollment":2654,"conditions":17399,"interventions":17400},"NCT02352753","Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w\u002F OI",[91],"2022-03-26","2015-06-24",[3604],[3670],{"nctId":17402,"briefTitle":17403,"status":217,"phases":17404,"primaryCompletion":2452,"completion":5151,"start":8692,"enrollment":16861,"conditions":17405,"interventions":17406},"NCT00890981","A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab",[91],[9729,3665,493,3666],[3670],{"nctId":8143,"briefTitle":8144,"status":217,"phases":17408,"primaryCompletion":2594,"completion":1638,"start":6777,"enrollment":8146,"conditions":17409,"interventions":17410},[91],[493,3612],[3668,3670],{"nctId":17412,"briefTitle":17413,"status":217,"phases":17414,"primaryCompletion":17415,"completion":17415,"start":2623,"enrollment":17416,"conditions":17417,"interventions":17418},"NCT00089791","A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis",[91],"2008-06-17",7808,[493],[3670],{"nctId":10480,"briefTitle":10481,"status":217,"phases":17420,"primaryCompletion":10483,"completion":3736,"start":10484,"enrollment":10485,"conditions":17421,"interventions":17422},[91],[10487],[3670,10469],{"nctId":17424,"briefTitle":17425,"status":217,"phases":17426,"primaryCompletion":1625,"completion":1625,"start":8367,"enrollment":340,"conditions":17427,"interventions":17429},"NCT01824342","Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer",[91],[17428],"Castrate-resistant Prostate Cancer",[3670],{"nctId":8150,"briefTitle":8151,"status":217,"phases":17431,"primaryCompletion":2439,"completion":6172,"start":6129,"enrollment":8153,"conditions":17432,"interventions":17433},[91],[3666],[8156,3670],{"nctId":17435,"briefTitle":17436,"status":217,"phases":17437,"primaryCompletion":2439,"completion":2451,"start":2540,"enrollment":8631,"conditions":17438,"interventions":17439},"NCT00515463","A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density",[91],[3665,3612,493],[4798,4798],{"nctId":17441,"briefTitle":17442,"status":336,"phases":17443,"primaryCompletion":17444,"completion":17445,"start":8433,"enrollment":17446,"conditions":17447,"interventions":17448},"NCT01077154","Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)",[91],"2017-08-31","2018-03-26",4509,[2794],[3670],{"nctId":6316,"briefTitle":6317,"status":217,"phases":17450,"primaryCompletion":2084,"completion":6319,"start":6320,"enrollment":6321,"conditions":17451,"interventions":17452},[91],[6323],[3670,6291],{"nctId":17454,"briefTitle":17455,"status":217,"phases":17456,"primaryCompletion":17457,"completion":3879,"start":17458,"enrollment":253,"conditions":17459,"interventions":17461},"NCT03164928","Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis",[91],"2021-12-13","2018-05-07",[17460,416],"Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With",[3670],{"nctId":8158,"briefTitle":8159,"status":217,"phases":17463,"primaryCompletion":2550,"completion":509,"start":8161,"enrollment":994,"conditions":17464,"interventions":17465},[91],[493],[8156,4798],{"nctId":10867,"briefTitle":10868,"status":336,"phases":17467,"primaryCompletion":10870,"completion":10870,"start":10871,"enrollment":4413,"conditions":17468,"interventions":17469},[91],[10873],[3670,10856],{"nctId":17471,"briefTitle":17472,"status":217,"phases":17473,"primaryCompletion":17474,"completion":17474,"start":17475,"enrollment":720,"conditions":17476,"interventions":17477},"NCT01419717","Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer",[91],"2018-08-10","2011-11-22",[8694,8695],[3670],{"nctId":6326,"briefTitle":6327,"status":217,"phases":17479,"primaryCompletion":6329,"completion":6330,"start":6331,"enrollment":6332,"conditions":17480,"interventions":17481},[91],[25,6334,31,2479,6323,6335],[3670,3671,3670],{"nctId":6338,"briefTitle":6339,"status":217,"phases":17483,"primaryCompletion":6341,"completion":6342,"start":6343,"enrollment":6344,"conditions":17484,"interventions":17485},[91],[2794],[3670,6347,6291],{"nctId":17487,"briefTitle":17488,"status":217,"phases":17489,"primaryCompletion":17490,"completion":17491,"start":17492,"enrollment":17493,"conditions":17494,"interventions":17496},"NCT00286091","Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer",[91],"2010-07-30","2014-04-09","2006-01-24",1435,[17495],"Hormone Refractory Prostate Cancer",[3670],{"nctId":17498,"briefTitle":17499,"status":217,"phases":17500,"primaryCompletion":17501,"completion":17501,"start":17502,"enrollment":17503,"conditions":17504,"interventions":17505},"NCT00523341","Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis",[91],"2015-07-19","2007-08-07",4550,[3612,493],[3670],{"nctId":6349,"briefTitle":6350,"status":217,"phases":17507,"primaryCompletion":6352,"completion":6353,"start":6354,"enrollment":6355,"conditions":17508,"interventions":17509},[91],[6323],[6358,4798],{"nctId":17511,"briefTitle":17512,"status":217,"phases":17513,"primaryCompletion":17514,"completion":17514,"start":6622,"enrollment":17515,"conditions":17516,"interventions":17517},"NCT00838201","Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer",[91],"2012-05-03",384,[25,2529,8500,1265,2478],[3670],{"nctId":6360,"briefTitle":6361,"status":217,"phases":17519,"primaryCompletion":6363,"completion":6364,"start":6354,"enrollment":6365,"conditions":17520,"interventions":17521},[91],[6323],[3670,6291],{"trials":17523,"activeCount":100},[17524,17531,17535],{"nctId":17525,"briefTitle":17526,"status":217,"phases":17527,"primaryCompletion":17528,"completion":17528,"start":7347,"enrollment":12301,"conditions":17529,"interventions":17530},"NCT03301857","Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004",[92],"2023-07-27",[441],[3670],{"nctId":6807,"briefTitle":6808,"status":131,"phases":17532,"primaryCompletion":1637,"completion":1637,"start":1637,"enrollment":100,"conditions":17533,"interventions":17534},[92],[6811,6812],[4798,6794],{"nctId":6371,"briefTitle":6372,"status":217,"phases":17536,"primaryCompletion":6374,"completion":6374,"start":6375,"enrollment":6376,"conditions":17537,"interventions":17538},[92],[6378],[3670,6291],{"trials":17540,"activeCount":100},[17541,17545],{"nctId":4790,"briefTitle":4791,"status":217,"phases":17542,"primaryCompletion":4793,"completion":4793,"start":4794,"enrollment":4795,"conditions":17543,"interventions":17544},[],[493],[4798,4771],{"nctId":17546,"briefTitle":17547,"status":217,"phases":17548,"primaryCompletion":4900,"completion":4900,"start":17549,"enrollment":4006,"conditions":17550,"interventions":17552},"NCT01652690","Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Denosumab (Prolia®) in Routine Clinical Practice",[],"2012-06-26",[17551],"Osteoporosis, Postmenopausal",[3670],{"intervention":8962,"totalTrials":1651,"cells":17554},{"EARLY_PHASE1":17555,"PHASE1":17557,"PHASE2":17565,"PHASE3":17668,"PHASE4":17841,"NA":17866},{"trials":17556,"activeCount":100},[],{"trials":17558,"activeCount":100},[17559],{"nctId":17560,"briefTitle":17561,"status":131,"phases":17562,"primaryCompletion":2732,"completion":2732,"start":8562,"enrollment":100,"conditions":17563,"interventions":17564},"NCT01428154","Study to Evaluate Darbepoetin Alfa in Pediatric Subjects With Anemia Due to Chronic Kidney Disease",[89],[16,28],[8971],{"trials":17566,"activeCount":100},[17567,17575,17583,17589,17595,17601,17607,17611,17618,17625,17632,17638,17644,17648,17652,17658,17662],{"nctId":17568,"briefTitle":17569,"status":336,"phases":17570,"primaryCompletion":6283,"completion":1567,"start":6274,"enrollment":17571,"conditions":17572,"interventions":17574},"NCT00989092","Darbepoetin Alfa and Anemia of Cancer",[90],287,[16,17573,25,2529,6286,8969],"Anemia of Cancer",[8962],{"nctId":17576,"briefTitle":17577,"status":217,"phases":17578,"primaryCompletion":6430,"completion":6430,"start":17579,"enrollment":4413,"conditions":17580,"interventions":17582},"NCT00526929","Fixed Dose NESP Study in Subjects With CRI",[90],"2000-05",[17581],"Pre-Dialysis",[8962],{"nctId":17584,"briefTitle":17585,"status":217,"phases":17586,"primaryCompletion":2662,"completion":2601,"start":6224,"enrollment":4671,"conditions":17587,"interventions":17588},"NCT00239239","Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies",[90],[8969,16,25],[8971],{"nctId":17590,"briefTitle":17591,"status":217,"phases":17592,"primaryCompletion":8976,"completion":8976,"start":11577,"enrollment":5354,"conditions":17593,"interventions":17594},"NCT00527215","Phase 2 Study of Darbepoetin Alfa Extended Dosing",[90],[17581],[8962],{"nctId":17596,"briefTitle":17597,"status":217,"phases":17598,"start":7610,"enrollment":13769,"conditions":17599,"interventions":17600},"NCT00095264","A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome",[90],[4424],[12035],{"nctId":17602,"briefTitle":17603,"status":217,"phases":17604,"conditions":17605,"interventions":17606},"NCT00036023","Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies",[90],[7438,5139,2837,31,16982],[8962],{"nctId":12015,"briefTitle":12016,"status":217,"phases":17608,"completion":12018,"start":7733,"conditions":17609,"interventions":17610},[90],[1971,16],[8962,12006],{"nctId":17612,"briefTitle":17613,"status":217,"phases":17614,"completion":17615,"start":6404,"enrollment":2076,"conditions":17616,"interventions":17617},"NCT00120705","Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy",[90],"2003-09",[6286,16],[8962],{"nctId":17619,"briefTitle":17620,"status":217,"phases":17621,"completion":6788,"start":6757,"conditions":17622,"interventions":17624},"NCT00117247","A Study of Repeat-Dose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control Subjects",[89,90],[16,17623],"Congestive Heart Failure",[8962],{"nctId":17626,"briefTitle":17627,"status":217,"phases":17628,"primaryCompletion":6469,"completion":17615,"start":17629,"enrollment":317,"conditions":17630,"interventions":17631},"NCT00540696","Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa",[90],"2001-09",[16,8969],[8962],{"nctId":17633,"briefTitle":17634,"status":217,"phases":17635,"start":2644,"enrollment":317,"conditions":17636,"interventions":17637},"NCT00049985","Heart Failure and Anemia",[90],[14938,16],[12035],{"nctId":17639,"briefTitle":17640,"status":217,"phases":17641,"conditions":17642,"interventions":17643},"NCT00111462","Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy",[90],[16,8969,25],[8971],{"nctId":14118,"briefTitle":14119,"status":217,"phases":17645,"primaryCompletion":6743,"completion":2439,"start":2833,"enrollment":14121,"conditions":17646,"interventions":17647},[90],[16,8969],[8962,14109],{"nctId":12022,"briefTitle":12023,"status":217,"phases":17649,"completion":12018,"start":7733,"conditions":17650,"interventions":17651},[90],[12026,12027,16],[8962,12006],{"nctId":17653,"briefTitle":17654,"status":217,"phases":17655,"start":6395,"enrollment":11578,"conditions":17656,"interventions":17657},"NCT00086086","Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & Anemia",[90],[17623,16],[12035],{"nctId":12030,"briefTitle":12031,"status":217,"phases":17659,"completion":12018,"start":7733,"conditions":17660,"interventions":17661},[90],[2794,16],[12035,12036],{"nctId":17663,"briefTitle":17664,"status":217,"phases":17665,"start":7610,"enrollment":112,"conditions":17666,"interventions":17667},"NCT00095277","Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer",[90],[16],[12035],{"trials":17669,"activeCount":100},[17670,17677,17687,17693,17700,17709,17715,17721,17727,17733,17740,17749,17753,17759,17763,17772,17779,17785,17794,17800,17809,17817,17821,17828,17835],{"nctId":17671,"briefTitle":17672,"status":217,"phases":17673,"primaryCompletion":1566,"completion":10327,"start":8349,"enrollment":17674,"conditions":17675,"interventions":17676},"NCT00925587","Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease",[91],358,[16,28],[8962],{"nctId":17678,"briefTitle":17679,"status":217,"phases":17680,"primaryCompletion":17681,"completion":17681,"start":17682,"enrollment":17683,"conditions":17684,"interventions":17686},"NCT01652872","Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease",[91],"2017-10-19","2012-07-30",756,[17685],"Anemia in Chronic Kidney Disease Patients Not on Dialysis",[8971],{"nctId":17688,"briefTitle":17689,"status":217,"phases":17690,"primaryCompletion":2662,"completion":7698,"start":6459,"enrollment":4006,"conditions":17691,"interventions":17692},"NCT00119613","A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa",[91],[1097],[8962],{"nctId":17694,"briefTitle":17695,"status":217,"phases":17696,"primaryCompletion":6059,"completion":6059,"start":3414,"enrollment":96,"conditions":17697,"interventions":17699},"NCT02175277","Darbepoetin Alfa MDS Companion Protocol",[91],[17698],"Myelodysplastic Syndrome (MDS)",[12035],{"nctId":17701,"briefTitle":17702,"status":217,"phases":17703,"primaryCompletion":17704,"completion":17705,"start":17706,"enrollment":6431,"conditions":17707,"interventions":17708},"NCT03776032","A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy",[91],"2000-11-08","2002-02-27","1999-09-14",[16],[8971],{"nctId":17710,"briefTitle":17711,"status":217,"phases":17712,"start":6756,"conditions":17713,"interventions":17714},"NCT00135317","AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies",[91],[25],[8962],{"nctId":17716,"briefTitle":17717,"status":217,"phases":17718,"primaryCompletion":7626,"completion":7626,"start":2542,"enrollment":11578,"conditions":17719,"interventions":17720},"NCT00111098","Treatment for Subjects With Chronic Kidney Disease (CKD) Not Receiving Dialysis",[91],[383],[12035],{"nctId":17722,"briefTitle":17723,"status":217,"phases":17724,"completion":17615,"start":2792,"conditions":17725,"interventions":17726},"NCT00119587","Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects",[91],[16],[8962],{"nctId":17728,"briefTitle":17729,"status":217,"phases":17730,"primaryCompletion":2662,"completion":2601,"start":2475,"enrollment":10055,"conditions":17731,"interventions":17732},"NCT00115167","A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 Study",[91],[16,25],[8971],{"nctId":17734,"briefTitle":17735,"status":217,"phases":17736,"primaryCompletion":6143,"completion":6282,"start":6994,"enrollment":17737,"conditions":17738,"interventions":17739},"NCT00110955","Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy",[91],391,[16,8969],[8971],{"nctId":17741,"briefTitle":17742,"status":217,"phases":17743,"primaryCompletion":17744,"completion":17745,"start":9682,"enrollment":17746,"conditions":17747,"interventions":17748},"NCT01362140","Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)",[91],"2015-02-11","2017-09-14",147,[4423],[8971],{"nctId":8955,"briefTitle":8956,"status":217,"phases":17750,"primaryCompletion":6756,"completion":6756,"start":8958,"enrollment":4814,"conditions":17751,"interventions":17752},[91],[8960,6268],[8962,8944],{"nctId":17754,"briefTitle":17755,"status":217,"phases":17756,"completion":12018,"start":6459,"conditions":17757,"interventions":17758},"NCT00117624","A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy",[91],[16],[8962],{"nctId":8964,"briefTitle":8965,"status":217,"phases":17760,"primaryCompletion":6478,"completion":7690,"start":2578,"enrollment":8967,"conditions":17761,"interventions":17762},[91],[25,8969],[8944,8971],{"nctId":17764,"briefTitle":17765,"status":217,"phases":17766,"primaryCompletion":17767,"completion":17767,"start":6320,"enrollment":17768,"conditions":17769,"interventions":17771},"NCT00358215","RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial",[91],"2012-10-11",2278,[14938,16,466,17770,17623],"Ventricular Dysfunction",[8971],{"nctId":17773,"briefTitle":17774,"status":217,"phases":17775,"primaryCompletion":2474,"completion":2833,"start":7690,"enrollment":17776,"conditions":17777,"interventions":17778},"NCT00091858","Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer",[91],1000,[16,25],[12035],{"nctId":17780,"briefTitle":17781,"status":336,"phases":17782,"primaryCompletion":2541,"completion":2832,"start":6129,"enrollment":2257,"conditions":17783,"interventions":17784},"NCT00364845","STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) Patients",[91],[16,28],[8971],{"nctId":17786,"briefTitle":17787,"status":336,"phases":17788,"primaryCompletion":17789,"completion":17789,"start":17790,"enrollment":17791,"conditions":17792,"interventions":17793},"NCT00858364","Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy",[91],"2017-06-07","2009-07-17",2549,[1971,16,25,2463],[8971],{"nctId":17795,"briefTitle":17796,"status":217,"phases":17797,"primaryCompletion":7626,"completion":7626,"start":7610,"enrollment":916,"conditions":17798,"interventions":17799},"NCT00096915","Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis",[91],[383,28],[12035],{"nctId":17801,"briefTitle":17802,"status":217,"phases":17803,"primaryCompletion":17804,"completion":17805,"start":2623,"enrollment":17806,"conditions":17807,"interventions":17808},"NCT00093015","Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)",[91],"2009-03-01","2009-07-01",4038,[383,11997,16],[8962],{"nctId":17810,"briefTitle":17811,"status":336,"phases":17812,"primaryCompletion":17813,"completion":17813,"start":17814,"enrollment":1628,"conditions":17815,"interventions":17816},"NCT00436748","Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease",[91],"2014-03-03","2008-09-16",[16,28,383],[12035],{"nctId":8973,"briefTitle":8974,"status":217,"phases":17818,"primaryCompletion":8976,"completion":7690,"start":2776,"enrollment":1536,"conditions":17819,"interventions":17820},[91],[6286,16],[8971,8944],{"nctId":17822,"briefTitle":17823,"status":217,"phases":17824,"primaryCompletion":8185,"completion":2474,"start":6143,"enrollment":17825,"conditions":17826,"interventions":17827},"NCT00121602","Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease",[91],446,[16,383],[12035],{"nctId":17829,"briefTitle":17830,"status":217,"phases":17831,"primaryCompletion":2662,"completion":2541,"start":2473,"enrollment":17832,"conditions":17833,"interventions":17834},"NCT00436995","Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving Dialysis",[91],114,[28],[12035],{"nctId":17836,"briefTitle":17837,"status":336,"phases":17838,"primaryCompletion":6173,"completion":6173,"start":2662,"enrollment":2895,"conditions":17839,"interventions":17840},"NCT00534456","An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial",[91],[16,466,17623,14938,17770],[8971],{"trials":17842,"activeCount":100},[17843,17852,17859],{"nctId":17844,"briefTitle":17845,"status":217,"phases":17846,"primaryCompletion":2542,"completion":7732,"start":6274,"enrollment":17847,"conditions":17848,"interventions":17851},"NCT00369733","STAAR-3 Clinical Study",[92],443,[28,17849,383,8960,17850],"Chronic Renal Insufficiency","Pre-ESRD",[8971],{"nctId":17853,"briefTitle":17854,"status":217,"phases":17855,"completion":7732,"start":6430,"enrollment":17856,"conditions":17857,"interventions":17858},"NCT00369772","STAAR-1 Clinical Study",[92],2000,[28,17849,383,8960,17850],[8962],{"nctId":17860,"briefTitle":17861,"status":217,"phases":17862,"primaryCompletion":2542,"completion":7732,"start":2776,"enrollment":17863,"conditions":17864,"interventions":17865},"NCT00368901","STAAR-2 Clinical Study",[92],618,[28,17849,383,8960,17850],[8971],{"trials":17867,"activeCount":100},[17868],{"nctId":17869,"briefTitle":17870,"status":217,"phases":17871,"completion":6788,"start":17872,"conditions":17873,"interventions":17874},"NCT00117234","Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia",[93],"2002-09",[17623,16],[8962],{"intervention":1268,"totalTrials":9045,"cells":17876},{"EARLY_PHASE1":17877,"PHASE1":17879,"PHASE2":17902,"PHASE3":17904,"PHASE4":18025,"NA":18109},{"trials":17878,"activeCount":100},[],{"trials":17880,"activeCount":100},[17881,17885,17889,17895],{"nctId":1257,"briefTitle":1258,"status":336,"phases":17882,"primaryCompletion":1260,"completion":1260,"start":1261,"enrollment":1262,"conditions":17883,"interventions":17884},[89],[1264,1265],[1267,1152,1268,1269],{"nctId":17261,"briefTitle":17262,"status":336,"phases":17886,"primaryCompletion":7388,"completion":7388,"start":2872,"enrollment":11519,"conditions":17887,"interventions":17888},[89],[3621,3612,19,493],[1268,3670],{"nctId":17890,"briefTitle":17891,"status":217,"phases":17892,"primaryCompletion":7867,"completion":6155,"start":6129,"enrollment":1907,"conditions":17893,"interventions":17894},"NCT00361634","Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis",[89],[19],[1268],{"nctId":17896,"briefTitle":17897,"status":217,"phases":17898,"primaryCompletion":6283,"completion":6283,"start":8976,"enrollment":439,"conditions":17899,"interventions":17901},"NCT02799498","Compare Actions in Healthy Volunteer of 50 mg Etanercept Injection Using an Auto-injector Device and Manual Injection",[89],[17900],"Healthy Men and Women",[1268],{"trials":17903,"activeCount":100},[],{"trials":17905,"activeCount":100},[17906,17913,17917,17924,17928,17936,17945,17949,17956,17960,17969,17977,17981,17987,17996,18004,18011,18017],{"nctId":17907,"briefTitle":17908,"status":217,"phases":17909,"primaryCompletion":6757,"completion":2644,"start":6995,"enrollment":17910,"conditions":17911,"interventions":17912},"NCT00317499","Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis",[91],205,[2078,22],[1268],{"nctId":3792,"briefTitle":3793,"status":336,"phases":17914,"primaryCompletion":3795,"completion":3796,"start":3797,"enrollment":32,"conditions":17915,"interventions":17916},[91],[3799],[1268,1765],{"nctId":17918,"briefTitle":17919,"status":217,"phases":17920,"primaryCompletion":6142,"completion":6142,"start":6429,"enrollment":17921,"conditions":17922,"interventions":17923},"NCT00111436","Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects",[91],912,[22],[1268],{"nctId":9878,"briefTitle":9879,"status":217,"phases":17925,"primaryCompletion":3868,"completion":6833,"start":9881,"enrollment":540,"conditions":17926,"interventions":17927},[91],[22],[6837,9867],{"nctId":17929,"briefTitle":17930,"status":217,"phases":17931,"primaryCompletion":2541,"completion":2661,"start":17932,"enrollment":17933,"conditions":17934,"interventions":17935},"NCT00356590","Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trial 016.0012",[91],"1998-12",468,[19],[1268],{"nctId":17937,"briefTitle":17938,"status":217,"phases":17939,"primaryCompletion":17940,"completion":6129,"start":13158,"enrollment":17941,"conditions":17942,"interventions":17944},"NCT00356356","16.0040 Ankylosing Spondylitis Study",[91],"2006-08",257,[17943],"Ankylosing Spondylitis",[1268],{"nctId":2233,"briefTitle":2234,"status":217,"phases":17946,"primaryCompletion":2236,"completion":2237,"start":2238,"enrollment":994,"conditions":17947,"interventions":17948},[91],[22,2078],[82,1268],{"nctId":17950,"briefTitle":17951,"status":217,"phases":17952,"primaryCompletion":14710,"completion":6173,"start":2833,"enrollment":17953,"conditions":17954,"interventions":17955},"NCT00413452","Etanercept SFP in RA Patients",[91],224,[19],[1268],{"nctId":3818,"briefTitle":3819,"status":217,"phases":17957,"primaryCompletion":3821,"completion":3822,"start":3823,"enrollment":3824,"conditions":17958,"interventions":17959},[91],[2078],[1268,1765],{"nctId":17961,"briefTitle":17962,"status":217,"phases":17963,"primaryCompletion":17964,"completion":17965,"start":17966,"enrollment":12186,"conditions":17967,"interventions":17968},"NCT00078819","Etanercept (Enbrel®) in Psoriasis - Pediatrics",[91],"2006-02-01","2007-06-01","2004-09-08",[22],[1268],{"nctId":17970,"briefTitle":17971,"status":217,"phases":17972,"primaryCompletion":2541,"completion":2661,"start":17973,"enrollment":17974,"conditions":17975,"interventions":17976},"NCT00357903","Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials",[91],"1997-04",639,[19],[1268],{"nctId":3828,"briefTitle":3829,"status":217,"phases":17978,"primaryCompletion":3831,"completion":3832,"start":3833,"enrollment":3834,"conditions":17979,"interventions":17980},[91],[22],[1765,1268],{"nctId":17982,"briefTitle":17983,"status":217,"phases":17984,"start":6469,"enrollment":4006,"conditions":17985,"interventions":17986},"NCT00111449","Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis",[91],[22],[1268],{"nctId":17988,"briefTitle":17989,"status":217,"phases":17990,"primaryCompletion":17991,"completion":8413,"start":17992,"enrollment":15693,"conditions":17993,"interventions":17995},"NCT00141921","Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis",[91],"2011-12-19","2005-08-11",[17994],"Pediatric Plaque Psoriasis",[1268],{"nctId":17997,"briefTitle":17998,"status":217,"phases":17999,"primaryCompletion":18000,"completion":18000,"start":18001,"enrollment":8207,"conditions":18002,"interventions":18003},"NCT03780959","Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)",[90,91],"1998-07-08","1997-05-01",[3799],[1268],{"nctId":18005,"briefTitle":18006,"status":217,"phases":18007,"start":7610,"enrollment":17737,"conditions":18008,"interventions":18010},"NCT00121615","Study of Etanercept in the Treatment of Psoriasis in Adult Subjects",[91],[18009,22],"Inflammation",[6837],{"nctId":18012,"briefTitle":18013,"status":217,"phases":18014,"conditions":18015,"interventions":18016},"NCT00111111","An Evaluation of Etanercept in the Treatment of Subjects With Psoriasis",[91],[22],[1268],{"nctId":18018,"briefTitle":18019,"status":336,"phases":18020,"primaryCompletion":18021,"completion":18021,"start":18022,"enrollment":11519,"conditions":18023,"interventions":18024},"NCT00078806","Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis",[91],"2004-05-06","2001-06-04",[3799],[1268],{"trials":18026,"activeCount":100},[18027,18031,18037,18044,18048,18052,18058,18064,18071,18078,18085,18092,18096,18103],{"nctId":6830,"briefTitle":6831,"status":217,"phases":18028,"primaryCompletion":3869,"completion":6833,"start":2872,"enrollment":6834,"conditions":18029,"interventions":18030},[92],[19],[6837,6817],{"nctId":18032,"briefTitle":18033,"status":217,"phases":18034,"primaryCompletion":4484,"completion":6155,"start":2643,"enrollment":2372,"conditions":18035,"interventions":18036},"NCT00791765","Moderate to Severe Plaque Psoriasis With Scalp Involvement",[92],[22],[1268],{"nctId":18038,"briefTitle":18039,"status":217,"phases":18040,"primaryCompletion":3033,"completion":18041,"start":13468,"enrollment":2579,"conditions":18042,"interventions":18043},"NCT00346294","An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-injector in Subjects With Rheumatoid Arthritis",[92],"2006-07",[19],[1268],{"nctId":6890,"briefTitle":6891,"status":217,"phases":18045,"primaryCompletion":4421,"completion":3033,"start":6143,"enrollment":2476,"conditions":18046,"interventions":18047},[92],[22],[6877,1268],{"nctId":3865,"briefTitle":3866,"status":217,"phases":18049,"primaryCompletion":3868,"completion":3869,"start":3870,"enrollment":3871,"conditions":18050,"interventions":18051},[92],[19],[1268,1765],{"nctId":18053,"briefTitle":18054,"status":217,"phases":18055,"start":7732,"enrollment":6234,"conditions":18056,"interventions":18057},"NCT00099554","Effectiveness and Safety of Enbrel® (Etanercept) in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (Infliximab)",[92],[19],[1268],{"nctId":18059,"briefTitle":18060,"status":217,"phases":18061,"start":6233,"enrollment":6234,"conditions":18062,"interventions":18063},"NCT00115219","Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)",[92],[19],[1268],{"nctId":18065,"briefTitle":18066,"status":217,"phases":18067,"primaryCompletion":8692,"completion":7548,"start":3033,"enrollment":18068,"conditions":18069,"interventions":18070},"NCT00332332","Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis",[92],246,[22],[6837],{"nctId":18072,"briefTitle":18073,"status":217,"phases":18074,"start":7610,"enrollment":18075,"conditions":18076,"interventions":18077},"NCT00094341","Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes",[92],215,[19],[1268],{"nctId":18079,"briefTitle":18080,"status":336,"phases":18081,"primaryCompletion":18082,"completion":18082,"start":2019,"enrollment":12445,"conditions":18083,"interventions":18084},"NCT01543204","Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab",[92],"2015-05-29",[22],[1268],{"nctId":18086,"briefTitle":18087,"status":217,"phases":18088,"primaryCompletion":12130,"completion":791,"start":18089,"enrollment":5508,"conditions":18090,"interventions":18091},"NCT02749370","Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast",[92],"2016-05-18",[2152],[1268],{"nctId":3886,"briefTitle":3887,"status":336,"phases":18093,"primaryCompletion":3889,"completion":3889,"start":3890,"enrollment":2126,"conditions":18094,"interventions":18095},[92],[3892],[1268,1765],{"nctId":18097,"briefTitle":18098,"status":217,"phases":18099,"primaryCompletion":2802,"completion":2802,"start":8490,"enrollment":18100,"conditions":18101,"interventions":18102},"NCT02274792","Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis",[92],132,[2152],[1268],{"nctId":18104,"briefTitle":18105,"status":217,"phases":18106,"primaryCompletion":6224,"completion":1636,"start":6224,"enrollment":916,"conditions":18107,"interventions":18108},"NCT00127842","REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®)",[92],[2078],[1268],{"trials":18110,"activeCount":100},[18111,18119],{"nctId":18112,"briefTitle":18113,"status":217,"phases":18114,"primaryCompletion":781,"completion":781,"start":6282,"enrollment":18115,"conditions":18116,"interventions":18118},"NCT00116272","Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project",[],830,[18117],"Pregnancy",[1268],{"nctId":18120,"briefTitle":18121,"status":217,"phases":18122,"primaryCompletion":18123,"completion":742,"start":8669,"enrollment":18124,"conditions":18125,"interventions":18126},"NCT00322439","Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis",[],"2012-12-11",2511,[22],[1268],{"intervention":2827,"totalTrials":32,"cells":18128},{"EARLY_PHASE1":18129,"PHASE1":18131,"PHASE2":18166,"PHASE3":18216,"PHASE4":18250,"NA":18252},{"trials":18130,"activeCount":100},[],{"trials":18132,"activeCount":100},[18133,18140,18144,18148,18154,18158,18162],{"nctId":18134,"briefTitle":18135,"status":217,"phases":18136,"primaryCompletion":14854,"completion":1684,"start":8491,"enrollment":14469,"conditions":18137,"interventions":18139},"NCT01949532","Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease",[89],[7391,18138],"End-stage Renal Disease",[2827],{"nctId":7328,"briefTitle":7329,"status":217,"phases":18141,"primaryCompletion":6183,"completion":6183,"start":7331,"enrollment":2197,"conditions":18142,"interventions":18143},[89],[7333,1584,7334,31],[2827,1656],{"nctId":7337,"briefTitle":7338,"status":217,"phases":18145,"primaryCompletion":2882,"completion":2882,"start":2873,"enrollment":6471,"conditions":18146,"interventions":18147},[89],[31],[2827,296,1656],{"nctId":18149,"briefTitle":18150,"status":217,"phases":18151,"primaryCompletion":4923,"completion":1694,"start":782,"enrollment":17,"conditions":18152,"interventions":18153},"NCT01949545","Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment",[89],[2441,6334,255],[2827],{"nctId":7369,"briefTitle":7370,"status":217,"phases":18155,"primaryCompletion":7372,"completion":7372,"start":7373,"enrollment":7374,"conditions":18156,"interventions":18157},[89],[7376],[2827,1656,7378,1767,7379,7380,7381,7382,296,7383,1764],{"nctId":7385,"briefTitle":7386,"status":217,"phases":18159,"primaryCompletion":6833,"completion":7388,"start":4420,"enrollment":7389,"conditions":18160,"interventions":18161},[89],[7391],[2827,7393,1656],{"nctId":7403,"briefTitle":7404,"status":217,"phases":18163,"primaryCompletion":1650,"completion":1650,"start":7406,"enrollment":9,"conditions":18164,"interventions":18165},[89],[31],[2827,7393,1656],{"trials":18167,"activeCount":100},[18168,18175,18179,18183,18191,18197,18201,18205,18209],{"nctId":18169,"briefTitle":18170,"status":217,"phases":18171,"primaryCompletion":1627,"completion":7260,"start":14710,"enrollment":7087,"conditions":18172,"interventions":18173},"NCT00511238","Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma",[90],[31],[18174,18174],"carfilzomib",{"nctId":7412,"briefTitle":7413,"status":217,"phases":18176,"primaryCompletion":7415,"completion":7416,"start":7417,"enrollment":3881,"conditions":18177,"interventions":18178},[90],[7322],[2827,1656,7326],{"nctId":7433,"briefTitle":7434,"status":217,"phases":18180,"primaryCompletion":4678,"completion":772,"start":2570,"enrollment":1106,"conditions":18181,"interventions":18182},[89,90],[2795,7437,1303,1097,2441,31,7438],[2827,1656],{"nctId":18184,"briefTitle":18185,"status":217,"phases":18186,"primaryCompletion":18187,"completion":18187,"start":18188,"enrollment":6952,"conditions":18189,"interventions":18190},"NCT00884312","A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols",[90],"2017-05-17","2009-04-09",[31,2441],[2827],{"nctId":18192,"briefTitle":18193,"status":217,"phases":18194,"primaryCompletion":12505,"completion":4707,"start":2570,"enrollment":709,"conditions":18195,"interventions":18196},"NCT00530816","Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma",[90],[31],[18174],{"nctId":2819,"briefTitle":2820,"status":217,"phases":18198,"primaryCompletion":2822,"completion":2823,"start":2824,"enrollment":26,"conditions":18199,"interventions":18200},[89,90],[1226],[2827,1109,1110],{"nctId":7449,"briefTitle":7450,"status":336,"phases":18202,"primaryCompletion":7452,"completion":7452,"start":7453,"enrollment":1454,"conditions":18203,"interventions":18204},[90],[7322],[1656,2827],{"nctId":7457,"briefTitle":7458,"status":217,"phases":18206,"primaryCompletion":7460,"completion":3348,"start":7461,"enrollment":1628,"conditions":18207,"interventions":18208},[89,90],[31],[2827,1656],{"nctId":18210,"briefTitle":18211,"status":217,"phases":18212,"primaryCompletion":8882,"completion":8882,"start":7853,"enrollment":1476,"conditions":18213,"interventions":18215},"NCT00721734","Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function",[90],[31,18214],"Renal Insufficiency",[2827],{"trials":18217,"activeCount":100},[18218,18222,18226,18230,18234,18238,18242,18246],{"nctId":7467,"briefTitle":7468,"status":217,"phases":18219,"primaryCompletion":7470,"completion":7471,"start":7472,"enrollment":7473,"conditions":18220,"interventions":18221},[91],[31],[2827,7476,1656],{"nctId":8506,"briefTitle":8507,"status":217,"phases":18223,"primaryCompletion":8509,"completion":3440,"start":8510,"enrollment":6080,"conditions":18224,"interventions":18225},[91],[31],[2827,7476,8494,295],{"nctId":7482,"briefTitle":7483,"status":217,"phases":18227,"primaryCompletion":7485,"completion":7486,"start":7487,"enrollment":7488,"conditions":18228,"interventions":18229},[91],[7391,7490],[1656,7492,2827],{"nctId":7494,"briefTitle":7495,"status":217,"phases":18231,"primaryCompletion":7497,"completion":7498,"start":7499,"enrollment":7500,"conditions":18232,"interventions":18233},[91],[7502],[1656,2827],{"nctId":7505,"briefTitle":7506,"status":217,"phases":18235,"primaryCompletion":3727,"completion":7508,"start":7509,"enrollment":7510,"conditions":18236,"interventions":18237},[91],[7391],[1656,7393,2827],{"nctId":7514,"briefTitle":7515,"status":217,"phases":18239,"primaryCompletion":7517,"completion":1626,"start":7518,"enrollment":3834,"conditions":18240,"interventions":18241},[91],[31],[2827,1656],{"nctId":10934,"briefTitle":10935,"status":217,"phases":18243,"primaryCompletion":1693,"completion":1694,"start":5352,"enrollment":1444,"conditions":18244,"interventions":18245},[91],[31],[2827,10923],{"nctId":7522,"briefTitle":7523,"status":217,"phases":18247,"primaryCompletion":7525,"completion":7525,"start":7526,"enrollment":7527,"conditions":18248,"interventions":18249},[91],[7322],[2827,2827,7393,1656],{"trials":18251,"activeCount":100},[],{"trials":18253,"activeCount":100},[18254],{"nctId":18255,"briefTitle":18256,"status":1246,"phases":18257,"conditions":18258,"interventions":18259},"NCT01410500","Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease",[],[31],[2827],{"intervention":3382,"totalTrials":6471,"cells":18261},{"EARLY_PHASE1":18262,"PHASE1":18264,"PHASE2":18274,"PHASE3":18329,"PHASE4":18389,"NA":18421},{"trials":18263,"activeCount":100},[],{"trials":18265,"activeCount":100},[18266],{"nctId":18267,"briefTitle":18268,"status":217,"phases":18269,"primaryCompletion":18270,"completion":18270,"start":18271,"enrollment":1907,"conditions":18272,"interventions":18273},"NCT01290029","Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease",[89],"2015-09-23","2011-01-25",[28,342,384],[3382],{"trials":18275,"activeCount":100},[18276,18282,18288,18296,18305,18312,18321],{"nctId":18277,"briefTitle":18278,"status":217,"phases":18279,"primaryCompletion":6421,"completion":6395,"start":6757,"enrollment":3881,"conditions":18280,"interventions":18281},"NCT00042432","Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients",[90],[384,17849],[386],{"nctId":18283,"briefTitle":18284,"status":217,"phases":18285,"conditions":18286,"interventions":18287},"NCT00113958","Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K\u002FDOQI) Levels",[90],[6268],[3382],{"nctId":18289,"briefTitle":18290,"status":217,"phases":18291,"primaryCompletion":12964,"completion":6744,"start":18292,"enrollment":20,"conditions":18293,"interventions":18295},"NCT00936988","A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism",[90],"2000-11",[18294],"Hyperparathyroidism, Primary",[386],{"nctId":18297,"briefTitle":18298,"status":217,"phases":18299,"primaryCompletion":18300,"completion":18300,"start":18301,"enrollment":1726,"conditions":18302,"interventions":18304},"NCT03776058","Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT)",[90],"2000-12-26","2000-06-15",[18303],"Primary Hyperparathyroidism",[3382],{"nctId":18306,"briefTitle":18307,"status":217,"phases":18308,"start":6414,"enrollment":18309,"conditions":18310,"interventions":18311},"NCT00113945","Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD)",[90],360,[6268],[3382],{"nctId":18313,"briefTitle":18314,"status":217,"phases":18315,"primaryCompletion":18316,"completion":18317,"start":18318,"enrollment":11482,"conditions":18319,"interventions":18320},"NCT00936650","A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)",[90],"2001-03","2001-06","1999-11",[18294],[386],{"nctId":18322,"briefTitle":18323,"status":217,"phases":18324,"primaryCompletion":18325,"completion":18325,"start":18326,"enrollment":2197,"conditions":18327,"interventions":18328},"NCT03774771","Safety, Pharmacokinetics, and Clinical Effects of Cinacalcet (AMG 073) in Primary Hyperparathyroidism",[90],"1999-12-13","1998-09-29",[18303],[3382],{"trials":18330,"activeCount":100},[18331,18335,18342,18351,18355,18365,18369,18377],{"nctId":3374,"briefTitle":3375,"status":217,"phases":18332,"primaryCompletion":3377,"completion":2065,"start":3378,"enrollment":3379,"conditions":18333,"interventions":18334},[91],[384,28],[3337,3382,3383,3384],{"nctId":18336,"briefTitle":18337,"status":217,"phases":18338,"primaryCompletion":7626,"completion":4421,"start":14284,"enrollment":18339,"conditions":18340,"interventions":18341},"NCT00117052","SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism",[91],673,[384,6268],[386],{"nctId":18343,"briefTitle":18344,"status":217,"phases":18345,"primaryCompletion":18346,"completion":18346,"start":18347,"enrollment":18348,"conditions":18349,"interventions":18350},"NCT00345839","E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events",[91],"2012-04-10","2006-08-22",3883,[384,28],[3382],{"nctId":3419,"briefTitle":3420,"status":217,"phases":18352,"primaryCompletion":3422,"completion":3422,"start":3423,"enrollment":3424,"conditions":18353,"interventions":18354},[91],[384,28],[3337,3382],{"nctId":18356,"briefTitle":18357,"status":217,"phases":18358,"primaryCompletion":18359,"completion":18360,"start":18361,"enrollment":2490,"conditions":18362,"interventions":18364},"NCT00975221","Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy",[91],"2012-07-12","2012-12-21","2010-03-10",[18294,18363],"Hypercalcemia",[3382],{"nctId":375,"briefTitle":376,"status":336,"phases":18366,"primaryCompletion":378,"start":379,"enrollment":380,"conditions":18367,"interventions":18368},[91],[28,382,342,383,384],[386,321],{"nctId":18370,"briefTitle":18371,"status":217,"phases":18372,"primaryCompletion":290,"completion":290,"start":18373,"enrollment":2044,"conditions":18374,"interventions":18376},"NCT02341417","Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis",[91],"2015-06-10",[18375],"Secondary Hyperparathyroidism, Chronic Kidney Disease",[3382],{"nctId":18378,"briefTitle":18379,"status":217,"phases":18380,"primaryCompletion":17307,"completion":18381,"start":18382,"enrollment":17832,"conditions":18383,"interventions":18388},"NCT00975000","Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients",[91],"2013-04-16","2009-12-03",[18384,28,6276,18385,6268,382,18386,383,6715,18387],"Chronic Allograft Nephropathy","Disordered Mineral Metabolism","Hypophosphatemia","Post Renal Transplantation",[3382],{"trials":18390,"activeCount":100},[18391,18395,18404,18411,18415],{"nctId":6617,"briefTitle":6618,"status":217,"phases":18392,"primaryCompletion":6620,"completion":6621,"start":6622,"enrollment":4485,"conditions":18393,"interventions":18394},[92],[28,384],[3382,6604],{"nctId":18396,"briefTitle":18397,"status":217,"phases":18398,"primaryCompletion":2499,"completion":3833,"start":6129,"enrollment":18309,"conditions":18399,"interventions":18403},"NCT00379899","ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis",[92],[28,6268,18400,18401,18402,466,6276,382,383,9007,384],"Coronary Artery Calcification","Vascular Calcification","Calcification",[386],{"nctId":18405,"briefTitle":18406,"status":217,"phases":18407,"primaryCompletion":6282,"completion":2570,"start":7732,"enrollment":18408,"conditions":18409,"interventions":18410},"NCT00110890","A Research Study for Patients With End-Stage Renal Disease (ESRD)",[92],552,[6268],[386],{"nctId":7081,"briefTitle":7082,"status":217,"phases":18412,"primaryCompletion":7084,"completion":7085,"start":7086,"enrollment":7087,"conditions":18413,"interventions":18414},[92],[342],[7068,3382],{"nctId":18416,"briefTitle":18417,"status":217,"phases":18418,"primaryCompletion":8349,"completion":6183,"start":6129,"enrollment":7556,"conditions":18419,"interventions":18420},"NCT00431496","A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K\u002FDOQI) Targets in Patients With End Stage Renal Disease (ESRD)",[92],[16,384],[3382],{"trials":18422,"activeCount":100},[18423],{"nctId":18424,"briefTitle":18425,"status":217,"phases":18426,"primaryCompletion":1685,"completion":8691,"start":6183,"enrollment":18427,"conditions":18428,"interventions":18429},"NCT00928408","PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice",[],305,[18294],[3382],{"intervention":3051,"totalTrials":231,"cells":18431},{"EARLY_PHASE1":18432,"PHASE1":18434,"PHASE2":18444,"PHASE3":18489,"PHASE4":18491,"NA":18493},{"trials":18433,"activeCount":100},[],{"trials":18435,"activeCount":100},[18436],{"nctId":18437,"briefTitle":18438,"status":217,"phases":18439,"conditions":18440,"interventions":18442},"NCT00002255","An Open-Label Phase I\u002FII Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or Severe AIDS-Related Complex (ARC)",[89],[18441],"HIV Infections",[7654,7263,18443],"Zidovudine",{"trials":18445,"activeCount":100},[18446,18450,18454,18458,18462,18466,18470,18477,18481,18485],{"nctId":7649,"briefTitle":7650,"status":217,"phases":18447,"completion":6994,"start":2644,"conditions":18448,"interventions":18449},[90],[1584],[2797,7654],{"nctId":3044,"briefTitle":3045,"status":3046,"phases":18451,"start":3048,"conditions":18452,"interventions":18453},[90],[2463],[3051,3052,3053],{"nctId":3055,"briefTitle":3056,"status":3046,"phases":18455,"start":3048,"conditions":18456,"interventions":18457},[90],[3059,1265],[3051,3061,3052,3062],{"nctId":3064,"briefTitle":3065,"status":3046,"phases":18459,"start":3048,"conditions":18460,"interventions":18461},[90],[3068,3069],[3051,3052,3071],{"nctId":8002,"briefTitle":8003,"status":3046,"phases":18463,"start":8005,"conditions":18464,"interventions":18465},[90],[7438],[3051,8008,3061,3062,8009,8010],{"nctId":7687,"briefTitle":7688,"status":217,"phases":18467,"primaryCompletion":7690,"completion":2475,"start":6421,"enrollment":7389,"conditions":18468,"interventions":18469},[90],[7692],[3051,2797],{"nctId":18471,"briefTitle":18472,"status":217,"phases":18473,"enrollment":994,"conditions":18474,"interventions":18476},"NCT00002126","A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection.",[90],[18441,18475],"Cytopenias",[7654],{"nctId":7695,"briefTitle":7696,"status":217,"phases":18478,"primaryCompletion":2662,"completion":7698,"start":6995,"enrollment":4671,"conditions":18479,"interventions":18480},[90],[7700,3082],[2797,3051],{"nctId":7703,"briefTitle":7704,"status":217,"phases":18482,"conditions":18483,"interventions":18484},[90],[1584],[2797,3051],{"nctId":14241,"briefTitle":14242,"status":217,"phases":18486,"primaryCompletion":2542,"completion":7610,"start":6429,"enrollment":1160,"conditions":18487,"interventions":18488},[90],[7438,8187,1584,4548,2479],[14232,3051,14246],{"trials":18490,"activeCount":100},[],{"trials":18492,"activeCount":100},[],{"trials":18494,"activeCount":100},[18495,18503],{"nctId":18496,"briefTitle":18497,"status":217,"phases":18498,"primaryCompletion":2540,"completion":2570,"start":6478,"enrollment":18499,"conditions":18500,"interventions":18502},"NCT00115128","Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors",[],309,[18501],"Normal PBPC Donors",[3051],{"nctId":18504,"briefTitle":18505,"status":217,"phases":18506,"enrollment":253,"conditions":18507,"interventions":18508},"NCT00002281","A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients With AIDS or AIDS-Related Complex",[93],[18441,18475],[7654,7263,18443],{"intervention":1351,"totalTrials":231,"cells":18510},{"EARLY_PHASE1":18511,"PHASE1":18513,"PHASE2":18540,"PHASE3":18583,"PHASE4":18589,"NA":18591},{"trials":18512,"activeCount":100},[],{"trials":18514,"activeCount":100},[18515,18524,18528,18536],{"nctId":18516,"briefTitle":18517,"status":217,"phases":18518,"primaryCompletion":18519,"completion":18520,"start":2679,"enrollment":340,"conditions":18521,"interventions":18523},"NCT03064763","Study to Evaluate the Safety\u002F Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma",[89],"2020-08-03","2023-01-12",[18522],"Unresectable Stage IIIB-IV Malignant Melanoma",[1404],{"nctId":5026,"briefTitle":5027,"status":217,"phases":18525,"primaryCompletion":5029,"completion":5030,"start":5031,"enrollment":439,"conditions":18526,"interventions":18527},[89],[5033,37],[1351,1111],{"nctId":18529,"briefTitle":18530,"status":217,"phases":18531,"primaryCompletion":18532,"completion":6524,"start":8413,"enrollment":124,"conditions":18533,"interventions":18535},"NCT02756845","Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors",[89],"2022-01-17",[18534],"Advanced Non CNS Tumors",[1351],{"nctId":1342,"briefTitle":1343,"status":217,"phases":18537,"primaryCompletion":1345,"completion":1346,"start":1347,"enrollment":439,"conditions":18538,"interventions":18539},[89],[1349],[1351,1152],{"trials":18541,"activeCount":100},[18542,18552,18556,18565,18569,18573],{"nctId":18543,"briefTitle":18544,"status":217,"phases":18545,"primaryCompletion":3441,"completion":18546,"start":18547,"enrollment":18548,"conditions":18549,"interventions":18551},"NCT02366195","Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma",[90],"2020-12-25","2015-04-07",112,[18550],"Unresected Stage IIIb to IVM1c Melanoma",[1351],{"nctId":13565,"briefTitle":13566,"status":217,"phases":18553,"primaryCompletion":13568,"completion":264,"start":600,"enrollment":7285,"conditions":18554,"interventions":18555},[89,90],[1402],[1404,13556],{"nctId":18557,"briefTitle":18558,"status":217,"phases":18559,"primaryCompletion":18560,"completion":18561,"start":18562,"enrollment":731,"conditions":18563,"interventions":18564},"NCT02014441","Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec",[90],"2016-01-25","2018-04-19","2014-04-07",[1402],[1404],{"nctId":1381,"briefTitle":1382,"status":217,"phases":18566,"primaryCompletion":1384,"completion":1385,"start":1386,"enrollment":1387,"conditions":18567,"interventions":18568},[89,90],[1389,1390,1391,1392],[1351,1152],{"nctId":1395,"briefTitle":1396,"status":217,"phases":18570,"primaryCompletion":1398,"completion":1399,"start":239,"enrollment":1400,"conditions":18571,"interventions":18572},[90],[1402],[1404,1152],{"nctId":18574,"briefTitle":18575,"status":217,"phases":18576,"primaryCompletion":18577,"completion":18578,"start":18579,"enrollment":11578,"conditions":18580,"interventions":18582},"NCT02211131","Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma",[90],"2019-04-30","2022-04-28","2015-02-03",[18581],"Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma",[1351],{"trials":18584,"activeCount":100},[18585],{"nctId":1408,"briefTitle":1409,"status":336,"phases":18586,"primaryCompletion":1411,"completion":1411,"start":1412,"enrollment":1413,"conditions":18587,"interventions":18588},[91],[1402],[1351,1152],{"trials":18590,"activeCount":100},[],{"trials":18592,"activeCount":100},[18593,18599],{"nctId":18594,"briefTitle":18595,"status":1830,"phases":18596,"conditions":18597,"interventions":18598},"NCT02147951","Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma",[],[18550],[1351],{"nctId":18600,"briefTitle":18601,"status":1830,"phases":18602,"conditions":18603,"interventions":18605},"NCT02297529","Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma",[],[18604],"Unresected Stage IIIB to IVM1c Melanoma",[1351],{"intervention":18607,"totalTrials":325,"cells":18608},"AMG 714",{"EARLY_PHASE1":18609,"PHASE1":18611,"PHASE2":18613,"PHASE3":18645,"PHASE4":18647,"NA":18649},{"trials":18610,"activeCount":100},[],{"trials":18612,"activeCount":100},[],{"trials":18614,"activeCount":100},[18615,18626,18632,18638],{"nctId":18616,"briefTitle":18617,"status":217,"phases":18618,"primaryCompletion":18619,"completion":18620,"start":18621,"enrollment":2044,"conditions":18622,"interventions":18625},"NCT02633020","Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease",[90],"2017-04-11","2017-05-02","2016-04-13",[18623,18624],"Type II Refractory Celiac Disease (RCD-II)","In-situ Small Bowel T-cell Lymphoma",[18607],{"nctId":18627,"briefTitle":18628,"status":217,"phases":18629,"primaryCompletion":2541,"completion":5353,"start":2601,"enrollment":6471,"conditions":18630,"interventions":18631},"NCT00443326","AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects",[90],[22],[18607],{"nctId":18633,"briefTitle":18634,"status":217,"phases":18635,"start":6459,"enrollment":188,"conditions":18636,"interventions":18637},"NCT00433875","Phase 2 AMG 714 in Rheumatoid Arthritis",[90],[19],[18607],{"nctId":18639,"briefTitle":18640,"status":217,"phases":18641,"primaryCompletion":18642,"completion":1747,"start":18621,"enrollment":12445,"conditions":18643,"interventions":18644},"NCT02637141","A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease",[90],"2017-02-15",[11860],[18607],{"trials":18646,"activeCount":100},[],{"trials":18648,"activeCount":100},[],{"trials":18650,"activeCount":100},[18651],{"nctId":18652,"briefTitle":18653,"status":1830,"phases":18654,"conditions":18655,"interventions":18656},"NCT03439475","AMG 714 Expanded Access Program",[],[11860],[18607],{"intervention":18658,"totalTrials":160,"cells":18659},"Enbrel®",{"EARLY_PHASE1":18660,"PHASE1":18662,"PHASE2":18664,"PHASE3":18666,"PHASE4":18668,"NA":18676},{"trials":18661,"activeCount":100},[],{"trials":18663,"activeCount":100},[],{"trials":18665,"activeCount":100},[],{"trials":18667,"activeCount":100},[],{"trials":18669,"activeCount":100},[18670],{"nctId":18671,"briefTitle":18672,"status":217,"phases":18673,"conditions":18674,"interventions":18675},"NCT00111124","Enbrel® in Psoriatic Arthritis",[92],[22],[18658],{"trials":18677,"activeCount":100},[18678,18686,18693],{"nctId":18679,"briefTitle":18680,"status":217,"phases":18681,"primaryCompletion":3870,"completion":2643,"start":7733,"enrollment":18682,"conditions":18683,"interventions":18684},"NCT00116727","Rheumatoid Arthritis DMARD Intervention and UtilizationStudy",[],5103,[19],[18685],"ENBREL®",{"nctId":18687,"briefTitle":18688,"status":217,"phases":18689,"primaryCompletion":1638,"completion":1638,"start":18690,"enrollment":4006,"conditions":18691,"interventions":18692},"NCT00078793","Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis",[],"2000-06",[3799],[18658],{"nctId":18694,"briefTitle":18695,"status":217,"phases":18696,"start":17872,"conditions":18697,"interventions":18698},"NCT00121056","REKinDLE: Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations",[],[19],[18658,18699],"Kineret®",{"intervention":7263,"totalTrials":160,"cells":18701},{"EARLY_PHASE1":18702,"PHASE1":18704,"PHASE2":18710,"PHASE3":18712,"PHASE4":18714,"NA":18731},{"trials":18703,"activeCount":100},[],{"trials":18705,"activeCount":100},[18706],{"nctId":18437,"briefTitle":18438,"status":217,"phases":18707,"conditions":18708,"interventions":18709},[89],[18441],[7654,7263,18443],{"trials":18711,"activeCount":100},[],{"trials":18713,"activeCount":100},[],{"trials":18715,"activeCount":100},[18716,18727],{"nctId":18717,"briefTitle":18718,"status":217,"phases":18719,"primaryCompletion":18720,"completion":8644,"start":18721,"enrollment":12324,"conditions":18722,"interventions":18726},"NCT02253654","Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis",[92],"2016-04-27","2015-04-01",[18723,16,18724,18725],"Renal Insufficiency, Chronic","Renal Dialysis","Erythrocyte Transfusion",[7263],{"nctId":7257,"briefTitle":7258,"status":336,"phases":18728,"primaryCompletion":5191,"completion":4707,"start":7260,"enrollment":1160,"conditions":18729,"interventions":18730},[92],[16],[7244,7263],{"trials":18732,"activeCount":100},[18733],{"nctId":18504,"briefTitle":18505,"status":217,"phases":18734,"enrollment":253,"conditions":18735,"interventions":18736},[93],[18441,18475],[7654,7263,18443],{"intervention":7352,"totalTrials":193,"cells":18738},{"EARLY_PHASE1":18739,"PHASE1":18741,"PHASE2":18756,"PHASE3":18758,"PHASE4":18760,"NA":18762},{"trials":18740,"activeCount":100},[],{"trials":18742,"activeCount":100},[18743,18752],{"nctId":18744,"briefTitle":18745,"status":131,"phases":18746,"primaryCompletion":18747,"completion":18748,"start":18749,"enrollment":100,"conditions":18750,"interventions":18751},"NCT04998747","A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)",[89],"2025-08-02","2025-08-28","2023-08-29",[7350],[7352,7352],{"nctId":7343,"briefTitle":7344,"status":336,"phases":18753,"primaryCompletion":7346,"completion":7346,"start":7347,"enrollment":7348,"conditions":18754,"interventions":18755},[89],[7350],[7352,7326,1656],{"trials":18757,"activeCount":100},[],{"trials":18759,"activeCount":100},[],{"trials":18761,"activeCount":100},[],{"trials":18763,"activeCount":100},[18764],{"nctId":18765,"briefTitle":18766,"status":1830,"phases":18767,"conditions":18768,"interventions":18769},"NCT05256446","AMG 701 Expanded Access Program",[],[],[7352],{"intervention":6747,"totalTrials":193,"cells":18771},{"EARLY_PHASE1":18772,"PHASE1":18774,"PHASE2":18776,"PHASE3":18782,"PHASE4":18784,"NA":18793},{"trials":18773,"activeCount":100},[],{"trials":18775,"activeCount":100},[],{"trials":18777,"activeCount":100},[18778],{"nctId":6740,"briefTitle":6741,"status":217,"phases":18779,"primaryCompletion":2460,"completion":6743,"start":6744,"enrollment":5508,"conditions":18780,"interventions":18781},[90],[2794],[6731,6747],{"trials":18783,"activeCount":100},[],{"trials":18785,"activeCount":100},[18786],{"nctId":18787,"briefTitle":18788,"status":217,"phases":18789,"completion":12018,"start":17872,"enrollment":18790,"conditions":18791,"interventions":18792},"NCT00117117","A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®",[92],2423,[16],[6747],{"trials":18794,"activeCount":100},[18795],{"nctId":18796,"briefTitle":18797,"status":336,"phases":18798,"primaryCompletion":8491,"completion":8491,"start":12056,"enrollment":2044,"conditions":18799,"interventions":18801},"NCT01890577","Study of South African Dialysis Patients",[],[18800],"Chronic Kidney Disease, Receiving Dialysis",[6747],{"intervention":18699,"totalTrials":985,"cells":18803},{"EARLY_PHASE1":18804,"PHASE1":18806,"PHASE2":18808,"PHASE3":18810,"PHASE4":18812,"NA":18820},{"trials":18805,"activeCount":100},[],{"trials":18807,"activeCount":100},[],{"trials":18809,"activeCount":100},[],{"trials":18811,"activeCount":100},[],{"trials":18813,"activeCount":100},[18814],{"nctId":18815,"briefTitle":18816,"status":217,"phases":18817,"conditions":18818,"interventions":18819},"NCT00121043","Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported Questionnaire",[92],[19],[18699],{"trials":18821,"activeCount":100},[18822],{"nctId":18694,"briefTitle":18695,"status":217,"phases":18823,"start":17872,"conditions":18824,"interventions":18825},[],[19],[18658,18699],{"intervention":6631,"totalTrials":985,"cells":18827},{"EARLY_PHASE1":18828,"PHASE1":18830,"PHASE2":18832,"PHASE3":18834,"PHASE4":18836,"NA":18842},{"trials":18829,"activeCount":100},[],{"trials":18831,"activeCount":100},[],{"trials":18833,"activeCount":100},[],{"trials":18835,"activeCount":100},[],{"trials":18837,"activeCount":100},[18838],{"nctId":6626,"briefTitle":6627,"status":217,"phases":18839,"primaryCompletion":2474,"completion":2833,"start":6224,"enrollment":2066,"conditions":18840,"interventions":18841},[92],[384],[6631,6604],{"trials":18843,"activeCount":100},[18844],{"nctId":18845,"briefTitle":18846,"status":217,"phases":18847,"start":2422,"enrollment":17776,"conditions":18848,"interventions":18849},"NCT00189501","A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)",[],[9007],[6631],{"intervention":18851,"totalTrials":985,"cells":18852},"CC-10004",{"EARLY_PHASE1":18853,"PHASE1":18855,"PHASE2":18857,"PHASE3":18867,"PHASE4":18869,"NA":18871},{"trials":18854,"activeCount":100},[],{"trials":18856,"activeCount":100},[],{"trials":18858,"activeCount":100},[18859],{"nctId":18860,"briefTitle":18861,"status":217,"phases":18862,"primaryCompletion":18863,"completion":18864,"start":6354,"enrollment":3472,"conditions":18865,"interventions":18866},"NCT00606450","Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis",[90],"2007-02-01","2007-05-01",[22],[18851,18851],{"trials":18868,"activeCount":100},[],{"trials":18870,"activeCount":100},[],{"trials":18872,"activeCount":100},[18873],{"nctId":18874,"briefTitle":18875,"status":1830,"phases":18876,"conditions":18877,"interventions":18879},"NCT03740516","Expanded Access for CC-10004",[],[18878],"Bechet's Disease",[18851],{"intervention":18443,"totalTrials":985,"cells":18881},{"EARLY_PHASE1":18882,"PHASE1":18884,"PHASE2":18890,"PHASE3":18892,"PHASE4":18894,"NA":18896},{"trials":18883,"activeCount":100},[],{"trials":18885,"activeCount":100},[18886],{"nctId":18437,"briefTitle":18438,"status":217,"phases":18887,"conditions":18888,"interventions":18889},[89],[18441],[7654,7263,18443],{"trials":18891,"activeCount":100},[],{"trials":18893,"activeCount":100},[],{"trials":18895,"activeCount":100},[],{"trials":18897,"activeCount":100},[18898],{"nctId":18504,"briefTitle":18505,"status":217,"phases":18899,"enrollment":253,"conditions":18900,"interventions":18901},[93],[18441,18475],[7654,7263,18443],{"intervention":18903,"totalTrials":204,"cells":18904},"Sensipar after Post Transplant",{"EARLY_PHASE1":18905,"PHASE1":18907,"PHASE2":18909,"PHASE3":18911,"PHASE4":18913,"NA":18915},{"trials":18906,"activeCount":100},[],{"trials":18908,"activeCount":100},[],{"trials":18910,"activeCount":100},[],{"trials":18912,"activeCount":100},[],{"trials":18914,"activeCount":100},[],{"trials":18916,"activeCount":100},[18917],{"nctId":18918,"briefTitle":18919,"status":217,"phases":18920,"start":6224,"enrollment":1476,"conditions":18921,"interventions":18923},"NCT00395902","Post Transplant Study",[],[18922,384,382],"Kidney Tansplant",[18903],{"intervention":18925,"totalTrials":204,"cells":18926},"Not applicable- observational study",{"EARLY_PHASE1":18927,"PHASE1":18929,"PHASE2":18931,"PHASE3":18933,"PHASE4":18935,"NA":18937},{"trials":18928,"activeCount":100},[],{"trials":18930,"activeCount":100},[],{"trials":18932,"activeCount":100},[],{"trials":18934,"activeCount":100},[],{"trials":18936,"activeCount":100},[],{"trials":18938,"activeCount":100},[18939],{"nctId":18940,"briefTitle":18941,"status":336,"phases":18942,"primaryCompletion":8491,"completion":8491,"start":2499,"enrollment":160,"conditions":18943,"interventions":18947},"NCT02090088","Nplate® Pregnancy Exposure Registry",[],[18944,18945,18946],"Birth Defect","Spontaneous Abortions","Low Birth Weight",[18925],{"intervention":18949,"totalTrials":204,"cells":18950},"RAYOS",{"EARLY_PHASE1":18951,"PHASE1":18953,"PHASE2":18955,"PHASE3":18957,"PHASE4":18959,"NA":18961},{"trials":18952,"activeCount":100},[],{"trials":18954,"activeCount":100},[],{"trials":18956,"activeCount":100},[],{"trials":18958,"activeCount":100},[],{"trials":18960,"activeCount":100},[],{"trials":18962,"activeCount":100},[18963],{"nctId":18964,"briefTitle":18965,"status":217,"phases":18966,"primaryCompletion":2113,"completion":2113,"start":1637,"enrollment":4413,"conditions":18967,"interventions":18968},"NCT02287610","A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis",[],[19],[18949],{"intervention":18970,"totalTrials":204,"cells":18971},"Phase I: Fumaric acid esters. Phase II: Apremilast",{"EARLY_PHASE1":18972,"PHASE1":18974,"PHASE2":18976,"PHASE3":18978,"PHASE4":18980,"NA":18982},{"trials":18973,"activeCount":100},[],{"trials":18975,"activeCount":100},[],{"trials":18977,"activeCount":100},[],{"trials":18979,"activeCount":100},[],{"trials":18981,"activeCount":100},[],{"trials":18983,"activeCount":100},[18984],{"nctId":18985,"briefTitle":18986,"status":217,"phases":18987,"primaryCompletion":18988,"completion":18988,"start":18989,"enrollment":18990,"conditions":18991,"interventions":18992},"NCT02954081","APremilast After FumaRic Acid Ester Treatment",[],"2022-08-15","2017-01-26",687,[22],[18970],{"intervention":18994,"totalTrials":204,"cells":18995},"Safety observation",{"EARLY_PHASE1":18996,"PHASE1":18998,"PHASE2":19000,"PHASE3":19002,"PHASE4":19004,"NA":19006},{"trials":18997,"activeCount":100},[],{"trials":18999,"activeCount":100},[],{"trials":19001,"activeCount":100},[],{"trials":19003,"activeCount":100},[],{"trials":19005,"activeCount":100},[],{"trials":19007,"activeCount":100},[19008],{"nctId":19009,"briefTitle":19010,"status":217,"phases":19011,"primaryCompletion":2587,"completion":2570,"start":12964,"enrollment":1337,"conditions":19012,"interventions":19013},"NCT00148369","A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of Liatermin",[],[12235],[18994],{"intervention":19015,"totalTrials":204,"cells":19016},"AMG 162 - Prolia",{"EARLY_PHASE1":19017,"PHASE1":19019,"PHASE2":19021,"PHASE3":19023,"PHASE4":19025,"NA":19027},{"trials":19018,"activeCount":100},[],{"trials":19020,"activeCount":100},[],{"trials":19022,"activeCount":100},[],{"trials":19024,"activeCount":100},[],{"trials":19026,"activeCount":100},[],{"trials":19028,"activeCount":100},[19029],{"nctId":19030,"briefTitle":19031,"status":217,"phases":19032,"primaryCompletion":19033,"completion":19034,"start":19035,"enrollment":19036,"conditions":19037,"interventions":19038},"NCT02347865","Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France",[],"2017-10-26","2018-09-27","2015-06-16",777,[6378],[19015,19015],{"intervention":19040,"totalTrials":204,"cells":19041},"Interferon gamma-1b",{"EARLY_PHASE1":19042,"PHASE1":19044,"PHASE2":19046,"PHASE3":19048,"PHASE4":19050,"NA":19052},{"trials":19043,"activeCount":100},[],{"trials":19045,"activeCount":100},[],{"trials":19047,"activeCount":100},[],{"trials":19049,"activeCount":100},[],{"trials":19051,"activeCount":100},[],{"trials":19053,"activeCount":100},[19054],{"nctId":19055,"briefTitle":19056,"status":217,"phases":19057,"enrollment":2895,"conditions":19058,"interventions":19059},"NCT00002433","The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS",[93],[18441],[19040],{"intervention":19061,"totalTrials":204,"cells":19062},"DMARD",{"EARLY_PHASE1":19063,"PHASE1":19065,"PHASE2":19067,"PHASE3":19069,"PHASE4":19071,"NA":19073},{"trials":19064,"activeCount":100},[],{"trials":19066,"activeCount":100},[],{"trials":19068,"activeCount":100},[],{"trials":19070,"activeCount":100},[],{"trials":19072,"activeCount":100},[],{"trials":19074,"activeCount":100},[19075],{"nctId":19076,"briefTitle":19077,"status":217,"phases":19078,"primaryCompletion":6743,"completion":2643,"start":6396,"enrollment":19079,"conditions":19080,"interventions":19081},"NCT00116714","Rheumatoid Arthritis (DMARD) Intervention and UtilizationStudy",[],4968,[19],[19061],{"intervention":19083,"totalTrials":204,"cells":19084},"Trifluridine",{"EARLY_PHASE1":19085,"PHASE1":19087,"PHASE2":19089,"PHASE3":19091,"PHASE4":19093,"NA":19095},{"trials":19086,"activeCount":100},[],{"trials":19088,"activeCount":100},[],{"trials":19090,"activeCount":100},[],{"trials":19092,"activeCount":100},[],{"trials":19094,"activeCount":100},[],{"trials":19096,"activeCount":100},[19097],{"nctId":19098,"briefTitle":19099,"status":217,"phases":19100,"enrollment":124,"conditions":19101,"interventions":19103},"NCT00002037","Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study",[93],[19102,18441],"Mycobacterium Avium-Intracellulare Infection",[19083],{"intervention":19105,"totalTrials":204,"cells":19106},"Database assessment of off-label XGEVA use",{"EARLY_PHASE1":19107,"PHASE1":19109,"PHASE2":19111,"PHASE3":19113,"PHASE4":19115,"NA":19117},{"trials":19108,"activeCount":100},[],{"trials":19110,"activeCount":100},[],{"trials":19112,"activeCount":100},[],{"trials":19114,"activeCount":100},[],{"trials":19116,"activeCount":100},[],{"trials":19118,"activeCount":100},[19119],{"nctId":19120,"briefTitle":19121,"status":217,"phases":19122,"primaryCompletion":4512,"completion":4512,"start":8491,"enrollment":19123,"conditions":19124,"interventions":19126},"NCT02066805","Estimation of Off-Label Use of XGEVA® (Denosumab) Using Population-Based Databases in Denmark",[],142,[19125],"XGEVA Off-label Use",[19105]]